"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2007/0169568 A1,004-000-091-079-792,2007-07-26,2007,US 48190406 A,2006-07-07,TW 95102365 A,2006-01-20,Digital torque display device for wrench and method for detecting the torque,"A wrench includes a handle and a head connected to an end of the handle. A driving member is received in a through hole in the head and a pawl is received in a first recess defined in an inner periphery of the through hole. The teeth of the pawl are engaged with the teeth of the driving member. At least one detection member is connected to the head so as to detect changes of voltage, resistance, deformation, current, phase differences, or displacement of the wrench. A display member is connected to an outside of the head and electrically connected with the at least one detection member. The user can check the digital value of the torque applied to the object. The method for detecting torque of a wrench includes steps of re-setting, operation, detection, deformation, transmitting digital signals, and displaying.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/004-000-091-079-792,Patent Application,yes,0,0,3,3,0,B25B23/1425;;B25B23/1425;;B25B13/463;;B25B13/463,B25B23/14,73/862.21,0,0,,,,DISCONTINUED
2,US,A1,US 2004/0212989 A1,047-064-231-766-096,2004-10-28,2004,US 43641203 A,2003-05-13,TW 92109545 A,2003-04-22,Illuminative universal joint,"
   An illuminative universal joint includes a first element, a second element, a third element connected between the first element and the second element, an illuminative device, a switch and a head. The first element is for engagement with a handle. The second element defines a space. The third element includes an end pivotally connected with the first element and an opposite end pivotally connected with the second element. The illuminative device is installed in the space for emitting light. The switch is mounted on the second element for turning on and off the illuminative device. The head includes a first insert fit in the space, a second insert for insertion into a tool bit and a hole defined therein for passing light. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/047-064-231-766-096,Patent Application,yes,5,3,4,4,0,B25B23/0014;;B25B23/18;;B60Q3/30;;F16D3/38;;B25B23/18;;B25B23/0014;;B60Q3/30,B25B23/00;;B25B23/18;;B60Q3/06,362/119;;362/109,0,0,,,,EXPIRED
3,US,A1,US 2005/0011315 A1,045-336-512-350-883,2005-01-20,2005,US 64820503 A,2003-08-27,TW 92119645 A,2003-07-18,Ratchet wrench,"A ratchet wrench includes a handle and an annular head from which the handle projects. The annular head defines a first space, a second space communicated with the first space and a third space communicated with the second space. An annular gear is rotationally put in the first space. The annular gear includes a toothed external face. A direction controller is put in the second space. The direction controller includes two pawls and a spring installed between the pawls. Each of the pawls includes a toothed face. The direction switch is rotationally mounted on the handle and partially put in the third space for bringing the toothed face of selective one of the pawls into engagement with the toothed external face of the annular gear.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/045-336-512-350-883,Patent Application,yes,15,17,3,3,0,B25B13/463;;B25B13/463,B25B13/46,81/63.1,0,0,,,,EXPIRED
4,US,A1,US 2004/0216565 A1,086-866-778-762-565,2004-11-04,2004,US 85436804 A,2004-05-27,US 85436804 A;;TW 91218181 U;;US 30802102 A,2002-11-11,Pawl having at least two supporting protrusions for contacting inside of recess of ratchet wrench,"
   A pawl of a ratchet tool includes two protrusions extending from a rear side thereof so as to contact the curve inside of the recess fro receiving the pawl of the wrench. A spring is biased between an end of the pawl and the inside of the recess. The curve inside of the recess applies two forces at different angles along the curve inside to the two protrusions of the pawl so as to push the pawl to match its driving teeth with the engaging teeth of the engaging wheel in the wrench. The multiple contact points between the pawl and the curve inside of the recess share the force so as to reduce damage of the pawl and the inside of the recess due to the stress concentration. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/086-866-778-762-565,Patent Application,yes,1,5,1,4,0,B25B13/463;;B25B13/463,B25B13/46,081 063200,0,0,,,,DISCONTINUED
5,US,A1,US 2004/0226413 A1,108-917-381-770-069,2004-11-18,2004,US 43778903 A,2003-05-14,US 43778903 A,2003-05-14,Joint for connecting wrench with socket,"
   A joint apparatus is provided for firmly connecting a head of a wrench with a socket. The joint apparatus includes a joint and a retainer. The joint includes a first portion for releasable engagement with the head of the wrench and a second portion for releasable engagement with a socket. The retainer is attached to the first portion of the joint for abutting the head of the wrench, thus avoiding the joint escaping the head of the wrench. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/108-917-381-770-069,Patent Application,yes,3,4,2,2,0,B25B13/462;;B25B13/462;;B25B15/001;;B25B15/001;;B25B23/0035;;B25B23/0035,B25B13/46;;B25B15/00;;B25B23/00,081 6,0,0,,,,EXPIRED
6,US,B2,US 6920809 B2,125-636-650-040-298,2005-07-26,2005,US 76052504 A,2004-01-21,TW 92132386 A,2003-11-19,Selective one-way wrench,"A selective one-way wrench includes an annular head, a gear, a pawl, a transmission and a switch. The annular head defines a first space, a second space communicated with the first space and an aperture communicated with the second space. The gear is rotationally put in the first space. The gear includes a toothed face. The pawl is put in the second space. The pawl includes a toothed side for engagement with the toothed face of the gear. The transmission is rotationally put in the second space. The transmission includes three protrusions selective one of which is put between the rods of the pawl so that the transmission can move the pawl. The switch is put into the second space through the aperture for connection with the transmission.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/125-636-650-040-298,Granted Patent,yes,1,0,4,4,0,B25B13/463;;B25B13/463,B25B13/46,81/63.2;;192/43.2,0,0,,,,EXPIRED
7,US,S,US D0493341 S,112-807-669-309-818,2004-07-27,2004,US 17644503 F,2003-02-21,US 17644503 F,2003-02-21,Ratchet wrench,,CHEN TERENCE,CHEN TERENCE,,https://lens.org/112-807-669-309-818,Design Right,no,0,8,1,1,0,,,D 8 25,0,0,,,,EXPIRED
8,US,A1,US 2007/0044600 A1,106-998-933-667-233,2007-03-01,2007,US 21263505 A,2005-08-29,US 21263505 A,2005-08-29,Wrench set having driving members with specific sizes,"A wrench includes a handle and two function heads on two ends of the handle. Two engaging holes are respectively defined in the two function heads so as to be engaged with two driving members. Each of the two driving members includes an engaging section for being engaged with the engaging hole and a polygonal driving portion which extends from the engaging section. The sizes of the two engaging sections can be 10 mm (⅜ inch) and 13 mm (½ inch), 10 mm (⅜ inch) and 19 mm (¾ inch), or 13 mm (½ inch) and 19 mm (¾ inch).",CHEN TERENCE,CHEN TERENCE,,https://lens.org/106-998-933-667-233,Patent Application,yes,22,9,1,1,0,B25B13/461;;B25B13/461;;B25B13/56;;B25B13/56,B25B13/58;;B25B13/00;;B25B23/16;;B25G1/00,81/185;;81/124.4;;81/177.85,0,0,,,,DISCONTINUED
9,CN,A,CN 101337343 A,125-332-098-202-878,2009-01-07,2009,CN 200710165443 A,2007-10-29,US 77248207 A,2007-07-02,Reversible wrench with fixing structure of direction switch button,"The present invention discloses a wrench which is provided with a birdirectional control button positioning structure. The wrench comprises a handle, a direction control device, a positioning device, and a connecting device. The handle is extended with a driving part that forms a driving hole. A driving piece is imbedded into the driving hole which is provided with an accommodating chamber at one side for accommodating more than one group of ratchet block. A restricting part and an accommodating part are provided adjacent to the accommodating chamber. The direction control device is provided with two reversing switches which are provided at the accommodating part and are restricted by the restricting part. The reversing switches drive the ratchet block and are respectively provided with a containing part and more than one group of positioning part. The positioning device is provided on the positioning part of the reversing switch. The connecting device comprises a connector and an elastic part. Two ends of the connector are respectively clamped on the containing part. The elastic part abuts against the connector and provides elastic force for resetting when the reversing switch is dialed to position the positioning device to the reversing switch. Therefore the purposes of fast clamping and positioning are achieved.",INFAR IND CO LTD,TERENCE CHEN,,https://lens.org/125-332-098-202-878,Patent Application,no,0,4,4,4,0,B25B13/463;;B25B13/463,B25B13/46;;B25B23/00,,0,0,,,,INACTIVE
10,US,B2,US 6857339 B2,124-880-673-282-570,2005-02-22,2005,US 42811403 A,2003-05-02,TW 92205935 U,2003-04-14,Wrench structure,"A wrench structure includes a drive head formed with a receiving chamber and having an end face formed with a direction control recess. The end face of the drive head is formed with a spacing portion. Thus, the spacing portion is continuously extended through the end face of the drive head and is not broken, so that the end face of the drive head is continuously extended through the drive head and is not broken, thereby preventing the stress from being concentrated on the portion between the receiving chamber and the direction control recess of the drive head, such that the structural strength of the drive head can be enhanced.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/124-880-673-282-570,Granted Patent,yes,5,23,3,3,0,B25B13/463;;B25B13/463,B25B13/46,81/63.1;;81/58;;81/60;;192/43.1,0,0,,,,EXPIRED
11,US,A1,US 2004/0211299 A1,126-932-278-146-418,2004-10-28,2004,US 43779103 A,2003-05-14,TW 92109544 A,2003-04-22,Joint for connecting wrench with socket,"
   A toolkit includes at least one socket made according to the metric system, a first joint for connecting a head of a wrench with the at least one socket made according to the metric system, a first ring made of a first color and mounted on the first joint, at least one socket made according to the British system, a second joint for connecting the head of the wrench with the at least one socket made according to the British system and a second ring made of a second color other than the first color and mounted on the second joint. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/126-932-278-146-418,Patent Application,yes,18,6,3,3,0,B25B13/463;;B25B15/001;;B25B13/463;;B25B15/001,B25B13/46;;B25B15/00,81/121.1,0,0,,,,DISCONTINUED
12,US,A1,US 2006/0118500 A1,135-956-361-125-733,2006-06-08,2006,US 3629005 A,2005-01-13,TW 93137578 A,2004-12-03,Tool-holding apparatus,"A tool-holding apparatus is provided for holding at least one tool. The tool-holding apparatus includes a board and at least two holders formed on the board. Each of the holders includes a stand extending from the board, a first pressing element extending from the stand and a second pressing element for cooperating with the first pressing element of the other holder in order to pinch the tool.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/135-956-361-125-733,Patent Application,yes,17,23,3,3,0,A47F7/0028;;A47F7/0028;;B25H3/04;;B25H3/04,A47F7/00,211/70.6,0,0,,,,DISCONTINUED
13,US,A1,US 2005/0051446 A1,178-833-667-711-559,2005-03-10,2005,US 69130403 A,2003-10-22,TW 92124963 A,2003-09-10,Tool-holding apparatus,"A tool-holding apparatus is provided for holding at least one tool. The tool-holding apparatus includes a board and at least one holder formed on the board. The holder includes a root extending from the board, a tip extending from the root for pressing the tool, a restraint formed thereon near the tip for restraining the tool and a concave portion defined therein near the root for receiving the tool.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/178-833-667-711-559,Patent Application,yes,1,13,4,4,0,B25H3/04;;B25H3/04,B25H3/04,206/376;;206/349,0,0,,,,EXPIRED
14,DE,A1,DE 10333286 A1,179-157-674-956-39X,2004-02-26,2004,DE 10333286 A,2003-07-22,US 20032002 A,2002-07-23,Werkzeugbox mit einer Ratschenwerkzeug-Prüfbasis,"Eine Werkzeugbox umfaßt eine Vielzahl von Haken und eine Vielzahl von Klemmelementen, die sich von einer Fläche der Werkzeugbox erstrecken. Die Haken und die Klemmelemente befinden sich miteinander ausgerichtet angeordnet, so daß Schäfte des Werkzeugs durch die Klemmelemente geklemmt sind und das Funktionsende sich in Eingriff mit den Haken befindet. Eine Prüfvorrichtung ist mit der Fläche des Werkzeugkastens verbunden und umfaßt ein schräg stehendes Halterungselement, mit dem ein Eingriffsstück verbunden ist, damit das Funktionsende des Schraubenschlüssels damit in Eingriff tritt. Ein Begrenzungsrahmen befindet sich auf der Prüfvorrichtung und begrenzt den Bereich des Schaftes des Werkzeugs für die Verschwenkung.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/179-157-674-956-39X,Patent Application,no,0,0,4,4,0,B25H3/003;;B25H3/003,B25H3/00,,0,0,,,,EXPIRED
15,US,A1,US 2008/0163730 A1,050-355-773-484-649,2008-07-10,2008,US 64977007 A,2007-01-05,US 64977007 A,2007-01-05,Adapter engaging structure,"An adapter engaging structure has an elastic pressing member on the surface of an adapter contacting with a driving head of a wrenching tool, the elastic pressing member is positioned inside the holding portion of the pressing member. With the engaging portion of the pressing member projecting slightly above the surface of the adapter, when the adapter is inserted into a driving portion of a tool, the projective engaging portion is engaged with the inner wall of the driving portion by means of an elastic engaging strength. In addition, when the pressing member is inserted into the holding portion, via the elastic pressing strength of the fixing portion of the pressing member to position the pressing member and the magnetic piece therein inside the holding portion, and without damaging the magnetic piece. Then the objectives of high stability and the engagement of the pressing member are attained.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/050-355-773-484-649,Patent Application,yes,8,2,1,1,0,B25B23/0035;;B25B23/0035,B25B23/00,81/438,0,0,,,,DISCONTINUED
16,US,B2,US 6691594 B2,081-462-474-269-533,2004-02-17,2004,US 18948702 A,2002-07-08,US 18948702 A,2002-07-08,Wrench structure,"
    A wrench structure includes a wrench handle, a drive body, two directional blocks, and a direction control member. The wrench handle has a drive head formed with a receiving chamber for mounting the drive body and a guide slot for mounting each of the two directional blocks. The drive head has an end face formed with a direction control recess and a spacing portion located between the receiving chamber and the direction control recess, for enhancing the structural strength of the wrench handle. The direction control recess is formed with a limit portion for limiting and guiding each of the two directional blocks, so that each of the two directional blocks may be moved to a determined position exactly, thereby changing the direction of operation of the wrench handle and the drive body actually. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/081-462-474-269-533,Granted Patent,yes,3,28,2,2,0,B25B13/463;;B25B13/463,B25B13/46,81/61;;81/62,0,0,,,,EXPIRED
17,US,B2,US 6976582 B2,160-864-060-742-744,2005-12-20,2005,US 69130403 A,2003-10-22,TW 92124963 A,2003-09-10,Tool-holding apparatus,"A tool-holding apparatus is provided for holding at least one tool. The tool-holding apparatus includes a board and at least one holder formed on the board. The holder includes a root extending from the board, a tip extending from the root for pressing the tool, a restraint formed thereon near the tip for restraining the tool and a concave portion defined therein near the root for receiving the tool.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/160-864-060-742-744,Granted Patent,yes,6,12,4,4,0,B25H3/04;;B25H3/04,B25H3/04,206/376;;206/480;;206/482;;211/70.6,0,0,,,,EXPIRED
18,EP,A3,EP 1413399 A3,030-651-056-043-497,2004-05-06,2004,EP 03019741 A,2003-08-29,US 25459202 A,2002-09-26,Ratchet wrench,"A one-way wrench includes an annular head, an annular gear, a pawl and an elastic element. The annular head includes a circular space defined therein and a crescent space defined in the wall of the circular space. The annular gear is put in the circular space. The annular gear includes teeth extending from an external face. The pawl is put in the crescent space. The pawl includes teeth extending from a side for engagement with the teeth of the annular gear and first and second protrusions both extending from an opposite side. The elastic element is compressed between the pawl and the wall of the crescent space. The wall of the crescent space pushes the first protrusion as the annular head drives the annular gear in a direction through the pawl. The wall of the crescent space pushes the second protrusion so as to pivot the pawl from the annular gear as the annular head rotates relative to the annular gear in an opposite direction.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/030-651-056-043-497,Search Report,yes,9,0,3,3,0,B25B13/463,B25B13/46,,0,0,,,,EXPIRED
19,US,A1,US 2005/0068764 A1,042-425-878-127-809,2005-03-31,2005,US 70065403 A,2003-11-03,TW 92127127 A,2003-09-30,Luminescent connective apparatus for wrench,"A luminescent connective apparatus is provided for connecting a wrench with a socket. The luminescent connective apparatus includes a joint defining a tunnel, a lighting device installed in the tunnel and a switch assembly installed on the joint so that the switch assembly is operable in order to turn the lighting device on and off.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/042-425-878-127-809,Patent Application,yes,2,6,2,2,0,B25B13/461;;B25B23/18;;B25B23/18;;B25B13/461,B25B13/46;;B25B23/18,362/119,0,0,,,,DISCONTINUED
20,US,A1,US 2004/0003684 A1,108-760-419-551-070,2004-01-08,2004,US 18948702 A,2002-07-08,US 18948702 A,2002-07-08,WRENCH STRUCTURE,"
   A wrench structure includes a wrench handle, a drive body, two directional blocks, and a direction control member. The wrench handle has a drive head formed with a receiving chamber for mounting the drive body and a guide slot for mounting each of the two directional blocks. The drive head has an end face formed with a direction control recess and a spacing portion located between the receiving chamber and the direction control recess, for enhancing the structural strength of the wrench handle. The direction control recess is formed with a limit portion for limiting and guiding each of the two directional blocks, so that each of the two directional blocks may be moved to a determined position exactly, thereby changing the direction of operation of the wrench handle and the drive body actually. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/108-760-419-551-070,Patent Application,yes,3,7,2,2,0,B25B13/463;;B25B13/463,B25B13/46,81/62,0,0,,,,EXPIRED
21,US,A1,US 2004/0261586 A1,182-899-748-918-654,2004-12-30,2004,US 61752203 A,2003-07-11,TW 92117206 A,2003-06-25,Multi-joint wrench,"
   A wrench includes a head, a first handle, a second handle and a retaining device. The first includes first and second end. The first end of the first handle is pivotally connected with the head about a first axis. The second handle is pivotally connected with the second end of the first handle about a second axis. The retaining device can retain the first handle in position relative to the head, and the second handle in position relative to the first handle. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/182-899-748-918-654,Patent Application,yes,5,12,3,6,0,B25G1/063;;B25G1/063;;B25B13/461;;B25B13/461,B25B13/46;;B25B23/00;;B25G1/06,81/177.7,0,0,,,,EXPIRED
22,EP,A1,EP 1537952 A1,178-926-637-985-607,2005-06-08,2005,EP 04024821 A,2004-10-19,US 72423103 A,2003-12-01,Selective one-way wrench,"A selective one-way wrench includes a handle (19), an annular head (11), a gear (40), a direction controller (20) and a direction switch (30). The handle projects from the annular head. The annular head defines a first space (12) and a second space (13) communicating with the first space. The gear is rotational in the first space. The gear includes a toothed external face (41). The direction controller is put in the second space, and includes two pawls (21;25) and a spring (22) installed between the pawls. Each of the pawls includes a toothed face (24;29). The direction switch includes a first element (31) installed rotationally on the handle and a second element (36) put in the second space and operably connected with the first element for bringing the toothed face of a selective one of the pawls into engagement with the toothed external face of the annular gear.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/178-926-637-985-607,Patent Application,yes,10,3,5,5,0,B25B13/463;;B25B13/463,B25B13/46;;B25B23/00,,0,0,,,,DISCONTINUED
23,US,S,US D0502094 S,061-650-161-574-02X,2005-02-22,2005,US 18823503 F,2003-08-14,US 18823503 F,2003-08-14,Hanger for wrenches,,CHEN TERENCE,CHEN TERENCE,,https://lens.org/061-650-161-574-02X,Design Right,yes,4,0,1,1,0,,,D 9415;;D3/905,0,0,,,,EXPIRED
24,US,A1,US 2004/0200321 A1,063-853-873-207-474,2004-10-14,2004,US 42811403 A,2003-05-02,TW 92205935 U,2003-04-14,WRENCH STRUCTURE,"
   A wrench structure includes a drive head formed with a receiving chamber and having an end face formed with a direction control recess. The end face of the drive head is formed with a spacing portion. Thus, the spacing portion is continuously extended through the end face of the drive head and is not broken, so that the end face of the drive head is continuously extended through the drive head and is not broken, thereby preventing the stress from being concentrated on the portion between the receiving chamber and the direction control recess of the drive head, such that the structural strength of the drive head can be enhanced. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/063-853-873-207-474,Patent Application,yes,5,9,3,3,0,B25B13/463;;B25B13/463,B25B13/46,81/63.1,0,0,,,,EXPIRED
25,US,A1,US 2005/0284268 A1,071-923-283-718-267,2005-12-29,2005,US 91956104 A,2004-08-16,TW 93118450 A,2004-06-25,Wrench combination,"A wrench combination includes a handle with an ear defining an aperture and an annular groove around the aperture. A wrench includes an annular head, an ear extending from the annular head and an annular gear put in the annular head. A washer is put in the annular groove defined in the ear of the handle. A washer is put in the annular groove defined in the ear of the wrench. Each washer includes two contact points on a side and three contact points on an opposite side. A joint includes a first pair of ears for sandwiching the ear of the handle and a second pair of ears for sandwiching the ear of the wrench. A first bolt is driven in the first pair of ears of the joint and the ear of the handle. A second bolt is driven in the second pair of ears of the joint and the ear of the wrench.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/071-923-283-718-267,Patent Application,yes,3,4,4,4,0,B25G1/063;;Y10T403/32827;;Y10T403/32827;;B25G1/063,B25B13/00;;B25B13/28;;B25B23/00;;B25B23/16;;B25G1/06,81/177.8,0,0,,,,INACTIVE
26,EP,B1,EP 1426144 B1,065-647-348-702-499,2006-12-06,2006,EP 03020160 A,2003-09-05,US 30802102 A,2002-12-03,One-way wrench,,CHEN TERENCE,CHEN TERENCE,,https://lens.org/065-647-348-702-499,Granted Patent,yes,5,0,6,6,0,B25B13/463,B25B13/46,,0,0,,,,EXPIRED
27,US,A1,US 2005/0257651 A1,072-362-635-536-838,2005-11-24,2005,US 19052305 A,2005-07-28,US 19052305 A;;US 72423103 A,2003-12-01,Selective one-way wrench,A selective one-way wrench includes a head defining a first space and a second space communicated with the first space. A gear is put pivotally in the first space. The gear includes a toothed external face. A direction controller is put in the second space. The direction controller includes two toothed faces. A spring pushes the direction controller to the gear. A direction switch includes a first element put pivotally on the head and a second element put in the second space and connected to the first element for bringing selected one of the toothed faces of the direction controller into engagement with the toothed external face of the gear.,CHEN TERENCE,CHEN TERENCE,,https://lens.org/072-362-635-536-838,Patent Application,yes,10,5,5,5,0,B25B13/463;;B25B13/463,B25B13/46;;B25B23/00,81/63.2,0,0,,,,EXPIRED
28,US,A1,US 2007/0022847 A1,125-345-061-508-403,2007-02-01,2007,US 19096005 A,2005-07-28,US 19096005 A,2005-07-28,Positioning device for positioning driving member in wrench,A positioning device for hand tools includes a driving member engaged with a hole in a wrench head and a groove is defined in an outer periphery of the driving member so as to receive a C-shaped clip therein. The clip includes an engaging section which is matched with a straight positioning part defined in an inner periphery of the groove so that the clip does not rotate relative to the driving member. The clip further has at least one curve biasing portion which extends out from the groove and is engaged with an inner periphery of the groove to position the driving member in the hole of the wrench head.,CHEN TERENCE,CHEN TERENCE,,https://lens.org/125-345-061-508-403,Patent Application,yes,13,9,1,1,0,B25B13/461;;B25B15/001;;B25B23/0035;;B25B15/001;;B25B23/0035;;B25B13/461,B25B13/06;;B25B23/16,81/180.1;;81/121.1;;81/177.85,0,0,,,,DISCONTINUED
29,DE,B3,DE 102007039978 B3,133-525-544-951-934,2008-10-09,2008,DE 102007039978 A,2007-08-23,DE 102007039978 A,2007-08-23,"Rotatable tool rack, has retaining unit with contact section for inserting through support section, and retaining section provided at section with decreased cross section, and exposed from rear side of suspension section","The tool rack has an anti-theft device, and a tool (10) comprising a head with a support section. A tool rack plate (20) has a suspension section (23), and a fastening element (24) is provided to fasten the tool to the suspension section. A retaining unit (30) has a contact section for inserting through the support section, and a stop flange is stopped at an outer edge of the support section. A retaining section is provided at a section with decreased cross section and exposed from a rear side of the suspension section.",INFAR IND CO LTD,CHEN TERENCE,,https://lens.org/133-525-544-951-934,Granted Patent,no,3,4,1,1,0,B65D73/0064;;B65D2211/00;;G09F3/0364,B65D85/20;;B25H3/04;;B65D73/00;;G09F3/03,,0,0,,,,ACTIVE
30,FR,A1,FR 2916995 A1,165-126-384-298-739,2008-12-12,2008,FR 0850197 A,2008-01-14,TW 96120999 A,2007-06-11,"Spanner, has switching unit including two buttons arranged in respective limitation parts, and connection unit including connection element that is stopped against buttons, and elastic element that is mounted on connection element","The spanner (10) has a head (12) extended from an end of a handle (11), and including a compartment (120) that receives a driving element (13) and a compartment (121) that receives ratchets (14) and limitation parts (122). A switching unit (20) has two buttons (21) that are arranged in respective parts, and a connection unit (A) elastically connecting the buttons with respect to one another. A positioning unit presses one of the buttons. The unit (A) has a connection element (22) that is stopped against the buttons, and an elastic element (23) that is mounted on the element (22).",INFAR IND CO LTD,CHEN TERENCE,,https://lens.org/165-126-384-298-739,Patent Application,no,0,0,4,4,0,B25B13/463,B25B13/46,,0,0,,,,DISCONTINUED
31,US,B2,US 6925913 B2,170-483-635-040-000,2005-08-09,2005,US 76067504 A,2004-01-21,TW 92134964 A,2003-12-11,Selective one-way wrench,"A selective one-way wrench includes an annular head defining a first space, a second space communicated with the first space and an aperture communicated with the second space. A gear is rotationally put in the first space and includes a toothed face. A pawl is put in the second space and includes a toothed face engaged with the toothed face of the gear and two concave faces. A transmission is rotationally put in the second space and includes two wings selective one of which is in contact with corresponding one of the concave faces of the pawl. A switch is put into the second space through the aperture for connection with the transmission. A spring is connected between the pawl and the transmission.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/170-483-635-040-000,Granted Patent,yes,1,4,4,4,0,B25B13/463;;B25B13/463,B25B13/46,81/63.2;;192/43.2,0,0,,,,EXPIRED
32,US,B2,US 7080579 B2,017-013-811-612-52X,2006-07-25,2006,US 64820503 A,2003-08-27,TW 92119645 A,2003-07-18,Ratchet wrench,"A ratchet wrench includes a handle and an annular head formed on the handle. The annular head defines a first space, a second space in communication with the first space and a third space in communication with the second space. An annular gear is positioned rotationally in the first space. In the second space is a direction controller including two pawls and a spring between the pawls. Partially in the third space is a direction switch for engaging selective one of the pawls with the annular gear. The direction switch defines a recess. On the annular head is a spring-biased rod detent for automatic insertion into the recess after the direction switch is moved partially in the third space, thus locking the direction switch to the annular head while allowing the rotation of the direction switch on the annular head.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/017-013-811-612-52X,Granted Patent,yes,15,18,3,3,0,B25B13/463;;B25B13/463,B25B13/46,81/63.1;;81/60;;81/62;;192/43.2,0,0,,,,EXPIRED
33,EP,A2,EP 1413399 A2,010-782-219-425-137,2004-04-28,2004,EP 03019741 A,2003-08-29,US 25459202 A,2002-09-26,Ratchet wrench,"A one-way wrench includes an annular head, an annular gear, a pawl and an elastic element. The annular head includes a circular space defined therein and a crescent space defined in the wall of the circular space. The annular gear is put in the circular space. The annular gear includes teeth extending from an external face. The pawl is put in the crescent space. The pawl includes teeth extending from a side for engagement with the teeth of the annular gear and first and second protrusions both extending from an opposite side. The elastic element is compressed between the pawl and the wall of the crescent space. The wall of the crescent space pushes the first protrusion as the annular head drives the annular gear in a direction through the pawl. The wall of the crescent space pushes the second protrusion so as to pivot the pawl from the annular gear as the annular head rotates relative to the annular gear in an opposite direction.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/010-782-219-425-137,Patent Application,yes,0,1,3,3,0,B25B13/463,B25B13/46,,0,0,,,,EXPIRED
34,US,B2,US 7171876 B2,038-498-499-000-405,2007-02-06,2007,US 91956104 A,2004-08-16,TW 93118450 A,2004-06-25,Wrench combination,"A wrench combination includes a handle with an ear defining an aperture and an annular groove around the aperture. A wrench includes an annular head, an ear extending from the annular head and an annular gear put in the annular head. A washer is put in the annular groove defined in the ear of the handle. A washer is put in the annular groove defined in the ear of the wrench. Each washer includes an aperture, first and second pairs of contact locations at opposite positions of the aperture on a first side. Each washer also includes a central contact location intermediate each pair of contact locations and two lateral contact locations on an opposite second side. The central contact locations are located intermediate the two lateral contact locations. A joint includes a first pair of ears for sandwiching the ear of the handle and a second pair of ears for sandwiching the ear of the wrench. A first bolt is driven in the first pair of ears of the joints, the ear of the handle and the aperture of the washer put in the annular groove defined therein. A second bolt is driven in the second pair of ears of the joint, the ear of the wrench and the aperture of the washer portion in the annular groove defined therein.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/038-498-499-000-405,Granted Patent,yes,3,8,4,4,0,B25G1/063;;Y10T403/32827;;Y10T403/32827;;B25G1/063,B25B13/00;;B25B23/16;;B25B13/28;;B25B23/00;;B25G1/06,81/177.8;;81/177.7;;411/154;;411/545;;403/146,0,0,,,,INACTIVE
35,US,B1,US 6637606 B1,054-040-267-232-763,2003-10-28,2003,US 19554102 A,2002-07-16,US 19554102 A,2002-07-16,Rack for wrenches,"
    A rack includes a board, a first group of holders formed on the board for holding a first group of wrenches and a second group of holders formed on the board for holding a second group of wrenches so that the first group of wrenches and the second group of wrenches are in different planes. Each of the holders of the first group includes two prongs extending from the board toward each other. Each of the holders of the second group includes a base formed on the board and two prongs extending from the base toward each other. A plurality of apertures is defined in the board corresponding to the first group of holders. A plurality of cylinders is formed on the board corresponding to the second group of holders. A fastener includes an anchor for insertion through a hole defined in one of the wrenches held via the holders and one of the apertures and the cylinders for hooking the board and a stop for abutment against the same wrench. A rail is pivotally connected with the rack at an end and includes a hook at an opposite end for hooking the rack in order to conceal the holders and further restrain the wrench. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/054-040-267-232-763,Granted Patent,yes,11,25,1,1,0,B25H3/04;;B25H3/04,B25H3/04,211/70.6;;206/372;;206/376,0,0,,,,EXPIRED
36,CN,C,CN 1290668 C,065-771-050-139-187,2006-12-20,2006,CN 200310116512 A,2003-11-14,US 30802102 A,2002-12-03,Ratchet handle brake block device,,CHEN TERENCE,CHEN TERENCE,,https://lens.org/065-771-050-139-187,Granted Patent,no,0,0,6,6,0,B25B13/463,B25B13/46,,0,0,,,,EXPIRED
37,US,A1,US 2004/0187648 A1,072-954-055-946-792,2004-09-30,2004,US 39616703 A,2003-03-24,US 39616703 A,2003-03-24,Annular wrench,"
   An annular wrench includes a first ring for engagement with a hand, a second ring rotationally installed in the first ring for engagement with a tool bit, a one-way driving device arranged between the first ring and the second ring so that the first ring can drive the second ring in a direction through the one-way driving device, and a tab pivotally mounted on the first ring between a lying position and a standing position. In the standing position, the tab can be pressed for rotating the first ring. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/072-954-055-946-792,Patent Application,yes,7,1,2,6,0,B25B13/462;;B25B13/463;;B25B13/463;;B25B13/462,B25B13/46,081 6,0,0,,,,EXPIRED
38,US,A1,US 2004/0089620 A1,126-160-401-571-990,2004-05-13,2004,US 30774102 A,2002-12-02,TW 91218039 U,2002-11-07,Hanger for wrenches,"
   A hanger includes a board and a cover for covering the board. The board includes at least one recess defined in a front face for receiving a wrench, at least one holder elastically and pivotally mounted thereon in the at least one recess for holding the wrench, and two holes each defined in a side. The cover includes two hooks formed thereon for insertion in the holes for retaining the board engaged with the cover. The at least one holder includes a stop formed thereon for restricting the wrench. The at least one recess is defined between two sidewalls one of which defines a hole in which the at least one holder is located. The hole defined in the one of the sidewalls includes an upper edge and a lower edge. The at least one holder includes an upper edge connected with the upper edge of the hole defined in the one of the sidewalls and a lower edge connected with lower edge of the hole defined in the one of the sidewalls. The hanger includes a joint formed between the upper edge of the at least one holder and the upper edge of the hole defined in the one of the sidewalls. The hanger includes a joint formed between the lower edge of the at least one holder and the lower edge of the hole defined in the one of the sidewalls. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/126-160-401-571-990,Patent Application,yes,7,7,3,3,0,B25H3/04;;B25H3/04,B25H3/04,211/70.6;;206/376,0,0,,,,EXPIRED
39,US,A1,US 2005/0092136 A1,146-439-971-602-799,2005-05-05,2005,US 73338203 A,2003-12-12,TW 92130014 A,2003-10-29,Selective one-way wrench,"In a selective one-way wrench, a handle projects from an annular head. The annular head defines a first space and a second space communicated with the first space. A gear is rotationally put in the first space and includes a toothed external face. A direction controller is put in the second space and includes two pawls and a spring installed between the pawls each including a rod formed thereon and a toothed face. A driver is put rotationally in the second space and includes two fingers selective one of which contacts the rod of selective one of the pawls so as to bring the toothed face of the selected pawl into engagement with the toothed external face of the gear. A direction switch is installed rotationally on the annular head and operably connected with the driver.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/146-439-971-602-799,Patent Application,yes,1,12,4,4,0,B25B13/463;;B25B13/463,B25B13/46,81/63.1,0,0,,,,EXPIRED
40,CN,A,CN 1504297 A,189-697-757-213-049,2004-06-16,2004,CN 200310116512 A,2003-11-14,US 30802102 A,2002-12-03,Ratchet handle brake block device,"A one-way wrench includes an annular head, an annular gear, a pawl and an elastic element. The annular head includes a circular space defined therein and a crescent space defined in the wall of the circular space. The annular gear is put in the circular space. The annular gear includes teeth extending from an external face. The pawl is put in the crescent space. The pawl includes teeth extending from a side for engagement with the teeth of the annular gear and first, second and third protrusions extending from an opposite side. The elastic element is compressed between the pawl and the wall of the crescent space. The wall of the crescent space pushes the first and second protrusions as the annular head drives the annular gear in a direction through the pawl.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/189-697-757-213-049,Patent Application,no,0,1,6,6,0,B25B13/463,B25B13/46,,0,0,,,,EXPIRED
41,US,A1,US 2005/0126347 A1,006-110-017-285-117,2005-06-16,2005,US 76067504 A,2004-01-21,TW 92134964 A,2003-12-11,SELECTIVE ONE-WAY WRENCH,"A selective one-way wrench includes an annular head defining a first space, a second space communicated with the first space and an aperture communicated with the second space. A gear is rotationally put in the first space and includes a toothed face. A pawl is put in the second space and includes a toothed face engaged with the toothed face of the gear and two concave faces. A transmission is rotationally put in the second space and includes two wings selective one of which is in contact with corresponding one of the concave faces of the pawl. A switch is put into the second space through the aperture for connection with the transmission. A spring is connected between the pawl and the transmission.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/006-110-017-285-117,Patent Application,yes,1,0,4,4,0,B25B13/463;;B25B13/463,B25B13/46,81/63.2,0,0,,,,EXPIRED
42,US,S,US D0520823 S,011-992-175-283-22X,2006-05-16,2006,US 21851404 F,2004-12-03,US 21851404 F,2004-12-03,Wrench,,CHEN TERENCE,CHEN TERENCE,,https://lens.org/011-992-175-283-22X,Design Right,no,0,2,1,1,0,,,0805;;D 8 25,0,0,,,,EXPIRED
43,US,A1,US 2004/0094444 A1,078-253-575-742-773,2004-05-20,2004,US 29837902 A,2002-11-18,US 29837902 A,2002-11-18,Hanger for wrenches,"
   A hanger is provided for holding at least one wrench including a head and a handle. The hanger includes a first shell and a second shell for releasable engagement with the first shell. The first shell includes a board with a thickened portion and at least one recess defined in the thickened portion for receiving the handle of the at least one wrench. The first shell can be disengaged from the second shell for mounting of the at least one wrench mounted onto the first shell. The first shell can be engaged with the second shell for firmly holding the at least one wrench on the hanger. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/078-253-575-742-773,Patent Application,yes,94,27,2,2,0,B25H3/04;;B25H3/04,B25H3/04,206/376;;211/70.6,0,0,,,,EXPIRED
44,US,B2,US 6840389 B2,100-094-983-187-481,2005-01-11,2005,US 33574203 A,2003-01-02,TW 91219051 U,2002-11-22,Hanger for wrench,"A hanger for holding a wrench includes a board, a first holder and a second holder. The first holder includes an external side pivotally mounted on the board and an internal side defining a recess for receiving a portion of the wrench. The second holder includes an external side pivotally mounted on the board and an internal side defining a recess for holding another portion of the wrench. The first holder may include at least one protrusion formed on a rear face for abutment against a rear face of the second holder when the first holder is pivoted from the second holder to an extent, thus avoiding further pivoting. The second holder may include at least one protrusion formed on the rear face for abutment against the rear face of the first holder when the second holder is pivoted from the first holder to an extent, thus avoiding farther pivoting.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/100-094-983-187-481,Granted Patent,yes,15,16,3,3,0,B65D73/0014;;B65D73/0014;;B25H3/006;;B25H3/006,B25H3/00;;B65D73/00,211/70.6;;206/376;;206/349,0,0,,,,EXPIRED
45,US,B2,US 6978700 B2,151-648-137-978-85X,2005-12-27,2005,US 5096905 A,2005-02-04,US 5096905 A;;US 39616703 A,2003-03-24,Wrench assembly,"A wrench assembly includes a handle and a wrench. The handle includes a head. The wrench includes a first annular ring non-rotationally put in the head of the handle, a second gear rotationally installed in the first annular ring for engagement with a tool bit and a one-way driving device arranged between the first annular ring and the second gear so that the first annular ring can drive the second gear in a direction through the one-way driving device.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/151-648-137-978-85X,Granted Patent,yes,13,5,2,6,0,B25B13/462;;B25B13/463;;Y10T403/57;;Y10T403/57;;B25B13/462;;B25B13/463,B25B13/46,81/60;;81/61;;81/62;;403/300;;192/43,0,0,,,,EXPIRED
46,US,S,US D0483180 S,138-797-465-755-792,2003-12-09,2003,US 16717802 F,2002-09-11,US 16717802 F,2002-09-11,Tool box,,CHEN TERENCE,CHEN TERENCE,,https://lens.org/138-797-465-755-792,Design Right,no,0,5,1,1,0,,,D 3282;;D3/315;;D3/905,0,0,,,,EXPIRED
47,US,B2,US 7013761 B2,178-111-482-902-880,2006-03-21,2006,US 77068604 A,2004-02-02,US 77068604 A,2004-02-02,Wrench,"A wrench includes a body, a control device, a pawl and a joint. The body includes a handle and a ring. The control device includes a disc pivotally received in the ring and a stem projecting from the disc and including upper, lower and intermediate sections. The pawl is connected with the disc and formed with a toothed end for engagement with the teeth of the ring and two arc-shaped sides. The joint includes a disc received in the ring, an insert installed beneath the disc, stops installed on the disc for selective engagement with the arc-shaped sides of the pawl, and a ball detent trapped in a hole defined in the insert for selective engagement with one of the intermediate and lower sections of the stem.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/178-111-482-902-880,Granted Patent,yes,4,0,2,2,0,B25B13/465;;B25B13/465,B25B13/46,81/63;;81/61;;81/62,0,0,,,,INACTIVE
48,US,A1,US 2005/0103166 A1,011-937-535-355-433,2005-05-19,2005,US 76052504 A,2004-01-21,TW 92132386 A,2003-11-19,SELECTIVE ONE-WAY WRENCH,"A selective one-way wrench includes an annular head, a gear, a pawl, a transmission and a switch. The annular head defines a first space, a second space communicated with the first space and an aperture communicated with the second space. The gear is rotationally put in the first space. The gear includes a toothed face. The pawl is put in the second space. The pawl includes a toothed side for engagement with the toothed face of the gear. The transmission is rotationally put in the second space. The transmission includes three protrusions selective one of which is put between the rods of the pawl so that the transmission can move the pawl. The switch is put into the second space through the aperture for connection with the transmission.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/011-937-535-355-433,Patent Application,yes,1,0,4,4,0,B25B13/463;;B25B13/463,B25B13/46,81/63.2,0,0,,,,EXPIRED
49,US,A1,US 2006/0137491 A1,027-471-251-474-544,2006-06-29,2006,US 20683305 A,2005-08-19,TW 93140838 A,2004-12-28,Control device for ratchet wrench,"A ratchet wrench includes a head having an engaging portion for mounting an object and a through hole which includes an engaging inner periphery and a smooth inner periphery, and is closed by a bottom plate with a central hole. A movable member is movably received in the second through hole and includes a driving section and a connection section. An operation portion includes a handle and a mounting portion which has a connection recess so as to be engaged with the connection section of the movable member. The driving section of the movable member is removably engaged with the engaging inner periphery. By moving the movable member relative to the mounting portion, the handle can be selectively rotated freely or co-rotated with the head.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/027-471-251-474-544,Patent Application,yes,10,19,4,4,0,B25B13/461;;B25G1/063;;Y10T403/32327;;Y10T403/32368;;Y10T403/32327;;Y10T403/32368;;B25G1/063;;B25B13/461,B25B13/46;;B25B13/00;;B25B23/16,81/58;;81/177.2;;81/177.9,0,0,,,,INACTIVE
50,US,S,US D0422103 S,024-093-820-983-740,2000-03-28,2000,US 10596499 F,1999-06-03,US 10596499 F,1999-06-03,Flashlight,,CHEN TERENCE,CHEN TERENCE,,https://lens.org/024-093-820-983-740,Design Right,yes,4,0,1,1,0,,,D26/37;;2602,0,0,,,,EXPIRED
51,US,A1,US 2004/0050216 A1,095-320-433-405-361,2004-03-18,2004,US 25459202 A,2002-09-26,TW 91214691 U,2002-09-16,Ratchet wrench that may prevent jamming during operation,"
   A ratchet wrench includes a wrench body, a ratchet wheel, a pawl member, and an elastic member. Thus, when the ratchet wrench jams during operation, the jamming prevention portion may force the pawl member to detach from the ratchet wheel, thereby preventing the ratchet wrench from jamming during operation. In addition, when the pawl member compresses the elastic member to a determined extent, the jamming prevention portion applies a reaction on the wall of the locking recess of the wrench body, so that the pawl member will not compress the elastic member to an excessive extent, thereby preventing from wearing the elastic member. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/095-320-433-405-361,Patent Application,yes,3,0,3,3,0,B25B13/463;;B25B13/463,B25B13/46,081 6,0,0,,,,EXPIRED
52,US,B2,US 6820520 B2,101-165-679-599-416,2004-11-23,2004,US 30802102 A,2002-12-03,TW 91218181 U,2002-11-11,Ratchet wrench having a rigid locking structure,"
    A ratchet wrench having a rigid locking structure includes a wrench body, a ratchet wheel, a pawl member, and a restoring member. Thus, the support blocks of the pawl member are urged on the wall of the receiving chamber of the wrench body, thereby forming a double-support or multi-support structure between the pawl member and the wall of the receiving chamber of the wrench body, so that the locking teeth of the pawl member are engaged with the ratchet teeth of the ratchet wheel actually, closely, rigidly and stably, thereby increasing the efficient torque of the ratchet wrench, and thereby facilitating the user operating the ratchet wrench. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/101-165-679-599-416,Granted Patent,yes,1,5,3,4,0,B25B13/463;;B25B13/463,B25B13/46,81/60;;81/59.1;;81/63.1;;81/63.2,0,0,,,,EXPIRED
53,US,A1,US 2004/0099553 A1,108-687-027-169-448,2004-05-27,2004,US 30318502 A,2002-11-25,US 30318502 A,2002-11-25,Hanger with locking device,"
   A hanger includes a first board, a second board foldable to the first board for retaining a tool between them and a locking device for locking the second board to the first board. The locking device includes a first flexible strip extending from the first or second board and a second flexible strip extending the first or second board. A plurality of ratchets is formed on the first flexible strip. A sleeve is formed on the second flexible strip. A ratchet is formed on an internal face of the sleeve. The first flexible strip can be inserted in the sleeve so that one of the ratchets formed on the first flexible strip is engaged with the ratchet formed on the second flexible strip. The locking device includes two slots defined in the second or first board for receiving the first and second flexible strips. The first or second board defines at least one slot, and the second or first board includes at least one hook for insertion through the at least one slot for engagement with first or second board. The first board defines a recess, and the second board defines a recess, the recesses together make a space for holding the tool when the second board is folded to the first board. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/108-687-027-169-448,Patent Application,yes,3,20,2,2,0,A45F2200/0575;;A45F2200/0575;;B65D73/00;;B65D73/00;;Y10S206/806;;Y10S206/806,B65D73/00,206/349;;206/376;;206/495,0,0,,,,EXPIRED
54,US,B1,US 6776500 B1,117-914-394-602-489,2004-08-17,2004,US 40842703 A,2003-04-07,US 40842703 A,2003-04-07,Luminescent extension for box-ended wrench,"
    A luminescent extension is provided for connecting a box-ended wrench with a socket. The luminescent extension includes a cylinder, an upper tubular insert, a light assembly, a cover and a lower tubular insert. The upper tubular insert 11 extends from an upper end of the cylinder for releasable connection with the box-ended wrench. The light assembly is installed in the cylinder. The cover is rotationally mounted on the upper end of the cylinder between an OFF position for turning off the light assembly and an ON position for turning on the light assembly. The lower tubular insert extends from a lower end of the cylinder for releasable connection with the socket. Light can emit from the light assembly through the lower tubular insert. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/117-914-394-602-489,Granted Patent,yes,8,9,1,1,0,B25B15/001;;B25B23/18;;B25B15/001;;B25B23/18,B25B15/00;;B25B23/18,362/119;;362/109;;362/120,0,0,,,,EXPIRED
55,US,A1,US 2006/0156868 A1,030-402-376-428-276,2006-07-20,2006,US 20683605 A,2005-08-19,TW 94101253 A,2005-01-14,Wrench driven directly to change its direction of operation,"A wrench includes a wrench body, an actuating member, a pawl member, a direction control knob, a positioning device, and a driving member. Thus, the direction control knob is mounted on the drive head of the wrench body after assembly of the pawl member and the driving member, so that the direction control knob is mounted on the drive head of the wrench body easily, rapidly and conveniently, thereby facilitating assembly of the wrench and thereby decreasing costs of production.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/030-402-376-428-276,Patent Application,yes,3,2,4,4,0,B25B13/463;;B25B13/463,B25B13/46,81/63.2,0,0,,,,INACTIVE
56,US,B2,US 6976581 B2,048-940-281-002-397,2005-12-20,2005,US 20032002 A,2002-07-23,US 20032002 A,2002-07-23,Tool box having a ratchet tool test base,A tool box includes a plurality of hooks and a plurality of clamping members extending from a surface of the tool box. The hooks and the clamping members are located in alignment with each other so that shanks of the tool is clamped by the clamping members and the function end is engaged with the hooks. A test device is connected to the surface of the tool box and includes an inclined support member on which an engaging piece is connected for function end of the wrench to engage with. A restriction frame is on the test device and restrain the range of the shank of the tool to swing.,CHEN TERENCE,CHEN TERENCE,,https://lens.org/048-940-281-002-397,Granted Patent,yes,5,5,4,4,0,B25H3/003;;B25H3/003,B25H3/00,206/373;;206/493,0,0,,,,EXPIRED
57,CN,B,CN 101337343 B,074-827-718-348-285,2011-05-11,2011,CN 200710165443 A,2007-10-29,US 77248207 A,2007-07-02,Reversible wrench with fixing structure of direction switch button,"The present invention discloses a wrench which is provided with a birdirectional control button positioning structure. The wrench comprises a handle, a direction control device, a positioning device, and a connecting device. The handle is extended with a driving part that forms a driving hole. A driving piece is imbedded into the driving hole which is provided with an accommodating chamber at oneside for accommodating more than one group of ratchet block. A restricting part and an accommodating part are provided adjacent to the accommodating chamber. The direction control device is provided with two reversing switches which are provided at the accommodating part and are restricted by the restricting part. The reversing switches drive the ratchet block and are respectively provided with acontaining part and more than one group of positioning part. The positioning device is provided on the positioning part of the reversing switch. The connecting device comprises a connector and an elastic part. Two ends of the connector are respectively clamped on the containing part. The elastic part abuts against the connector and provides elastic force for resetting when the reversing switch isdialed to position the positioning device to the reversing switch. Therefore the purposes of fast clamping and positioning are achieved.",INFAR IND CO LTD,TERENCE CHEN,,https://lens.org/074-827-718-348-285,Granted Patent,no,0,0,4,4,0,B25B13/463;;B25B13/463,B25B13/46;;B25B23/00,,0,0,,,,INACTIVE
58,US,S,US D0481543 S,075-497-018-814-22X,2003-11-04,2003,US 17184602 F,2002-12-02,TW 91306473 F,2002-11-07,Hanger for wrenches,,CHEN TERENCE,CHEN TERENCE,,https://lens.org/075-497-018-814-22X,Design Right,no,0,0,1,1,0,,,D 3315;;D3/905,0,0,,,,EXPIRED
59,US,A1,US 2004/0163504 A1,169-725-045-067-792,2004-08-26,2004,US 37447603 A,2003-02-24,US 37447603 A,2003-02-24,Wrench,"
   A wrench is provided for driving an object formed with a plurality of facets and a plurality of corners. The wrench includes a head and a handle extending from the head. The head includes two jaws and a throat formed between the jaws. Each of the jaws includes a convex face formed on an internal side thereof for contact with one of the facets of the object. The throat includes two convex faces formed on an internal side thereof each for contact with one of the facets of the object. A recess is defined between each of the convex faces and one of the convex faces. A recess is defined between the convex faces. Each of the recesses receives one of the corners of the object. The recesses may be rounded. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/169-725-045-067-792,Patent Application,yes,6,8,1,1,0,B25B13/08;;B25B13/08,B25B13/08,81/186,0,0,,,,DISCONTINUED
60,US,A1,US 2006/0117913 A1,193-869-173-386-897,2006-06-08,2006,US 33478006 A,2006-01-17,US 33478006 A;;US 64820503 A,2003-08-27,Selective one-way wrench,"A selective one-way wrench includes a handle and a head from which the handle projects. The head defines a first space, a second space in communication with the first space, a third space in communication with the second space and an aperture. An annular gear is rotationally positioned in the first space. A direction controller is positioned in the second space. The direction controller includes two pawls and a spring installed between the pawls. The direction switch is partially positioned in the third space for engaging selected one of the pawls with the annular gear. The direction switch defines a recess. A fastener is driven into the recess of the direction switch through the aperture of the head so as to pivotally install the direction switch on the head.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/193-869-173-386-897,Patent Application,yes,19,15,2,2,0,B25B13/463;;B25B13/463,B25B13/46,81/63.1,0,0,,,,DISCONTINUED
61,EP,B1,EP 1413399 B1,019-817-721-499-777,2011-11-09,2011,EP 03019741 A,2003-08-29,US 25459202 A,2002-09-26,Ratchet wrench,,CHEN TERENCE,CHEN TERENCE,,https://lens.org/019-817-721-499-777,Granted Patent,yes,9,0,3,3,0,B25B13/463,B25B13/46,,0,0,,,,EXPIRED
62,US,A1,US 2004/0216564 A1,073-848-472-595-230,2004-11-04,2004,US 85434404 A,2004-05-27,US 85434404 A;;US 42811403 A,2003-05-02,Reinforcement structure for wrench head,"
   A wrench includes a head with an engaging wheel rotatably received in a through hole in the head and a recess is defined in an inner periphery of the through hole so as to receive two pawls therein. A recessed area is defined in a surface of the head and a bridge portion is located between the through hole and the recessed area. A space is defined in an underside of the bridge portion and in communication with the through hole. Each pawl has a protrusion and the space allows the protrusions of the pawl to be inserted in the recess without any orientation adjustment. A control member is rotatably received in the recessed area and has a concavity for retaining the two protrusions therein. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/073-848-472-595-230,Patent Application,yes,3,8,2,2,0,B25B13/463;;B25B13/463,B25B13/46,81/63.1,0,0,,,,EXPIRED
63,EP,A1,EP 1426144 A1,073-989-913-491-031,2004-06-09,2004,EP 03020160 A,2003-09-05,US 30802102 A,2002-12-03,One-way wrench,"A one-way wrench (10) includes an annular head (11), an annular gear (12), a pawl (20) and an elastic element (30). The annular head includes a circular space (13) defined therein and a crescent space (14) defined in the wall of the circular space. The annular gear is put in the circular space. The annular gear includes teeth (16) extending from an external face. The pawl is put in the crescent space. The pawl includes teeth (21) extending from a side for engagement with the teeth of the annular gear and first, second and third protrusions (23;24;25) extending from an opposite side. The elastic element is compressed between the pawl and the wall of the crescent space. The wall of the crescent space pushes the first and second protrusions as the annular head drives the annular gear in a direction through the pawl.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/073-989-913-491-031,Patent Application,yes,5,0,6,6,0,B25B13/463,B25B13/46,,0,0,,,,EXPIRED
64,US,A1,US 2005/0166719 A1,135-770-471-442-443,2005-08-04,2005,US 77068604 A,2004-02-02,US 77068604 A,2004-02-02,Wrench,"A wrench includes a body, a control device, a pawl and a joint. The body includes a handle, a ring formed at an end of the handle and with an internal face and a plurality of teeth formed on the internal face of the ring. The control device includes a disc pivotally received in the ring and a stem projecting from the disc and including an upper section, a lower section and an intermediate section thinner than the lower section. The pawl is connected with the disc and formed with a toothed end for engagement with the teeth and two arc-shaped sides, the pawl defining a slot. The joint includes a disc received in the ring, an insert installed beneath the disc, two stops installed on the disc each for selective engagement with one of the arc-shaped sides of the pawl, a hole defined in the disc and the insert, a hole defined in the insert and communicated with the hole and a ball detent trapped in the hole for selective engagement with one of the intermediate and lower sections of the stem.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/135-770-471-442-443,Patent Application,yes,4,0,2,2,0,B25B13/465;;B25B13/465,B25B13/46,81/63,0,0,,,,EXPIRED
65,DE,B4,DE 10333286 B4,151-146-001-510-289,2006-09-07,2006,DE 10333286 A,2003-07-22,US 20032002 A,2002-07-23,Werkzeugbox mit einer Ratschenwerkzeug-Prüfvorrichtung,,CHEN TERENCE,CHEN TERENCE,,https://lens.org/151-146-001-510-289,Granted Patent,no,4,0,4,4,0,B25H3/003;;B25H3/003,B25H3/02;;B25H3/00;;B65D85/20,,0,0,,,,EXPIRED
66,US,B2,US 6843579 B2,004-893-758-553-415,2005-01-18,2005,US 43641203 A,2003-05-13,TW 92109545 A,2003-04-22,Illuminative universal joint,"An illuminative universal joint includes a first element, a second element, a third element connected between the first element and the second element, an illuminative device, a switch and a head. The first element is for engagement with a handle. The second element defines a space. The third element includes an end pivotally connected with the first element and an opposite end pivotally connected with the second element. The illuminative device is installed in the space for emitting light. The switch is mounted on the second element for turning on and off the illuminative device. The head includes a first insert fit in the space, a second insert for insertion into a tool bit and a hole defined therein for passing light.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/004-893-758-553-415,Granted Patent,yes,5,7,4,4,0,B25B23/0014;;B25B23/18;;B60Q3/30;;F16D3/38;;B25B23/18;;B25B23/0014;;B60Q3/30,B25B23/00;;B25B23/18;;B60Q3/06,362/119;;362/199,0,0,,,,EXPIRED
67,US,S,US D0577991 S,037-370-431-632-378,2008-10-07,2008,US 29985408 F,2008-01-04,US 29985408 F,2008-01-04,Tool display package,,INFAR IND CO LTD,CHEN TERENCE,INFAR INDUSTRIAL CO. LTD (2008-01-07),https://lens.org/037-370-431-632-378,Design Right,no,0,2,1,1,0,,,0903;;D 9415,0,0,,,,EXPIRED
68,US,A1,US 2006/0000317 A1,063-561-724-923-069,2006-01-05,2006,US 90283004 A,2004-08-02,TW 93119733 A,2004-06-30,Selective one-way wrench,"A selective one-way wrench includes an annular head comprising a first space defined therein, a second space communicated with the first space and a third space communicated with the second space. A gear is put rotationally in the first space. A transmission is put in the second space for transmitting torque from the annular head to the gear in selective one of two opposite directions. A switch is put in the second space through the third space and connected with the transmission. The transmission prevents the switch from rotating and rocking on the annular head.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/063-561-724-923-069,Patent Application,yes,8,5,3,3,0,B25B13/463;;B25B13/463,B25B13/46,81/63.2,0,0,,,,DISCONTINUED
69,US,A1,US 2005/0061117 A1,104-407-487-979-404,2005-03-24,2005,US 98340904 A,2004-11-08,US 98340904 A;;TW 93130816 A;;TW 92117206 A;;US 61752203 A,2003-06-25,Multi-joint wrench,"A wrench includes a head, a first handle and a second handle. The first handle includes first and second ends. The first end of the first handle is pivotally connected with the head. The first handle defines a hole and a recess communicated with the hole. The second handle is pivotally connected with the second end of the first handle. A retaining device includes two detents, a switch and a spring. The detents are movable in the hole between a releasing position and a locking position for locking the head and the second handle in position. The switch is movable in the recess between a releasing position and a locking position for locking the detents in the locking position. The spring is put in the recess for biasing the switch to the locking position.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/104-407-487-979-404,Patent Application,yes,6,13,1,6,0,B25B13/461;;B25G1/063;;B25G1/063;;B25B13/461,B25B13/46;;B25B23/00;;B25G1/06,81/177.7,0,0,,,,DISCONTINUED
70,US,A1,US 2004/0129114 A1,160-250-516-122-724,2004-07-08,2004,US 68942703 A,2003-10-20,US 68942703 A;;US 33574003 A,2003-01-02,Versatile wrench,"
   A wrench includes a head, a handle, a socket, a pawl and a switch. The head defines a horizontal tunnel. The handle extends movably through the horizontal tunnel and includes two stops attached thereto for retaining the handle on the head. The socket is rotationally connected with the head. The socket includes an internal face including a toothed portion and a non-circular portion. The pawl is put between the head and the socket. The pawl includes a first member with a toothed side and a second member with a toothed front side. The toothed side of selective one of the members of the pawl engages with the toothed portion of the internal face of the socket so that the head can drive the socket through the pawl in selective one of two directions. The switch is connected with the pawl so that the switch can be switched so as to engage the toothed side of selective one of the members of the pawl with the toothed portion of the internal face of the socket. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/160-250-516-122-724,Patent Application,yes,12,9,1,1,0,B25B13/465;;B25B15/001;;B25B15/001;;B25B13/465,B25B13/46,81/63,0,0,,,,DISCONTINUED
71,CN,A,CN 1623736 A,174-936-371-323-473,2005-06-08,2005,CN 200410083628 A,2004-10-13,US 72423103 A,2003-12-01,Selective one-way wrench,,CHEN TERENCE,CHEN TERENCE,,https://lens.org/174-936-371-323-473,Patent Application,no,0,3,5,5,0,B25B13/463;;B25B13/463,B25B13/46;;B25B23/00,,0,0,,,,INACTIVE
72,US,A1,US 2004/0089107 A1,190-456-570-877-601,2004-05-13,2004,US 30802102 A,2002-12-03,TW 91218181 U,2002-11-11,Ratchet wrench having a rigid locking structure,"
   A ratchet wrench having a rigid locking structure includes a wrench body, a ratchet wheel, a pawl member, and a restoring member. Thus, the support blocks of the pawl member are urged on the wall of the receiving chamber of the wrench body, thereby forming a double-support or multi-support structure between the pawl member and the wall of the receiving chamber of the wrench body, so that the locking teeth of the pawl member are engaged with the ratchet teeth of the ratchet wheel actually, closely, rigidly and stably, thereby increasing the efficient torque of the ratchet wrench, and thereby facilitating the user operating the ratchet wrench. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/190-456-570-877-601,Patent Application,yes,1,1,3,4,0,B25B13/463;;B25B13/463,B25B13/46,081 6,0,0,,,,EXPIRED
73,US,B2,US 7055689 B2,001-643-218-295-039,2006-06-06,2006,US 29837902 A,2002-11-18,US 29837902 A,2002-11-18,Hanger for wrenches,A hanger holds at least one wrench including a head and a handle. The hanger includes a first shell and a second shell for releasable engagement with the first shell. The first shell includes a board with a thickened portion and at least one recess defined in the thickened portion for receiving the handle of the at least one wrench. The first shell can be disengaged from the second shell for mounting of the at least one wrench mounted onto the first shell. The first shell can be engaged with the second shell for firmly holding the at least one wrench on the hanger.,CHEN TERENCE,CHEN TERENCE,,https://lens.org/001-643-218-295-039,Granted Patent,yes,97,28,2,2,0,B25H3/04;;B25H3/04,B65D85/28;;B25H3/04,206/376;;206/349,0,0,,,,EXPIRED
74,DE,D1,DE 60321337 D1,026-462-426-509-702,2008-07-10,2008,DE 60321337 T,2003-08-25,EP 03019148 A,2003-08-25,Ratschenschlüssel,,CHEN TERENCE,CHEN TERENCE,,https://lens.org/026-462-426-509-702,Granted Patent,no,0,0,3,3,0,B25B13/463,B25B13/46,,0,0,,,,EXPIRED
75,US,B2,US 6976408 B2,043-967-553-648-158,2005-12-20,2005,US 39616703 A,2003-03-24,US 39616703 A,2003-03-24,Annular wrench,"An annular wrench includes a first ring for engagement with a hand, a second ring rotationally installed in the first ring for engagement with a tool bit, a one-way driving device arranged between the first ring and the second ring so that the first ring can drive the second ring in a direction through the one-way driving device, and a tab pivotally mounted on the first ring between a lying position and a standing position. In the standing position, the tab can be pressed for rotating the first ring.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/043-967-553-648-158,Granted Patent,yes,7,21,2,6,0,B25B13/462;;B25B13/463;;B25B13/463;;B25B13/462,B25B13/46,81/60;;81/58,0,0,,,,EXPIRED
76,US,S,US D0473713 S,055-785-023-160-102,2003-04-29,2003,US 16160802 F,2002-05-28,US 16160802 F,2002-05-28,Tool box,,CHEN TERENCE,CHEN TERENCE,,https://lens.org/055-785-023-160-102,Design Right,no,0,1,1,1,0,,,D 3282;;D3/905;;D3/315,0,0,,,,EXPIRED
77,US,A1,US 2004/0228114 A1,094-875-040-843-312,2004-11-18,2004,US 45995403 A,2003-06-12,TW 92113016 A,2003-05-14,Luminescent toolbox apparatus,"
   A luminescent toolbox apparatus includes a toolbox and a luminescent device attached to the toolbox in order to provide luminescence. The luminescent device includes a driver, a sensor connected with the driver and a light source connected with the driver. The driver turns on the light source as it receives a signal from the sensor. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/094-875-040-843-312,Patent Application,yes,12,20,3,3,0,B25H3/02;;B60R11/06;;F21V23/0435;;F21V23/0442;;F21V33/0084;;F21V23/0442;;F21V23/0435;;F21V33/0084;;B25H3/02;;B60R11/06,B25H3/02;;B60R11/06;;F21V9/16;;F21V23/04;;F21V33/00,362/84,0,0,,,,DISCONTINUED
78,US,B2,US 7146883 B2,101-855-912-068-282,2006-12-12,2006,US 20683605 A,2005-08-19,TW 94101253 A,2005-01-14,Wrench driven directly to change its direction of operation,"A wrench includes a wrench body, an actuating member, a pawl member, a direction control knob, a positioning device, and a driving member. Thus, the direction control knob is mounted on the drive head of the wrench body after assembly of the pawl member and the driving member, so that the direction control knob is mounted on the drive head of the wrench body easily, rapidly and conveniently, thereby facilitating assembly of the wrench and thereby decreasing costs of production.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/101-855-912-068-282,Granted Patent,yes,3,9,4,4,0,B25B13/463;;B25B13/463,B25B13/46,81/63.2;;81/61;;81/62;;81/63,0,0,,,,INACTIVE
79,DE,T2,DE 60310183 T2,130-920-048-266-699,2007-09-20,2007,DE 60310183 T,2003-09-05,US 30802102 A,2002-12-03,Unidirektionaler Ratschenschlüssel,,CHEN TERENCE,CHEN TERENCE,,https://lens.org/130-920-048-266-699,Granted Patent,no,0,0,6,6,0,B25B13/463,B25B13/46,,0,0,,,,EXPIRED
80,US,A1,US 2008/0302743 A1,183-841-750-949-470,2008-12-11,2008,US 80820107 A,2007-06-07,US 80820107 A,2007-06-07,Simplified rotatable anti-theft tool rack,"A simplified rotatable anti-theft tool rack comprises a tool rack body and an inserting body that cooperate with each other to position a tool. The tool rack body includes a limiting portion used to receive an inserting portion of the head of the tool and connected with a guiding portion. At the end of the guiding portion is disposed with a fastening portion for restricting the tool by cooperating with a fixing element. The inserting body includes a multangular engaging portion. One end of the engaging portion is disposed with a stopping flange, and the other end of the engaging portion is extended to form a neck-shaped inserting portion. At the end of the inserting portion which has inserted through the limiting portion is formed a big-diameter check portion, thus forming a simplified structure, achieving the anti-theft and rotatable effect.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/183-841-750-949-470,Patent Application,yes,8,8,2,2,0,A47F5/0006;;A47F5/0006;;A47F7/0021;;A47F7/0021;;Y10S206/806,A47F7/00,211/70.6,0,0,,,,ACTIVE
81,EP,A1,EP 1510293 A1,026-446-487-966-405,2005-03-02,2005,EP 03019148 A,2003-08-25,EP 03019148 A,2003-08-25,Ratchet wrench,"A ratchet wrench includes a handle (10) and an annular head (11) from which the handle projects. The annular head defines a first space (12), a second space (13) communicated with the first space and a third space (14) communicated with the second space. An annular gear (20) is rotationally put in the first space. The annular gear includes a toothed external face (21). A direction controller (30) is put in the second space. The direction controller includes two pawls (31,32) and a spring (33) installed between the pawls. Each of the pawls includes a toothed face (312;322). The direction switch (40) is rotationally mounted on the handle and partially put in the third space for bringing the toothed face of selective one of the pawls into engagement with the toothed external face of the annular gear.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/026-446-487-966-405,Patent Application,yes,10,3,3,3,0,B25B13/463,B25B13/46,,0,0,,,,EXPIRED
82,US,B2,US 7207244 B2,056-731-174-814-241,2007-04-24,2007,US 19052305 A,2005-07-28,US 19052305 A;;US 72423103 A,2003-12-01,Selective one-way wrench,A selective one-way wrench includes a head defining a first space and a second space communicated with the first space. A gear is put pivotally in the first space. The gear includes a toothed external face. A direction controller is put in the second space. The direction controller includes two toothed faces. A spring pushes the direction controller to the gear. A direction switch includes a first element put pivotally on the head and a second element put in the second space and connected to the first element for bringing selected one of the toothed faces of the direction controller into engagement with the toothed external face of the gear.,CHEN TERENCE,CHEN TERENCE,,https://lens.org/056-731-174-814-241,Granted Patent,yes,10,10,5,5,0,B25B13/463;;B25B13/463,B25B13/46;;B25B23/00,81/63.2;;81/63,0,0,,,,EXPIRED
83,US,A1,US 2007/0034058 A1,082-266-797-572-893,2007-02-15,2007,US 58515606 A,2006-10-24,US 58515606 A;;TW 93140838 A;;US 20683305 A,2004-12-28,Control device for ratchet wrench,"A ratchet wrench includes a head having a first through hole with a polygonal inner periphery to be engaged with an object and a second through hole which includes a first engaging inner periphery. A rod portion is movably received in the second through hole and has a flange which is removably engaged with the first engaging inner periphery. The cap member has a polygonal recess so as to be engaged with a first end of the rod portion so that the rod portion is co-rotated with the cap member. The cap member has an annular lip which has a second engaging outer periphery. An operation portion includes a connection recess to retain the cap member therein. By operating the rod portion or the cap member, the handle can be selectively rotated freely or co-rotated with the head.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/082-266-797-572-893,Patent Application,yes,6,11,4,4,0,B25B13/461;;B25G1/063;;Y10T403/32327;;Y10T403/32368;;Y10T403/32327;;Y10T403/32368;;B25G1/063;;B25B13/461,B25B23/16;;B25B13/00,81/58;;81/177.8,0,0,,,,DISCONTINUED
84,US,A1,US 2004/0016667 A1,090-740-022-781-011,2004-01-29,2004,US 20032002 A,2002-07-23,US 20032002 A,2002-07-23,Tool box having a ratchet tool test base,"
   A tool box includes a plurality of hooks and a plurality of clamping members extending from a surface of the tool box. The hooks and the clamping members are located in alignment with each other so that shanks of the tool is clamped by the clamping members and the function end is engaged with the hooks. A test device is connected to the surface of the tool box and includes an inclined support member on which an engaging piece is connected for function end of the wrench to engage with. A restriction frame is on the test device and restrain the range of the shank of the tool to swing. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/090-740-022-781-011,Patent Application,yes,5,7,4,4,0,B25H3/003;;B25H3/003,B25H3/00,206/373,0,0,,,,EXPIRED
85,US,A1,US 2003/0230173 A1,090-581-077-595-448,2003-12-18,2003,US 17285702 A,2002-06-17,US 17285702 A,2002-06-17,Wrench for selectively driving in one of two opposite directions,"
   A wrench includes a hollow head, a ring received in the hollow head for rotation, first and second brake shoes received in the hollow head for pivoting and a direction controller received in the hollow head between the brake shoes and pivoted between first and second positions. In the first position, the first brake shoe contacts the ring. When rotation of the hollow head relative to the ring in a first direction is attempted, pivoting of the first brake shoe is allowed, thus allowing rotation of the hollow head relative to the ring. When rotation of the hollow head relative to the ring in a second direction is attempted, the direction controller hinders pivoting of the first brake shoe so as to avoid rotation of the hollow head relative to the ring. In the second position, the second brake shoe contacts the ring. When rotation of the hollow head relative to the ring in the second direction is attempted, pivoting of the second brake shoe is allowed, thus allowing rotation of the hollow head relative to the ring. When rotation of the hollow head relative to the ring in the first direction is attempted, the direction controller hinders pivoting of the second brake shoe so as to avoid rotation of the hollow head relative to the ring. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/090-581-077-595-448,Patent Application,yes,6,0,1,1,0,B25B13/462;;B25B13/462,B25B13/46,81/58,0,0,,,,DISCONTINUED
86,DE,A1,DE 102008003655 A1,120-930-764-081-579,2008-12-18,2008,DE 102008003655 A,2008-01-09,TW 96120999 A,2007-06-11,Schraubenschlüssel mit Schalteinrichtung zum Umschalten der Drehrichtung,"Ein Schraubenschlüssel (10) mit einem Schaltmittel (20) zum Einstellen der Drehrichtung umfasst einen Handgriff (11), einen Kopf (12), der sich von einem Ende des Handgriffs aus erstreckt und einen ersten Raum (120) zur Aufahme eines Antriebselements (13) umfasst, einen zweiten Raum (121), der an einer Seite des ersten Raums benachbart dem Handgriff angeordnet ist und geeignet ist, wenigstens ein Paar von Sperrklinken aufzunehmen, und zwei zweite Begrenzungsabschnitte (122), die an der Oberseite und Unterseite des Schraubenschlüssels ausgebildet sind. Das Schaltmittel (20) umfasst zwei Knöpfe (21), die in den zweiten Begrenzungsabschnitten (122) jeweils angeordnet sind, ein Verbindungsmittel A, das im Schraubenschlüssel zur elastischen Verbindung miteinander vorgesehen ist.",INFAR IND CO LTD,CHEN TERENCE,,https://lens.org/120-930-764-081-579,Patent Application,no,0,0,4,4,0,B25B13/463,B25B13/46,,0,0,,,,DISCONTINUED
87,US,B2,US 7648029 B2,136-333-445-062-536,2010-01-19,2010,US 80820107 A,2007-06-07,US 80820107 A,2007-06-07,Simplified rotatable anti-theft tool rack,"A simplified rotatable anti-theft tool rack comprises a tool rack body and an inserting body that cooperate with each other to position a tool. The tool rack body includes a limiting portion used to receive an inserting portion of the head of the tool and connected with a guiding portion. At the end of the guiding portion is disposed with a fastening portion for restricting the tool by cooperating with a fixing element. The inserting body includes a multangular engaging portion. One end of the engaging portion is disposed with a stopping flange, and the other end of the engaging portion is extended to form a neck-shaped inserting portion. At the end of the inserting portion which has inserted through the limiting portion is formed a big-diameter check portion, thus forming a simplified structure, achieving the anti-theft and rotatable effect.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/136-333-445-062-536,Granted Patent,yes,9,13,2,2,0,A47F5/0006;;A47F5/0006;;A47F7/0021;;A47F7/0021;;Y10S206/806,B65D75/56,206/376;;206/806;;211/70.6,0,0,,,,ACTIVE
88,US,A1,US 2005/0126346 A1,165-185-499-993-942,2005-06-16,2005,US 5096905 A,2005-02-04,US 5096905 A;;US 39616703 A,2003-03-24,Wrench assembly,"A wrench assembly consists of a handle and a wrench. The handle includes a head. The wrench includes a first gear non-rotationally put in the head of the handle, a second gear rotationally installed in the first gear for engagement with a tool bit and a one-way driving device arranged between the first gear and the second gear so that the first gear can drive the second gear in a direction through the one-way driving device.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/165-185-499-993-942,Patent Application,yes,13,1,2,6,0,B25B13/462;;B25B13/463;;Y10T403/57;;Y10T403/57;;B25B13/462;;B25B13/463,B25B13/46,81/60,0,0,,,,EXPIRED
89,US,A1,US 2004/0099621 A1,171-410-351-901-680,2004-05-27,2004,US 33574203 A,2003-01-02,TW 91219051 U,2002-11-22,Hanger for wrench,"
   A hanger for holding a wrench includes a board, a first holder and a second holder. The first holder includes an external side pivotally mounted on the board, an internal side defining a recess for receiving a portion of the wrench and a rear side formed with at least one protrusion. The second holder includes an external side pivotally mounted on the board, an internal side defining a recess for holding another portion of the wrench and a rear side formed with at least one protrusion. When the first and second holders are pivoted from each other to a limit, the at least one protrusion of the first holder abuts against the rear face of the second holder and the at least one protrusion of the second holder abuts against the rear face of the first holder, thus avoiding further pivoting of the first and second holders and from each other. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/171-410-351-901-680,Patent Application,yes,23,7,3,3,0,B65D73/0014;;B65D73/0014;;B25H3/006;;B25H3/006,B25H3/00;;B65D73/00,211/70.6;;206/376,0,0,,,,EXPIRED
90,US,B2,US 7278338 B2,008-909-361-428-017,2007-10-09,2007,US 20683305 A,2005-08-19,TW 93140838 A,2004-12-28,Control device for ratchet wrench,"A ratchet wrench includes a head having an engaging portion for mounting an object and a through hole which includes an engaging inner periphery and a smooth inner periphery, and is closed by a bottom plate with a central hole. A movable member is movably received in the second through hole and includes a driving section and a connection section. An operation portion includes a handle and a mounting portion which has a connection recess so as to be engaged with the connection section of the movable member. The driving section of the movable member is removably engaged with the engaging inner periphery. By moving the movable member relative to the mounting portion, the handle can be selectively rotated freely or co-rotated with the head.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/008-909-361-428-017,Granted Patent,yes,10,15,4,4,0,B25B13/461;;B25G1/063;;Y10T403/32327;;Y10T403/32368;;Y10T403/32327;;Y10T403/32368;;B25G1/063;;B25B13/461,B25B13/00;;B25B23/16;;B25G1/00;;B25G1/02;;F16C1/12;;F16C3/00;;F16C11/00,81/58;;81/58.3;;81/177.6;;81/177.7;;403/92;;403/97,0,0,,,,INACTIVE
91,DE,D1,DE 60310183 D1,011-777-592-688-744,2007-01-18,2007,DE 60310183 T,2003-09-05,US 30802102 A,2002-12-03,Unidirektionaler Ratschenschlüssel,,CHEN TERENCE,CHEN TERENCE,,https://lens.org/011-777-592-688-744,Granted Patent,no,0,0,6,6,0,B25B13/463,B25B13/46,,0,0,,,,EXPIRED
92,US,A1,US 2004/0124106 A1,053-097-271-673-263,2004-07-01,2004,US 36014803 A,2003-02-07,TW 91221426 U,2002-12-26,Tool hanger,"
   A tool hanger includes a body, a tooth formed on the body, a retainer formed on the body so as to define a space between the body and the retainer, a strap extending from the body into the space defined between the body and the retainer, and a plurality of teeth formed on the strap for engagement with the tooth formed on the body. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/053-097-271-673-263,Patent Application,yes,8,10,2,2,0,B25H3/006;;B25H3/006,B25H3/00,206/376,0,0,,,,DISCONTINUED
93,US,S,US D0524613 S,145-162-748-667-201,2006-07-11,2006,US 22564005 F,2005-03-18,US 22564005 F,2005-03-18,Wrench,,CHEN TERENCE,CHEN TERENCE,,https://lens.org/145-162-748-667-201,Design Right,no,0,9,1,1,0,,,0805;;D 8 25;;D8/21,0,0,,,,EXPIRED
94,US,B2,US 6779422 B2,011-611-340-588-229,2004-08-24,2004,US 25459202 A,2002-09-26,TW 91214691 U,2002-09-16,Ratchet wrench that may prevent jamming during operation,"
    A ratchet wrench includes a wrench body, a ratchet wheel, a pawl member, and an elastic member. Thus, when the ratchet wrench jams during operation, the jamming prevention portion may force the pawl member to detach from the ratchet wheel, thereby preventing the ratchet wrench from jamming during operation. In addition, when the pawl member compresses the elastic member to a determined extent, the jamming prevention portion applies a reaction on the wall of the locking recess of the wrench body, so that the pawl member will not compress the elastic member to an excessive extent, thereby preventing from wearing the elastic member. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/011-611-340-588-229,Granted Patent,yes,3,6,3,3,0,B25B13/463;;B25B13/463,B25B13/46,81/60;;81/63;;81/63.2,0,0,,,,EXPIRED
95,EP,B1,EP 1510293 B1,105-323-957-639-630,2008-05-28,2008,EP 03019148 A,2003-08-25,EP 03019148 A,2003-08-25,Ratchet wrench,,CHEN TERENCE,CHEN TERENCE,,https://lens.org/105-323-957-639-630,Granted Patent,yes,10,0,3,3,0,B25B13/463,B25B13/46,,0,0,,,,EXPIRED
96,US,B2,US 6827210 B2,165-013-909-837-31X,2004-12-07,2004,US 30318502 A,2002-11-25,US 30318502 A,2002-11-25,Tool hanger with locking device,"
    A hanger includes a first board, a second board foldable to the first board for retaining a tool between them and a locking device for locking the second board to the first board. The locking device includes a first flexible strip extending from the first or second board and a second flexible strip extending from the first or second board. A plurality of ratchets is formed on the first flexible strip. A sleeve is formed on the second flexible strip. A ratchet is formed on an internal face of the sleeve. The first flexible strip can be inserted in the sleeve so that one of the ratchets formed on the first flexible strip is engaged with the ratchet formed on the second flexible strip. The locking device includes two slots defined in the second or first board for receiving the first and second flexible strips. The first or second board defines at least one slot, and the second or first board includes at least one hook for insertion through the at least one slot for engagement with first or second board. The first board defines a recess, and the second board defines a recess, the recesses together make a space for holding the tool when the second board is folded to the first board. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/165-013-909-837-31X,Granted Patent,yes,4,31,2,2,0,A45F2200/0575;;A45F2200/0575;;B65D73/00;;B65D73/00;;Y10S206/806;;Y10S206/806,B65D73/00,206/349;;206/376;;206/495;;206/806,0,0,,,,EXPIRED
97,US,A1,US 2009/0007731 A1,158-389-944-036-739,2009-01-08,2009,US 77248207 A,2007-07-02,US 77248207 A,2007-07-02,FIXING STRUCTURE OF DIRECTION SWITCH BUTTON FOR REVERSIBLE WRENCH,"The present invention refers to a fixing structure of direction switch buttons for a reversible wrench, in which a wrench is equipped with two direction switch buttons on the driving portion, button-restricting portions and location-restricting portions relative to the driving portion. The two direction switch buttons are arranged inside the driving portion by the method of insertion. Moreover, a button-fixing device is provided between the two direction switch buttons, the button-fixing device mainly includes an actuating member and a restoring member. The two ends of the actuating member are wedged into the two direction switch buttons respectively to drive the two direction switch buttons simultaneously. In addition, the actuating member is able to move elastically between the two direction switch buttons by means of the restoring member so as to connect the two direction switch buttons elastically. The objectives of fast connection, exact positioning and simultaneous actuation are achieved.",INFAR IND CO LTD,CHEN TERENCE,INFAR INDUSTRIAL CO. LTD (2007-06-27),https://lens.org/158-389-944-036-739,Patent Application,yes,5,9,4,4,0,B25B13/463;;B25B13/463,B25B13/46,81/62,0,0,,,,ACTIVE
98,US,B2,US 6971285 B2,199-522-480-174-267,2005-12-06,2005,US 73338203 A,2003-12-12,TW 92130014 A,2003-10-29,Selective one-way wrench,"In a selective one-way wrench, a handle projects from an annular head. The annular head defines a first space and a second space communicated with the first space. A gear is rotationally put in the first space and includes a toothed external face. A direction controller is put in the second space and includes two pawls and a spring installed between the pawls each including a rod formed thereon and a toothed face. A driver is put rotationally in the second space and includes two fingers selective one of which contacts the rod of selective one of the pawls so as to bring the toothed face of the selected pawl into engagement with the toothed external face of the gear. A direction switch is installed rotationally on the annular head and operably connected with the driver.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/199-522-480-174-267,Granted Patent,yes,1,25,4,4,0,B25B13/463;;B25B13/463,B25B13/46,81/63.1;;81/177.85,0,0,,,,EXPIRED
99,EP,A1,EP 1808270 A1,070-674-130-251-554,2007-07-18,2007,EP 06013156 A,2006-06-26,US 33478006 A,2006-01-17,Selective one-way wrench,"A selective one-way wrench includes a handle (10) and a head (11) from which the handle projects. The head defines a first space (12), a second space (13) in communication with the first space, a third space (14) in communication with the second space and an aperture (15). An annular gear (20) is rotationally positioned in the first space. A direction controller (30) is positioned in the second space. The direction controller includes two pawls (31,32) and a spring (33) installed between the pawls. A direction switch (40) is partially positioned in the third space for engaging selected one of the pawls with the annular gear. The direction switch defines a recess (44). A fastener (18) is driven into the recess of the direction switch through the aperture of the head so as to pivotally install the direction switch on the head.
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/070-674-130-251-554,Patent Application,yes,8,1,2,2,0,B25B13/463;;B25B13/463,B25B13/46,,0,0,,,,DISCONTINUED
100,US,B2,US 7661337 B2,107-816-174-622-443,2010-02-16,2010,US 77248207 A,2007-07-02,US 77248207 A,2007-07-02,Fixing structure of direction switch button for reversible wrench,"A fixing structure of direction switch buttons for a reversible wrench, in which the wrench is equipped with two direction switch buttons on a driving portion of the wrench. The wrench includes button-restricting portions and location-restricting portions relative to the driving portion. The two direction switch buttons can be inserted and arranged inside the driving portion. Moreover, a button-fixing device is provided between the two direction switch buttons, the button-fixing device includes an actuating member and a restoring member. The two ends of the actuating member are wedged into the two direction switch buttons respectively so that the two direction switch buttons are driven simultaneously. The actuating member is able to move elastically between the two direction switch buttons by the restoring member so as to connect the two direction switch buttons elastically.",INFAR IND CO LTD,CHEN TERENCE,INFAR INDUSTRIAL CO. LTD (2007-06-27),https://lens.org/107-816-174-622-443,Granted Patent,yes,5,14,4,4,0,B25B13/463;;B25B13/463,B25B13/46,81/62;;81/63.1;;81/63,0,0,,,,ACTIVE
101,US,B2,US 6981434 B2,134-414-694-237-183,2006-01-03,2006,US 85434404 A,2004-05-27,US 85434404 A;;US 42811403 A,2003-05-02,Reinforcement structure for wrench head,A wrench includes a head with an engaging wheel rotatably received in a through hole in the head and a recess is defined in an inner periphery of the through hole so as to receive two pawls therein. A recessed area is defined in a surface of the head and a bridge portion is located between the through hole and the recessed area. A space is defined in an underside of the bridge portion and in communication with the through hole. Each pawl has a protrusion and the space allows the protrusions of the pawl to be inserted in the recess without any orientation adjustment. A control member is rotatably received in the recessed area and has a concavity for retaining the two protrusions therein.,CHEN TERENCE,CHEN TERENCE,,https://lens.org/134-414-694-237-183,Granted Patent,yes,3,37,2,2,0,B25B13/463;;B25B13/463,B25B13/46,81/63.1;;81/58;;81/60;;192/43.1,0,0,,,,EXPIRED
102,US,B2,US 6964216 B2,166-039-784-173-709,2005-11-15,2005,US 72423103 A,2003-12-01,TW 92130012 A,2003-10-29,Selective one-way wrench,"A selective one-way wrench includes a handle, an annular head, a gear, a direction controller and a direction switch. The handle projects from an annular head. The annular head defines a first space and a second space communicated with the first space. The gear is rotationally put in the first space. The gear includes a toothed external face. A direction controller is put in the second space. The direction controller includes two pawls and a spring installed between the pawls. Each of the pawls includes a toothed face. The direction switch includes a first element installed rotationally on the handle and a second element put in the second space and operably connected with the first element for bringing the toothed face of selective one of the pawls into engagement with the toothed external face of the annular gear.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/166-039-784-173-709,Granted Patent,yes,2,17,4,4,0,B25B13/463;;B25B13/463,B25B13/46,81/63.1,0,0,,,,EXPIRED
103,US,B2,US 6837382 B2,043-883-683-639-577,2005-01-04,2005,US 30774102 A,2002-12-02,TW 91218039 U,2002-11-07,Hanger for wrenches,"A hanger includes a board and a cover for covering the board. The board includes at least one recess defined in a front face for receiving a wrench, at least one holder elastically and pivotally mounted in the at least one recess for holding the wrench, and two holes each defined in a side. The cover includes two hooks formed thereon for insertion in the holes for retaining the board engaged with the cover. The at least one holder includes a stop formed thereon for restricting the wrench. The at least one recess is defined between two sidewalls one of which defines a hole in which the at least one holder is located. The hole defined in the one of the sidewalls includes an upper edge and a lower edge. The at least one holder includes an upper edge connected with the upper edge of the hole defined in the one of the sidewalls and a lower edge connected with lower edge of the hole defined in the one of the sidewalls. The hanger includes a joint formed between the upper edge of the at least one holder and the upper edge of the hole defined in the one of the sidewalls. The hanger includes a joint formed between the lower edge of the at least one holder and the lower edge of the hole defined in the one of the sidewalls.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/043-883-683-639-577,Granted Patent,yes,7,13,3,3,0,B25H3/04;;B25H3/04,B25H3/04,211 706,0,0,,,,EXPIRED
104,US,A1,US 2005/0092135 A1,100-146-666-666-325,2005-05-05,2005,US 72423103 A,2003-12-01,TW 92130012 A,2003-10-29,Selective one-way wrench,"A selective one-way wrench includes a handle, an annular head, a gear, a direction controller and a direction switch. The handle projects from an annular head. The annular head defines a first space and a second space communicated with the first space. The gear is rotationally put in the first space. The gear includes a toothed external face. A direction controller is put in the second space. The direction controller includes two pawls and a spring installed between the pawls. Each of the pawls includes a toothed face. The direction switch includes a first element installed rotationally on the handle and a second element put in the second space and operably connected with the first element for bringing the toothed face of selective one of the pawls into engagement with the toothed external face of the annular gear.",CHEN TERENCE,CHEN TERENCE,,https://lens.org/100-146-666-666-325,Patent Application,yes,2,12,4,4,0,B25B13/463;;B25B13/463,B25B13/46,81/63.1,0,0,,,,EXPIRED
105,US,A1,US 2004/0226415 A1,146-746-298-888-677,2004-11-18,2004,US 45424503 A,2003-06-05,TW 92113014 A,2003-05-14,Apparatus for firmly connecting wrench with socket,"
   An apparatus is provided for connecting an annular gear of a wrench with a socket. The apparatus includes a joint and a C-ring. The joint includes a first insert for insertion in the annular gear, a second insert extending from the first insert for insertion in the socket and a neck formed at the first insert. The C-ring includes a middle section, two lateral sections extending from the middle section and two ends each extending from one of the lateral sections. Before the first insert is inserted in the annular gear, the middle section and the ends contact the neck while the lateral sections extend from the neck. 
",CHEN TERENCE,CHEN TERENCE,,https://lens.org/146-746-298-888-677,Patent Application,yes,6,3,2,2,0,B25B13/462;;B25B13/462;;B25B15/001;;B25B15/001;;B25B23/0035;;B25B23/0035,B25B13/46;;B25B15/00;;B25B23/00,81/63.1,0,0,,,,DISCONTINUED
106,CN,C,CN 1332784 C,190-091-118-120-953,2007-08-22,2007,CN 200410083628 A,2004-10-13,US 72423103 A,2003-12-01,Selective one-way wrench,,CHEN TERENCE,CHEN TERENCE,,https://lens.org/190-091-118-120-953,Granted Patent,no,9,1,5,5,0,B25B13/463;;B25B13/463,B25B13/46;;B25B23/00,,0,0,,,,INACTIVE
107,TW,A,TW 200608291 A,193-195-175-578-157,2006-03-01,2006,TW 93126161 A,2004-08-31,TW 93126161 A,2004-08-31,"Circuit simulation method, system and machine-readable storage medium","A circuit simulation method is loaded and executed by a processing unit. The method first receives manufacturing parameter data, geometry data and a status, and inputs in an extreme mismatch model, in which the model comprises at least one simulation configuration instruction for electrical value simulation for the given parameter data, geometry data and status. The method sequentially simulates the extreme mismatch model using a normal simulation method to acquire an extreme electrical value, and outputs the extreme electrical.",AIROHA TECH CORP,CHANG HSIN-LAN;;CHEN TERENCE,,https://lens.org/193-195-175-578-157,Patent of Addition,no,0,0,2,2,0,G06F30/367;;G06F30/367,,,0,0,,,,PENDING
108,US,B1,US 10082530 B1,052-186-195-319-796,2018-09-25,2018,US 201314102431 A,2013-12-10,US 201314102431 A,2013-12-10,Method and apparatus for rapid and scalable testing of antennas,"A system and method for testing an antenna feed to be incorporated into an operational antenna is disclosed. The system and method uses a scaled reflector with the antenna feed to permit testing that correlates well with a full sized reflector, yet permits testing in a quiet zone of a compact antenna test range. Embodiments are also disclosed for offset feed designs.",DIRECTV GROUP INC,WU TERENCE;;CHEN ERNEST C,THE DIRECTV GROUP INC (2013-10-29);;DIRECTV LLC (2021-07-28),https://lens.org/052-186-195-319-796,Granted Patent,yes,9,10,1,1,0,G01R29/10;;G01R29/10;;H01Q19/12,G01R29/10;;H01Q19/12,,7,5,050-575-807-626-292;;069-998-804-005-76X;;105-653-321-759-68X;;086-037-813-709-754;;011-894-257-444-112,10.1109/aero.2015.7118963;;10.1049/ip-map:20045132;;10.1109/proc.1973.9358;;10.1109/8.55587;;10.1109/tap.1971.1139876,"Cooley, “Phased Array-Fed Reflector (PAFR) Antenna Architectures for Space-Based Sensors,” Northrop Grumman Electronic Systems, Feb. 2014, 11 pages.;;Hakli et al. “Numerical synthesis method for designing a shaped dual reflector feed system,” IEEE Proc.-Microwave Antennas Propagation, vol. 152, No. 5, Oct. 2005, pp. 311-318.;;Johnson et al. “Determination of Far-Field Antenna Patterns From Near-Field Measurements,” Proceedings of the IEEE, vol. 61, No. 12, Dec. 1973, pp. 1668-1704.;;Lee et al., “Pattern Measurements of Reflector Antennas in the Compact Range and Validation with Computer Code Simulation,” IEEE Transactions on Antennas and Propagation, vol. 38, No. 6, Jun. 1990, pp. 889-895.;;Fournier “Freedom Reflector Design with Extended Sources, A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in CREOL, the College of Optics and Photonics at the University of Central Florida Orlando, Florida, Summer Term 2010, p. 76”.;;Mitchell et al. “Scaling Charcteristics of Inflatable Paraboloid Concentrators, The American Society of Mechanical Engineerings, Solar Engineering, Book No. H00630-1991”.;;Davis et al. “Reflector Efficiency Evaluation by Frequency Scaling” IEEE Transactions on Antennas and Propagation, vol. AP-19, No. 1, Jan. 1971.",ACTIVE
109,WO,A1,WO 2007/021247 A1,018-065-865-807-374,2007-02-22,2007,SG 2005000282 W,2005-08-17,SG 2005000282 W,2005-08-17,COMPACT ANTENNAS FOR ULTRA-WIDEBAND APPLICATIONS,"The antenna (100) has a radiating element (104) for transmitting and receiving signals. The radiating element (104) comprises a first portion (110), a second portion (112) and a notch (114). The notch (114) extends from a portion o the periphery of the radiating element into the radiating element and is for substantially segregating the radiating element into the first portion (110) and the second portion (112). The radiating element (104) also has an interconnecting portion (108) for structurally interconnecting the first portion and the second portion. The interconnecting portion is formed substantially distal to the portion of the periphery of the radiating element. In addition, the antenna (100) has a first arm (116) that extends from the first portion of the radiating element for modifying the operating frequency range of the antenna.",AGENCY SCIENCE TECH & RES;;CHEN ZHINING;;SEE SHIE PING TERENCE,CHEN ZHINING;;SEE SHIE PING TERENCE,,https://lens.org/018-065-865-807-374,Patent Application,yes,0,6,5,5,0,H01Q1/38;;H01Q1/38;;H01Q5/371;;H01Q5/371;;H01Q9/40;;H01Q9/40,H01Q9/00;;H01Q13/08,,3,0,,,PATENT ABSTRACTS OF JAPAN;;PATENT ABSTRACTS OF JAPAN;;PATENT ABSTRACTS OF JAPAN,PENDING
110,WO,A1,WO 2009/048428 A1,188-705-999-815-852,2009-04-16,2009,SG 2008000388 W,2008-10-09,US 97842907 P,2007-10-09,ANTENNAS FOR DIVERSITY APPLICATIONS,"An antenna for ultra-wideband applications is disclosed. The antenna has a first radiating element shaped for defining a first notch, the first radiating element having a first feeding structure. The antenna further has a second radiating element operatively couplable to the first radiating element and shaped for defining a second notch. The second radiating element having a second feeding structure, the first and second feeding structures being substantially orthogonal to each other and the first and second radiating elements having an inter-displacement. More specifically, the first radiating element and the first feeding structure is substantially symmetrical to the second radiating element and the second feeding structure respectively about a line of symmetry passing through the inter-displacement between the first and second radiating elements for achieving orthogonal polarization and radiating pattern diversity between the first and second radiating elements.",AGENCY SCIENCE TECH & RES;;SEE SHIE PING TERENCE;;CHEN ZHINING,SEE SHIE PING TERENCE;;CHEN ZHINING,,https://lens.org/188-705-999-815-852,Patent Application,yes,6,0,2,2,0,H01Q9/0435;;H01Q21/24;;H01Q21/29;;H01Q21/29;;H01Q9/0435;;H01Q21/24,H01Q13/10;;H01Q1/38;;H01Q21/24;;H01Q21/29,,0,0,,,,PENDING
111,US,A1,US 2010/0295750 A1,096-417-555-291-259,2010-11-25,2010,US 73408308 A,2008-10-09,US 73408308 A;;US 97842907 P;;SG 2008000388 W,2007-10-09,ANTENNA FOR DIVERSITY APPLICATIONS,"An antenna for ultra-wideband applications is disclosed. The antenna has a first radiating element shaped for defining a first notch, the first radiating element having a first feeding structure. The antenna further has a second radiating element operatively couplable to the first radiating element and shaped for defining a second notch. The second radiating element having a second feeding structure, the first and second feeding structures being substantially orthogonal to each other and the first and second radiating elements having an inter-displacement. More specifically, the first radiating element and the first feeding structure is substantially symmetrical to the second radiating element and the second feeding structure respectively about a line of symmetry passing through the inter-displacement between the first and second radiating elements for achieving orthogonal polarization and radiating pattern diversity between the first and second radiating elements.",AGENCY SCIENCE TECH & RES,SEE SHIE PING TERENCE;;CHEN ZHINING,AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH (2010-04-29),https://lens.org/096-417-555-291-259,Patent Application,yes,6,24,2,2,0,H01Q9/0435;;H01Q21/24;;H01Q21/29;;H01Q21/29;;H01Q9/0435;;H01Q21/24,H01Q21/24,343/893,0,0,,,,DISCONTINUED
112,US,A1,US 2008/0316108 A1,114-756-837-830-158,2008-12-25,2008,US 6399205 A,2005-08-17,SG 2005000282 W,2005-08-17,Compact Antennas for Ultra-Wideband Applications,"The antenna ( 100 ) has a radiating element ( 104 ) for transmitting and receiving signals. The radiating element ( 104 ) comprises a first portion ( 110 ), a second portion ( 112 ) and a notch ( 114 ). The notch ( 114 ) extends from a portion o the periphery of the radiating element into the radiating element and is for substantially segregating the radiating element into the first portion ( 110 ) and the second portion ( 112 ). The radiating element ( 104 ) also has an interconnecting portion ( 108 ) for structurally interconnecting the first portion and the second portion. The interconnecting portion is formed substantially distal to the portion of the periphery of the radiating element. In addition, the antenna ( 100 ) has a first arm ( 116 ) that extends from the first portion of the radiating element for modifying the operating frequency range of the antenna.",AGENCY SCIENCE TECH & RES,CHEN ZHINING;;SEE SHIE PING TERENCE,AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH (2008-05-08),https://lens.org/114-756-837-830-158,Patent Application,yes,0,6,5,5,0,H01Q1/38;;H01Q1/38;;H01Q5/371;;H01Q5/371;;H01Q9/40;;H01Q9/40,H01Q9/04,343700MS,0,0,,,,INACTIVE
113,WO,A1,WO 2008/156429 A1,073-865-232-427-320,2008-12-24,2008,SG 2008000216 W,2008-06-19,US 92924507 P,2007-06-19,BROADBAND ANTENNA FOR WIRELESS COMMUNICATIONS,"An antenna formable on a ground plane for wireless communications is disclosed. The antenna has a first structure spatially displaced from a ground plane. The antenna also has a second structure coupled to the first structure and extending away from the ground plane. The antenna further has a third structure configured for disposing at least a portion of the first structure between the third structure and the ground plane, the third structure being grounded to the ground plane and being spatially displaced from the second structure, the second structure and the third structure being inter-configured for electromagnetic coupling therebetween for forming a magnetic loop. More specifically, electromagnetic field generated by the first structure and the second structure electromagnetically couples the third structure for inducing generation of broadband electromagnetic waves from the first, second and third structures.",AGENCY SCIENCE TECH & RES;;SEE SHIE PING TERENCE;;CHEN ZHINING,SEE SHIE PING TERENCE;;CHEN ZHINING,,https://lens.org/073-865-232-427-320,Patent Application,yes,3,7,2,2,0,H01Q21/205;;H01Q21/205;;H01Q1/2291;;H01Q1/2291;;H01Q5/25;;H01Q5/25;;H01Q9/0421;;H01Q9/0421;;H01Q9/0457;;H01Q9/0457;;Y10T29/49016;;Y10T29/49016,H01Q1/38,,3,2,144-821-796-858-395;;022-712-762-990-834,10.1109/lawp.2003.822211;;10.1109/tap.2007.898575,"CETINER ET AL.: ""Small - Size Broadband Multi-Element Antenna For RF/Wireless Systems"", IEEE ANTENNAS AND WIRELESS PROPAGATION, LETTERS, vol. 2, 2003;;CHEN ET AL.: ""Low - Profile Embedded Ultra - Wideband Antennas For Portable Devices"", PROCEEDINGS 'EU-CAP 2005', NICE, FRANCE, 6 November 2006 (2006-11-06) - 10 November 2006 (2006-11-10);;RUVIO G. ET AL.: ""Wideband Reconfigurable Rolled Planar Monopole Antenna"", IEEE TRANSACTIONS ON ANTENNAS AND PROPAGATION, vol. 55, no. 6, June 2007 (2007-06-01), pages 1760 - 1767, XP011185372",PENDING
114,US,B2,US 7855686 B2,030-241-480-422-179,2010-12-21,2010,US 6399205 A,2005-08-17,SG 2005000282 W,2005-08-17,Compact antennas for ultra-wideband applications,"The antenna ( 100 ) has a radiating element ( 104 ) for transmitting and receiving signals. The radiating element ( 104 ) comprises a first portion ( 110 ), a second portion ( 112 ) and a notch ( 114 ). The notch ( 114 ) extends from a portion o the periphery of the radiating element into the radiating element and is for substantially segregating the radiating element into the first portion ( 110 ) and the second portion ( 112 ). The radiating element ( 104 ) also has an interconnecting portion ( 108 ) for structurally interconnecting the first portion and the second portion. The interconnecting portion is formed substantially distal to the portion of the periphery of the radiating element. In addition, the antenna ( 100 ) has a first arm ( 116 ) that extends from the first portion of the radiating element for modifying the operating frequency range of the antenna.",AGENCY SCIENCE TECH & RES,CHEN ZHINING;;SEE SHIE PING TERENCE,AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH (2008-05-08),https://lens.org/030-241-480-422-179,Granted Patent,yes,6,3,5,5,0,H01Q1/38;;H01Q1/38;;H01Q5/371;;H01Q5/371;;H01Q9/40;;H01Q9/40,H01Q1/24,343700MS;;343/846,0,0,,,,INACTIVE
115,US,B1,US 10381346 B1,054-189-378-984-306,2019-08-13,2019,US 201815879181 A,2018-01-24,US 201815879181 A,2018-01-24,Logic gate designs for 3D monolithic direct stacked VTFET,"Logic gate designs (e.g., NAND, NOR, Inverter) for stacked VTFET designs are provided. In one aspect, a logic gate device is provided. The logic gate device includes: at least one top vertical transport field-effect transistor (VTFET 1 ) sharing a fin with at least one bottom VTFET (VTFET 2 ); a power rail connected to a power contact of the logic gate device; and a ground rail, adjacent to the power rail, connected to a ground contact of the logic gate device. A method of forming a logic gate device is also provided.",IBM,ZHANG CHEN;;YAMASHITA TENKO;;HOOK TERENCE B,INTERNATIONAL BUSINESS MACHINES CORPORATION (2018-01-19),https://lens.org/054-189-378-984-306,Granted Patent,yes,13,3,4,4,0,H03K19/215;;H03K19/0948;;H03K19/20;;H01L27/0207;;H01L27/092;;H01L27/0688;;H01L21/823885;;H01L21/823871;;H01L21/8221;;H01L29/66666;;H01L29/7827;;H01L29/78642;;H01L21/743;;H01L23/5286;;H01L27/0688;;H03K19/215;;H01L29/1037;;H01L23/5286;;H01L27/092;;H01L29/0847;;H01L21/823885;;H01L21/84;;H01L21/2255;;H01L21/823871;;H01L29/6656;;H03K19/0948;;H01L27/1203;;H01L21/8221;;H03K19/20;;H01L29/7827;;H01L29/66666;;H01L27/0207,H01L27/06;;H01L21/225;;H01L21/822;;H01L21/8238;;H01L21/84;;H01L23/528;;H01L27/092;;H01L27/12;;H01L29/08;;H01L29/10;;H01L29/66;;H01L29/78;;H03K19/0948;;H03K19/20;;H03K19/21,,0,0,,,,INACTIVE
116,US,B2,US 10833069 B2,136-615-786-670-164,2020-11-10,2020,US 201916455665 A,2019-06-27,US 201916455665 A;;US 201815879181 A,2018-01-24,Logic gate designs for 3D monolithic direct stacked VTFET,"Logic gate designs (e.g., NAND, NOR, Inverter) for stacked VTFET designs are provided. In one aspect, a logic gate device is provided. The logic gate device includes: at least one top vertical transport field-effect transistor (VTFET 1 ) sharing a fin with at least one bottom VTFET (VTFET 2 ); a power rail connected to a power contact of the logic gate device; and a ground rail, adjacent to the power rail, connected to a ground contact of the logic gate device. A method of forming a logic gate device is also provided.",IBM,ZHANG CHEN;;YAMASHITA TENKO;;HOOK TERENCE B,INTERNATIONAL BUSINESS MACHINES CORPORATION (2018-01-19),https://lens.org/136-615-786-670-164,Granted Patent,yes,16,1,4,4,0,H03K19/215;;H03K19/0948;;H03K19/20;;H01L27/0207;;H01L27/092;;H01L27/0688;;H01L21/823885;;H01L21/823871;;H01L21/8221;;H01L29/66666;;H01L29/7827;;H01L29/78642;;H01L21/743;;H01L23/5286;;H01L27/0688;;H03K19/215;;H01L29/1037;;H01L23/5286;;H01L27/092;;H01L29/0847;;H01L21/823885;;H01L21/84;;H01L21/2255;;H01L21/823871;;H01L29/6656;;H03K19/0948;;H01L27/1203;;H01L21/8221;;H03K19/20;;H01L29/7827;;H01L29/66666;;H01L27/0207,H01L27/06;;H01L21/225;;H01L21/822;;H01L21/8238;;H01L21/84;;H01L23/528;;H01L27/02;;H01L27/092;;H01L27/12;;H01L29/08;;H01L29/10;;H01L29/66;;H01L29/78;;H01L29/786;;H03K19/0948;;H03K19/20;;H03K19/21,,1,0,,,List of IBM Patents or Applications Treated as Related (2 pages).,ACTIVE
117,US,A1,US 2019/0326279 A1,090-305-471-990-525,2019-10-24,2019,US 201916455665 A,2019-06-27,US 201916455665 A;;US 201815879181 A,2018-01-24,Logic Gate Designs for 3D Monolithic Direct Stacked VTFET,"Logic gate designs (e.g., NAND, NOR, Inverter) for stacked VTFET designs are provided. In one aspect, a logic gate device is provided. The logic gate device includes: at least one top vertical transport field-effect transistor (VTFET 1 ) sharing a fin with at least one bottom VTFET (VTFET 2 ); a power rail connected to a power contact of the logic gate device; and a ground rail, adjacent to the power rail, connected to a ground contact of the logic gate device. A method of forming a logic gate device is also provided",IBM,ZHANG CHEN;;YAMASHITA TENKO;;HOOK TERENCE B,INTERNATIONAL BUSINESS MACHINES CORPORATION (2018-01-19),https://lens.org/090-305-471-990-525,Patent Application,yes,3,2,4,4,0,H03K19/215;;H03K19/0948;;H03K19/20;;H01L27/0207;;H01L27/092;;H01L27/0688;;H01L21/823885;;H01L21/823871;;H01L21/8221;;H01L29/66666;;H01L29/7827;;H01L29/78642;;H01L21/743;;H01L23/5286;;H01L27/0688;;H03K19/215;;H01L29/1037;;H01L23/5286;;H01L27/092;;H01L29/0847;;H01L21/823885;;H01L21/84;;H01L21/2255;;H01L21/823871;;H01L29/6656;;H03K19/0948;;H01L27/1203;;H01L21/8221;;H03K19/20;;H01L29/7827;;H01L29/66666;;H01L27/0207,H01L27/06;;H01L21/225;;H01L21/822;;H01L21/8238;;H01L21/84;;H01L23/528;;H01L27/092;;H01L27/12;;H01L29/08;;H01L29/10;;H01L29/66;;H01L29/78;;H03K19/0948,,0,0,,,,ACTIVE
118,TW,A,TW 200715655 A,056-196-324-329-582,2007-04-16,2007,TW 95130354 A,2006-08-17,SG 2005000282 W,2005-08-17,Compact antennas for ultra-wideband applications,"An antenna formable on at least a first surface of a substrate for ultra-wideband applications is disclosed. The antenna has a radiating element for transmitting and receiving signals. The radiating element comprises a first portion, a second portion and a notch. The notch extends from a portion of the periphery of the radiating element into the radiating element and is for substantially segregating the radiating element into the first portion and the second portion. The radiating element also has an interconnecting portion for structurally interconnecting the first portion and the second portion. The interconnecting portion is formed substantially distal to the portion of the periphery of the radiating element. In addition, the antenna has a first arm that extends from the first portion of the radiating element for modifying the operating frequency range of the antenna.",AGENCY SCIENCE TECH & RES,CHEN ZHI-NING;;SEE SHIE-PING TERENCE,,https://lens.org/056-196-324-329-582,Patent of Addition,no,0,1,5,5,0,H01Q1/38;;H01Q1/38;;H01Q5/371;;H01Q5/371;;H01Q9/40;;H01Q9/40,H01Q9/16,,0,0,,,,PENDING
119,TW,U,TW M439974 U,106-966-528-485-528,2012-10-21,2012,TW 101211639 U,2012-06-15,CN 201220267723 U,2012-06-07,Display and frame structure thereof,,WISTRON CORP,WU LI-CHEN;;JIA TERENCE;;SU SILEN,,https://lens.org/106-966-528-485-528,Limited Patent,no,0,0,2,2,0,,,,0,0,,,,EXPIRED
120,US,A1,US 2019/0229117 A1,029-935-368-938-539,2019-07-25,2019,US 201815879181 A,2018-01-24,US 201815879181 A,2018-01-24,Logic Gate Designs for 3D Monolithic Direct Stacked VTFET,"Logic gate designs (e.g., NAND, NOR, Inverter) for stacked VTFET designs are provided. In one aspect, a logic gate device is provided. The logic gate device includes: at least one top vertical transport field-effect transistor (VTFET 1 ) sharing a fin with at least one bottom VTFET (VTFET 2 ); a power rail connected to a power contact of the logic gate device; and a ground rail, adjacent to the power rail, connected to a ground contact of the logic gate device. A method of forming a logic gate device is also provided",IBM,ZHANG CHEN;;YAMASHITA TENKO;;HOOK TERENCE B,INTERNATIONAL BUSINESS MACHINES CORPORATION (2018-01-19),https://lens.org/029-935-368-938-539,Patent Application,yes,0,7,4,4,0,H03K19/215;;H03K19/0948;;H03K19/20;;H01L27/0207;;H01L27/092;;H01L27/0688;;H01L21/823885;;H01L21/823871;;H01L21/8221;;H01L29/66666;;H01L29/7827;;H01L29/78642;;H01L21/743;;H01L23/5286;;H01L27/0688;;H03K19/215;;H01L29/1037;;H01L23/5286;;H01L27/092;;H01L29/0847;;H01L21/823885;;H01L21/84;;H01L21/2255;;H01L21/823871;;H01L29/6656;;H03K19/0948;;H01L27/1203;;H01L21/8221;;H03K19/20;;H01L29/7827;;H01L29/66666;;H01L27/0207,H01L27/06;;H01L21/225;;H01L21/822;;H01L21/8238;;H01L21/84;;H01L23/528;;H01L27/092;;H01L27/12;;H01L29/08;;H01L29/10;;H01L29/66;;H01L29/78;;H03K19/0948,,0,0,,,,INACTIVE
121,CN,A,CN 116216978 A,053-089-579-883-849,2023-06-06,2023,CN 202310003006 A,2023-01-03,CN 202310003006 A,2023-01-03,Membrane method tap water purification treatment system,"The invention relates to the field of tap water purification, and particularly discloses a membrane method tap water purification treatment system which comprises a raw water tank, a flocculation device, an ultrafiltration membrane device, a disinfection device and a water storage tank which are sequentially connected, the flocculation device comprises a flocculation barrel and a disturbance plate, a rotating base shaft is rotationally connected into the flocculation barrel, and a driving device is arranged on the flocculation barrel; at least two pairs of disturbance plates are arranged on the rotating base shaft, a rotation driving assembly is arranged on the rotating base shaft, and the inner circumferential wall of the flocculation barrel and the outer circumferential wall of the rotating base shaft are both attached to the end walls of the disturbance plates; a plurality of disturbance through grooves are formed in the disturbance plate in a penetrating mode, a flocculate filter screen and a closing plate are movably arranged on the disturbance base plate, and a driving assembly is arranged on the disturbance base plate; a flocculate discharging assembly is arranged on the flocculation barrel, a water discharging assembly and a water inlet assembly are further arranged on the flocculation barrel, the water inlet assembly is connected with the raw water tank, and the water discharging assembly is connected with the ultrafiltration membrane device. According to the invention, the flocculate sedimentation efficiency can be improved, so that the tap water purification efficiency is improved.",JIANGSU BOHN ENV ENGINEERING WHOLE SET EQUIPMENT CO LTD,LIU YUAN;;CHEN FUQIANG;;WONG KA CHEONG TERENCE,,https://lens.org/053-089-579-883-849,Patent Application,no,0,0,1,1,0,C02F9/00;;C02F2103/02;;C02F1/5281;;C02F1/444;;C02F1/001;;C02F1/325;;C02F2303/04;;Y02A20/131,C02F9/00;;C02F1/00;;C02F1/32;;C02F1/44;;C02F1/52;;C02F103/02,,0,0,,,,PENDING
122,CN,A,CN 116747522 A,149-777-905-039-943,2023-09-15,2023,CN 202310826777 A,2023-07-06,CN 202310826777 A,2023-07-06,"Static scene detection method and device, electronic equipment and readable storage medium","The invention provides a static scene detection method and apparatus, an electronic device and a readable storage medium. The method comprises the steps of obtaining a to-be-detected static scene; generating a reachable point position set corresponding to the static scene according to a preset initial point position; wherein the reachable point location set comprises a plurality of reachable point locations communicated with the preset initial point location; controlling a virtual character to move in the static scene according to the reachable point position set so as to collect a performance data set of each reachable point position in the reachable point position set; and determining a performance detection result corresponding to the static scene based on the performance data set at each reachable point location. According to the method, the performance data of the static scene can be automatically and accurately acquired, the time cost and the labor cost consumed by acquiring the performance data are remarkably reduced, and the accuracy of performing performance detection on the static scene is effectively improved.",SHANGHAI WANGZHIYI CUICAN NETWORK TECH CO LTD,SOH WOON LIANG TERENCE;;LIAO LIUTIAN;;CHEN JUNYONG,,https://lens.org/149-777-905-039-943,Patent Application,no,0,0,1,1,0,A63F13/56;;A63F13/52,A63F13/56;;A63F13/52,,0,0,,,,PENDING
123,EP,A1,EP 2966590 A1,171-233-822-418-536,2016-01-13,2016,EP 15169123 A,2015-05-26,US 201414324797 A,2014-07-07,LANE LEVEL TRAFFIC,"Lane level traffic levels are determined based on traffic camera images. A controller aligns a three-dimensional map with a traffic camera view, and identifies multiple lanes in the traffic camera view based on lane delineations of the three-dimensional map. The controller calculates a traffic parameter based on the multiple lanes in image frames from the traffic camera view and provides a traffic graphic based on the traffic parameter.",HERE GLOBAL BV,CHEN XIN;;MA XIANG;;OSTROVSKIY ROMAN;;ZHAO TERENCE,HERE GLOBAL B.V. (2016-06-22),https://lens.org/171-233-822-418-536,Patent Application,yes,0,1,6,6,0,G06V20/54;;G06V20/647;;G06V10/74;;G06Q10/063;;G06Q50/40;;G08G1/0104;;G06T17/05;;G06V20/56;;G06V20/54,G06K9/00,,6,5,061-420-565-903-228;;077-627-065-875-215;;000-122-946-719-709;;012-092-692-833-982;;128-642-223-693-171,10.1109/tits.2003.821213;;10.1109/icsmc.2006.385034;;10.1007/s00138-011-0404-2;;10.1109/ivs.2008.4621318;;10.1016/s0262-8856(03)00004-0,"DAILEY D J ET AL: ""Dynamic camera calibration of roadside traffic management cameras for vehicle speed estimation"", IEEE TRANSACTIONS ON INTELLIGENT TRANSPORTATION SYSTEMS, IEEE, PISCATAWAY, NJ, USA, vol. 4, no. 2, 1 June 2003 (2003-06-01), pages 90 - 98, XP011104438, ISSN: 1524-9050, DOI: 10.1109/TITS.2003.821213;;YAO-JAN WU ET AL: ""Traffic Monitoring and Vehicle Tracking using Roadside Cameras"", 2006 IEEE CONFERENCE ON SYSTEMS, MAN, AND CYBERNETICS, 8-11 OCT. 2006, TAIPEI, TAIWAN, IEEE, PISCATAWAY, NJ, USA, 1 October 2006 (2006-10-01), pages 4631 - 4636, XP031117689, ISBN: 978-1-4244-0099-7;;AHARON BAR HILLEL ET AL: ""Recent progress in road and lane detection: a survey"", MACHINE VISION AND APPLICATIONS, vol. 25, no. 3, 1 April 2014 (2014-04-01), pages 727 - 745, XP055113665, ISSN: 0932-8092, DOI: 10.1007/s00138-011-0404-2;;SOREN KAMMEL ET AL: ""Lidar-based lane marker detection and mapping"", INTELLIGENT VEHICLES SYMPOSIUM, 2008 IEEE, IEEE, PISCATAWAY, NJ, USA, 4 June 2008 (2008-06-04), pages 1137 - 1142, XP031318963, ISBN: 978-1-4244-2568-6;;KASTRINAKI V ET AL: ""A survey of video processing techniques for traffic applications"", IMAGE AND VISION COMPUTING, ELSEVIER, GUILDFORD, GB, vol. 21, no. 4, 1 April 2003 (2003-04-01), pages 359 - 381, XP002410024, ISSN: 0262-8856, DOI: 10.1016/S0262-8856(03)00004-0;;ANONYMOUS: ""Camera calibration - Wikipedia, the free encyclopedia"", 5 October 2015 (2015-10-05), XP055230922, Retrieved from the Internet <URL:https://en.wikipedia.org/wiki/Camera_resectioning> [retrieved on 20151124]",ACTIVE
124,EP,B1,EP 2966590 B1,028-472-777-677-777,2023-04-05,2023,EP 15169123 A,2015-05-26,US 201414324797 A,2014-07-07,LANE LEVEL TRAFFIC,,HERE GLOBAL BV,CHEN XIN;;MA XIANG;;OSTROVSKIY ROMAN;;ZHAO TERENCE,HERE GLOBAL B.V. (2016-06-22),https://lens.org/028-472-777-677-777,Granted Patent,yes,0,0,6,6,0,G06V20/54;;G06V20/647;;G06V10/74;;G06Q10/063;;G06Q50/40;;G08G1/0104;;G06T17/05;;G06V20/56;;G06V20/54,G06T17/05;;G06Q50/30;;G06V10/74;;G06V20/54;;G06V20/64,,6,0,,,"DAILEY D J ET AL: ""Dynamic camera calibration of roadside traffic management cameras for vehicle speed estimation"", IEEE TRANSACTIONS ON INTELLIGENT TRANSPORTATION SYSTEMS, IEEE, PISCATAWAY, NJ, USA, vol. 4, no. 2, 1 June 2003 (2003-06-01), pages 90-98, XP011104438, ISSN: 1524-9050, DOI: 10.1109/TITS.2003.821213;;YAO-JAN WU ET AL: ""Traffic Monitoring and Vehicle Tracking using Roadside Cameras"", 2006 IEEE CONFERENCE ON SYSTEMS, MAN, AND CYBERNETICS, 8-11 OCT. 2006, TAIPEI, TAIWAN, IEEE, PISCATAWAY, NJ, USA, 1 October 2006 (2006-10-01), pages 4631-4636, XP031117689, ISBN: 978-1-4244-0099-7;;AHARON BAR HILLEL ET AL: ""Recent progress in road and lane detection: a survey"", MACHINE VISION AND APPLICATIONS, vol. 25, no. 3, 1 April 2014 (2014-04-01), pages 727-745, XP055113665, ISSN: 0932-8092, DOI: 10.1007/s00138-011-0404-2;;SOREN KAMMEL ET AL: ""Lidar-based lane marker detection and mapping"", INTELLIGENT VEHICLES SYMPOSIUM, 2008 IEEE, IEEE, PISCATAWAY, NJ, USA, 4 June 2008 (2008-06-04), pages 1137-1142, XP031318963, ISBN: 978-1-4244-2568-6;;KASTRINAKI V ET AL: ""A survey of video processing techniques for traffic applications"", IMAGE AND VISION COMPUTING, ELSEVIER, GUILDFORD, GB, vol. 21, no. 4, 1 April 2003 (2003-04-01), pages 359-381, XP002410024, ISSN: 0262-8856, DOI: 10.1016/S0262-8856(03)00004-0;;Anonymous: ""Camera calibration - Wikipedia, the free encyclopedia"", , 5 October 2015 (2015-10-05), XP055230922, Retrieved from the Internet: URL:https://en.wikipedia.org/wiki/Camera_r esectioning [retrieved on 2015-11-24]",ACTIVE
125,EP,A1,EP 3379491 A1,186-386-177-258-809,2018-09-26,2018,EP 18157804 A,2018-02-21,GB 201704373 A,2017-03-20,SURFACE DEFECT DETECTION,"A method is provided of forming a neural network for detecting surface defects in aircraft engine components. The method includes: providing (i) a pre-trained deep learning network having, in sequence, an input layer for receiving pixel values of pixelated images of objects, a set of convolutional layers, a set of fully-connected layers, and an output layer, wherein the pre-trained deep learning network has fixed weights and is pre-trained, and (ii) a learning machine network having, in sequence, an input layer, at least one hidden layer, and an output layer, wherein the values of the nodes of the input layer of the learning machine network derive from the values of the nodes of one of the convolutional layers of the pre-trained deep learning network, the weights from at least one of the layers of the learning machine network to the next layer of the learning machine network are trainable but the weights from at least another one of the layers of the learning machine network to the next layer of the learning machine network are fixed, and the nodes of the output layer of the learning machine network indicate whether a given surface defect class is displayed by a given image. The method further includes: providing a set of pixelated training images of aircraft engine components exhibiting examples of different classes of surface defect, the training images being labelled with the surface defect classes exhibited by their respective components such that each class of surface defect is represented by a respective subset of the training images, and each training image being divided into one or more patches which are respective sub-areas of that image. The method further includes: training the trainable weights of the learning machine network on the set of training images by inputting each patch into the input layer of the pre-trained deep learning network and adjusting the trainable weights on the basis of a comparison between the node values of the output layer of the learning machine network and the surface defect class label of the parent training image of that patch. The layers of the pre-trained deep learning network from its input layer to its convolutional layer from which the values of the nodes of the input layer of the learning machine network derive, together with the layers of the learning machine network after the training of its trainable weights form a combined network for detecting surface defects in aircraft engine components having an input layer which is the input layer of the pre-trained deep learning network and an output layer which is the output layer of the learning machine network.",ROLLS ROYCE PLC,REN RUO XU;;HUNG TERENCE;;CHEN TAN-KAY,ROLLS-ROYCE PLC (2020-02-26),https://lens.org/186-386-177-258-809,Patent Application,yes,3,3,5,5,0,G06T7/0004;;G06T2207/20021;;G06T2207/20084;;G06T2207/20081;;G06T2207/30164;;G06T2207/20084;;G06T7/0004;;G06T2207/20021;;G06F18/214;;G06N3/04;;G06N3/084;;G06T7/001;;G06T2207/20081;;G06T2207/30164,G06T7/00,,2,1,036-344-779-686-507,28252414;;10.1109/tcyb.2017.2668395,"RUOXU REN ET AL: ""A Generic Deep-Learning-Based Approach for Automated Surface Inspection"", IEEE TRANSACTIONS ON CYBERNETICS, vol. 48, no. 3, 24 February 2017 (2017-02-24), Piscataway, NJ, USA, pages 929 - 940, XP055492817, ISSN: 2168-2267, DOI: 10.1109/TCYB.2017.2668395;;JEFF DONAHUE ET AL: ""DeCAF: A Deep Convolutional Activation Feature for Generic Visual Recognition"", 5 October 2013 (2013-10-05), XP055326544, Retrieved from the Internet <URL:http://www.jmlr.org/proceedings/papers/v32/donahue14.pdf>",ACTIVE
126,US,A1,US 2018/0268257 A1,054-821-989-237-939,2018-09-20,2018,US 201815925010 A,2018-03-19,GB 201704373 A,2017-03-20,SURFACE DEFECT DETECTION,A method is provided of forming a neural network for detecting surface defects in aircraft engine components. The method includes: providing (i) a pre-trained deep learning network and (ii) a learning machine network; providing a set of pixelated training images of aircraft engine components exhibiting examples of different classes of surface defect; training the trainable weights of the learning machine network on the set of training images.,ROLLS ROYCE PLC,REN RUX XU;;HUNG TERENCE;;TAN KAY CHEN,ROLLS-ROYCE PLC (2017-03-27),https://lens.org/054-821-989-237-939,Patent Application,yes,0,59,5,5,0,G06T7/0004;;G06T2207/20021;;G06T2207/20084;;G06T2207/20081;;G06T2207/30164;;G06T2207/20084;;G06T7/0004;;G06T2207/20021;;G06F18/214;;G06N3/04;;G06N3/084;;G06T7/001;;G06T2207/20081;;G06T2207/30164,G06K9/62;;G06N3/04;;G06N3/08;;G06T7/00,,0,0,,,,ACTIVE
127,US,A1,US 2017/0372148 A1,062-951-007-874-687,2017-12-28,2017,US 201715686297 A,2017-08-25,US 201715686297 A;;US 201414324797 A,2014-07-07,LANE LEVEL TRAFFIC,"Lane level traffic levels are determined based on traffic camera images. A controller aligns a three-dimensional map with a traffic camera view, and identifies multiple lanes in the traffic camera view based on lane delineations of the three-dimensional map. The controller calculates a traffic parameter based on the multiple lanes in image frames from the traffic camera view and provides a traffic graphic based on the traffic parameter.",HERE GLOBAL BV,CHEN XIN;;MA XIANG;;OSTROVSKIY ROMAN;;ZHAO TERENCE,HERE GLOBAL B.V (2014-06-24),https://lens.org/062-951-007-874-687,Patent Application,yes,0,14,6,6,0,G06V20/54;;G06V20/647;;G06V10/74;;G06Q10/063;;G06Q50/40;;G08G1/0104;;G06T17/05;;G06V20/56;;G06V20/54,G06K9/00;;G06T17/05;;G08G1/01,,0,0,,,,ACTIVE
128,US,B2,US 10467502 B2,088-367-631-766-146,2019-11-05,2019,US 201815925010 A,2018-03-19,GB 201704373 A,2017-03-20,Surface defect detection,A method is provided of forming a neural network for detecting surface defects in aircraft engine components. The method includes: providing (i) a pre-trained deep learning network and (ii) a learning machine network; providing a set of pixelated training images of aircraft engine components exhibiting examples of different classes of surface defect; training the trainable weights of the learning machine network on the set of training images.,ROLLS ROYCE PLC,REN RUO XU;;HUNG TERENCE;;TAN KAY CHEN,ROLLS-ROYCE PLC (2017-03-27),https://lens.org/088-367-631-766-146,Granted Patent,yes,17,7,5,5,0,G06T7/0004;;G06T2207/20021;;G06T2207/20084;;G06T2207/20081;;G06T2207/30164;;G06T2207/20084;;G06T7/0004;;G06T2207/20021;;G06F18/214;;G06N3/04;;G06N3/084;;G06T7/001;;G06T2207/20081;;G06T2207/30164,G06K9/00;;G06K9/62;;G06N3/04;;G06N3/08;;G06T7/00,,18,9,061-825-427-815-006;;050-454-692-883-844;;021-026-994-254-143;;175-719-206-467-655;;121-892-685-665-949;;003-545-725-100-842;;170-753-343-936-750;;059-149-073-001-124;;107-730-924-229-003,10.1016/j.eswa.2010.04.082;;10.2991/icismme-15.2015.163;;28113885;;10.1109/tpami.2016.2552172;;27071163;;10.1109/cvpr.2007.383098;;10.1109/cvpr.2010.5540060;;10.1109/cvpr.2014.408;;10.1007/s13042-011-0019-y;;26017442;;10.1038/nature14539;;10.1016/j.neucom.2005.12.126,"Valavanis, et al., “Multiclass defect detection and classification in weld radiographic images using geometric and texture features”, Expert Systems with Applications, vol. 37, pp. 7606-7614, 2010.;;Song, et al., “Wood Materials Defects Detection Using Image Block Percentile Color Histogram and Eigenvector Texture Feature”, International Conference on Information Sciences, Machinery, Materials and Energy (ICISMME 2015), pp. 780-784.;;Silven, et al., “Wood inspection with non-supervised clustering”, Machine Vision and Applications (2003) 13, pp. 275-285, Digital Object Identifier (DOI) 10.1007/s00138-002-0084-z.;;Lu, et al., “Learning from Weak and Noisy Labels for Semantic Segmentation”, IEEE Transactions on Pattern Analysis and Machine Intelligence, vol. 39, No. 3, Mar. 2017, pp. 486-500.;;Verbeek, et al., “Region Classification with Markov Field Aspect Models”, IEEE 1-4244-1180-7/07, 2007.;;Vezhnevets, et al., “Towards Weekly Supervised Semantic Segmentation by Means of Multiple Instance and Multitask Learning”, IEEE 978-4244-6985-7/10, 2010.;;Liu, et al., “Weakly-Supervised Dual Clustering for Image Semantic Segmentation”, NLPR, Institute of Automation, Chinese Academy of Sciences, Beijing, China, 100190.;;Xu, et al., “Tell Me What You See and I Will Show You Where It Is”, IEEE Computer Society Conference on Computer Vision and Pattern Recognition (CVPR), Jun. 2014.;;Chai, et al., “Exploiting Sparsity for Image-Based Object Surface Anomaly Detection”, Rolls-Royce@Nanyang Technological University Corporate Lab, Singapore, IEEE 978-1-4799-9988-01/16, 2016.;;K. Simonyan, et al., “Very Deep Convolutional Networks for Large-Scale Image Recognition”, Visual Geometry Group, Department of Engineering Science, University of Oxford, arXiv technical report, 2014.;;Huang, et al., “Extreme learning machines: a survey”, International J. Machine. Learn. & Cyber, 2, pp. 107-122, 2011.;;LeCun, et al., “Deep learning”, Nature, vol. 521, May 28, 2015.;;Donahue, et al., “DeCAF: A Deep Convolutional Activation Feature for Generic Visual Recognition”, arXiv:1310.1531v1 [cs.CV], Oct. 6, 2013.;;Schmidhuber, “Deep Learning in Neural Networks: An Overview”, Technical Report IDSIA-03-14/arXiv:1404.7828, v4, 88 pages.;;Sermanet, et al., “OverFeat: Integrated Recognition, Localization and Detection using Convolutional Networks”, arXiv:1312.6229v4 [cs.CV], Feb. 24, 2014.;;Montavon et al., “Neural Networks: Tricks of the Trade”, 2nd edition, LNCS 7700, pp. 1-5, 2012.;;Huang, et al., “Extreme learning machine: Theory and applications”, Neurocomputing 70 2006, pp. 489-501.;;Great Britain Search Report dated Aug. 31, 2017 issued in GB Patent Application No. 1704373.8.",ACTIVE
129,US,A1,US 2016/0004915 A1,001-542-981-896-716,2016-01-07,2016,US 201414324797 A,2014-07-07,US 201414324797 A,2014-07-07,Lane Level Traffic,"Lane level traffic levels are determined based on traffic camera images. A controller aligns a three-dimensional map with a traffic camera view, and identifies multiple lanes in the traffic camera view based on lane delineations of the three-dimensional map. The controller calculates a traffic parameter based on the multiple lanes in image frames from the traffic camera view and provides a traffic graphic based on the traffic parameter.",HERE GLOBAL BV,CHEN XIN;;MA XIANG;;OSTROVSKIY ROMAN;;ZHAO TERENCE,HERE GLOBAL B.V (2014-06-24),https://lens.org/001-542-981-896-716,Patent Application,yes,13,29,6,6,0,G06V20/54;;G06V20/647;;G06V10/74;;G06Q10/063;;G06Q50/40;;G08G1/0104;;G06T17/05;;G06V20/56;;G06V20/54,G06K9/00;;G06T17/05;;G08G1/01,,1,1,111-134-623-670-317,10.1117/1.1606458,"Fung et al., Camera calibration from road lane markings, October 2003, Society of Photo-Optical Instrumentation Engineers, pages 2967-2977",ACTIVE
130,US,B2,US 9747505 B2,092-072-665-415-703,2017-08-29,2017,US 201414324797 A,2014-07-07,US 201414324797 A,2014-07-07,Lane level traffic,"Lane level traffic levels are determined based on traffic camera images. A controller aligns a three-dimensional map with a traffic camera view, and identifies multiple lanes in the traffic camera view based on lane delineations of the three-dimensional map. The controller calculates a traffic parameter based on the multiple lanes in image frames from the traffic camera view and provides a traffic graphic based on the traffic parameter.",HERE GLOBAL BV,CHEN XIN;;MA XIANG;;OSTROVSKIY ROMAN;;ZHAO TERENCE,HERE GLOBAL B.V (2014-06-24),https://lens.org/092-072-665-415-703,Granted Patent,yes,17,2,6,6,0,G06V20/54;;G06V20/647;;G06V10/74;;G06Q10/063;;G06Q50/40;;G08G1/0104;;G06T17/05;;G06V20/56;;G06V20/54,G06K9/00;;G06T17/05;;G08G1/01,,8,6,111-134-623-670-317;;000-122-946-719-709;;061-420-565-903-228;;128-642-223-693-171;;012-092-692-833-982;;077-627-065-875-215,10.1117/1.1606458;;10.1007/s00138-011-0404-2;;10.1109/tits.2003.821213;;10.1016/s0262-8856(03)00004-0;;10.1109/ivs.2008.4621318;;10.1109/icsmc.2006.385034,"Fung et al., Camera calibration from road lane markings, Oct. 2003, Society of Photo-Optical Instrumentation Engineers, pp. 2967-2977.;;AHARON BAR HILLEL, RONEN LERNER, DAN LEVI, GUY RAZ: ""Recent progress in road and lane detection: a survey"", MACHINE VISION AND APPLICATIONS, SPRINGER INTERNATIONAL, vol. 25, no. 3, 1 April 2014 (2014-04-01), pages 727 - 745, XP055113665, ISSN: 09328092, DOI: 10.1007/s00138-011-0404-2;;Anonymous: “Camera calibration—Wikipedia, the free encyclopedia,” Oct. 5, 2015, Retrieved from the Internet. URL: https://en.wikipedia.org/wiki/Camera—resectioning [retrieved on Nov. 24, 2015].;;DAILEY D.J., SCHOEPFLIN T.N.: ""Dynamic camera calibration of roadside traffic management cameras for vehicle speed estimation"", IEEE TRANSACTIONS ON INTELLIGENT TRANSPORTATION SYSTEMS, IEEE, PISCATAWAY, NJ, USA, vol. 4, no. 2, 1 June 2003 (2003-06-01), Piscataway, NJ, USA, pages 90 - 98, XP011104438, ISSN: 1524-9050, DOI: 10.1109/TITS.2003.821213;;European Search Report for related European Application No. 15169123.5, dated Dec. 8, 2015.;;Kastrinaki V et al: “A survey of video processing techniques for traffic applications,” Image and Vision Computing, Elsevier, Guildford, GB, vol. 21, No. 4, Apr. 1, 2003, pp. 359-381.;;Soren Kammel et al: “Lidar-based lane marker detection and mapping,” Intelligent Vehicles Symposium, 2008 IEEE, Piscataway, NJ, USA, Jun. 4, 2008, pp. 1137-1142, XP031318963.;;YAO-JAN WU ; FENG-LI LIAN ; TANG-HSIEN CHANG: ""Traffic Monitoring and Vehicle Tracking using Roadside Cameras"", 2006 IEEE CONFERENCE ON SYSTEMS, MAN, AND CYBERNETICS, 8-11 OCT. 2006, TAIPEI, TAIWAN, IEEE, PISCATAWAY, NJ, USA, 1 October 2006 (2006-10-01), Piscataway, NJ, USA, pages 4631 - 4636, XP031117689, ISBN: 978-1-4244-0099-7",ACTIVE
131,US,B2,US 10846540 B2,189-133-337-275-952,2020-11-24,2020,US 201715686297 A,2017-08-25,US 201715686297 A;;US 201414324797 A,2014-07-07,Lane level traffic,"Lane level traffic levels are determined based on traffic camera images. A controller aligns a three-dimensional map with a traffic camera view, and identifies multiple lanes in the traffic camera view based on lane delineations of the three-dimensional map. The controller calculates a traffic parameter based on the multiple lanes in image frames from the traffic camera view and provides a traffic graphic based on the traffic parameter.",HERE GLOBAL BV,CHEN XIN;;MA XIANG;;OSTROVSKIY ROMAN;;ZHAO TERENCE,HERE GLOBAL B.V (2014-06-24),https://lens.org/189-133-337-275-952,Granted Patent,yes,26,0,6,6,0,G06V20/54;;G06V20/647;;G06V10/74;;G06Q10/063;;G06Q50/40;;G08G1/0104;;G06T17/05;;G06V20/56;;G06V20/54,G06K9/00;;G06T17/05;;G08G1/01,,14,7,108-000-900-915-801;;000-122-946-719-709;;061-420-565-903-228;;111-134-623-670-317;;128-642-223-693-171;;012-092-692-833-982;;077-627-065-875-215,17036815;;10.1109/tsmcb.2006.872271;;10.1007/s00138-011-0404-2;;10.1109/tits.2003.821213;;10.1117/1.1606458;;10.1016/s0262-8856(03)00004-0;;10.1109/ivs.2008.4621318;;10.1109/icsmc.2006.385034,"Song et al., Dynamic Calibration of Pan-Tilt-Zoom Cameras for Traffic Monitoring, IEEE, IEEE Transaction on Systems, Man, and Cybernetics, Part B (Cybernetics) vol. 36, Issue: 5, Oct. 2006 (Year: 2006).;;Office Action for European Application No. 15169123.5 dated Jun. 19, 2018, 6 pages.;;AHARON BAR HILLEL, RONEN LERNER, DAN LEVI, GUY RAZ: ""Recent progress in road and lane detection: a survey"", MACHINE VISION AND APPLICATIONS, SPRINGER INTERNATIONAL, vol. 25, no. 3, 1 April 2014 (2014-04-01), pages 727 - 745, XP055113665, ISSN: 09328092, DOI: 10.1007/s00138-011-0404-2;;Anonymous: “Camera calibration—Wikipedia, the free encyclopedia,” Oct. 5, 2015, Retrieved from the Internet. https://en.wikipedia.org/wiki/Camera_resectioning [retrieved on Nov. 24, 2015].;;DAILEY D.J., SCHOEPFLIN T.N.: ""Dynamic camera calibration of roadside traffic management cameras for vehicle speed estimation"", IEEE TRANSACTIONS ON INTELLIGENT TRANSPORTATION SYSTEMS, IEEE, PISCATAWAY, NJ, USA, vol. 4, no. 2, 1 June 2003 (2003-06-01), Piscataway, NJ, USA, pages 90 - 98, XP011104438, ISSN: 1524-9050, DOI: 10.1109/TITS.2003.821213;;European Search Report for related European Application No. 15169123.5, dated Dec. 8, 2015, 8 pages.;;Fung et al., Camera calibration from road lane markings, Oct. 2003, Society of Photo-Optical Instrumentation Engineers, pp. 2967-2977.;;Kastrinaki V et al: “A survey of video processing techniques for traffic applications,” Image and Vision Computing, Elsevier, Guildford, GB, vol. 21, No. 4, Apr. 1, 2003, pp. 359-381.;;Notice of Allowance for corresponding U.S. Appl. No. 14/324,797 dated Apr. 27, 2017.;;Office Action for corresponding U.S. Appl. No. 14/324,797 dated Dec. 30, 2016.;;Office Action for corresponding U.S. Appl. No. 14/324,797 dated Jun. 17, 2016.;;Soren Kammel et al: “Lidar-based lane marker detection and mapping,” Intelligent Vehicles Symposium, 2008 IEEE, Piscataway, NJ, USA, Jun. 4, 2008, pp. 1137-1142, XP031318963.;;YAO-JAN WU ; FENG-LI LIAN ; TANG-HSIEN CHANG: ""Traffic Monitoring and Vehicle Tracking using Roadside Cameras"", 2006 IEEE CONFERENCE ON SYSTEMS, MAN, AND CYBERNETICS, 8-11 OCT. 2006, TAIPEI, TAIWAN, IEEE, PISCATAWAY, NJ, USA, 1 October 2006 (2006-10-01), Piscataway, NJ, USA, pages 4631 - 4636, XP031117689, ISBN: 978-1-4244-0099-7;;Office Action for European Application No. 15169123.5 dated Aug. 24, 2020, 6 pages.",ACTIVE
132,EP,B1,EP 3379491 B1,028-183-684-795-976,2020-08-12,2020,EP 18157804 A,2018-02-21,GB 201704373 A,2017-03-20,SURFACE DEFECT DETECTION,,ROLLS ROYCE PLC,REN RUO XU;;HUNG TERENCE;;CHEN TAN-KAY,ROLLS-ROYCE PLC (2020-02-26),https://lens.org/028-183-684-795-976,Granted Patent,yes,3,0,5,5,0,G06T7/0004;;G06T2207/20021;;G06T2207/20084;;G06T2207/20081;;G06T2207/30164;;G06T2207/20084;;G06T7/0004;;G06T2207/20021;;G06F18/214;;G06N3/04;;G06N3/084;;G06T7/001;;G06T2207/20081;;G06T2207/30164,G06T7/00,,2,0,,,"RUOXU REN ET AL: ""A Generic Deep-Learning-Based Approach for Automated Surface Inspection"", IEEE TRANSACTIONS ON CYBERNETICS, vol. 48, no. 3, 24 February 2017 (2017-02-24), pages 929-940, XP055492817, Piscataway, NJ, USA ISSN: 2168-2267, DOI: 10.1109/TCYB.2017.2668395;;Jeff Donahue ET AL: ""DeCAF: A Deep Convolutional Activation Feature for Generic Visual Recognition"", , 5 October 2013 (2013-10-05), XP055326544, Retrieved from the Internet: URL:http://www.jmlr.org/proceedings/papers /v32/donahue14.pdf",ACTIVE
133,ZA,B,ZA 97988 B,043-182-831-322-060,1998-09-07,1998,ZA 97988 A,1997-02-06,US 1127496 P,1996-02-07,Thiophenypyrimidines,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;MCCARTHY JAMES R;;WEBB THOMAS R;;MORAN TERENCE J,,https://lens.org/043-182-831-322-060,Granted Patent,no,0,0,1,25,0,,A61K/;;C07D/,,0,0,,,,EXPIRED
134,NO,D0,NO 981356 D0,136-910-639-811-037,1998-03-25,1998,NO 981356 A,1998-03-25,EP 9700457 W;;US 1127496 P;;US 2768996 P,1996-02-07,Tiofenpyrimidiner,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;MCCARTHY JAMES R;;WEBB THOMAS R;;MORAN TERENCE J,,https://lens.org/136-910-639-811-037,Patent Application,no,0,0,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,,0,0,,,,DISCONTINUED
135,NZ,A,NZ 330118 A,197-672-946-886-962,2000-03-27,2000,NZ 33011898 A,1998-01-30,EP 9700457 W;;US 1127496 P;;US 2768996 P,1996-02-07,"Thiophenopyrimidines, pharmaceutical compositions thereof and use in treating endocrine, psychiatric and neurologic conditions","This application concerns compounds of formula (I) including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein X is S, SO or SO2; R1 is NR4R5 or OR5; R2 is C1-6alkyl, C1-6alkyloxy or C1-6alkylthio; R3 is hydrogen, C1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfoxy or C1-6alkylthio; R4 is hydrogen, C1-6alkyl, mono- or di(C3-6cycloalkyl)methyl, C3-6cycloalkyl, C3-6alkenyl, hydroxyC1-6alkyl, C1-6alkylcarbonyloxyC1-6alkyl or C1-6alkyloxyC1-6alkyl; R5 is C1-8alkyl, mono- or di(C3-6cycloalkyl)methyl, Ar1CH2, C1-6alkyloxy-C1-6alkyl, hydroxyC1-6alkyl, C3-6alkenyl, thienylmethyl, furanylmethyl, C1-6alkylthioC1-6 alkyl, morpholinyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)amino, C1-6alkylcarbonylC1-6alkyl, C1-6alkyl substituted with imidazolyl; or a radical of the formula: -Alk-O-CO-Ar1; or R4 and R5 taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; Ar is a phenyl, substituted phenyl, pyridinyl or substituted pyridinyl; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).",JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J,,https://lens.org/197-672-946-886-962,Patent Application,no,0,0,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,,0,0,,,,PENDING
136,EP,A1,EP 0882051 A1,171-420-167-743-028,1998-12-09,1998,EP 97904368 A,1997-01-30,EP 9700457 W;;US 1127496 P;;US 2768996 P,1996-02-07,THIOPHENOPYRIMIDINES,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J,"JANSSEN PHARMACEUTICA N.V. (1999-12-29);;NEUROCRINE BIOSCIENCES, INC. (2004-02-02)",https://lens.org/171-420-167-743-028,Patent Application,yes,0,1,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,,0,0,,,,EXPIRED
137,PT,E,PT 882051 E,075-789-211-887-716,2002-04-29,2002,PT 97904368 T,1997-01-30,US 1127496 P;;US 2768996 P,1996-02-07,TIOFENOPIRIMIDINAS,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,MCCARTHY JAMES R;;CHEN CHEN;;WEBB THOMAS R;;MORAN TERENCE J,,https://lens.org/075-789-211-887-716,Granted Patent,no,0,0,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,,0,0,,,,EXPIRED
138,US,B2,US 6469166 B2,162-203-103-537-762,2002-10-22,2002,US 89625001 A,2001-06-29,US 89625001 A;;US 11771598 A;;US 1127496 P;;US 2768996 P,1996-02-07,Thiophenopyrimidines,"
    This invention concerns compounds of formula 

    including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein X is S, SO or SO _{ 2 } ; R ^{ 1 } is NR ^{ 4 } R ^{ 5 } or OR ^{ 5 } ; R ^{ 2 } is C _{ 1-6 } alkyl, C _{ 1-6 } alkyloxy or C _{ 1-6 } alkylthio; R ^{ 3 } is hydrogen, C _{ 1-6 } alkyl, C _{ 1-6 } alkylsulfonyl, C _{ 1-6 } alkylsulfoxy or C _{ 1-6 } alkylthio; R ^{ 4 } is hydrogen, C _{ 1-6 } alkyl, mono- or di(C _{ 3-6 } cycloalkyl)methyl, C _{ 3-6 } cycloalkyl, C _{ 3-6 } alkenyl, hydroxyC _{ 1-6 } alkyl, C _{ 1-6 } alkylcarbonyloxyC _{ 1-6 } alkyl or C _{ 1-6 } alkyloxyC _{ 1-6 } alkyl; R ^{ 5 } is C _{ 1-6 } alkyl, mono- or di(C _{ 3-6 } cycloalkyl)methyl, Ar ^{ 1 } CH _{ 2 } , C _{ 1-6 } alkyloxy-C _{ 1-6 } alkyl, hydroxyC _{ 1-6 } alkyl, C _{ 3-6 } alkenyl, thienylmethyl, furanylmethyl, C _{ 1-6 } alkylthioC _{ 1-6 } alkyl, morpholinyl, mono- or di(C _{ 1-6 } alkyl)aminoC _{ 1-6 } alkyl, di(C _{ 1-6 } alkyl)amino, C _{ 1-6 } alkylcarbonylC _{ 1-6 } alkyl, C _{ 1-6 } alkyl substituted with imidazolyl; or a radical of formula -Alk-OCO-Ar ^{ 1 } ; or R ^{ 4 } and R ^{ 5 } taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; Ar is phenyl, substituted phenyl, pyridinyl or substituted pyridinyl; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I). 
",NEUROCRINE BIOSCIENCES INC;;JANSSEN PHARMACEUTICA NV,WEBB THOMAS R;;CHEN CHEN;;MCCARTHY JAMES R;;MORAN TERENCE J,,https://lens.org/162-203-103-537-762,Granted Patent,yes,9,12,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,544/278,2,0,,,"Shishoo, et al. Indian J. Chem, Sect. B. Org. Chem 33B(5), 436-40.;;Shishoo, et al. ""Synthesis of some 2-substituted-6-phenyl-and 7-phenyl-thieno [3,2-d] pyrimidin-4(3H)-ones"", Indian Journal of Chemistry, vol. 33B, May 1994, pp. 436-440.",EXPIRED
139,DK,T3,DK 0882051 T3,153-047-036-653-086,2002-02-25,2002,DK 97904368 T,1997-01-30,EP 9700457 W;;US 1127496 P;;US 2768996 P,1996-02-07,Thiophenopyrimidiner,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J,,https://lens.org/153-047-036-653-086,Granted Patent,no,0,0,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,,0,0,,,,EXPIRED
140,NO,L,NO 981356 L,025-021-824-762-324,1998-07-09,1998,NO 981356 A,1998-03-25,EP 9700457 W;;US 1127496 P;;US 2768996 P,1996-02-07,Tiofenpyrimidiner,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;MCCARTHY JAMES R;;WEBB THOMAS R;;MORAN TERENCE J,,https://lens.org/025-021-824-762-324,Abstract,no,0,0,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,,0,0,,,,DISCONTINUED
141,US,A1,US 2002/0052362 A1,028-739-535-213-427,2002-05-02,2002,US 89625001 A,2001-06-29,US 89625001 A;;US 11771598 A;;US 1127496 P;;US 2768996 P,1996-02-07,Thiophenopyrimidines,"
    This invention concerns compounds of formula 

    including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein X is S, SO or SO ₂ ; R ¹ is NR ⁴ R ⁵ or OR ⁵ ; R ² is C ₁₋₆ alkyl, C ₁₋₆ alkyloxy or C ₁₋₆ alkylthio; R ³ is hydrogen, C ₁₋₆ alkyl, C ₁₋₆ alkylsulfonyl, C ₁₋₆ alkylsulfoxy or C ₁₋₆ alkylthio; R ⁴ is hydrogen, C ₁₋₆ alkyl, mono- or di(C ₃₋₆ cycloalkyl)methyl, C ₃₋₆ cycloalkyl, C ₃₋₆ alkenyl, hydroxyC ₁₋₆ alkyl, C ₁₋₆ alkylcarbonyloxyC ₁₋₆ alkyl or C ₁₋₆ alkyloxyC ₁₋₆ alkyl; R ⁵ is C ₁₋₈ alkyl, mono- or di(C ₃₋₆ cycloalkyl)methyl, Ar ¹ CH ₂ , C ₁₋₆ alkyloxy-C ₁₋₆ alkyl, hydroxyC ₁₋₆ alkyl, C ₃₋₆ alkenyl, thienylmethyl, furanylmethyl, C ₁₋₆ alkylthioC ₁₋₆ alkyl, morpholinyl, mono- or di(C ₁₋₆ alkyl)aminoC ₁₋₆ alkyl, di(C ₁₋₆ alkyl)amino, C ₁₋₆ alkylcarbonylC ₁₋₆ alkyl, C ₁₋₆ alkyl substituted with imidazolyl; or a radical of formula AlkOCOAr ¹ ; or R ⁴ and R ⁵ taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; Ar is phenyl, substituted phenyl, pyridinyl or substituted pyridinyl; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I). 
",WEBB THOMAS R.;;CHEN CHEN;;MCCARTHY JAMES R.;;MORAN TERENCE J.,WEBB THOMAS R;;CHEN CHEN;;MCCARTHY JAMES R;;MORAN TERENCE J,,https://lens.org/028-739-535-213-427,Patent Application,yes,0,0,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,514/217.06;;514/234.2;;514/258;;544/278;;544/117;;X5406,0,0,,,,EXPIRED
142,ES,T3,ES 2167710 T3,008-560-015-088-890,2002-05-16,2002,ES 97904368 T,1997-01-30,US 1127496 P;;US 2768996 P,1996-02-07,TIOFENOPIRIMIDINAS.,"LA INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I), INCLUYENDO LOS ESTEREOISOMEROS Y LAS SALES DE ADICION ACIDAS FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, DONDE X ES S, SO O SO2; R1 ES NR4 R5 O OR5 ; R2 ES ALQUILO C1-6 , ALQUILOXI C1-6 O ALQUILTIO C16 ; R3 ES HIDROGENO, ALQUILO C1-6, ALQUILSULFONILO C1-6 , ALQUILSULFOXI C1-6 O ALQUILTIO C1-6 ; R4 ES HIDROGENO, ALQUILO C1-6 , MONO- O DI(CICLOALQUIL C3-6 )METILO, CICLOALQUILO C3-6 , ALQUENILO C3-6 , HIDROXIALQUILO C1-6 , ALQUILCARBONILOXI C1-6 AL QUILO C1-6 O ALQUILOXI C1-6 - ALQUILO C1-6 ; R5 ES ALQUILO C1-8 , MONO - O DI (CICLOALQUIL C3-6 ) METILO, AR1 CH2 , ALQUILOXI C1-6 - ALQU ILO C1-6 , HIDROXIALQUILO C1-6 , ALQUENILO C3-6, TIENILMETILO, FURANIL - METILO, ALQUILTIO C1-6 ALQUILO C1-6 , MORFOLINILO, MONO- O DI (ALQUILO C1-6 ) AMINOALQUILO C1-6 , DI(ALQUIL C1-6 ) AMINO, ALQUILCARBON ILO C1-6 ALQUILO C1-6 , ALQUILO C1-6 SUSTITUIDO POR IMIDAZOLILO; O UN RADICAL DE FORMULA: - ALK - O CO - AR1 -; O R4 Y R5 , CONJUNTAMENTE CON EL ATOMO DE NITROGENO AL CUAL ESTAN UNIDOS, PUEDEN FORMAR UN GRUPO MORFOLINILO, HOMOPIPERIDINILO, PIPERIDINILO O PIRROLIDINILO, OPCIONALMENTE SUSTITUIDO; AR ES FENILO, FENILO SUSTITUIDO, PIRIDINILO O PIRIDINILO SUSTITUIDO. DICHOS COMPUESTOS MUESTRAN PROPIEDADES ANTAGONISTAS DEL RECEPTOR CRF; SE DESCRIBEN ASIMISMO COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHOS COMPUESTOS COMO INGREDIENTES ACTIVOS; METODOS DE TRATAMIENTO DE ALTERACIONES RELACIONADAS CON LA HIPERSECRECION DE CRF, COMO DEPRESION, ANSIEDAD, ABUSO DE SUSTANCIAS, MEDIANTE LA ADMINISTRACION DE UNA CANTIDAD EFECTIVA DEL COMPUESTO DE FORMULA (I).",JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J,,https://lens.org/008-560-015-088-890,Granted Patent,no,0,0,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,,0,0,,,,EXPIRED
143,WO,A1,WO 1997/029110 A1,105-764-225-690-995,1997-08-14,1997,EP 9700457 W,1997-01-30,US 1127496 P;;US 2768996 P,1996-02-07,THIOPHENOPYRIMIDINES,"This invention concerns compounds of formula (I) including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein X is S, SO or SO2; R?1 is NR4R5 or OR5; R2¿ is C¿1-6?alkyl, C1-6alkyloxy or C1-6alkylthio; R?3¿ is hydrogen, C¿1-6?alkyl, C1-6alkylsulfonyl, C1-6alkylsulfoxy or C1-6alkylthio; R?4¿ is hydrogen, C¿1-6?alkyl, mono- or di(C3-6cycloalkyl)methyl, C3-6cycloalkyl, C3-6alkenyl, hydroxyC1-6alkyl, C1-6alkylcarbonyloxyC1-6alkyl or C1-6alkyloxyC1-6alkyl; R?5¿ is C¿1-8?alkyl, mono- or di(C3-6cycloalkyl)methyl, Ar?1CH¿2, C1-6alkyloxy-C1-6alkyl, hydroxyC1-6alkyl, C3-6alkenyl, thienylmethyl, furanylmethyl, C1-6alkylthioC1-6 alkyl, morpholinyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)amino, C1-6alkylcarbonylC1-6alkyl, C1-6alkyl substituted with imidazolyl; or a radical of the formula: -Alk-O-CO-Ar?1; or R4 and R5¿ taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; Ar is a phenyl, substituted phenyl, pyridinyl or substituted pyridinyl; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).",JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC;;CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J,,https://lens.org/105-764-225-690-995,Patent Application,yes,8,51,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,,1,0,,,"C. J. SHISHOO ET AL.: ""Synthesis of some 2-substituted-6-phenyl- and 7-phenyl- thieno[3,2-d]pyrimidin-4(3H)-ones"", INDIAN JOURNAL OF CHEMISTRY, vol. 33B, May 1994 (1994-05-01), pages 436 - 40, XP000197476",PATENTED
144,AU,B2,AU 725674 B2,119-759-111-479-755,2000-10-19,2000,AU 1997/017209 A,1997-01-30,EP 9700457 W;;US 1127496 P;;US 2768996 P,1996-02-07,Thiophenopyrimidines,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J,NEUROCRINE BIOSCIENCES INC. (2004-03-11),https://lens.org/119-759-111-479-755,Granted Patent,no,1,0,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,,0,0,,,,EXPIRED
145,TW,B,TW 448178 B,107-060-224-052-155,2001-08-01,2001,TW 86101374 A,1997-02-05,US 1127496 P;;US 2768996 P,1996-02-07,Thiophenopyrimidines,"This invention concerns compounds of formula, including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein X is S, SO or SO2; R1 is NR4 R5 or OR5; R2 is C1-6alkyl, C1-6alkyloxy or C1-6alkylthio; R3 is hydrogen, C1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfoxy or C1-6alkylthio; R4 is hydrogen, C1-6alkyl, mono- or di(C3-6cycloalkyl)methyl, C3-6cycloalkyl, C3-6alkenyl, hydroxyC1-6alkyl, C1-6alkylcarbonyloxyC1-6alkyl or C1-6alkyloxyC1-6alkyl; R5 is C1-8alkyl, mono- or di(C3-6cycloalkyl)methyl, Ar1CH2, C1-6alkyloxy-C1-6alkyl, hydroxyC1-6alkyl, C3-6alkenyl, thienylmethyl, furanylmethyl, C1-6alkylthioC1-6alkyl, morpholinyl, mono-or di(C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)amino, C1-6alkylcarbonylC1-6alkyl, C1-6alkyl substituted with imidazolyl; or a radical of formula -Alk-O-CO-Ar1; or R4 and R5 taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; Ar is phenyl, substituted phenyl, pyridinyl or substituted pyridinyl; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).",JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J,,https://lens.org/107-060-224-052-155,Granted Patent,no,0,0,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,,0,0,,,,EXPIRED
146,DE,T2,DE 69708059 T2,162-057-195-908-90X,2002-07-18,2002,DE 69708059 T,1997-01-30,EP 9700457 W;;US 1127496 P;;US 2768996 P,1996-02-07,THIOPHENOPYRIMIDINE,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J,"NEUROCRINE BIOSCIENCES, INC., SAN DIEGO, CALIF., U (2004-04-08)",https://lens.org/162-057-195-908-90X,Granted Patent,no,0,0,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,,0,0,,,,EXPIRED
147,AT,T1,AT E208395 T1,117-817-589-043-66X,2001-11-15,2001,AT 97904368 T,1997-01-30,EP 9700457 W;;US 1127496 P;;US 2768996 P,1996-02-07,THIOPHENOPYRIMIDINE,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J,,https://lens.org/117-817-589-043-66X,Granted Patent,no,0,0,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,,0,0,,,,DISCONTINUED
148,AU,A,AU 1997/017209 A,117-175-587-492-355,1997-08-28,1997,AU 1997/017209 A,1997-01-30,EP 9700457 W;;US 1127496 P;;US 2768996 P,1996-02-07,Thiophenopyrimidines,,NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J,NEUROCRINE BIOSCIENCES INC. (2004-03-11),https://lens.org/117-175-587-492-355,Patent Application,no,0,0,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,,0,0,,,,EXPIRED
149,CA,A1,CA 2233307 A1,090-682-739-996-13X,1997-08-14,1997,CA 2233307 A,1997-01-30,US 2768996 P;;US 1127496 P,1996-02-07,THIOPHENOPYRIMIDINES,"This invention concerns compounds of formula (I) including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein X is S, SO or SO2; R1 is NR4R5 or OR5; R2 is C1-6alkyl, C1-6alkyloxy or C16alkylthio; R3 is hydrogen, C1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfoxy or C1-6alkylthio; R4 is hydrogen, C1-6alkyl, mono- or di(C3-6cycloalkyl)methyl, C3-6cycloalkyl, C3-6alkenyl, hydroxyC1-6alkyl, C1-6alkylcarbonyloxyC1-6alkyl or C1-6alkyloxyC1-6alkyl; R5 is C1-8alkyl, mono- or di(C3-6cycloalkyl)methyl, Ar1CH2, C1-6alkyloxy-C1-6alkyl, hydroxyC1-6alkyl, C3-6alkenyl, thienylmethyl, furanylmethyl, C1-6alkylthioC1-6 alkyl, morpholinyl, mono- or di(C16alkyl)aminoC1-6alkyl, di(C1-6alkyl)amino, C1-6alkylcarbonylC1-6alkyl, C16alkyl substituted with imidazolyl; or a radical of the formula: -Alk-O-CO-Ar1; or R4 and R5 taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; Ar is a phenyl, substituted phenyl, pyridinyl or substituted pyridinyl; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).",JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J,,https://lens.org/090-682-739-996-13X,Patent Application,no,0,0,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,,0,0,,,,DISCONTINUED
150,DE,D1,DE 69708059 D1,061-292-268-454-987,2001-12-13,2001,DE 69708059 T,1997-01-30,EP 9700457 W;;US 1127496 P;;US 2768996 P,1996-02-07,THIOPHENOPYRIMIDINE,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J,"NEUROCRINE BIOSCIENCES, INC., SAN DIEGO, CALIF., U (2004-04-08)",https://lens.org/061-292-268-454-987,Granted Patent,no,0,0,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,,0,0,,,,EXPIRED
151,MY,A,MY 119118 A,070-392-816-779-470,2005-03-31,2005,MY PI9700490 A,1997-02-06,US 1127496 P;;US 2768996 P,1996-02-07,THIOPHENOPYRIMIDINES,"THIS INVENTION CONCERNS COMPOUNDS OF FORMULA( FORMULA 1 )INCLUDING THE STEREOISOMERS AND THE PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT FORMS THEREOF, WHEREIN X IS S, SO OR SO2; R1 IS NR4R5 OROR5; R2 IS C1-6ALKYL,C1-6ALKYLOXY OR C1-6ALKYLTHIO; R3 IS HYDROGEN, C1-6ALKYL, C1-6ALKYLSULFONYL, C1-6ALKYLSULFOXY OR C1-6ALKYLTHIO; R4 IS HYDROGEN, C1-6ALKYL, MONO- OR DI(C3-6CYCLOALKYL)METHYL, C3-6CYCLOALKYL, C3-6ALKENYL, HYDROXYC1-6ALKYL,C1-6ALKYLCARBONYLOXYC1-6ALKYL OR C1-6ALKYLOXYC1-6ALKYL; R5 IS C1-8ALKYL, MONO- OR DI(C3-6CYCLOALKYL)METHYL, AR1CH2, C1-6ALKYLOXY-C1-6ALKYLOXY-C1-6ALKYL, HYDROXYC1-6ALKYL,C3-6ALKENYL, THIENYLMETHYL, FURANYLMETHYL, C1-6ALKYLTHIOC1-6ALKYL, MORPHOLINYL, MONO- OR DI(C1-6ALKYL)AMINOC1-6ALKYL, DI(C1-6ALKYL)AMINO, C1-6ALKYLCARBONYLC1-6ALKYL, C1-6ALKYL SUBSTITUTED WITH IMIDAZOLYL; OR A RADICAL OF FORMULA -ALK-O-CO-AR1; OR R4 AND R5 TAKEN TOGETHER WITH THE NITROGEN ATOM TO WHICH THEY ARE ATTACHED MAY FORM AN OPTIONALLY SUBSTITUTED PYRROLIDINYL, PIPERIDINYL, HOMOPIPERIDINYL OR MORPHOLINYL GROUP; AR IS PHENYL, SUBSTITUTED PHENYL, PYRIDNYL OR SUBSTITUTED PYRIDINYL; HAVING CRF RECEPTOR ANTAGONISTIC PROPERTIES; PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS AS ACTIVE INGREDIENTS; METHOD OF TREATING DISORDERS RELATED TO HYPERSECRETION OF CRF SUCH ASD DEPRESSION, ANXIETY, SUBSTANCE ABUSE, BY ADMINISTERING AN EFFECTIVE AMOUNT OF A COMPOUND OF FORMULA (I).",NEUROCRINE BIOSCIENCES INC;;JANSSEN PHARMACEUTICA NV,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J,,https://lens.org/070-392-816-779-470,Granted Patent,no,0,0,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,C07D495/04;;A61K31/505;;A61P5/04;;A61P25/18,,0,0,,,,EXPIRED
152,US,B1,US 6255310 B1,121-665-566-242-505,2001-07-03,2001,US 11771598 A,1998-12-28,US 11771598 A;;EP 9700457 W;;US 2768996 P;;US 1127496 P,1996-02-07,Thiophenopyrimidines,"This invention concerns compounds of formula ##STR1## including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein X is S, SO or SO.sub.2 ; R.sup.1 is NR.sup.4 R.sup.5 or OR.sup.5 ; R.sup.2 is C.sub.1-6 alkyl, C.sub.1-6 alkyloxy or C.sub.1-6 alkylthio; R.sup.3 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkylsulfonyl, C.sub.1-6 alkylsulfoxy or C.sub.1-6 alkylthio; R.sup.4 is hydrogen, C.sub.1-6 alkyl, mono- or di(C.sub.3-6 cycloalkyl)methyl, C.sub.3-6 cycloalkyl, C.sub.3-6 alkenyl, hydroxyC.sub.1-6 alkyl, C.sub.1-6 alkylcarbonyloxyC.sub.1-6 alkyl or C.sub.1-6 alkyloxyC.sub.1-6 alkyl; R.sup.5 is C.sub.1-8 alkyl, mono- or di(C.sub.3-6 cycloalkyl)methyl, Ar.sup.1 CH.sub.2, C.sub.1-6 alkyloxy-C.sub.1-6 alkyl, hydroxyC.sub.1-6 alkyl, C.sub.3-6 alkenyl, thienylmethyl, furanylmethyl, C.sub.1-6 alkylthioC.sub.1-6 alkyl, morpholinyl, mono- or di(C.sub.1-6 alkyl)aminoC.sub.1-6 alkyl, di(C.sub.1-6 alkyl)amino, C.sub.1-6 alkylcarbonylC.sub.1-6 alkyl, C.sub.1-6 alkyl substituted with imidazolyl; or a radical of formula --Alk--O--CO--Ar.sup.1 ; or R.sup.4 and R.sup.5 taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; Ar is phenyl, substituted phenyl, pyridinyl or substituted pyridinyl; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).",NEUROCRINE BIOSCIENCES INC,WEBB THOMAS R;;CHEN CHEN;;MCCARTHY JAMES R;;MORAN TERENCE J,NEUROCRINE BIOSCIENCES INC (1998-04-22),https://lens.org/121-665-566-242-505,Granted Patent,yes,8,11,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,514/258;;544/278,2,0,,,"Shishoo et al. Indian J. Chem, Sect. B. Org. Chem 33B(5), 436-40, 1994.;;Shishoo, C.J., et al., ""Synthesis of some 2-substituted-6-phenyl-and 7-phenyl-thieno[3,2-d]pyrimidin-4(3H)-ones"", Indian Journal of Chemistry, vol. 33B, May 1994, pp. 436-440.",EXPIRED
153,EP,B1,EP 0882051 B1,199-522-049-160-044,2001-11-07,2001,EP 97904368 A,1997-01-30,EP 9700457 W;;US 1127496 P;;US 2768996 P,1996-02-07,THIOPHENOPYRIMIDINES,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J,"JANSSEN PHARMACEUTICA N.V. (1999-12-29);;NEUROCRINE BIOSCIENCES, INC. (2004-02-02)",https://lens.org/199-522-049-160-044,Granted Patent,yes,8,0,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,,1,0,,,"INDIAN JOURNAL OF CHEMISTRY, vol. 33B, May 1994, pages 436-40, XP000197476 C. J. SHISHOO ET AL.: ""Synthesis of some 2-substituted-6-phenyl- and 7-phenyl- thieno[3,2-d]pyrimidin-4(3H)-ones""",EXPIRED
154,US,A,US 5026656 A,100-599-093-333-241,1991-06-25,1991,US 48836090 A,1990-03-02,US 48836090 A;;US 15079988 A,1988-02-01,MOS transistor with improved radiation hardness,"An MOS transistor is disclosed which has a guard ring for prevention of source-to-drain conduction through the isolation oxide after exposure to ionizing radiation. In the described example of an n-channel transistor, a p+ region is formed at the edges of the source region in a self-aligned fashion relative to the gate electrode so as not to extend under the gate to contact the drain region. This p+ region forms a diode which retards source-drain conduction even if a channel is formed under the isolating field oxide where the gate electrode overlaps onto the field oxide. The structure may be silicided for improved series resistance. An example of the transistor formed in an SOI configuration is also disclosed.",TEXAS INSTRUMENTS INC,MATLOUBIAN MISHEL;;CHEN CHENG-ENG D;;BLAKE TERENCE G,,https://lens.org/100-599-093-333-241,Granted Patent,yes,6,30,1,8,0,H01L23/4825;;H01L23/4825;;H01L21/743;;H01L21/743;;H01L29/78609;;H01L29/78609;;H01L29/78612;;H01L29/78612;;H01L2924/0002;;H01L2924/0002;;Y10S438/953;;Y10S438/953,H01L21/74;;H01L23/482;;H01L29/786,H1K KKA           KA,3,2,012-837-841-030-563;;039-925-479-751-439,10.1109/t-ed.1978.19209;;10.1109/t-ed.1975.18262,"Lee et al., Island Effects in CMOS/SOS Transistors , IEEE Trans. E.D., vol. ED 25, No. 8 (Aug. 1978), pp. 971 978.;;Tihanyi, et al., Properties of ESFI MOS Transistors Due to the Floating Substrate and the Finite Volume , IEEE Trans. E.D., vol. ED 22, No. 11, (Nov. 1975), pp. 1017 1023.;;Tihany, et al., Influence of the Floating Substrate Potential on the Characteristics of EFSI MOS Transistors , Solid State Electrons, vol. 18 (Pergamon, 1975), pp. 309 314.",EXPIRED
155,US,A,US 4974051 A,082-853-539-919-360,1990-11-27,1990,US 15079988 A,1988-02-01,US 15079988 A,1988-02-01,MOS transistor with improved radiation hardness,"An MOS transistor is disclosed which has a guard ring for prevention of source-to-drain conduction through the isolation oxide after exposure to ionizing radiation. In the described example of an n-channel transistor, a p+ region is formed at the edges of the source region in a self-aligned fashion relative to the gate electrode so as not to extend under the gate to contact the drain region. This p+ region forms a diode which retards source-drain conduction even if a channel is formed under the isolating field oxide where the gate electrode overlaps onto the field oxide. The structure may be silicided for improved series resistance. An example of the transistor formed in an SOI configuration is also disclosed.",TEXAS INSTRUMENTS INC,MATLOUBIAN MISHEL;;CHEN CHENG-ENG D;;BLAKE TERENCE G,TEXAS INSTRUMENTS INCORPORATED 13500 NORTH CENTRAL EXPRESSWAY DALLAS TEXAS 75265 A CORP. OF DE;;TEXAS INSTRUMENTS INCORPORATION 75265 A CORP. OF DE (1988-05-24);;TEXAS INSTRUMENTS INCORPORATED A CORP. OF DE (1988-02-01),https://lens.org/082-853-539-919-360,Granted Patent,yes,3,32,3,8,0,H01L21/743;;H01L23/4825;;H01L29/78609;;H01L29/78612;;H01L2924/0002;;H01L23/4825;;H01L21/743;;H01L29/78612;;H01L29/78609;;H01L2924/0002,H01L21/74;;H01L23/482;;H01L21/76;;H01L27/10;;H01L29/78;;H01L29/786,H1K KCAX          CAX,3,3,012-837-841-030-563;;039-925-479-751-439;;140-898-708-353-590,10.1109/t-ed.1978.19209;;10.1109/t-ed.1975.18262;;10.1016/0038-1101(75)90083-0,"Lee et al., Island Edge Effects in CMOS/SOS Transistors, IEEE Trans. E.D., vol. ED 25, No. 8 (Aug. 1978), pp. 971 978.;;Tihanyi et al., Properties of ESFI MOS Transistors Due to the Floating Substrate and the Finite Volume, IEEE TRans. E.D., vol. ED 22, No. 11 (Nov. 1975), pp. 1017 1023.;;Tihanyi et al., Influence of the Floating Substrate Potential on the Characteristics of ESFI MOS Transistors, Solid State Electronics, vol. 18 (Pergamon, 1975), pp. 309 314.",EXPIRED
156,US,A,US 5562770 A,115-326-766-149-31X,1996-10-08,1996,US 34315294 A,1994-11-22,US 34315294 A,1994-11-22,Semiconductor manufacturing process for low dislocation defects,"The present invention provides a method of global stress modification which results in reducing number of dislocations in an epitaxially grown semiconducting device layer on a semiconductor substrate where the device layer and the substrate have a lattice mismatch. The invention teaches a method of imparting a convex curvature to the substrate by removing layer(s) of thin film from or adding layers of thin film to the back side of the substrate, so as to achieve a reduced dislocation density in the device layer.",IBM,CHEN BOMY A;;HOOK TERENCE B;;KULKARNI SUBHASH B,INTERNATIONAL BUSINESS MACHINES CORPORATION (1994-11-08),https://lens.org/115-326-766-149-31X,Granted Patent,yes,15,41,3,3,0,C30B25/18;;C30B25/18;;Y10S438/938,H01L21/205;;C30B25/18;;H01L21/8249;;H01L27/06,117/90;;117/95;;117/96;;117/106;;437/95;;437/96,4,2,093-447-211-557-832;;030-994-564-942-59X,10.1063/1.1658146;;10.1063/1.100953,"R. Beanland, et al., Dislocations in Heteroepitaxial Films Handbook on Semiconductors, vol. 3, Chapter 15, pp. 1174 1212, 1994.;;W. R. Runyan, The Status of Silicon Epitaxy published in Semiconductor Silicon, ed. by R. R. Haberecht, Electrochemical Society, Inc., pp. 169 187, May 1969.;;Y. Sugita, et al., Misfit Dislocations in Bicrystal of Epitaxially Grown Silicon on Boron Doped Silicon Substrates Journal of Applied Physics, vol. 40, No. 8, pp. 3089 3094, Jul. 1969.;;H. Kikuchi, et al., New Gettering Using Misfit Dislocations in Homoepitaxial Wafers with Heavily Boron Doped Silicon Substrates Appl. Phys. Lett. 54 (5), pp. 463 465, 1989.",EXPIRED
157,DE,T1,DE 880523 T1,002-541-298-137-928,2002-07-04,2002,DE 97902295 T,1997-01-30,EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,PYRAZOLOPYRIMIDINE ALS CRF REZEPTOR-ANTAGONISTEN,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN-NEUROCRINE BIOSCIENC;;WEBB THOMAS;;MCCARTHY JAMES;;MORAN TERENCE;;WILCOXEN KEITH,,https://lens.org/002-541-298-137-928,Granted Patent,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
158,ID,A,ID 15904 A,071-376-630-201-861,1997-08-14,1997,ID 970391 A,1997-02-07,US 1127496 P;;US 2768996 P,1996-02-07,SENYAWA-SENYAWA TIOFENOPIRIMIDINA,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;CHARTY JAMES R MC;;MORAN TERENCE J,,https://lens.org/071-376-630-201-861,Patent Application,no,0,0,24,25,0,C07D495/04;;A61P25/18;;A61P25/22;;A61P25/24;;A61P5/04;;C07D495/04;;C07D495/04,A61P5/04;;A61P25/18;;C07D495/04,,0,0,,,,PENDING
159,EP,A2,EP 1248161 A2,198-278-226-454-329,2002-10-09,2002,EP 02005332 A,2002-03-14,US 82741001 A,2001-04-06,Roller structure for operation at elevated temperatures,"Gegenstand der Erfindung ist eine Walze (10) zur Verwendung in einer Fixiervorrichtung für ein Reproduktionsgerät, die für den Betrieb unter erhöhten Temperaturen im Bereich bis ca. 400°C ausgelegt ist. Die Walze (10) umfasst ein allgemein langgestrecktes, im Wesentlichen zylindrisches Rohr (12). Zur Abdichtung der Enden des zylindrischen Rohres (12) sind Abschlusszapfen (14) vorgesehen. Jeder Abschlusszapfen (14) ist seinerseits mit einem Ende des zylindrischen Rohres (12) derart verbunden, dass nach Bildung einer Schweißverbindung zwischen dem zylindrischen Rohr (12) und dem Abschlusszapfen (14) der Abschlusszapfen (14) eine Pressverbindung eingeht, was verhindert, dass sich das zylindrische Rohr (12) von dem Abschlusszapfen (14) aufgrund einer bei höheren Betriebstemperaturen auftretenden Materialdauerdehnung trennt.",NEXPRESS SOLUTIONS LLC,BLEIL RAINER;;CHEN JIANN-HSING;;KASS ALLEN;;MILLER TERENCE M,EASTMAN KODAK COMPANY (2004-10-27),https://lens.org/198-278-226-454-329,Patent Application,yes,0,0,6,6,0,F16C13/00;;G03G15/2053;;G03G15/2053;;F16C13/00,F16C13/00;;G03G15/20,,0,0,,,,DISCONTINUED
160,EP,A3,EP 1248161 A3,126-056-561-000-089,2004-11-24,2004,EP 02005332 A,2002-03-14,US 82741001 A,2001-04-06,Roller structure for operation at elevated temperatures,"Gegenstand der Erfindung ist eine Walze (10) zur Verwendung in einer Fixiervorrichtung für ein Reproduktionsgerät, die für den Betrieb unter erhöhten Temperaturen im Bereich bis ca. 400°C ausgelegt ist. Die Walze (10) umfasst ein allgemein langgestrecktes, im Wesentlichen zylindrisches Rohr (12). Zur Abdichtung der Enden des zylindrischen Rohres (12) sind Abschlusszapfen (14) vorgesehen. Jeder Abschlusszapfen (14) ist seinerseits mit einem Ende des zylindrischen Rohres (12) derart verbunden, dass nach Bildung einer Schweißverbindung zwischen dem zylindrischen Rohr (12) und dem Abschlusszapfen (14) der Abschlusszapfen (14) eine Pressverbindung eingeht, was verhindert, dass sich das zylindrische Rohr (12) von dem Abschlusszapfen (14) aufgrund einer bei höheren Betriebstemperaturen auftretenden Materialdauerdehnung trennt.",EASTMAN KODAK CO,BLEIL RAINER;;CHEN JIANN-HSING;;KASS ALLEN;;MILLER TERENCE M,EASTMAN KODAK COMPANY (2004-10-27),https://lens.org/126-056-561-000-089,Search Report,yes,3,0,6,6,0,F16C13/00;;G03G15/2053;;G03G15/2053;;F16C13/00,F16C13/00;;G03G15/20,,2,0,,,"PATENT ABSTRACTS OF JAPAN vol. 007, no. 041 (M - 194) 18 February 1983 (1983-02-18);;PATENT ABSTRACTS OF JAPAN vol. 017, no. 474 (P - 1602) 27 August 1993 (1993-08-27)",DISCONTINUED
161,US,B1,US 9680230 B1,106-774-468-795-199,2017-06-13,2017,US 201514753928 A,2015-06-29,US 201514753928 A,2015-06-29,Antenna reflector hydrophobic coating and method for applying same,"An improved antenna reflector coating and a method for applying the coating is disclosed. A region of the reflector surface smaller than the entire reflective surface is identified and designated for hydrophobic treatment, and thereafter hydrophobically treated. Provision is made for identifying the region according to desired parameters and in consideration of multiple LNB embodiments.",DIRECTV GROUP INC,SANTORU JOSEPH;;CHEN ERNEST C;;COMEAUX CECILIA C;;WU TERENCE,THE DIRECTV GROUP INC (2016-04-25);;DIRECTV LLC (2021-07-28),https://lens.org/106-774-468-795-199,Granted Patent,yes,10,0,1,1,0,B05D5/02;;H01Q1/02;;H01Q15/141;;H01Q15/14;;H01Q15/141;;H01Q15/16;;H01Q19/10;;H01Q19/132,H01Q15/14;;B05D5/02;;H01Q19/10,,0,0,,,,ACTIVE
162,DE,A1,DE 10211111 A1,045-140-954-975-325,2002-10-17,2002,DE 10211111 A,2002-03-14,US 82741001 A,2001-04-06,Walzenkonstruktion für den Betrieb unter erhöhten Temperaturen,"Gegenstand der Erfindung ist eine Walze (10) zur Verwendung in einer Fixiervorrichtung für ein Reproduktionsgerät, die für den Betrieb unter erhöhten Temperaturen im Bereich bis ca. 400 DEG C ausgelegt ist. Die Walze (10) umfasst ein allgemein langgestrecktes, im Wesentlichen zylindrisches Rohr (12). Zur Abdichtung der Enden des zylindrischen Rohres (12) sind Abschlusszapfen (14) vorgesehen. Jeder Abschlusszapfen (14) ist seinerseits mit einem Ende des zylindrischen Rohres (12) derart verbunden, dass nach Bildung einer Schweißverbindung zwischen dem zylindrischen Rohr (12) und dem Abschlusszapfen (14) der Abschlusszapfen (14) eine Pressverbindung eingeht, was verhindert, dass sich das zylindrische Rohr (12) von dem Abschlusszapfen (14) aufgrund einer bei höheren Betriebstemperaturen auftretenden Materialdauerdehnung trennt.",NEXPRESS SOLUTIONS LLC,BLEIL RAINER;;CHEN JIANN-HSING;;KASS ALLEN;;MILLER TERENCE M,"EASTMAN KODAK CO., ROCHESTER, N.Y., US (2006-03-23)",https://lens.org/045-140-954-975-325,Patent Application,no,0,0,6,6,0,F16C13/00;;G03G15/2053;;G03G15/2053;;F16C13/00,F16C13/00;;G03G15/20,,0,0,,,,DISCONTINUED
163,US,B2,US 11152507 B2,143-597-057-736-212,2021-10-19,2021,US 201816183214 A,2018-11-07,US 201816183214 A,2018-11-07,Vertical field-effect transistor with a bottom contact that exhibits low electrical resistance,"Techniques regarding one or more VFETs operably coupled to bottom contacts with low electrical resistance are provided. For example, one or more embodiments described herein can comprise an apparatus, which can comprise a vertical field-effect transistor device that can comprise a semiconductor fin positioned on a source/drain region, which can comprise a semiconductor substrate. The apparatus can also comprise a metal contact layer positioned on the source/drain region and at least partially surrounding a base of the semiconductor fin. Further, the metal contact layer can be in electrical communication with the source/drain region.",IBM,ZHANG CHEN;;YAMASHITA TENKO;;HOOK TERENCE B;;ANDERSON BRENT ALAN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2018-11-01),https://lens.org/143-597-057-736-212,Granted Patent,yes,9,0,2,2,0,H01L29/66666;;H01L29/7827;;H01L27/088;;H01L29/0847;;H01L29/41741;;H01L29/41741;;H01L29/66666;;H01L29/7827,H01L29/76;;H01L27/088;;H01L29/08;;H01L29/417;;H01L29/66;;H01L29/78,,0,0,,,,ACTIVE
164,US,B1,US 6197568 B1,128-161-954-527-76X,2001-03-06,2001,US 12377098 A,1998-07-28,US 12377098 A;;US 5382897 P,1997-07-29,"Method and compositions for isolation, diagnosis and treatment of polyanion-binding microorganisms","Methods and compositions for the isolation, diagnosis and treatment of microorganisms such as flaviviruses and other hemorrhagic fever viruses are based on the sulfated polyanion-dependent interaction of flaviviruses and hemorrhagic fever viruses, in particular dengue virus, with target cells. The cellular receptors targeted by these viruses have been identified as sulfated polyanionic glycoproteins, that include highly sulfated heparan sulfate glycosaminoglycans for some target cell types, and as a sulfated mucin on vascular endothelium. Compounds such as heparin, highly sulfated heparan sulfate, and synthetic polyanions such as Suramin, inhibit the interaction between the microorganisms and target cells, thereby disrupting the infective process.",UNIV MICHIGAN;;UNIV IOWA RES FOUND;;NZ HEALTH RES COUNCIL,MARKS RORY M;;CHEN YAPING;;MAGUIRE TERENCE;;LINHARDT ROBERT J,HEALTH RESEARCH COUNCIL OF NEW ZEALAND THE (1998-09-01);;IOWA RESEARCH FOUNDATION UNIVERSITY OF IOWA THE (1998-09-01);;REGENTS OF THE UNIVERSITY OF MICHIGAN THE (1998-09-01),https://lens.org/128-161-954-527-76X,Granted Patent,yes,1,45,1,1,10,C12N7/00;;C12N15/85;;C12N2770/24151;;C12N2810/60;;C12Q1/70;;G01N33/56983;;Y10S435/803;;Y10S435/948;;C12N7/00;;C12N15/85;;G01N33/56983;;C12N2770/24151;;C12N2810/60;;C12Q1/70;;Y10S435/803;;Y10S435/948;;Y02A50/30,C12N7/02;;C12N15/85;;C12Q1/70;;G01N33/569,435/239;;435/5;;435/7.1;;435/7.8;;435/29;;435/803;;435/948;;424/185;;424/193.1;;424/196.11;;424/197.11;;424/279.1;;514/23;;514/54;;514/55;;514/56;;514/57;;514/58;;514/59;;514/60;;514/61;;514/62,67,60,061-892-509-836-548;;040-420-714-634-550;;021-777-533-262-295;;062-966-040-373-034;;004-731-819-988-980;;005-322-661-796-530;;040-306-894-903-842;;124-952-635-605-172;;066-003-063-804-099;;009-527-579-755-574;;004-371-318-570-301;;068-266-634-244-193;;025-710-148-809-396;;120-814-714-111-567;;092-094-354-625-794;;058-019-674-955-693;;043-365-903-444-326;;048-512-049-867-459;;143-196-961-601-693;;030-388-307-578-301;;056-651-814-284-542;;063-180-704-627-343;;002-567-810-947-301;;017-308-094-474-029;;077-814-202-592-451;;054-080-357-642-148;;010-397-301-772-380;;110-623-555-502-338;;024-090-726-528-641;;070-454-619-037-655;;069-710-985-338-938;;107-520-827-427-125;;072-662-301-626-82X;;040-716-905-898-666;;006-979-290-234-610;;003-219-255-309-540;;020-024-093-158-044;;119-055-829-995-921;;076-727-262-749-252;;048-220-826-936-638;;147-246-286-964-703;;105-832-760-109-930;;100-231-048-990-482;;029-100-930-310-461;;107-460-021-751-24X;;069-703-945-232-199;;058-901-249-518-781;;032-802-332-370-119;;011-173-411-986-201;;065-678-110-707-195;;027-209-493-268-133;;033-115-131-004-798;;107-298-529-358-681;;015-334-426-658-446;;069-045-505-632-584;;020-129-749-440-271;;083-054-074-637-085;;070-376-559-044-288;;114-866-485-851-269;;059-649-500-596-718,10.1099/0022-1317-73-8-2155;;1645154;;208980;;pmc421926;;10.1128/iai.20.3.776-781.1978;;10.1016/0092-8674(90)90694-a;;1694723;;3026396;;10.1016/s0006-291x(86)80253-4;;10.1016/s0021-9258(18)83150-7;;2524478;;10.1146/annurev.cellbio.8.1.365;;1335744;;10.1146/annurev.cb.08.110192.002053;;10.1016/s0022-2836(84)71582-8;;10.1006/jmbi.1994.1582;;7932691;;pmc414649;;10.1128/iai.26.2.534-541.1979;;121109;;2463827;;10.1161/01.atv.9.1.21;;1704661;;10.1016/0042-6822(91)90471-m;;8112591;;10.1016/0378-1119(94)90525-8;;pmc190973;;8971005;;10.1128/jvi.70.12.8765-8772.1996;;10.1038/nm0897-866;;9256277;;pmc332338;;10.1093/nar/18.19.5889;;2216784;;10.1128/iai.32.2.469-473.1981;;7251133;;pmc351468;;10.1016/0042-6822(91)90055-g;;1984665;;pmc346710;;10.1073/pnas.79.15.4540;;6812050;;10.1073/pnas.82.10.3197;;pmc397742;;3858816;;10.1016/s0021-9258(18)45335-5;;2957376;;10.1126/science.271.5252.1116;;8599088;;7487089;;10.1006/abbi.1995.9963;;1356919;;10.1038/icb.1992.14;;4198027;;10.1093/infdis/128.1.7;;3277268;;10.1126/science.3277268;;10.1126/science.239.4839.476;;2665015;;10.1093/clinids/11.supplement_4.s830;;1462664;;2564270;;10.1007/bf01313814;;7666046;;10.1002/jmv.1890450417;;10.1128/cmr.3.4.376;;2224837;;10.1128/cmr.3.4.376-396.1990;;pmc358169;;pmc248008;;2398538;;10.1128/jvi.64.10.5156-5159.1990;;10.1002/jmv.1890420304;;8006634;;pmc190485;;10.1128/jvi.70.8.5282-5287.1996;;8764038;;10.1007/978-1-4613-2825-4_1;;7908925;;10.1093/infdis/169.3.512;;8388021;;10.1099/0022-1317-74-5-931;;10.1007/bf01310705;;2178591;;pmc48638;;10.1073/pnas.89.6.2267;;1532254;;7518164;;10.1006/viro.1994.1410;;10.1016/0166-0934(94)90083-3;;7525622;;10.1074/jbc.271.30.17804;;8663266;;8291250;;10.1006/viro.1994.1081;;8898196;;10.1016/s0092-8674(00)81363-x;;10.1016/0092-8674(91)90192-2;;1655283;;8674685;;10.1042/bst0240274;;2428214;;10.1016/s0065-3527(08)60268-7;;2561233;;10.1016/0049-3848(89)90289-2;;10.1093/oxfordjournals.aje.a118408;;10.1038/375291a0;;7753193;;8975885;;10.1128/iai.65.1.1-8.1997;;pmc174549;;10.1126/science.2821619;;2821619;;808927;;10.1099/0022-1317-77-10-2541;;8887488;;7434071;;10.1016/s0021-9258(18)47059-7;;7929389;;7877230;;10.1016/s0741-5214(95)70290-3;;10.1128/iai.13.3.688-695.1976;;pmc420665;;57925;;10.1021/bi00179a006;;8142385;;8943254;;10.1074/jbc.271.50.32040;;pmc1218218;;10.1042/bj3220499;;9065769;;21877;;10.1016/s0021-9258(19)75264-8,"Anderson, R et al. ""Correlation of E protein binding with cell susceptibility to dengue 4 virus infection"" Journal of General Virology (1992), vol. 73, pp. 2155-2159.;;Andrews, BS et al. ""Replication of Dengue and Junin viruses in cultured rabbit and human endothelial cells"" Infection and Immunity (Jun. 1978), vol. 20, No. 3, pp. 776-781.;;Aruffo, A et al. ""CD44 is the principal cell surface receptor for hyaluronate"" Cell (Jun. 29, 1990) vol. 61, pp. 1303-1313.;;Baeuerle PA and WB Huttner ""Chlorate-A Potent Inhibitor of Protein Sulfaction in Intact Cells"" Biochemical and Biophysical Research Communications (Dec. 15, 1986) vol. 141, No. 2.;;Bame, KJ and JD Esko ""Undersulfated Heparan Sulfate in a Chinese Hamster Ovary Cell Mutant Defective in Heparan Sulfate N-Sulfotransferase"" The Journal of Biological Chemistry (May 15, 1989) vol. 264, No. 14.;;Bernfield, M et al. ""Biology of the Syndecans: A family of transmembrane heparan sulfate proteoglycans"" Annual Review of Cell Biology (1992) vol. 8, pp. 365-393.;;Bork, P et al. ""The Immunoglobulin Fold: Structural Classification, Sequence Patterns and Common Core"" J. Mol. Biol. (1994) vol. 242, pp. 309-320.;;Brandt, WE et al. ""Effect of passage history on Dengue-2 Virus Replication in Subpopulations of Human Leukocytes"" Infection and Immunity (Nov. 1979) vol. 26, pp. 534-541.;;Cardin, AD and HJR Weintraub ""Molecular Modeling of Protein-Glycosaminoglycan Interactions"" Arteriosclerosis (Jan./Feb. 1989) vol. 9. No. 1, pp. 21-32.;;Cecilia, D and EA Gould ""Nucleotide Changes Responsible for Loss of Neuroinvasiveness in Japanese Encephalitis Virus Neutralization-Resistant Mutants"" Virology (1991), vol. 181, pp. 70-77.;;Chen, BPC and T Hai ""Expression vectors for affinity purification and radiolabeling of proteins using Eschdrichia coli as host"" Gene (1994) vol. 130, pp. 73-75.;;Chen, et al. ""Demonstration of Binding of Dengue Virus Envelope Protein to Target Cells"" Supplement to the American Journal of Tropical Medicine and Hygiene (1994) vol. 55, No. 2 pp. 269-270, abstract 517.;;Chen, Y et al. ""Demonstration of Binding of Dengue Virus Envelope Protein to Target Cells"" (Dec. 1996) Journal of Virology. vol. 70, No. 12, pp. 8765-8772.;;Chen, Y et al. ""Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate"" (Aug. 1997) Nature Medicine, vol. 3, No. 8, pp. 866-871.;;Chen, W and T Maguire ""Nucleotide sequence of the envelope glycoprotein gene of a dengue-2 virus isolated during an epidemic of benign dengue fever in Tonga in 1974"" Nucleic Acids Research (1990) vol. 18, No. 19, p. 5889.;;Daughaday, CC et al. ""Evidence for two mechanisms of dengue virus infection of adherent human monocytes; Trypsin-sensitive virus receptors and trypsin-resistant immune complex receptors"" Infection and Immunity (May 1981) vol. 32, No. 2, pp. 469-473.;;Davis, BD et al. ""The Nature of Viruses: Assay of Viruses"" Principles of Microbiology and Immunology (1967) pp. 664-671.;;Deubel, V., et al. ""Processing, secretion, and immunoreactivity of carboxy terminally truncated dengue-2 virus envelope proteins expressed in insect cells by recombinant baculoviruses"" Virology (1991) 180:442-447.;;Elder, J. H. et al. ""Endo-beta-N-acetylglucosaminidase F: Endoglycosidase from Flavobacterium. meningosepticum that cleaves both high-mannose and complex glycoproteins."" Proc. Natl. Acad. Sci. (USA) (1982) 79:4540-4544.;;Esko, J. D. et al. ""Animal cell mutants defective in glycosaminoglycan biosynthesis"" Proc. Nati. Acad. Sci. (USA) (1985) 82:3197-3201.;;Esko, J. D. et al. ""Inhibition of chondroitin and heparan sulfate biosynthesis in Chinese hamster ovary cell mutants defective in galactosyltransferase"" 1. J. Biol. Chem. (1985) 262:12189-95.;;Faham, S. et al. ""Heparin structure and interactions with basic fibroblast growth factor"" Science (1996) 271:1116-20.;;Fromm, J. R. et al. ""Differences in the interaction of heparin with arginine and lysine and the importance of these basic amino acids in the binding of heparin to acidic fibroblast growth factor"" Arch Biochem Biophys. (1995) 323:279-87.;;Grattage, L. P. et al. ""Effects of PMA, cytokines and dexamethasone on the expression of cell surface Fc receptors and mRNA in U937 cells"" Immunology and Cell Biology (1992) 70:97-105.;;Halstead, S. B. et al. ""Studies on the pathogenesis of dengue infection in monkeys. 1. Clinical laboratory responses to primary infection"" J. Infect. Dis. (1973) 128:7-14.;;Halstead, S. B. ""Pathogenesis of dengue: Challenges to molecular biology"" Science (1988) 239:476-486.;;Halstead, S. B. ""Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade"" Rev. Infect. Dis. (1989) 11:S830-S839.;;Halstead, S. B. ""The XXth century dengue pandemic: need for surveillance and research"" World Health Stat Q. (1992) 45:292-298.;;Hase, T. et al. ""Flavivirus entry into cultured mosquito cells and human peripheral blood monocytes"" Arch. Virol. (1989) 104:129-143.;;He, R.-T. et al. ""Antibodies that block virus attachment to Vero cells are a major component of the human neutralizing antibody response against dengue virus type 2"" J. Med. Virol. (1995) 45:451-461.;;Henchal, E. A., and J. R. Putnak ""The dengue viruses"" Clinical Microbiology Reviews (1990) 3:376-396.;;Holzmann, H. et al. ""A single amino acid substitution in envelope protein E of tick-borne encephalitis virus leads to attenuation in the mouse model"" J. Virology (1990) 64:5156-5159.;;Imbert, J. L. et al. ""Dengue virus infects mouse cultured neurons but not astrocytes"" J. Med. Virol. (1994) 42:228-33.;;Jackson, T. et al. ""Efficient Infection of Cells in Culture by Type O Foot-and-Mouth Disease Virus Requires Binding to Cell Surface Heparan Sulfate"" J. Virology (1996) 70:5282-5287.;;Jaffe, E. A. ""Culture and identification of large vessel endothelial cells."" In E. A. Jaffe ed, Biology of endothelial cells Martinus Nihoff, The Hague (1984).;;Jennings, A.D. et al. ""Analysis of a yello fever virus isolated from a fatal case of vaccine-associated human encephalitis"" J. Infect. Dis. (1994) 169:512-8.;;Jiang, W. R. et al. ""Single amino acid codon changes detected in louping ill virus antibody-resistant mutants with reduced neurovirulence"" J. Gen. Virology (1993) 74:931-935.;;Kurane, I. et al. ""Dengue-2 virus infection of human mononuclear cell lines and establishment of persistent infections"" Arch Virol. 110:91-101.;;Lidholt, K. et al. ""A single mutation affects both N-acetylglucosaminyltransferase and glucuronosyltransferase activities in a Chinese hamster ovary cell mutant defective in heparan sulfate biosynthesis"" Proc. Natl. Acad. Sci. (USA) (1992) 89:2267-2271.;;Lin, B. et al. ""Localization of a neutrlization epitope on the envelope protein of dengue virust type2"" Virology (1994) 202:885-890.;;Linhardt, R J. ""Analysis of glycogonjugates, pp. 17.13.17-17.13.32. In A. Varki (ed.), Current Protocols in Molecular Biology"" Wiley Interscience, Boston (1994).;;Linhardt, R. J. et al. ""Heparin oligosaccharides-new analogs development and application"" In Z.B. Witczak and K. A. Nieforth (ed.), Carbohydrates as Drugs. Marcel Dekker, New York (1997).;;Lucia, H. L. et al. ""Identification of dengue virus-infected cells in parrafin-embedded tissue using in situ polymerase chain reaction and DNA hybridization"" J. Virol. Methods (1994) 48:1-8.;;Maccarana, M. et al. ""Domain structure of heparan sulfates from bovine organs"" J. Biol. Chem. (196) 271:17804-17810.;;McClain, D.S. et al. ""Cell-specific kinetics and efficiency of herpes simplex virus type 1 entry are determined by two distinct phases of attachment"" Virology (1994) 198:690-702.;;Montgomery, R. I. et al. ""Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family"" Cell (1996) 87:427-436.;;Ortega-Barria, E. et al. ""A novel T. cruzi heparin-binding protein promotes fibroblast adhesion and penetration of engineered bacteria and trypanosomes into mammalian cells"" Cell (1991) 67:411-21.;;Peitsch, M. C. ""ProMod and Swiss-Model: Internet-based tools for automated comparative protein modelling"" Biochem Soc. Trans. (1996) 24:274-279.;;Porterfield, J.S. ""Antibody-dependent enhancement of viral infectivity"" Adv. Virus Research (1986) 31:335-355.;;Raake, W. et al. ""Anticoagulant and antithrombotic properties of synthetic sulfated bis-lactobionic acid amides"" Thromb Res. (1989) 56:719-30.;;Reed, L. J. et al. ""A simple method of estimating fifty per cent end points"" Amer. J. Hygiene (1938) 27:493-497.;;Rey, F. A. et al. ""The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution"" Nature (1995) 375:291-8.;;Rice, C. M. ""Flaviviridae: the viruses and their replication"", pp. 931-959. In B. N. Fields and D. M. Knipe A-17y and P. M. Howley (ed.), Fields Virology 3rd edition, vol. 1 Lippincott-Raven, Philadelphia (1996).;;Rostand, K. S. et al. ""Microbial adherence and invasion through proteoglycans"" Infect. Immun. (1997) 65:1-8.;;Ruoslahti, E. et al. ""New perspectives in cell adhesion: RGD and integrins"" Science (1987) 238:491-497.;;Salzman, G. C. et al. ""Cell classification by laser light scattering: identification and separation of unstained leukocytes"" Acta. Cytol. (1975) 19: 374-377.;;Sanchez, I. J. et al. ""A single nucleotide change in the E protein of dengue virus 2 mexican strain affects neurovirulence in mice"" J. General Virology (1996) 77:2541-2545.;;Sahaphong, S. et al. ""Electron microscopic study of the vascular endothelial cell in dengue hemorrhagic fever"" Southeast. Asian. J. Trop. Med. Pub. Health (1980) 11:194-204.;;Shao, H. et al. ""cDNA cloning and characterization of a ligand for the Cek5 receptor protein-tyrosine kinase"" J. Biol. Chem. (1994) 269:26606-26609.;;Sternbergh, W. C. et al. ""Heparinoids with low anticoagulant potency attenuate postischernic endothelial cell dysfunction"" J Vasc Surg. (1995) 21:477-83.;;Tarr, G. C. et al. ""Chemically induced temperature-sensitive mutants of dengue virus type 2: comparison of temperature sensitivity in vitro with infectivity in suckling mice, hamsters, and rhesus monkeys"" Infect. Immun. (1976) 13:688-695.;;Thompson, L. D. et al. ""Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain"" Biochemistry (1994) 33:3831-3840.;;Toida, T. et al. ""Enzymatic preparation of heparin oligosaccharides containing antithrombin III binding sites"" J. Biol. Chem. (1996) 271:32040-32047.;;Toida, T. et al. ""Structural differences in heparan sulfates from different tissues and species"" Biochemical Journal (1997) 322:499-506.;;Tyler, K. L. et al. ""Pathogenesis of viral infections"", pp. 173-217. In B. N. Fields and D. M. Knipe and P. M. Howley (ed.), Fields Virology 3rd edition, vol. 1. Lippincott-Raven, Philadelphia (1996).;;Umemoto, J. et al. ""Purification and properties of an endo-alpha-N-acetyl-D-galactosaminidase from Diplococcus pneurnoniae"" J. Biol. Chem. (1977) 252:8609-8614.;;Wimmer, E. ""Introduction, pp. 1-13. In E. Winimer (ed.),""Cellular receptors for animal viruses vol. 1. Cold Spring Harbor Laboratory Press, New York (1994).",EXPIRED
165,JP,A,JP 2002310138 A,162-767-614-591-289,2002-10-23,2002,JP 2001401433 A,2001-12-28,US 82741001 A,2001-04-06,ROLLER STRUCTURE FOR OPERATION IN HIGH TEMPERATURE CONDITION,PROBLEM TO BE SOLVED: To provide a roller structure capable of maintaining a connection even in a high temperature condition. SOLUTION: This roller 10 to be used for a fusion assembly of a copying device appropriate for the operation in the high temperature condition is provided with a cylindrical tube 12 and end gudgeons 14 for sealing both ends of the cylindrical tube. Each end gudgeon is provided at each corresponding end of the cylindrical tube to prevent the movement of the cylindrical tube in the direction for separating from the end gudgeon with the creep deformation of the material when operating in the high temperature condition after connecting the cylindrical tube and the end gudgeon by welding. The end gudgeon is formed with a recessed dovetail shape 20 for installation in the corresponding end of the cylindrical tube.,NEXPRESS SOLUTIONS LLC,KASS ALLEN;;MILLER TERENCE MICHAEL;;BLEIL RAINER;;CHEN JIANN-HSING,,https://lens.org/162-767-614-591-289,Patent Application,no,0,0,6,6,0,F16C13/00;;G03G15/2053;;G03G15/2053;;F16C13/00,F16C13/00;;G03G15/20,,0,0,,,,DISCONTINUED
166,US,A1,US 2020/0144416 A1,191-089-168-568-151,2020-05-07,2020,US 201816183214 A,2018-11-07,US 201816183214 A,2018-11-07,VERTICAL FIELD-EFFECT TRANSISTOR WITH A BOTTOM CONTACT THAT EXHIBITS LOW ELECTRICAL RESISTANCE,"Techniques regarding one or more VFETs operably coupled to bottom contacts with low electrical resistance are provided. For example, one or more embodiments described herein can comprise an apparatus, which can comprise a vertical field-effect transistor device that can comprise a semiconductor fin positioned on a source/drain region, which can comprise a semiconductor substrate. The apparatus can also comprise a metal contact layer positioned on the source/drain region and at least partially surrounding a base of the semiconductor fin. Further, the metal contact layer can be in electrical communication with the source/drain region.",IBM,ZHANG CHEN;;YAMASHITA TENKO;;HOOK TERENCE B;;ANDERSON BRENT ALAN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2018-11-01),https://lens.org/191-089-168-568-151,Patent Application,yes,2,1,2,2,0,H01L29/66666;;H01L29/7827;;H01L27/088;;H01L29/0847;;H01L29/41741;;H01L29/41741;;H01L29/66666;;H01L29/7827,H01L29/78;;H01L27/088;;H01L29/08;;H01L29/417;;H01L29/66,,0,0,,,,ACTIVE
167,PT,E,PT 880523 E,192-405-619-465-716,2007-01-31,2007,PT 97902295 T,1997-01-30,US 1127996 P;;US 2768896 P,1996-02-07,PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS,,NEUROCRINE BIOSCIENCES INC,CHEN-CHEN;;WEBB THOMAS R;;MCCARTHY JAMES;;MORAN TERENCE J;;WILCOXEN KEITH M,,https://lens.org/192-405-619-465-716,Granted Patent,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
168,US,A1,US 2016/0225919 A1,135-255-342-053-736,2016-08-04,2016,US 201514612639 A,2015-02-03,US 201514612639 A,2015-02-03,DEVICE STRUCTURE WITH NEGATIVE RESISTANCE CHARACTERISTICS,Device structures that exhibit negative resistance characteristics and fabrication methods for such device structures. A signal is applied to a metal layer of a metal-insulator-semiconductor capacitor to cause a breakdown of an insulator layer of the metal-insulator-semiconductor capacitor at a location. The breakdown at the location of the insulator layer causes the metal-insulator-semiconductor capacitor to exhibit negative resistance. The metal layer may be comprised of a polycrystalline metal. A grain of the polycrystalline metal may penetrate through the insulator layer and into a portion of a substrate at the location of the breakdown.,GLOBALFOUNDRIES INC,CHEN FEN;;GRAAS CAROLE D;;KANE TERENCE L;;SHINOSKY MICHAEL A,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-01-27);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/135-255-342-053-736,Patent Application,yes,6,2,5,5,0,H01L29/94;;H01L29/945;;H10N80/01;;H01L29/945;;H01L29/495;;H01L29/518;;H10N80/01,H01L29/94;;H01L29/32,,0,0,,,,DISCONTINUED
169,CN,A,CN 105845744 A,023-545-993-891-033,2016-08-10,2016,CN 201610069313 A,2016-02-01,US 201514612639 A,2015-02-03,Device structure with negative resistance characteristics,The invention provides device structures that exhibit negative resistance characteristics and fabrication methods for such device structures. A signal is applied to a metal layer of a metal-insulator-semiconductor capacitor to cause a breakdown of an insulator layer of the metal-insulator-semiconductor capacitor at a location. The breakdown at the location of the insulator layer causes the metal-insulator-semiconductor capacitor to exhibit negative resistance. The metal layer may be comprised of a polycrystalline metal. A grain of the polycrystalline metal may penetrate through the insulator layer and into a portion of a substrate at the location of the breakdown.,GLOBALFOUNDRIES INC,SHINOSKY MICHAEL A;;CHEN FEN;;KANE TERENCE L;;GRAAS CAROLE D,,https://lens.org/023-545-993-891-033,Patent Application,no,4,0,5,5,0,H01L29/94;;H01L29/945;;H10N80/01;;H01L29/945;;H01L29/495;;H01L29/518;;H10N80/01,H01L29/94,,0,0,,,,INACTIVE
170,TW,B,TW I633661 B,181-575-617-668-66X,2018-08-21,2018,TW 105101219 A,2016-01-15,US 201514612639 A,2015-02-03,Device structure with negative resistance characteristics,,GLOBALFOUNDRIES US INC,CHEN FEN;;GRAAS CAROLE D;;KANE TERENCE L;;SHINOSKY MICHAEL A,,https://lens.org/181-575-617-668-66X,Granted Patent,no,1,0,5,5,0,H01L29/94;;H01L29/945;;H10N80/01;;H01L29/945;;H01L29/495;;H01L29/518;;H10N80/01,,,0,0,,,,INACTIVE
171,WO,A1,WO 1997/047144 A1,024-907-154-138-712,1997-12-11,1997,US 9708706 W,1997-05-21,US 65681896 A,1996-06-03,METHOD AND APPARATUS FOR REGISTRATION STATUS INDICATION IN A ROAMING SYSTEM,A method for receiving a registration status indication at a one-way roaming selective call receiver comprises the steps of scanning (1051) a predetermined set of frequencies for an identifier(s) (1052 or 1056) broadcast on the frequencies that match identifier(s) stored at the receiver. The method provides an indication of being registered in a 'home' zone (1054) if an identifier transmitted on the communication resource matches a 'home' zone identifier stored in the receiver or provides for an indication of being registered in a 'roaming' zone (1058) if an identifier transmitted on the frequencies matches a 'roaming' zone identifier stored in the receiver or provides for an indication of not being registered (1055 or 1059) when the identifier transmitted on the frequencies do(es) not match either the 'home' zone identifier or the 'roaming' zone identifier stored in the receiver.,MOTOROLA INC,SUMNER TERENCE EDWARD;;BRIANCON ALAIN C;;CHEN XUMING;;HERTZ ALLEN D,,https://lens.org/024-907-154-138-712,Patent Application,yes,4,6,3,3,0,G08B3/1066;;H04W88/026,G08B3/10;;H04W88/02,,1,0,,,"ADVISOR MESSAGE RECEIVER ADVERTISEMENT, 1990.",PENDING
172,HU,A2,HU P9900575 A2,039-222-395-272-00X,1999-06-28,1999,HU P9900575 A,1997-01-30,US 1127996 P;;US 2768896 P,1996-02-07,PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS,"A találmány új, (I) általánős képletű pirazőlő-pirimidin-származékőkravőnatkőzik, amelyek kőrtikőtrőpint kibőcsátó faktőr receptőrantagőnista hatásúak. Az (I) általánős képletben R1 jelentése -NR4R5vagy -OR5 általánős képletű csőpőrt; R2 jelentése alkil-, alkőxi- vagyalkil-tiőcsőpőrt; R3 jelentése hidrőgénatőm vagy alkil-, alkil-szlfőnil-, alkil-szűlfőxi- vagy alkil-tiőcsőpőrt; R4 jelentésehidrőgénatőm vagy alkil-, mőnő- vagy diciklőalkil-metil-, ciklőalkil-,alkenil-, hidrőxi-alkil-, alkil-karbőnil-őxi-alkil- vagy alkőxi-alkilcsőpőrt; R5 jelentése alkil-, mőnő- vagy diciklőalkil-metil-,Ar1-CH2-, alkőxi-alkil-, hidrőxi-alkil-, alkenil-, tienil-metil-,fűranil-metil-, alkil-tiő-alkil-, mőrfőlinil-, mőnő- vagy dialkil-aminő-alkil-, dialkil-aminő-, alkil-karbőnil-alkil-, imidazőlil-alkil-vagy -Alk-O-CO-Ar1 általánős képletű csőpőrt; vagy R4 és R5 együttalkil- vagy alkőxi-alkilcsőpőrttal adőtt esetben szűbsztitűáltpirrőlidinil-, piperidinil-, hőmőpiperidinil- vagy mőrfőlinilcsőpőrtőtalkőtnak azzal a nitrőgénatőmmal, amelyhez kapcsőlódnak; és Arjelentése fenilcsőpőrt; 1, 2 vagy 3 szűbsztitűenssel, éspedigegymástól függetlenül megválasztőtt halőgénatőmők vagy alkil-,triflűőr-metil-, hidrőxi-, cianő-, alkőxi-, benzil-őxi-, alkil-tiő-,nitrő-, aminő- és mőnő- vagy dialkil-aminőcsőpőrtők közülmegválasztőtt helyettesítővel szűbsztitűált fenilcsőpőrt;piridinilcsőpőrt; 1, 2 vagy 3 szűbsztitűenssel, éspedig egymástólfüggetlenül megválasztőtt halőgénatőmők vagy alkil-, triflűőr-metil-,hidrőxi-, cianő-, alkőxi-, benzil-őxi-, alkil-tiő-, nitrő-, aminő-,mőnő- vagy dialkil-aminő- és piperidinilcsőpőrtők közül megválasztőtthelyettesítővel szűbsztitűált piridinilcsőpőrt; és az említettszűbsztitűált fenilcsőpőrt adőtt esetben tővább lehet szűbsztitűálvaegy vagy több halőgénatőmmal; Ar1 jelentése fenilcsőpőrt; 1, 2 vagy 3szűbsztitűenssel, éspedig egymástól függetlenül megválasztőtthalőgénatőmők vagy alkil-, alkőxi-, dialkil-aminő-alkil-, triflűőr-metil- és mőrfőlinil-alkilcsőpőrtők közül megválasztőtt helyettesítettfenilcsőpőrt; vagy piridinilcsőpőrt; és Alk jelentése alkándiilcsőpőrt ŕ",JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;MCCARTHY JAMES R;;MORAN TERENCE J;;WEBB THOMAS R;;WILCOXEN KEITH M,,https://lens.org/039-222-395-272-00X,Patent Application,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,PENDING
173,EP,A1,EP 0880523 A1,032-667-132-248-62X,1998-12-02,1998,EP 97902295 A,1997-01-30,EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M,"JANSSEN PHARMACEUTICA N.V. (1999-12-29);;NEUROCRINE BIOSCIENCES, INC. (2011-03-15);;*NEUROCRINE BIOSCIENCES INC.12790 EL CAMINO REAL, (2006-08-16);;NEUROCRINE BIOSCIENCES, INC., US (2007-03-05)",https://lens.org/032-667-132-248-62X,Patent Application,yes,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
174,US,A1,US 2020/0135457 A1,162-258-931-300-152,2020-04-30,2020,US 201816170465 A,2018-10-25,US 201816170465 A,2018-10-25,STACK VIABAR STRUCTURES,"Various methods and structures for fabricating a semiconductor structure. The semiconductor structure includes in a top layer of a semiconductor stack a semiconductor contact located according to a first horizontal pitch. A first metallization layer is disposed directly on the top layer and includes a metallization contact located according to a second horizontal pitch, the second horizontal pitch being different from the first horizontal pitch such that the location of the metallization contact is vertically mismatched from the location of the semiconductor contact. A second metallization layer is disposed directly on the first metallization layer. The second metallization layer includes a super viabar structure that forms an electrical interconnect, in the second metallization layer, between the semiconductor contact in the top layer of the semiconductor stack and the metallization contact in the first metallization layer.",IBM,FAN SU CHEN;;CHEN HSUEH-CHUNG;;MIGNOT YANN;;KELLY JAMES J;;HOOK TERENCE B,INTERNATIONAL BUSINESS MACHINES CORPORATION (2018-10-24),https://lens.org/162-258-931-300-152,Patent Application,yes,0,0,4,4,0,H01L21/76811;;H01L23/5226;;H01L21/76849;;H01L21/76858;;H01L23/5283;;H01L21/02244;;H01L21/76879;;H01L21/3213;;H01L25/074,H01L21/02;;H01L21/3213;;H01L21/768;;H01L25/07,,0,0,,,,ACTIVE
175,WO,A1,WO 1997/029109 A1,127-676-730-097-461,1997-08-14,1997,EP 9700459 W,1997-01-30,US 1127996 P;;US 2768896 P,1996-02-07,PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS,"This invention concerns compounds of formula (I), including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R?1 is NR4R5 or OR5; R2¿ is C¿1-6?alkyl, C1-6alkyloxy or C1-6alkylthio; R?3¿ is hydrogen, C¿1-6?alkyl, C1-6alkylsulfonyl, C1-6alkylsulfoxy or C1-6alkylthio; R?4¿ is hydrogen, C¿1-6?alkyl, mono- or di(C3-6cycloalkyl)methyl, C3-6cycloalkyl, C3-6alkenyl, hydroxyC1-6alkyl, C1-6alkylcarbonyloxyC1-6alkyl or C1-6alkyloxyC1-6alkyl; R?5¿ is C¿1-8?alkyl, mono- or di(C3-6cycloalkyl)methyl, Ar?1CH¿2, C1-6alkyloxyC1-6alkyl, hydroxyC1-6alkyl, C3-6alkenyl, thienylmethyl, furanylmethyl, C1-6alkylthioC1-6alkyl, morpholinyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)amino, C1-6alkylcarbonylC1-6alkyl, C1-6alkyl substituted with imidazolyl; or a radical of the formula -Alk-O-CO-Ar?1; or R4 and R5¿ taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).",JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC;;CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M,,https://lens.org/127-676-730-097-461,Patent Application,yes,3,110,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,2,2,021-684-841-248-564;;001-169-215-850-206,10.1021/jm00226a013;;817023;;10.1021/jm00137a023;;7241518,"NOVINSON, THOMAS ET AL: ""Novel heterocyclic nitrofurfural hydrazones. In vivo antitrypanosomal activity"", J. MED. CHEM. (1976), 19(4), 512-16 CODEN: JMCMAR, 1976, XP002030876;;SENGA, KEITARO ET AL: ""Synthesis and antischistosomal activity of certain pyrazolo[1,5-a]pyrimidines"", J. MED. CHEM. (1981), 24(5), 610-13 CODEN: JMCMAR;ISSN: 0022-2623, 1981, XP002030877",PATENTED
176,US,S,US D0528125 S,066-468-360-407-161,2006-09-12,2006,US 23466805 F,2005-07-21,EM 28878205 F,2005-02-03,Centerplayer of home theater system,,KONINKL PHILIPS ELECTRONICS NV,CHEN JUI YUAN;;JOHANSSON PERNILLA MARIA CECIL;;LOH TERENCE TZE KOK,KONINKLIJKE PHILIPS ELECTRONICS N.V (2005-07-06),https://lens.org/066-468-360-407-161,Design Right,no,0,0,4,4,0,,,1403;;D14/496,0,0,,,,EXPIRED
177,US,A,US 5842210 A,171-635-577-955-603,1998-11-24,1998,US 74148296 A,1996-10-30,US 74148296 A,1996-10-30,Method and apparatus for selectively retrieving data from a database in a data communication system,"In a data communication system a first controller (102) selectively retrieves data from a database (316) in a second controller (106). Data corresponding to a plurality of entities is programmed (602) into the database. The data includes a plurality of parameters for each of the plurality of entities. Ones of the plurality of parameters are selectively defined (604) to belong to parameter groups in accordance with a predetermined grouping plan. The first controller generates (612) a request for the data corresponding to one of the plurality of entities from the database, the request further indicating a desired one of the parameter groups. The second controller returns (620) the desired one of the parameter groups corresponding to the one of the plurality of entities, in response to the request.",MOTOROLA INC,CHEN XUMING;;PHILLIPS W GARLAND;;BRIANCON ALAIN C;;SUMNER TERENCE EDWARD,MOTOROLA MOBILITY LLC (2012-06-22);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;MOTOROLA INC (1996-10-29),https://lens.org/171-635-577-955-603,Granted Patent,yes,9,36,1,1,0,H04W4/06;;H04W8/20;;H04W28/06;;H04L67/306;;H04L69/329;;H04L67/306;;H04W4/06;;H04W28/06;;H04W8/20;;Y10S707/99945;;H04L69/329;;H04L9/40,H04L29/06;;H04L29/08;;H04W4/06;;H04W8/20;;H04W28/06,707/10;;707/104;;340/825.44;;455/418;;379/67,1,0,,,"Daniel Gilly, UNIX in a Nutshell, 2 71, Aug. 1994, U.S.A.",EXPIRED
178,US,S,US D0538262 S,046-316-827-253-875,2007-03-13,2007,US 23466705 F,2005-07-21,EM 28878205 F,2005-02-03,Subwoofer for a home theater system,,KONINKL PHILIPS ELECTRONICS NV,CHEN JUI YUAN;;LOH TERENCE TZE KOK;;JOHANSSON PERNILLA MARIA CECIL,KONINKLIJKE PHILIPS ELECTRONICS N.V (2005-07-06),https://lens.org/046-316-827-253-875,Design Right,yes,7,1,4,4,0,,,1401;;D14/214,0,0,,,,EXPIRED
179,DK,T3,DK 0880523 T3,050-603-274-916-072,2007-03-26,2007,DK 97902295 T,1997-01-30,US 1127996 P;;US 2768896 P;;EP 9700459 W,1996-02-07,Pyrazolopyrimidiner som CRF-receptorantagonister,,NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M,,https://lens.org/050-603-274-916-072,Granted Patent,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
180,US,A1,US 2020/0203156 A1,048-067-198-995-929,2020-06-25,2020,US 202016804710 A,2020-02-28,US 202016804710 A;;US 201816170465 A,2018-10-25,STACK VIABAR STRUCTURES,"Various methods and structures for fabricating a semiconductor structure. The semiconductor structure includes in a top layer of a semiconductor stack a semiconductor contact located according to a first horizontal pitch. A first metallization layer is disposed directly on the top layer and includes a metallization contact located according to a second horizontal pitch, the second horizontal pitch being different from the first horizontal pitch such that the location of the metallization contact is vertically mismatched from the location of the semiconductor contact. A second metallization layer is disposed directly on the first metallization layer. The second metallization layer includes a super viabar structure that forms an electrical interconnect, in the second metallization layer, between the semiconductor contact in the top layer of the semiconductor stack and the metallization contact in the first metallization layer.",IBM,FAN SU CHEN;;CHEN HSUEH-CHUNG;;MIGNOT YANN;;KELLY JAMES J;;HOOK TERENCE B,INTERNATIONAL BUSINESS MACHINES CORPORATION (2018-10-24),https://lens.org/048-067-198-995-929,Patent Application,yes,0,1,4,4,0,H01L21/76811;;H01L23/5226;;H01L21/76849;;H01L21/76858;;H01L23/5283;;H01L21/02244;;H01L21/76879;;H01L21/3213;;H01L25/074,H01L21/02;;H01L21/3213;;H01L21/768;;H01L25/07,,0,0,,,,ACTIVE
181,US,B2,US 10971356 B2,086-799-243-750-229,2021-04-06,2021,US 202016804710 A,2020-02-28,US 202016804710 A;;US 201816170465 A,2018-10-25,Stack viabar structures,"Various methods and structures for fabricating a semiconductor structure. The semiconductor structure includes in a top layer of a semiconductor stack a semiconductor contact located according to a first horizontal pitch. A first metallization layer is disposed directly on the top layer and includes a metallization contact located according to a second horizontal pitch, the second horizontal pitch being different from the first horizontal pitch such that the location of the metallization contact is vertically mismatched from the location of the semiconductor contact. A second metallization layer is disposed directly on the first metallization layer. The second metallization layer includes a super viabar structure that forms an electrical interconnect, in the second metallization layer, between the semiconductor contact in the top layer of the semiconductor stack and the metallization contact in the first metallization layer.",IBM,FAN SU CHEN;;CHEN HSUEH-CHUNG;;MIGNOT YANN;;KELLY JAMES J;;HOOK TERENCE B,INTERNATIONAL BUSINESS MACHINES CORPORATION (2018-10-24),https://lens.org/086-799-243-750-229,Granted Patent,yes,14,0,4,4,0,H01L21/76811;;H01L23/5226;;H01L21/76849;;H01L21/76858;;H01L23/5283;;H01L21/02244;;H01L21/76879;;H01L21/3213;;H01L25/074,H01L21/3213;;H01L21/02;;H01L21/768;;H01L25/07,,1,0,,,List of IBM Patents or Patent Applications Treated as Related.,ACTIVE
182,ID,A,ID 18236 A,054-874-001-575-25X,1998-03-19,1998,ID 971865 A,1997-06-02,US 65681896 A,1996-06-03,METODA DAN PERALATAN UNTUK INDIKASI STATUS PENDAFTARAN DALAM SISTEM PENGEMBARAAN,,MOTOROLA INC,SUMNER TERENCE EDWARD;;BRIANCON ALAIN C;;CHEN XUMING;;HERTZ ALLEN D,,https://lens.org/054-874-001-575-25X,Patent Application,no,0,0,3,3,0,G08B3/1066;;H04W88/026,G08B3/10;;H04W88/02,,0,0,,,,PENDING
183,TW,A,TW 201639155 A,061-000-235-551-572,2016-11-01,2016,TW 105101219 A,2016-01-15,US 201514612639 A,2015-02-03,Device structure with negative resistance characteristics,Device structures that exhibit negative resistance characteristics and fabrication methods for such device structures. A signal is applied to a metal layer of a metal-insulator-semiconductor capacitor to cause a breakdown of an insulator layer of the metal-insulator-semiconductor capacitor at a location. The breakdown at the location of the insulator layer causes the metal-insulator-semiconductor capacitor to exhibit negative resistance. The metal layer may be comprised of a polycrystalline metal. A grain of the polycrystalline metal may penetrate through the insulator layer and into a portion of a substrate at the location of the breakdown.,GLOBALFOUNDRIES US INC,CHEN FEN;;GRAAS CAROLE D;;KANE TERENCE L;;SHINOSKY MICHAEL A,,https://lens.org/061-000-235-551-572,Patent of Addition,no,0,0,5,5,0,H01L29/94;;H01L29/945;;H10N80/01;;H01L29/945;;H01L29/495;;H01L29/518;;H10N80/01,H01L29/32;;H01L29/94,,0,0,,,,INACTIVE
184,TW,B,TW 340293 B,105-733-607-384-334,1998-09-11,1998,TW 86111276 A,1997-08-06,US 65681896 A,1996-06-03,Method and apparatus for registration status indication in a roaming system,"A sort of method or receiving a registration status indication at a one-way roaming selective call receiver, including: scanning a predetermined set of frequencies for an identifier broadcast on the frequencies matching identifier stored at the receiver, providing the method an indication of registration in a ""home"" zone if an identifier transmitted on the communication resource matches a ""home"" zone identifier stored in the receiver or providing for an indication of not being registered when the identifier transmitted on the frequencies do not match either the ""home"" zone identifier or the ""roaming"" zone identifier stored in the receiver.",MOTOROLA INC,TERENCE EDWARD SUMNER;;ALAIN C BRIANCON;;XUMING CHEN;;ALLAN D HERTZ,,https://lens.org/105-733-607-384-334,Granted Patent,no,0,1,3,3,0,G08B3/1066;;H04W88/026,G08B3/10;;H04W88/02,,0,0,,,,EXPIRED
185,US,A1,US 2014/0117490 A1,122-534-326-702-791,2014-05-01,2014,US 201213661683 A,2012-10-26,US 201213661683 A,2012-10-26,SEMICONDUCTOR DEVICE INCLUDING ESD PROTECTION DEVICE,"A semiconductor device includes a semiconductor-on-insulator (SOI) substrate having a bulk substrate layer, an active semiconductor layer and a buried insulator layer disposed between the bulk substrate layer and the active semiconductor layer. A trench is formed through the SOI substrate to expose the bulk substrate layer. A doped well is formed in an upper region of the bulk substrate layer adjacent trench. The semiconductor device further includes a first doped region different from the doped well that is formed in the trench.",IBM,YAMASHITA TENKO;;HOOK TERENCE B;;BASKER VEERARAGHAVAN S;;YEH CHUN-CHEN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2012-10-18);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/122-534-326-702-791,Patent Application,yes,7,7,3,3,0,H01L2924/0002;;H01L29/66136;;H01L29/861;;H01L29/1608;;H01L29/161;;H01L27/0255;;H01L2924/0002;;H01L29/861;;H01L29/1608;;H01L29/66136;;H01L29/161;;H01L27/0255;;H01L29/6609;;H01L29/66121,H01L29/02;;H01L21/22,257/506;;438/510;;257/659;;X257E29002;;X257E21135,0,0,,,,INACTIVE
186,DE,D1,DE 69736513 D1,136-318-797-436-428,2006-09-28,2006,DE 69736513 T,1997-01-30,US 1127996 P;;US 2768896 P;;EP 9700459 W,1996-02-07,PYRAZOLOPYRIMIDINE ALS CRF REZEPTOR-ANTAGONISTEN,,NEUROCRINE BIOSCIENCES INC,CHEN SAN DIEGO;;WEBB THOMAS;;MCCARTHY JAMES;;MORAN TERENCE;;WILCOXEN KEITH,,https://lens.org/136-318-797-436-428,Granted Patent,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
187,WO,A1,WO 2014/065927 A1,159-693-145-770-040,2014-05-01,2014,US 2013/0054065 W,2013-08-08,US 201213661683 A,2012-10-26,SEMICONDUCTOR DEVICE INCLUDING ESD PROTECTION DEVICE,"A semiconductor device includes a semiconductor-on-insulator (SOI) substrate having a bulk substrate layer, an active semiconductor layer and a buried insulator layer disposed between the bulk substrate layer and the active semiconductor layer. A trench is formed through the SOI substrate to expose the bulk substrate layer. A doped well is formed in an upper region of the bulk substrate layer adjacent trench. The semiconductor device further includes a first doped region different from the doped well that is formed in the trench.",IBM,YAMASHITA TENKO;;HOOK TERENCE B;;BASKER VEERARAGHAVAN S;;YEH CHUN-CHEN,,https://lens.org/159-693-145-770-040,Patent Application,yes,5,0,3,3,0,H01L2924/0002;;H01L29/66136;;H01L29/861;;H01L29/1608;;H01L29/161;;H01L27/0255;;H01L2924/0002;;H01L29/861;;H01L29/1608;;H01L29/66136;;H01L29/161;;H01L27/0255;;H01L29/6609;;H01L29/66121,H01L23/60,,0,0,,,,PENDING
188,DE,T2,DE 69736513 T2,028-152-873-995-73X,2007-04-05,2007,DE 69736513 T,1997-01-30,US 1127996 P;;US 2768896 P;;EP 9700459 W,1996-02-07,PYRAZOLOPYRIMIDINE ALS CRF REZEPTOR-ANTAGONISTEN,,NEUROCRINE BIOSCIENCES INC,CHEN SAN DIEGO;;WEBB THOMAS;;MCCARTHY JAMES;;MORAN TERENCE;;WILCOXEN KEITH,,https://lens.org/028-152-873-995-73X,Granted Patent,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
189,EA,A1,EA 199800394 A1,041-561-727-236-928,1998-10-29,1998,EA 199800394 A,1997-01-30,EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,Pyrazolopyrimidines as CRF receptor antagonists,"Изобретение относится к соединениям формулы (I)включая их стереоизомеры и фармацевтически приемлемые кислотно-аддитивные соли, где Rпредставляет собой NRRили OR; Rпредставляет C-алкил, C-алкилокси или C-алкилтио; Rпредставляет водород, C-алкил, C-алкилсульфонил, C-алкилсульфокси или C-алкилтио; Rпредставляет водород, C-алкил, моно- или ди(C-циклоалкил)метил, C-циклоалкил, C-алкенил, гидрокси-C-алкил, C-алкилкарбонилокси-C-алкил или C-алкилокси-C-алкил; Rпредставляет C-алкил, моно- или ди(C-циклоалкил)метил, ArCH, C-алкилокси-C-алкил, гидрокси-C-алкил, C-алкенил, тиенилметил, фуранилметил, C-алкилтио-C-алкил, морфолинил, моно- или ди(C-алкил)амино-C-алкил, ди(C-алкил)амино, C-алкилкарбонил-C-алкил, C-алкил, замещенный имидазолилом; или радикал формулы -Alk-O-CO-Ar; или Rи Rвместе с атомом азота, к которому они присоединены, могут образовывать пирролидинил, пиперидинил, гомопиперидинил или морфолинил; обладающим свойствами антагонистов рецепторов КРФ; фармацевтическим композициям, содержащим такие соединения в качестве активных ингредиентов; способам лечения заболеваний, связанных с гиперсекрецией КРФ, таких как депрессия, патологический страх, пристрастия к различным веществам, путем введения эффективного количества соединения формулы (I).Международная заявка была опубликована вместе с отчетом о международном поиске.",JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MORAN TERENCE J;;MCCARTHY JAMES R;;WILCOXEN KEITH M,,https://lens.org/041-561-727-236-928,Patent Application,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
190,AT,T1,AT E336495 T1,110-044-457-831-713,2006-09-15,2006,AT 97902295 T,1997-01-30,US 1127996 P;;US 2768896 P,1996-02-07,PYRAZOLOPYRIMIDINE ALS CRF REZEPTOR-ANTAGONISTEN,,NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M,,https://lens.org/110-044-457-831-713,Granted Patent,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
191,TW,B,TW 449599 B,102-948-752-679-082,2001-08-11,2001,TW 86101373 A,1997-02-05,US 1127996 P;;US 2768896 P,1996-02-07,"Pyrazolo[1,5-a]pyrimidines having corticotropin-releasing factor (CRF) receptor antagonistic properties, their preparation and pharmaceutical composition containing the same","This invention concerns compounds of formula, including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R1 is NR4R5 or C1-6alkyloxy; R2 is C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfoxy or C1-6alkylthio; R4 is hydrogen, C1-6alkyl, C3-6alkenyl, hydroxyC1-6alkyl, C1-6alkylcarbonyloxyC1-6alkyl or C1-6alkyloxyC1-6alkyl; R5 is C1-8alkyl, (C3-6cycloalkyl)methyl, Ar1CH2, C3-6alkenyl, C1-6alkyloxyC1-6alkyl, hydroxyC1-6alkyl or C1-6alkylthio C1-6alkyl; or R4 and R5 taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl or homopiperidinyl group, optionally substituted with C1-6alkyl or C1-6alkyloxyC1-6alkyl; and Ar is phenyl substituted with halo, C1-6alkyl or C1-6alkyloxy; pyridinyl pyridinyl substituted with halo, C1-6alkyl, trifluoromethyl, C1-6alkyloxy, nitro, amino, mono- or di(C1-6alkyl)amino or piperidinyl; Ar1 is phenyl; phenyl substituted with C1-6alkyloxy; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).",JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M,,https://lens.org/102-948-752-679-082,Granted Patent,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
192,EA,B1,EA 000803 B1,142-917-323-642-926,2000-04-24,2000,EA 199800394 A,1997-01-30,EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS,"1. A compound of formula including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R<1> is NR<4>R<5> or OR<5>; R<2> is C1-C6-alkyl, C1-C6-alkyloxy or C1-C6-alkylthio; R<3> is hydrogen, C1-C6-alkyl, C1-C6-alkylsulfonyl, C1-C6-alkylsulfoxy or C1-C6-alkylthio; R<4> is hydrogen, C1-C6-alkyl, mono- or di(C3-C6-cycloalkyl)methyl, C3-C6-cycloalkyl, C3-C6-alkenyl, hydroxy- C1-C6-alkyl, C1-C6-alkylcarbonyloxy- C1-C6-alkyl or C1-C6-alkyloxy- C1-C6-alkyl; R<5> is C1-C8-alkyl, mono- or di(C3-C6-cycloalkyl)methyl, Ar<1>CH2, C3-C6-alkenyl, C1-C6-alkyloxy- C1-C6-alkyl, hydroxy- C1-C6-alkyl, thienylmethyl, furanylmethyl, C1-C6-alkylthio- C1-C6-alkyl, morpholinyl, mono- or di(C1-C6-alkyl)amino-C1-6alkyl, di(C1-C6-alkyl)amino, C1-C6-alkylcarbonyl- C1-C6-alkyl, C1-C6-alkyl substituted with imidazolyl; or a radical of formula -Alk-O-CO-Ar<1>; or R<4> and R<5> taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C1-C6-alkyl or C1-C6-alkyloxy-C1-6alkyl; and Ar is phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from halo, C1-C6-alkyl, trifluoromethyl, hydroxy, cyano, C1-C6-alkyloxy, benzyloxy, C1-C6-alkylthio, nitro, amino and mono- or di(C1-C6-alkyl)amino; pyridinyl; pyridinyl substituted with 1, 2 or 3 substituents independently selected from halo, C1-C6-alkyl, trifluoromethyl, hydroxy, cyano, C1-C6-alkyloxy, benzyloxy, C1-C6-alkylthio, nitro, amino, mono- or di(C1-C6-alkyl)amino and piperidinyl; and wherein said substituted phenyl may optionally be further substituted with one or more halogens; Ar<1> is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C1-C6-alkyl, C1-C6-alkyloxy, di(C1-C6-alkyl)amino-C1-C6-alkyl, trifluoromethyl and C1-C6-alkyl substituted with orpholinyl; or pyridinyl; and Alk is C1-C6-alkanediyl; with the proviso that 5-methyl-3-phenyl-7-(phenylmethoxy)-pyrazolo[1,5-a]-pyrimidine and 2,5-dimethyl-7-(methylamino)-3-phenyl-pyrazolo[1,5-a]pyrimidine are not included. 2. A compound according to claim 1 wherein R<1> is OR<5> and R<5> is C1-C6-alkyl; or R<1> is NR<4>R<5> and R<4> is hydrogen, C1-C6-alkyl, hydroxy- C1-C6-alkyl, C1-C6-alkylcarbonyloxy- C1-C6-alkyl or C3-C6-alkenyl; R<5> is C1-C8-alkyl, C3-C6-alkenyl, hydroxy- C1-C6-alkyl, C1-C6-alkyloxy- C1-C6-alkyl, phenylmethyl or C3-C6-cycloalkylmethyl; or R<4> and R<5> are taken together with the nitrogen atom to which they are attached to form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C1-C6-alkyl or C1-C6-alkyloxy- C1-C6-alkyl; R<2> is C1-C6-alkyl; R<3> is hydrogen, C1-C6-alkyl or C1-C6-alkylthio; and Ar is a phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C1-C6-alkyl or C1-C6-alkyloxy; or Ar is a pyridinyl substituted with 1, 2 or 3 substituents each independently selected from halo, amino, nitro, trifluoromethyl, mono- or di(C16alkyl)amino, piperidinyl or C1-C6-6alkyl. 3. A compound according to any of claims 1 to 2 wherein R<1> is NR<4>R<5> and R<4> is C2-C4-alkyl, hydroxy- C1-C2-alkyl, C3-C4-alkenyl or C1-C2-alkylcarbonyloxy-C2-C4-alkyl; R<5> is C2-C4 -alkyl, C3-C4-alkenyl, hydroxy-C2-C4-alkyl or cyclopropylmethyl; R<2> is C1-C2-alkyl; R<3> is hydrogen, C1-C2-alkyl or C1-C2-alkylthio. 4. A compound according to any of claims 1 to 3 wherein R<1> is NR<4>R<5> and R<4> is C3-C4-alkyl or allyl; R<5> is C2-C4-alkyl, allyl or cyclopropylmethyl; R<2> is methyl; R<3> is methyl; and Ar is phenyl substituted in the 3-, 4-, 6-, 2,4- or 2,4,6-positions with halo, C1-C6-alkyl or C1-C6-alkyloxy. 5. A compound according to any of claims 1 to 3 wherein R<1> is NR<4>R<5> and R<4> is C3-C4-alkyl or allyl; R<5> is C3-C4-alkyl, allyl or cyclopropylmethyl; R<2> is methyl; R<3> is methyl; and Ar is 3-pyridinyl substituted on the 4- and/or 6-position with methyl or dimethylamino. 6. A compound according to claim 1 wherein the compound is 3-[6-(dimethylamino)-3-pyridinyl]-2,5-dimethyl-N,N-dipropylpyrazolo[2,3-a]pyrimidin-7-amine, or 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N,N-dipropylpyrazolo[2,3-a]pyrimidin-7-amine; the stereochemically isomeric forms, or the pharmaceutically acceptable acid addition salts thereof. 7. A composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as claimed in any one of claims 1 to 6. 8. A process for preparing a composition as claimed in claim 7 characterized in that a therapeutically effective amount of a compound as claimed in any one of claims 1 to 6 is intimately mixed with a pharmaceutically acceptable carrier. 9. A compound according to any one of claims 1 to 6 for use as a medicine. 10. The use of compounds of formula I including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R<1>, R<2>, R<3> and Ar are as defined in claim 1, including the compounds 5-methyl-3-phenyl-7-(phenylmethoxy)-pyrazolo[1,5-a]-pyrimidine and 2,5-dimethyl-7-(methylamino)-3-phenyl-pyrazolo[1,5-a]pyrimidine, for manufacture of a medicament for treating physiological conditions or disorders arising from the hypersecretion of corticotropin-releasing factor (CRF). 11. A compound of formula (II') wherein the radicals R<2>, R<3> and Ar are as defined in any of claims 1 to 5 and radical W' is hydroxy, halo, mesyloxy or tosyloxy; a stereoisomeric form or an acid addition salt form thereof, with the proviso that compounds wherein Ar is unsubstituted phenyl are not included, and compounds wherein Ar is 4-chlorophenyl, 4-fluorophenyl or 3-methylphenyl, when W' is hydroxy or chlorine. 12. A process of preparing a compound as claimed in claim 1, characterized by a) reacting an intermediate of formula (II) with an intermediate of formula (III) in a reaction-inert solvent, b) O-alkylating an intermediate of formula (VI) with an intermediate of formula (VII) in a reaction-inert solvent and in the presence of a suitable base, yielding compounds of formula (I-a), defined as compounds of formula (I) wherein R<1> is OR<5>, wherein in the above reaction schemes the radicals R<1>, R<2>, R<3>, R<5> and Ar are as defined in claim 1 and W is an appropriate leaving group; or, if desired, converting compounds of formula (I) into each other following art known transformation reactions; and further, if desired, converting the compounds of formula (I), into an acid addition salt by treatment with an acid, or conversely, converting the acid addition salt form into the free base by treatment with alkali; and, if desired, preparing stereochemically isomeric forms thereof. 13. A process of preparing a compound of formula (II') as claimed in claim 11 characterized by reacting an intermediate of formula (IV) with a β-keto ester (V) in a reaction-inert solvent, thereby yielding compounds of formula (II'-a), defined as compounds of formula (II') wherein W' is hydroxy; and optionally converting compounds of formula (II'-a) into compounds of formula (II'-b), defined as compounds of formula (II') wherein W' is other than hydroxy; wherein in the above reaction schemes the radicals R<2>, R<3> and Ar are as defined in claim 1 and W' is hydroxy, halo, mesyloxy or tosyloxy; or, if desired, converting compounds of formula (II') into each other following art known transformation reactions; and further, if desired, converting the compounds of formula (II'), into an acid addition salt by treatment with an acid, or conversely, converting the acid addition salt form into the free base by treatment with alkali; and, if desired, preparing stereochemically isomeric forms thereof.",JANSSEN PHARMACEUTICA NV,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M,,https://lens.org/142-917-323-642-926,Granted Patent,no,3,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,2,2,039-459-043-451-990;;001-169-215-850-206,10.1002/chin.197631278;;10.1021/jm00137a023;;7241518,"J. MED. CHEM. (1976), 19(4), 5l2-16 CODEN: JMCMAR, 1976, XP002030876 NOVINSON, THOMAS ET AL: ""Novel heterocyclic nitrofurfural hydrazones. In vivo antitrypanosomal activity"" see page 516, compounds 7a. 7b;;J. MED. CHEM. (1981), 24(5), 610-13 CODEN: JMCMAR:ISSN: 0022-2623, 1981, XP002030877 SENGA, KEITARO ET AL: ""Synthesis ahd antischistosomal activity of certain pyrazolo [1,5-a]pyrimidines"" see Table.II. no. 33,35",EXPIRED
193,CN,U,CN 204179373 U,064-059-009-756-612,2015-02-25,2015,CN 201420587151 U,2014-10-13,US 201462001084 P,2014-05-21,Electric connector,"The utility model provides an electric connector which can be connected with a butting connector in an inserted mode. The electric connector comprises a terminal base and two rows of terminals arranged on the terminal base, wherein the terminal base comprises a butting tongue plate located at the front side and a body portion located at the rear side, the butting tongue plate is provided with two opposite surfaces, each of the two rows of terminals comprises a contact portion used for being butted with the butting connector and a connection pin extending out of the body portion, the two opposite surfaces of the butting tongue plate are provided with a plurality of terminal grooves, the contact portions of the terminals are accommodated in the terminal grooves respectively, and at least part of each terminal groove further sinks in an area of the corresponding contact portion so as to form a groove or a through hole. The electric connector provided by the utility model reduces a capacitance effect of the signal terminals at an inserting part through changing the plastic thickness near the contact portions of the terminals, thereby achieving an effect of improving the impedance. The electric connector has excellent electrical characteristics, and is compact and light weighted in structure and convenient to manufacture and assemble.",FOXCONN KUNSHAN COMP CONNECTOR,YU CHUNMING;;ZHOU HAO;;HU BINGBO;;CHEN KEHAO;;TERENCE F LITO,,https://lens.org/064-059-009-756-612,Limited Patent,no,0,10,7,270,0,H01R13/6585;;H01R13/6585;;H01R24/60;;H01R2107/00,H01R13/6473,,0,0,,,,ACTIVE
194,US,A1,US 2002/0146660 A1,099-449-437-127-445,2002-10-10,2002,US 82741001 A,2001-04-06,US 82741001 A,2001-04-06,Roller construction for operation at elevated temperatures,"
   A roller for use in a fuser assembly of a reproduction apparatus adapted to operate at an elevated temperature up to in the range of approximately 750 F. The roller includes a generally elongated substantially cylindrical tube. End gudgeons are provided for sealing the ends of the cylindrical tube. Each of the end gudgeons is respectively associated with an end of the cylindrical tube such that after a weld joint is formed between the cylindrical tube and the end gudgeon, the end gudgeon provides a compression joint to prevent the cylindrical tube from separating from the end gudgeon, due to material creep, at elevated operating temperatures. 
",KASS ALLEN;;MILLER TERENCE MICHAEL;;BLEIL RAINER J.;;CHEN JIANN-HSING,KASS ALLEN;;MILLER TERENCE MICHAEL;;BLEIL RAINER J;;CHEN JIANN-HSING,NEXPRESS SOLUTIONS LLC (2001-05-29);;EASTMAN KODAK COMPANY (2004-09-09),https://lens.org/099-449-437-127-445,Patent Application,yes,0,0,6,6,0,F16C13/00;;G03G15/2053;;G03G15/2053;;F16C13/00,F16C13/00;;G03G15/20,432/236;;432/228;;X432 6,0,0,,,,EXPIRED
195,US,B2,US 6589048 B2,066-228-606-190-626,2003-07-08,2003,US 82741001 A,2001-04-06,US 82741001 A,2001-04-06,Roller construction for operation at elevated temperatures,"
    A roller for use in a fuser assembly of a reproduction apparatus adapted to operate at an elevated temperature up to in the range of approximately 750 F. The roller includes a generally elongated substantially cylindrical tube. End gudgeons are provided for sealing the ends of the cylindrical tube. Each of the end gudgeons is respectively associated with an end of the cylindrical tube such that after a weld joint is formed between the cylindrical tube and the end gudgeon, the end gudgeon provides a compression joint to prevent the cylindrical tube from separating from the end gudgeon, due to material creep, at elevated operating temperatures. 
",NEXPRESS SOLUTIONS LLC,KASS ALLEN;;MILLER TERENCE MICHAEL;;BLEIL RAINER J;;CHEN JIANN-HSING,NEXPRESS SOLUTIONS LLC (2001-05-29);;EASTMAN KODAK COMPANY (2004-09-09),https://lens.org/066-228-606-190-626,Granted Patent,yes,4,6,6,6,0,F16C13/00;;G03G15/2053;;G03G15/2053;;F16C13/00,F16C13/00;;G03G15/20,432/60;;432/228;;492/46;;492/47,0,0,,,,EXPIRED
196,ID,A,ID 15905 A,097-192-697-857-950,1997-08-14,1997,ID 970392 A,1997-02-07,US 1127996 P;;US 2768896 P,1996-02-07,PIRAZOLOPIRIMIDIN,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCHARTY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M,,https://lens.org/097-192-697-857-950,Patent Application,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,PENDING
197,EP,B1,EP 0880523 B1,011-151-473-792-034,2006-08-16,2006,EP 97902295 A,1997-01-30,EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS,,NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M,"JANSSEN PHARMACEUTICA N.V. (1999-12-29);;NEUROCRINE BIOSCIENCES, INC. (2011-03-15);;*NEUROCRINE BIOSCIENCES INC.12790 EL CAMINO REAL, (2006-08-16);;NEUROCRINE BIOSCIENCES, INC., US (2007-03-05)",https://lens.org/011-151-473-792-034,Granted Patent,yes,3,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,2,0,,,"J. MED. CHEM. (1976), 19(4), 512-16 CODEN: JMCMAR, 1976, XP002030876 NOVINSON, THOMAS ET AL: ""Novel heterocyclic nitrofurfural hydrazones. In vivo antitrypanosomal activity"";;J. MED. CHEM. (1981), 24(5), 610-13 CODEN: JMCMAR;ISSN: 0022-2623, 1981, XP002030877 SENGA, KEITARO ET AL: ""Synthesis and antischistosomal activity of certain pyrazolo[1,5-a]pyrimidines""",EXPIRED
198,ES,T3,ES 2168237 T3,039-240-173-652-946,2007-04-01,2007,ES 97902295 T,1997-01-30,US 1127996 P;;US 2768896 P,1996-02-07,PIRAZOLOPIRIMIDINAS COMO ANTAGONISTAS DE RECEPTORES DE CRF.,"ESTA INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I), INCLUIDOS ESTEREOISOMEROS Y LAS FORMAS DE SALES DE ADICION ACIDAS FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, EN LA QUE R 1 ES NR 4 R 5 U OR 5 ; R 2 ES ALQUILO C 1-6 , ALQUILOXI C 1-6 O ALQUILTIO C 1-6 ; R 3 ES HIDROGENO, ALQUILO C 1-6 , ALQUILSULFONILO C 1-6 , ALQUILSULFOXI C 1-6 O ALQUILTIO C 1-6 ; R 4 ES HIDR OGENO, ALQUILO C 1-6 , MONO - O DI(CICLOALQUIL C 36 ) METILO, CICLOALQUILO C 3-6 , ALQUENILO C 3-6 , HIDROXIALQUILO C 3-6 , ALQUILCARBONILOXI C 1-6 ALQUILO C SUB ,1-6 O ALQUILOXI C 1-6 ALQUILO C 1-6 ; R 5 ES ALQUILO C 1-8 , MONO - O DI(CICLOALQUIL C 3-6 )METILO, AR 1 CH 2 , ALQUILOXI C 1-6 ALQUILO C 1-6 , HIDROXIALQUILO C 1-6 , ALQUENILO C 3-6 , TIENILMETILO, FURANILMETILO, ALQUILTIO C 1-6 ALQUILO C 1-6 , MORFOLINILO, MONO - O DI(ALQUIL C 1-6 )AMINOALQUILO C 16 , D I(ALQUIL C 1-6 )AMINO, ALQUILCARBONIL C 1-6 ALQUILO C1-6 , ALQUILO C 1-6 SUSTITUIDO CON IMIDAZOLILO; O UN RADICAL DE LA FORMULA - ALK - O - CO - AR 1 ; O R 4 O R 5 TOMADOS JUNTO CON EL ATOMO DE NITROGENO AL QUE ESTAN UNIDOS PUEDEN FORMAR UN GRUPO PIRROLIDINILO, PIPERIDINILO, HOMOPIPERIDINILO O MORFOLINILO OPCIONALMENTE SUSTITUIDO; QUE POSEEN PROPIEDADES ANTAGONISTICAS AL RECEPTOR DEL CRF; A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN TALES COMPUESTOS COMO INGREDIENTES ACTIVOS; METODO PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA HIPERSECRECION DE CRF TALES COMO LA DEPRESION, ANSIEDAD, ABUSO DE SUSTANCIAS, MEDIANTE LA ADMINISTRACION DE UNA CANTIDAD EFECTIVA DE UN COMPUESTO DE FORMULA (I).",NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M,,https://lens.org/039-240-173-652-946,Granted Patent,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
199,US,B1,US 10615027 B1,047-374-805-785-338,2020-04-07,2020,US 201816170465 A,2018-10-25,US 201816170465 A,2018-10-25,Stack viabar structures,"Various methods and structures for fabricating a semiconductor structure. The semiconductor structure includes in a top layer of a semiconductor stack a semiconductor contact located according to a first horizontal pitch. A first metallization layer is disposed directly on the top layer and includes a metallization contact located according to a second horizontal pitch, the second horizontal pitch being different from the first horizontal pitch such that the location of the metallization contact is vertically mismatched from the location of the semiconductor contact. A second metallization layer is disposed directly on the first metallization layer. The second metallization layer includes a super viabar structure that forms an electrical interconnect, in the second metallization layer, between the semiconductor contact in the top layer of the semiconductor stack and the metallization contact in the first metallization layer.",IBM,FAN SU CHEN;;CHEN HSUEH-CHUNG;;MIGNOT YANN;;KELLY JAMES J;;HOOK TERENCE B,INTERNATIONAL BUSINESS MACHINES CORPORATION (2018-10-24),https://lens.org/047-374-805-785-338,Granted Patent,yes,13,2,4,4,0,H01L21/76811;;H01L23/5226;;H01L21/76849;;H01L21/76858;;H01L23/5283;;H01L21/02244;;H01L21/76879;;H01L21/3213;;H01L25/074,H01L21/3213;;H01L21/02;;H01L21/768;;H01L25/07,,0,0,,,,ACTIVE
200,US,B2,US 9012997 B2,024-267-939-819-056,2015-04-21,2015,US 201213661683 A,2012-10-26,US 201213661683 A,2012-10-26,Semiconductor device including ESD protection device,"A semiconductor device includes a semiconductor-on-insulator (SOI) substrate having a bulk substrate layer, an active semiconductor layer and a buried insulator layer disposed between the bulk substrate layer and the active semiconductor layer. A trench is formed through the SOI substrate to expose the bulk substrate layer. A doped well is formed in an upper region of the bulk substrate layer adjacent trench. The semiconductor device further includes a first doped region different from the doped well that is formed in the trench.",IBM,YAMASHITA TENKO;;HOOK TERENCE B;;BASKER VEERARAGHAVAN S;;YEH CHUN-CHEN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2012-10-18);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/024-267-939-819-056,Granted Patent,yes,24,1,3,3,0,H01L2924/0002;;H01L29/66136;;H01L29/861;;H01L29/1608;;H01L29/161;;H01L27/0255;;H01L2924/0002;;H01L29/861;;H01L29/1608;;H01L29/66136;;H01L29/161;;H01L27/0255;;H01L29/6609;;H01L29/66121,H01L23/62;;H01L27/02;;H01L29/66,257/355;;257/328;;257/546;;438/237,3,0,,,"Machine translation of JP 1996032057 A.;;International Search Report for corresponding PCT Application No. PCT/US2013/054065, dated Jan. 29, 2014, pp. 1-7.;;Written Opinion of the International Searching Authority for corresponding PCT Application No. PCT/US2013/054065, dated Jan. 29, 2014, pp. 1-6.",INACTIVE
201,CN,U,CN 202308401 U,120-929-798-687-335,2012-07-04,2012,CN 201120370340 U,2011-09-28,CN 201120370340 U,2011-09-28,Electric connector and terminals thereof,"Provided are an electric connector and terminals thereof, wherein the electric connector comprises an insulation body and a plurality of terminals held in the insulation body; the insulation body is provided with a lengthwise bottom wall and a plurality of accepting grooves arranged along a lengthwise direction and penetrating the bottom wall; the terminals possess a flat part which possesses a flat surface and a processing surface located on different surfaces with the flat surface; the terminals are inserted into the accepting grooves from the bottom wall in a vertical direction perpendicular to the lengthwise direction; each terminal is provided with a holding part held in the insulation body, a contact arm extending from the holding part to an accepting groove and a welding part extending to the outside of the insulation body from the holding part. The contact arm comprises a contact zone which protrudes to the outside of the accepting grooves and is located on the processing surface; the contact zone possesses a widened part which is extending along the lengthwise direction and projects to the outer side of the flat surface of the flat part, which can increase the contact area with abutting terminals and is in favor of realizing stable electric contact.",FOXCONN KUNSHAN COMP CONNECTOR;;HON HAI PREC IND CO LTD,ZHIGANG HE;;LITTLE TERENCE F;;QINAN LIAO;;QIMING CHEN;;JIABIN LIU,,https://lens.org/120-929-798-687-335,Limited Patent,no,0,3,1,1,0,,H01R13/02;;H01R12/51,,0,0,,,,EXPIRED
202,AU,A,AU 1973/061962 A,190-584-822-357-474,1975-05-01,1975,AU 1973/061962 A,1973-10-29,US 30332772 A,1972-11-03,MAGNETIC DEVICES,,WESTERN ELECTRIC CO,NELSON TERENCE JOHN;;SHAPIRO HERBERT MEYER;;CHEN YU-SSU;;GEUSIC JOSEPH EDWARD,,https://lens.org/190-584-822-357-474,Patent Application,no,0,0,18,18,0,G11C19/0858;;G11C19/0858,G11C11/14;;G11C19/08,,0,0,,,,DISCONTINUED
203,US,B2,US 7230728 B2,051-668-466-253-182,2007-06-12,2007,US 62423103 A,2003-07-22,US 62423103 A,2003-07-22,Disc imbalance compensation during disc drive assembly,A method and system is provided for compensating for imbalance in a data storage disc stack during assembly of the data storage device. An optical measurement system downstream of the disc clamp installation operation measures one or more parameters of a predetermined sample of disc-stacks produced on the assembly line A moving average of the sampled measurements is utilized to determine a component configuration type that will compensate for any measured disc stack imbalance.,SEAGATE TECHNOLOGY LLC,SU GUO CHUN;;CHEN MING HUI;;NG HWA LIANG;;CHENG TERENCE CHEEKWONG,SEAGATE TECHNOLOGY LLC (2003-06-16),https://lens.org/051-668-466-253-182,Granted Patent,yes,13,4,2,2,0,G11B17/0287;;G11B17/0287;;G11B17/028;;G11B17/028;;G11B17/038;;G11B17/038,G01B11/14;;G11B5/09;;G11B17/028;;G11B17/038,356/625,0,0,,,,INACTIVE
204,EP,B1,EP 1106782 B1,119-460-297-711-025,2006-04-19,2006,EP 00310957 A,2000-12-08,US 45765299 A,1999-12-09,Cooled airfoil for gas turbine engine and method of making the same,,GEN ELECTRIC,TSAI GENE CHEN-FU;;TUNG SUNG;;FLAHERTY TERENCE CARROLL;;MANNING ROBERT FRANCIS,,https://lens.org/119-460-297-711-025,Granted Patent,yes,4,0,9,9,0,F01D5/186;;F01D5/187;;F05D2250/12;;F05D2260/202;;F05D2250/14;;Y02T50/60;;F01D5/187;;F01D5/186;;F05D2260/202;;F05D2250/14;;F05D2250/12;;Y02T50/60,F01D5/18;;F01D9/02;;F01D9/04,,0,0,,,,EXPIRED
205,CA,A,CA 959168 A,187-025-087-449-09X,1974-12-10,1974,CA 170823 A,1973-05-09,US 30332772 A,1972-11-03,SINGLE WALL DOMAIN NUCLEATOR,,WESTERN ELECTRIC CO,CHEN YU-SSU;;NELSON TERENCE J;;GEUSIC JOSEPH E;;SHAPIRO HERBERT M,,https://lens.org/187-025-087-449-09X,Granted Patent,no,0,0,18,18,0,G11C19/0858;;G11C19/0858,G11C11/14;;G11C19/08,352-37.3,0,0,,,,EXPIRED
206,DE,A1,DE 2354120 A1,105-296-240-737-574,1974-05-16,1974,DE 2354120 A,1973-10-29,US 30332772 A,1972-11-03,ANORDNUNG ZUR ERZEUGUNG EINWANDIGER DOMAENEN,,WESTERN ELECTRIC CO,GEUSIC JOSEPH EDWARD;;NELSON TERENCE JOHN;;SHAPIRO HERBERT MEYER;;CHEN YU-SSU,,https://lens.org/105-296-240-737-574,Patent Application,no,0,0,18,18,0,G11C19/0858;;G11C19/0858,G11C11/14;;G11C19/08,,1,0,,,NICHTS-ERMITTELT,EXPIRED
207,US,A1,US 2005/0018338 A1,045-400-189-282-174,2005-01-27,2005,US 62423103 A,2003-07-22,US 62423103 A,2003-07-22,Method and system for of compensating for data storage disc stack imbalance during disc drive assembly,"A method and system of compensating for imbalance in a data storage disc stack during assembly of the data storage device. The method introduces an optical measurement system downstream of the disc clamp installation operation. The system measures multiple parameters of a most recent N incoming disc-stacks produced on the assembly line, where N is a suitable sample size, such as 30 disc stacks. The measured parameters can comprise disc clamp offset, clamp offset angle, and ring outer diameter. After measuring parameters for a suitable sample size N, the optical system calculates a dynamic or moving average of the most recent N disc stack component offsets and/or offset angles. The calculated averages are then utilized to determine a component configuration type that will compensate for the disc stack imbalance according to the offset trend. The system then feeds back the clamp configuration type to a clamp installation operation where the configuration type is installed during assembly of the next disc stack.",SU GUO CHUN;;CHEN MING HUI;;NG HWA LIANG;;CHENG TERENCE CHEEKWONG,SU GUO CHUN;;CHEN MING HUI;;NG HWA LIANG;;CHENG TERENCE CHEEKWONG,SEAGATE TECHNOLOGY LLC (2003-06-16),https://lens.org/045-400-189-282-174,Patent Application,yes,13,5,2,2,0,G11B17/0287;;G11B17/0287;;G11B17/028;;G11B17/028;;G11B17/038;;G11B17/038,G01B11/14;;G11B5/09;;G11B17/028;;G11B17/038,360/51,0,0,,,,EXPIRED
208,EP,A2,EP 1106782 A2,042-880-465-090-774,2001-06-13,2001,EP 00310957 A,2000-12-08,US 45765299 A,1999-12-09,Cooled airfoil for gas turbine engine and method of making the same,An airfoil (40) for use in a gas turbine engine includes a pressure side (42) and a suction side (44) joined at a trailing edge wall (60) that defines a trailing edge (48). The airfoil (40) includes at least one cooling hole (68) extending through the trailing edge wall (60) so as to pass cooling fluid from the pressure side (42) of the airfoil (40) to the suction side (44).,GEN ELECTRIC,TSAI GENE CHEN-FU;;TUNG SUNG;;FLAHERTY TERENCE CARROLL;;MANNING ROBERT FRANCIS,,https://lens.org/042-880-465-090-774,Patent Application,yes,0,9,9,9,0,F01D5/186;;F01D5/187;;F05D2250/12;;F05D2260/202;;F05D2250/14;;Y02T50/60;;F01D5/187;;F01D5/186;;F05D2260/202;;F05D2250/14;;F05D2250/12;;Y02T50/60,F01D9/02;;F01D5/18,,0,0,,,,EXPIRED
209,CN,U,CN 216182415 U,166-237-541-190-253,2022-04-05,2022,CN 202122567472 U,2021-10-25,CN 202122567472 U,2021-10-25,Injection mold,"The utility model provides an injection mold which comprises a fixed mold plate, a movable mold plate and an oil cylinder core-pulling mechanism, and the oil cylinder core-pulling mechanism comprises an oil cylinder and a pulling core; a wedge block is fixedly arranged on the movable mold plate, the wedge block is provided with a limiting hook part, an inclined plane is formed on the limiting hook part, and a through part is formed on the loose core; and during mold closing action, the inclined surface is in contact with the through part so as to drive the loose core to move towards the extraction direction, and in a mold closing state, the wedge block penetrates through the through part and the limiting hook part is hooked on the loose core. The mold can be opened only when the loose core is pulled out, and the situation that the loose core is pulled to be damaged or even the oil cylinder is damaged due to mold opening when the loose core is not pulled out is avoided; and during mold closing, even if the oil cylinder is in a non-extraction state and when the mold is closed until the inclined surface of the limiting hook part of the wedge block is in contact with the end part of the through part, the inclined surface can drive the loose core to move towards the extraction direction until the loose core is completely pulled, so that mold collision during mold closing can be avoided, manual operation is replaced by a mechanical structure to ensure that mold collision is avoided, and the reliability is high.",QINGDAO HAIXIN MOULD CO LTD,LUO DAILIANG;;ZHANG WEILUN;;LIU QIN;;CHEN SHUNLI;;WONG KA CHEONG TERENCE,,https://lens.org/166-237-541-190-253,Limited Patent,no,0,0,1,1,0,,B29C45/33,,0,0,,,,ACTIVE
210,EP,A3,EP 1106782 A3,146-355-052-574-952,2003-01-15,2003,EP 00310957 A,2000-12-08,US 45765299 A,1999-12-09,Cooled airfoil for gas turbine engine and method of making the same,An airfoil (40) for use in a gas turbine engine includes a pressure side (42) and a suction side (44) joined at a trailing edge wall (60) that defines a trailing edge (48). The airfoil (40) includes at least one cooling hole (68) extending through the trailing edge wall (60) so as to pass cooling fluid from the pressure side (42) of the airfoil (40) to the suction side (44).,GEN ELECTRIC,TSAI GENE CHEN-FU;;TUNG SUNG;;FLAHERTY TERENCE CARROLL;;MANNING ROBERT FRANCIS,,https://lens.org/146-355-052-574-952,Search Report,yes,4,0,9,9,0,F01D5/186;;F01D5/187;;F05D2250/12;;F05D2260/202;;F05D2250/14;;Y02T50/60;;F01D5/187;;F01D5/186;;F05D2260/202;;F05D2250/14;;F05D2250/12;;Y02T50/60,F01D9/02;;F01D5/18,,0,0,,,,EXPIRED
211,US,B2,US 8835330 B2,085-287-635-557-748,2014-09-16,2014,US 201213622755 A,2012-09-19,US 201213622755 A;;US 201213344885 A,2012-01-06,Integrated circuit including DRAM and SRAM/logic,"A method includes providing a substrate having an N+ type layer; forming a P type region in the N+ type layer disposed within the N+ type layer; forming a first deep trench isolation structure extending through a silicon layer and into the N+ type layer to a depth that is greater than a depth of the P type layer; forming a dynamic RAM FET in the silicon layer, forming a first logic/static RAM FET in the silicon layer above the P type region, the P type region being functional as a P-type back gate of the first logic/static RAM FET; and forming a first contact through the silicon layer and an insulating layer to electrically connect to the N+ type layer and a second contact through the silicon layer and the insulating layer to electrically connect to the P type region.",IBM,CHEN KANGGUO;;DORIS BRUCE B;;HOOK TERENCE B;;KHAKIFIROOZ ALI;;KULKARNI PRANITA,GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/085-287-635-557-748,Granted Patent,yes,16,3,4,8,0,H01L21/84;;H01L29/945;;H01L27/1203;;H01L27/1207;;H10B99/00;;H10B12/0387;;H10B12/05;;H10B10/18;;H10B12/09;;H01L29/945;;H01L21/84;;H01L27/1203;;H01L27/1207;;H10B10/18;;H10B12/05;;H10B12/09;;H10B12/0387;;H10B99/00,H01L21/762;;H01L21/70,438/761;;438/479;;438/232;;438/244;;438/243;;438/238;;X257E21564,1,1,004-976-128-533-077,10.1093/ietele/e90-c.4.735,"Kawahara, ""Low-Voltage Embedded RAMs in Nanometer Era"", IEEE Trans. Electron., vol. E90-C, No. 4, Apr. 2007.",INACTIVE
212,DE,D1,DE 60027390 D1,042-318-847-315-416,2006-05-24,2006,DE 60027390 T,2000-12-08,US 45765299 A,1999-12-09,Gekühlte Gasturbinenschaufel und deren Herstellungsmethode,,GEN ELECTRIC,TSAI GENE CHEN-FU;;TUNG SUNG;;FLAHERTY TERENCE CARROLL;;MANNING ROBERT FRANCIS,,https://lens.org/042-318-847-315-416,Granted Patent,no,0,0,9,9,0,F01D5/186;;F01D5/187;;F05D2250/12;;F05D2260/202;;F05D2250/14;;Y02T50/60;;F01D5/187;;F01D5/186;;F05D2260/202;;F05D2250/14;;F05D2250/12;;Y02T50/60,F01D5/18;;F01D9/02;;F01D9/04,,0,0,,,,EXPIRED
213,CN,U,CN 220158594 U,082-389-522-969-760,2023-12-12,2023,CN 202320948774 U,2023-04-25,CN 202320948774 U,2023-04-25,Leg bending mechanism for nursing bed,"The utility model provides a leg curving mechanism for nursing bed, the nursing bed includes bedstead and install hip bed board and leg curving mechanism on the bedstead, the leg curving mechanism includes thigh bed board, crus bed board, line-shaped pull rod and lifting subassembly, thigh bed board and crus bed board are rotatingly connected, crus bed board and line-shaped pull rod are rotatingly connected, and the lifting subassembly is equipped with the lifting subassembly. The lifting assembly is located at the bottom of the thigh bed plate and used for driving the thigh bed plate to ascend and descend. According to the leg bending mechanism disclosed by the utility model, during leg bending movement, the extrusion on the thigh roots of a patient is avoided, and the comfort of the leg bending movement is improved.",MAIFU SHANDONG SCIENT INSTRUMENT CO LTD,DONG CHUNGENG;;CHANG SHENGYU;;CHEN LEI;;WONG KA CHEONG TERENCE;;ZHU GUANXU,,https://lens.org/082-389-522-969-760,Limited Patent,no,0,0,1,1,0,,A61G7/015;;A61G7/05;;A61G7/075,,0,0,,,,ACTIVE
214,BR,A,BR 0005809 A,062-975-290-039-615,2001-07-17,2001,BR 0005809 A,2000-12-08,US 45765299 A,1999-12-09,Aerofólio refrigerado para motor de turbina a gás e método para a fabricação do mesmo,"Patente de Invenção: <B>""AEROFóLIO REFRIGERADO PARA MOTOR DE TURBINA A GáS E MéTODO PARA A FABRICAçãO DO MESMO""<D>. Um aerofólio (40) para uso em um motor de turbina a gás inclui um lado de pressão (42) e um lado de sucção",GEN ELECTRIC,TSAI GENE CHEN-FU;;TUNG SUNG;;FLAHERTY TERENCE CARROLL;;MANNING ROBERT FRANCIS,,https://lens.org/062-975-290-039-615,Patent Application,no,0,0,9,9,0,F01D5/186;;F01D5/187;;F05D2250/12;;F05D2260/202;;F05D2250/14;;Y02T50/60;;F01D5/187;;F01D5/186;;F05D2260/202;;F05D2250/14;;F05D2250/12;;Y02T50/60,F01D9/02;;F01D5/18,,0,0,,,,DISCONTINUED
215,DE,T2,DE 60027390 T2,199-539-136-714-309,2007-03-29,2007,DE 60027390 T,2000-12-08,US 45765299 A,1999-12-09,Gekühlte Gasturbinenschaufel und deren Herstellungsmethode,,GEN ELECTRIC,TSAI GENE CHEN-FU;;TUNG SUNG;;FLAHERTY TERENCE CARROLL;;MANNING ROBERT FRANCIS,,https://lens.org/199-539-136-714-309,Granted Patent,no,0,0,9,9,0,F01D5/186;;F01D5/187;;F05D2250/12;;F05D2260/202;;F05D2250/14;;Y02T50/60;;F01D5/187;;F01D5/186;;F05D2260/202;;F05D2250/14;;F05D2250/12;;Y02T50/60,F01D5/18;;F01D9/02;;F01D9/04,,0,0,,,,EXPIRED
216,CZ,A3,CZ 244598 A3,085-407-324-888-359,1998-10-14,1998,CZ 244598 A,1997-01-30,US 1127996 P;;US 2768896 P,1996-02-07,PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M;;HUANG CHARLES,,https://lens.org/085-407-324-888-359,Patent Application,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,PENDING
217,JP,A,JP 2002121194 A,122-805-631-984-854,2002-04-23,2002,JP 2001265611 A,2001-09-03,US 1127996 P;;US 2768896 P,1996-02-07,PYRAZOLOPYRIMIDINE,"PROBLEM TO BE SOLVED: To provide pyrazolopyrimidine that is antagonistic to CRF receptor and a pharmaceutical composition that contain the same as active ingredients. SOLUTION: The objective compound is a pyrazolopyrimidine is represented by general formula (II') [R2 is an alkyl, an alkyloxy or an alkylthio; R3 is H, an alkyl, an alkyl-sulfonyl, an alkylsulfonyloxy or an alkylthio; Ar is phenyl, a substituted phenyl, pyridinyl, substituted pyridinyl; W' is hydroxy, a halogen, mesityloxy or tosyloxy], typically 3-(2,4-dichlorophenyl)-5-methyl-7-(N-propyl-N- cyclopropane-methylamino)-pyrazolo[2,3-a]pyrimidine. The pharmaceutical composition is effective for treating the endocrinological, psychiatric and neurological conditions or diseases including the disorders relating to general stress, for example, depression.",JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M;;CHARLES FANG,,https://lens.org/122-805-631-984-854,Patent Application,no,0,1,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,DISCONTINUED
218,CA,A1,CA 2233285 A1,112-248-330-420-770,1997-08-14,1997,CA 2233285 A,1997-01-30,US 1127996 P;;US 2768896 P;;EP 9700459 W,1996-02-07,PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS,"This invention concerns compounds of formula (I), including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R1 is NR4R5 or OR5; R2 is C1-6alkyl, C1-6alkyloxy or C1-6alkylthio; R3 is hydrogen, C1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfoxy or C1-6alkylthio; R4 is hydrogen, C1-6alkyl, mono- or di(C3-6cycloalkyl)methyl, C3-6cycloalkyl, C36alkenyl, hydroxyC1-6alkyl, C1-6alkylcarbonyloxyC1-6alkyl or C1-6alkyloxyC1-6alkyl; R5 is C1-8alkyl, mono- or di(C3-6cycloalkyl)methyl, Ar1CH2, C16alkyloxyC1-6alkyl, hydroxyC1-6alkyl, C3-6alkenyl, thienylmethyl, furanylmethyl, C1-6alkylthioC1-6alkyl, morpholinyl, mono- or di(C16alkyl)aminoC1-6alkyl, di(C1-6alkyl)amino, C1-6alkylcarbonylC1-6alkyl, C16alkyl substituted with imidazolyl; or a radical of the formula -Alk-O-CO-Ar1; or R4 and R5 taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).",JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,WILCOXEN KEITH M;;HUANG CHARLES;;MCCARTHY JAMES R;;WEBB THOMAS R;;CHEN CHEN;;MORAN TERENCE J,,https://lens.org/112-248-330-420-770,Patent Application,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
219,TR,T2,TR 199800792 T2,148-546-806-014-842,1998-07-21,1998,TR 9800792 T,1997-01-30,US 1127996 P;;US 2768896 P,1996-02-07,CRF reseptör antagonistleri olarak pirazolopirimidinler.,"Bu bulus, CRF reseptör antagonist özelliklerine sahip formül (I)e sahip bilesikler, bunlarin stereoizomerleri ve farmasötik açidan kabul edilebilir asit katilma tuzu sekilleri ile ilgili olup, burada R1, NR4R5 veya OR5 dir; R2, C1-6 alkil, C1-6 alkiloksi veya C1-6 alkiltiodur; R3, hidrojen, C1-6 alkilsülfonil, C1-6 alkilsülfoksi veya C1-6 alkiltiodur; R4, hidrojen, C1-6 alkil, mono-veya di (C3-6 sikloalkil)metil, C3-6 sikloalkil, C3-6 alkenil, hidroksi C1-6 alkil, C1-6 alkil-karboniloksi C1-6 alkil veya C1-6 alkiloksi C1-6 alkildir; R5, C1-8 alkil, mono-veya di (C3-6 sikloalkil) metil, Ar1CH2, C1-6 alkiloksi C1-6 alkil, hidroksi C1-6 alkil, C3-6 alkenil, tienil-metil, furanilmetil, C1-6 alkiltio C1-6 alkil, morfolinil, mono- veya di (C1-6 alkil) amino C1-6 alkil, di (C1-6 alkil) amino, C1-6 alkilkarbonil C1-6 alkil, imidazolil ile sübstitüe edilmis C1-6 alkil; veya -Alk-O-CO-Ar1 formülüne sahip bir radikaldir; veya R4 ile R5 bagli olduklari asot atomu ile birlikte (DEVAMI VAR).",JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M;;HUANG CHARLES,,https://lens.org/148-546-806-014-842,Patent Application,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,PENDING
220,NO,B1,NO 310292 B1,043-767-642-486-027,2001-06-18,2001,NO 981357 A,1998-03-25,EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,Pyrazolpyrimidiner,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;MORAN TERENCE J;;MCCARTHY JAMES R;;WILCOXEN KEITH M;;WEBB THOMAS R;;HUANG CHARLES,,https://lens.org/043-767-642-486-027,Granted Patent,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
221,NZ,A,NZ 330119 A,067-536-543-512-237,2000-02-28,2000,NZ 33011997 A,1997-01-30,EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,Pyrazolopyrimidines as crf receptor antagonists,"Disclosed are compounds of formula (I), including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R1 is NR4R5 or OR5; R2 is C1-6alkyl, C1-6alkyloxy or C1-6alkylthio; R3 is hydrogen, C1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfoxy or C1-6alkylthio; R4 is hydrogen, C1-6alkyl, mono- or di(C3-6cycloalkyl)methyl, C3-6cycloalkyl, C3-6alkenyl, hydroxyC1-6alkyl, C1-6alkylcarbonyloxyC1-6alkyl or C1-6alkyloxyC1-6alkyl; R5 is C1-8alkyl, mono- or di(C3-6cycloalkyl)methyl, Ar1CH2, C1-6alkyloxyC1-6alkyl, hydroxyC1-6alkyl, C3-6alkenyl, thienylmethyl, furanylmethyl, C1-6alkylthioC1-6alkyl, morpholinyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)amino, C1-6alkylcarbonylC1-6alkyl, C1-6alkyl substituted with imidazolyl; or a radical of the formula -Alk-O-CO-Ar1; or R4 and R5 taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).",JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M;;HUANG CHARLES,"NEUROCRINE BIOSCIENCES INC., US (2004-01-30)",https://lens.org/067-536-543-512-237,Patent Application,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,DISCONTINUED
222,ZA,B,ZA 97989 B,181-164-634-387-812,1998-08-06,1998,ZA 97989 A,1997-02-06,US 1127996 P,1996-02-07,Pyrazolopyrimides,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M;;HUANG CHARLES,,https://lens.org/181-164-634-387-812,Granted Patent,no,0,0,2,52,0,,A61K/;;C07D/,,0,0,,,,EXPIRED
223,NO,L,NO 981357 L,011-817-084-481-740,1998-08-03,1998,NO 981357 A,1998-03-25,EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,Pyrazolpyrimidiner,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;MORAN TERENCE J;;MCCARTHY JAMES R;;WILCOXEN KEITH M;;WEBB THOMAS R;;HUANG CHARLES,,https://lens.org/011-817-084-481-740,Abstract,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
224,AU,B2,AU 713673 B2,125-936-488-263-024,1999-12-09,1999,AU 1997/015991 A,1997-01-30,EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,Pyrazolopyrimidines as crf receptor antagonists,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M;;HUANG CHARLES,NEUROCRINE BIOSCIENCES INC. (2004-03-11),https://lens.org/125-936-488-263-024,Granted Patent,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
225,AU,A,AU 1997/015991 A,048-685-069-161-993,1997-08-28,1997,AU 1997/015991 A,1997-01-30,EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,Pyrazolopyrimidines as crf receptor antagonists,,NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M;;HUANG CHARLES,NEUROCRINE BIOSCIENCES INC. (2004-03-11),https://lens.org/048-685-069-161-993,Patent Application,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
226,US,B2,US 6664261 B2,059-534-919-406-354,2003-12-16,2003,US 11771799 A,1999-03-02,US 11771799 A;;EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,Pyrazolopyrimidines as CRF receptor antagonists,"
    This invention concerns compounds of formula 

    including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R ^{ 1 } is NR ^{ 4 } R ^{ 5 } or OR ^{ 5 } ; R ^{ 2 } is C _{ 1-6 } alkyl, C _{ 1-6 } alkyloxy or C _{ 1-6 } alkylthio; R ^{ 3 } is hydrogen, C _{ 1-6 } alkyl, C _{ 1-6 } alkylsulfonyl, C _{ 1-6 } alkylsulfoxy or C _{ 1-6 } alkylthio; R ^{ 4 } is hydrogen, C _{ 1-6 } alkyl, mono- or di(C _{ 3-6 } cycloalkyl)methyl, C _{ 3-6 } cycloalkyl, C _{ 3-6 } alkenyl, hydroxyC _{ 1-6 } alkyl, C _{ 1-6 } alkylcarbonyloxyC _{ 1-6 } alkyl or C _{ 1-6 } alkyloxyC _{ 1-6 } alkyl; R ^{ 5 } is C _{ 1-6 } alkyl, mono- or di(C _{ 3-6 } cycloalkyl)methyl, Ar ^{ 1 } CH _{ 2 } , C _{ 1-6 } alkyloxyC _{ 1-6 } alkyl, hydroxyC _{ 1-6 } alkyl, C _{ 3-6 } alkenyl, thienylmethyl, furanylmethyl, C _{ 1-6 } alkylthioC _{ 1-6 } alkyl, morpholinyl, mono- or di(C _{ 1-6 } alkyl)aminoC _{ 1-6 } alkyl, di(C _{ 1-6 } alkyl)amino, C _{ 1-6 } alkylcarbonylC _{ 1-6 } alkyl, C _{ 1-6 } alkyl substituted with imidazolyl; or a radical of formula AlkOCOAr ^{ 1 } ; or R ^{ 4 } and R ^{ 5 } taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I). 
",NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M;;HUANG CHARLES,JANSSEN PHARMACEUTICA N.V (1998-04-22);;NEUROCRINE BIOSCIENCES INC (1998-04-22),https://lens.org/059-534-919-406-354,Granted Patent,yes,22,24,5,52,0,C07D487/04;;C07D487/04,C07D487/04,514/258;;544/250;;544/281,18,9,034-093-093-626-925;;119-390-847-595-84X;;076-335-136-735-244;;076-483-882-067-713;;017-798-770-596-502;;021-684-841-248-564;;001-169-215-850-206;;016-668-355-824-166;;020-772-902-239-340,10.1016/s1062-1458(98)00019-1;;10.1021/jm00366a009;;6606043;;10.1002/jps.2600820510;;8395598;;10.1002/ardp.19873200603;;3662773;;10.1002/prac.19793210224;;10.1021/jm00226a013;;817023;;10.1021/jm00137a023;;7241518;;2778;;10.1021/jm00224a017;;15111;;10.1021/jm00213a014,"Derwent Abstract of JP 61-57587-Acc No. 1986-116678, 1998.*;;Japan Abstract Publication No. 05017470, dated Jan. 26, 1993.;;Japan Abstract Publication No. 07309872, dated Nov. 28, 1995.;;Japan Abstract Publication No. 08003167, dated Sep. 1, 1996.;;Chem. Abstract, vol. 67, No. 23, Dec. 4, 1967, Abstract No. 108663R.;;Chem. Abstract, vol. 105, No. 25, Dec. 22, 1996, Abstract No. 226617e.;;Derwent Abstract, Japanese Patent No. 61-57587.;;Derwent Abstract, Japanese Patent No. 44-30512, 2000.;;Auzzi et al. (1983) ""2-Phenylphyrazolo [1,5-a] pyrimidin-7-ones. A new Class of Nonsteroidal Antinflammatory Drugs Devoid of Ucerogenic Activity"", J. Med. Chem., vol. 26, pp. 1706-1709.;;Bruni et al. (1993) ""Synthesis and Study of the Anti-Inflammatory Properties of Some Pyrazolo [1,5-a] pyrimidine Derivatives"", Journal of Pharmaceutical Sciences, vol. 82, No. 5.;;Ibrahim, et al. (1987) ""Synthesis of New 3-(Pyridin-6-yl) pyrazolo [1,5a]n pyrimidines"", Arch. Pharm. (Weinheim) 320. 487-491 (1987).;;Joshi, et al. (1979) ""Synthesis of Some New Fluorine Containing Pyrazolo [1,5a] pyrimidines"", Journal f.prakt.Chemie. Band 321, Heft 2, 1979, S. 341-344.;;Novinson, et al. (1976) ""Novel Heterocyclic Nitrofurfal Hydrazones. In Vivo Antitrypanosomal Activity"" Journal of Medicinal Chemistry, vol. 19, No. 4, pp. 512-1516.;;Senga, et al. (1981) ""Synthesis and Antishistosomal Activity of Certain Pyrazolo [1,5-a] pyrimidines"", J. Med. Chem, vol. 24, pp. 610-613.;;Springer, et al. (1976) ""Synthesis and Enzymic Activity of Some Novel Xanthine Oxidasse Inhibitors. 3-Substituted 5, 7-Dihydroxypyrazolo [1,5-a] pyrimidines"" Journal of Medicinal Chemistry, vol. 19, No. 2, pp. 291-296.;;Journal of Medicinal Chemistry, 1977 vol. 20, No. 3 Novinson et al. 386-393.;;Abstract of Japanese Application No. 45-30335, 1991.;;Abstract of Japanese Application No. 3-204877, 1970.",EXPIRED
227,NO,D0,NO 981357 D0,108-151-141-820-243,1998-03-25,1998,NO 981357 A,1998-03-25,EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,Pyrazolpyrimidiner,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;MORAN TERENCE J;;MCCARTHY JAMES R;;WILCOXEN KEITH M;;WEBB THOMAS R;;HUANG CHARLES,,https://lens.org/108-151-141-820-243,Patent Application,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
228,EE,A,EE 9800124 A,019-877-484-781-799,1998-10-15,1998,EE 9800124 A,1997-01-30,EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,Pürasoolpürimidiinid kui CRF retseptori antagonistid,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,THOMAS R WEBB;;JAMES R MCCARTHY;;TERENCE J MORAN;;KEITH M WILCOXEN;;CHEN CHEN;;CHARLES HUANG,,https://lens.org/019-877-484-781-799,Patent Application,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
229,US,A1,US 2003/0125341 A1,142-174-629-984-633,2003-07-03,2003,US 11771799 A,1999-03-02,US 11771799 A;;EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS,"
    This invention concerns compounds of formula 

    including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R ¹ is NR ⁴ R ⁵ or OR ⁵ ; R ² is C ₁₋₆ alkyl, C ₁₋₆ alkyloxy or C ₁₋₆ alkylthio; R ³ is hydrogen, C ₁₋₆ alkyl, C ₁₋₆ alkylsulfonyl, C ₁₋₆ alkylsulfoxy or C ₁₋₆ alkylthio; R ⁴ is hydrogen, C ₁₋₆ alkyl, mono- or di(C ₃₋₆ cycloalkyl)methyl, C ₃₋₆ cycloalkyl, C ₃₋₆ alkenyl, hydroxyC ₁₋₆ alkyl, C ₁₋₆ alkylcarbonyloxyC ₁₋₆ alkyl or C ₁₋₆ alkyloxyC ₁₋₆ alkyl; R ⁵ is C ₁₋₈ alkyl, mono- or di(C ₃₋₆ cycloalkyl)methyl, Ar ¹ CH ₂ , C ₁₋₆ alkyloxyC ₁₋₆ alkyl, hydroxyC ₁₋₆ alkyl, C ₃₋₆ alkenyl, thienylmethyl, furanylmethyl, C ₁₋₆ alkylthioC ₁₋₆ alkyl, morpholinyl, mono- or di(C ₁₋₆ alkyl)aminoC ₁₋₆ alkyl, di(C ₁₋₆ alkyl)amino, C ₁₋₆ alkylcarbonylC ₁₋₆ alkyl, C ₁₋₆ alkyl substituted with imidazolyl; or a radical of formula Alk-OCOAr ¹ ; or R ⁴ and R ⁵ taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I). 
",CHEN CHEN;;WEBB THOMAS R.;;MACARTY JAMES R.;;MORAN TERENCE J.;;WILCOXEN KEITH M.;;HUANG CHARLES,CHEN CHEN;;WEBB THOMAS R;;MACARTY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M;;HUANG CHARLES,JANSSEN PHARMACEUTICA N.V (1998-04-22);;NEUROCRINE BIOSCIENCES INC (1998-04-22),https://lens.org/142-174-629-984-633,Patent Application,yes,0,1,5,52,0,C07D487/04;;C07D487/04,C07D487/04,514/262.1;;544/262,0,0,,,,EXPIRED
230,PL,A1,PL 327284 A1,152-393-363-813-61X,1998-12-07,1998,PL 32728497 A,1997-01-30,EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,PYRAZOLE PYRIMIDINES AS ANTAGONISTS OF CRF RECEPTOR,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M;;HUANG CHARLES,,https://lens.org/152-393-363-813-61X,Patent Application,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
231,US,B2,US 7074797 B2,142-107-012-746-109,2006-07-11,2006,US 66574003 A,2003-09-19,US 66574003 A;;US 11771799 A;;EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,Pyrazolopyrimidines as CRF receptor antagonists,"This invention concerns compounds of formula including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R 1 is NR 4 R 5 or OR 5 ; R 2 is C 1-6 alkyl, C 1-6 alkyloxy or C 1-6 alkylthio; R 3 is hydrogen, C 1-6 alkyl, C 1-6 alkylsulfonyl, C 1-6 alkylsulfoxy or C 1-6 alkylthio; R 4 is hydrogen, C 1-6 alkyl, mono- or di(C 3-6 cycloalkyl)methyl, C 3-6 cycloalkyl, C 3-6 alkenyl, hydroxyC 1-6 alkyl, C 1-6 alkylcarbonyloxyC 1-6 alkyl or C 1-6 alkyloxyC 1-6 alkyl; R 5 is C 1-8 alkyl, mono- or di(C 3-6 cycloalkyl)methyl, A 1 CH 2 , C 1-6 alkyloxyC 1-6 alkyl, hydroxyC 1-6 alkyl, C 3-6 alkenyl, thienylmethyl, furanylmethyl, C 1-6 alkylthioC 1-6 alkyl, morpholinyl, mono- or di(C 1-6 alkyl)aminoC 1-6 alkyl, di(C 1-6 alkyl)amino, C 1-6 alkylcarbonylC 1-6 alkyl, C 1-6 alkyl substituted with imidazolyl; or a radical of formula —Alk—O—CO—Ar 1 ; or R 4 and R 5 taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).",NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE;;WILCOXEN KEITH M;;HUANG CHARLES Q,,https://lens.org/142-107-012-746-109,Granted Patent,yes,27,6,5,52,0,C07D487/04;;C07D487/04,A61K31/505;;C07D239/00;;C07D487/00;;C07D487/04,514/258;;544/250;;544/251,17,8,119-390-847-595-84X;;076-335-136-735-244;;076-483-882-067-713;;017-798-770-596-502;;021-684-841-248-564;;020-772-902-239-340;;001-169-215-850-206;;016-668-355-824-166,10.1021/jm00366a009;;6606043;;10.1002/jps.2600820510;;8395598;;10.1002/ardp.19873200603;;3662773;;10.1002/prac.19793210224;;10.1021/jm00226a013;;817023;;15111;;10.1021/jm00213a014;;10.1021/jm00137a023;;7241518;;2778;;10.1021/jm00224a017,"Abstract of Japanese Application No. 45-30335, 1970.;;Abstract of Japanese Application No. 3-204877, 1991.;;Japan Abstract Publication No. 05017470, dated Jan. 26, 1993.;;Japan Abstract Publication No. 07309872, dated Nov. 28, 1995.;;Japan Abstract Publication No. 08003167, dated Sep. 1, 1996.;;Chem. Abstract, vol. 67, No. 23, Dec. 4, 1967, Abstract No. 108663R.;;Chem. Abstract, vol. 105, No. 25, Dec. 22, 1996, Abstract No. 226617e.;;Derwent Abstract, Japanese Patent No. 44-30512, 2000.;;Derwent Abstract of JP 61-57587 - Acc No. 1986-11678, 1998.;;Auzzi et al., ""2-Phenylphyrazolo [1,5-a] Purimidin 7-ones. A New Class of Nonsteroidal Antiflammatory Drugs Devoid of Ucerogenic Activity,"" J. Med. Chem. 26:1706-1709, 1983.;;Bruni et al., ""Synthesis and Study of the Anti-Inflammatory Properties of Some Pyrazolo [1,5-a] Pyrimidine Derivatives,"" J. Pharma. Sci. 82(5), 1993.;;Ibrahim et al., ""Synthesis of New 3- (Pyrimidin-6-yl) Pyrazolo [1, 5a]n Pyrimidines,"" Arch Pharm. (Weinheim) 320:487-191, 1987.;;Joshi et al., ""Synthesis of Some New Fluorine Containing Pyrazolo [1, 5a] Pyrimidines,"" J. f.prakt.Chemie. Band 321, Heft 2:341-344, 1979.;;Novinson et al., ""Novel Heterocyclic Nitrofural Hydrazones. In Vivo Antitrypanosomal Activity,"" J. Med. Chem. 19(4):512-1516, 1976.;;Novinson et al., ""3-Halo-5,7-Dimethylpyrazolo [1,5-A]Pyrimidines, A Nonbenzodiazepinoid Class Of Antianxiety Agents Devoid Of Potentiation Of Central Nervous System Depressant Effects Of Ethanol Or Barbiturates,"" J. Med. Chem. 20(3):386-393, 1977.;;Senga et al., ""Synthesis and Antishistomal Activity of Certain Pyrazolo [1,5-a] Pyrimidines,"" J. Med. Chem. 24:610-613, 1981.;;Springer et al., ""Synthesis and Enzymic Activity of Some Novel Xanthine Oxidasse Inhibitors. 3 Substituted 5, 7-Dihydroxypyrazolo [1,5-a] Pyrimidines,"" J. Med. Chem. 19(2):291-296, 1976.",EXPIRED
232,PL,B1,PL 191271 B1,166-042-826-588-10X,2006-04-28,2006,PL 32728497 A,1997-01-30,EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,Pyrazole pyrimidines as antagonists of CRF receptor,,NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M;;HUANG CHARLES,,https://lens.org/166-042-826-588-10X,Granted Patent,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P5/00;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
233,BG,A,BG 102349 A,077-791-631-247-366,1999-02-26,1999,BG 10234998 A,1998-03-25,EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS,"The invention relates to compounds with the formulawhere R1 is NR4R5 or OR5, R4 is hydrogen, C1-6 alkyl, mono- ordi(C3-6 cycloalkyl)methyl, C3-6 cycloalkyl, C3-6 alkenyl, hydroxyC1-6 alkyl, C1-6 alkylcarbonyloxy C1-6 alkyl or C1-6 alkyloxy C1-6alkyl, hydroxy C1-6 alkyl, C3-6 alkenyl, thienylmethyl,furanylmethyl, C1-6 alkylthio, morpholinyl, mono- or di(C1-6alkyl)amino C1-6 alkyl, di(C1-6 alkyl)amino, C1-6 alkylcarbonylC1-6 alkyl, C1-6 alkyl substituted by imidazolyl or radical withthe formula -Alk-O-CO-Ar1, or R4 & R5 together with the nitrogenatom to which they are bound can optionally form substitutedpyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group;R2 is C1-6 alkyl, C1-6 alkyloxy or C1-6 alkylthio, R3 is hydrogen,C1-6 alkyl. C1-6 alkylsulphonyl, C1-6 alkylsulphoxy or C1-6alkylthio. They have antagonistic properties to the CRF receptor.The invention also relates to pharmaceutical compositionscontaining these compounds as active substances, to methods forthe treatment of indispositions related to SFR supersecretion,such as depression, fear states, giving up the reception ofsubstances by the application of an effective amount of compoundswith formulation I.13 claims",JANSSEN PHARMACEUTICA NV,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M;;HUANG CHARLES,,https://lens.org/077-791-631-247-366,Patent Application,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,PENDING
234,EE,B1,EE 04282 B1,165-799-204-529-621,2004-04-15,2004,EE 9800124 A,1997-01-30,EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,"Pürasoolpürimidiinid, nende valmistamine ja kasutamine ravimina ning neid sisaldav kompositsioon",,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M;;CHEN CHEN;;HUANG CHARLES,,https://lens.org/165-799-204-529-621,Granted Patent,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
235,SK,A3,SK 106398 A3,020-056-119-797-757,1998-12-02,1998,SK 106398 A,1997-01-30,EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M;;HUANG CHARLES,,https://lens.org/020-056-119-797-757,Patent Application,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,PENDING
236,US,A1,US 2006/0270659 A1,014-337-241-392-298,2006-11-30,2006,US 41361006 A,2006-04-28,US 41361006 A;;US 66574003 A;;US 11771799 A;;EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,Pyrazolopyrimidines as CRF receptor antagonists,"This invention concerns compounds of formula including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R 1 is NR 4 R 5 or OR 5 ; R 2 is C 1-6 alkyl, C 1-6 alkyloxy or C 1-6 alkylthio; R 3 is hydrogen, C 1-6 alkyl, C 1-6 alkylsulfonyl, C 1-6 alkylsulfoxy or C 1-6 alkylthio; R 4 is hydrogen, C 1-6 alkyl, mono- or di(C 3-6 cycloalkyl)methyl, C 3-6 cycloalkyl, C 3-6 alkenyl, hydroxyC 1-6 alkyl, C 1-6 alkylcarbonyloxyC 1-6 alkyl or C 1-6 alkyloxyC 1-6 alkyl; R 5 is C 1-8 alkyl, mono- or di(C 3-6 cycloalkyl)methyl, Ar 1 CH 2 , C 1-6 alkyloxyC 1-6 alkyl, hydroxyC 1-6 alkyl, C 3-6 alkenyl, thienylmethyl, furanylmethyl, C 1-6 alkylthioC 1-6 alkyl, morpholinyl, mono- or di(C 1-6 alkyl)aminoC 1-6 alkyl, di(C 1-6 alkyl)amino, C 1-6 alkylcarbonylC 1-6 alkyl, C 1-6 alkyl substituted with imidazolyl; or a radical of formula -Alk-O—CO—Ar 1 ; or R 4 and R 5 taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).",NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M;;HUANG CHARLES,,https://lens.org/014-337-241-392-298,Patent Application,yes,8,5,5,52,0,C07D487/04;;C07D487/04,A61K31/55;;A61K31/519;;A61K31/5377;;C07D487/04,514/217.06;;514/234.2;;514/259.3;;544/117;;544/281;;540/600,0,0,,,,DISCONTINUED
237,CA,C,CA 2233285 C,113-809-638-062-774,2006-07-04,2006,CA 2233285 A,1997-01-30,US 1127996 P;;US 2768896 P;;EP 9700459 W,1996-02-07,PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS,"This invention concerns compounds of formula (I), including the stereoisome rs and the pharmaceutically acceptable acid addition salt forms thereof, wherein R1 is NR4R5 or OR5; R2 is C1-6alkyl, C1-6alkyloxy or C1-6alkylthio; R3 is hydrogen, C1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfoxy or C1-6alkylthio ; R4 is hydrogen, C1-6alkyl, mono- or di(C3-6cycloalkyl)methyl, C3-6cycloalkyl, C 3- 6alkenyl, hydroxyC1-6alkyl, C1-6alkylcarbonyloxyC1-6alkyl or C1-6alkyloxyC1- 6alkyl; R5 is C1-8alkyl, mono- or di(C3-6cycloalkyl)methyl, Ar1CH2, C1- 6alkyloxyC1-6alkyl, hydroxyC1-6alkyl, C3-6alkenyl, thienylmethyl, furanylmethyl, C1-6alkylthioC1-6alkyl, morpholinyl, mono- or di(C1- 6alkyl)aminoC1-6alkyl, di(C1-6alkyl)amino, C1-6alkylcarbonylC1-6alkyl, C1- 6alkyl substituted with imidazolyl; or a radical of the formula -Alk-O-CO-Ar1; or R4 and R5 taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorde rs related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formu la (I).",JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,MCCARTHY JAMES R;;CHEN CHEN;;WILCOXEN KEITH M;;MORAN TERENCE J;;WEBB THOMAS R;;HUANG CHARLES,,https://lens.org/113-809-638-062-774,Granted Patent,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,C07D487/04;;A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
238,US,A,US 5974535 A,044-394-360-421-206,1999-10-26,1999,US 85300997 A,1997-05-09,US 85300997 A,1997-05-09,Method and system in data processing system of permitting concurrent processing of instructions of a particular type,"A method and system in a data processing system of permitting concurrent processing of multiple conditional branch instructions are disclosed. A condition register is established within the processing system. First and second conditional branch instructions are dispatched during a single cycle of the processing system. Prior to speculatively executing the first conditional branch instruction, a first copy of the condition register is stored. Prior to speculatively executing the second conditional branch instruction, a second copy of the condition register is stored. Multiple copies of the condition register are concurrently maintained so that the first and second conditional branch instructions may be concurrently processed during a single cycle of the processing system.",IBM;;MOTOROLA INC,PENG CHIH-JUI RAY;;CHOW DANIEL CHEN;;POTTER TERENCE MATTHEW;;ROSSBACH PAUL CHARLES,INTERNATIONAL BUSINESS MACHINES CORPORATION (1997-03-25);;FREESCALE SEMICONDUCTOR INC (2004-04-04);;MOTOROLA INC (1997-04-20),https://lens.org/044-394-360-421-206,Granted Patent,yes,4,19,3,3,0,G06F9/30094;;G06F9/30101;;G06F9/384;;G06F9/3863;;G06F9/3885;;G06F9/30094;;G06F9/30101;;G06F9/3804;;G06F9/384;;G06F9/3863;;G06F9/3867;;G06F9/3885;;G06F9/30094;;G06F9/3863;;G06F9/30101;;G06F9/384;;G06F9/3885,G06F9/30;;G06F9/32;;G06F9/38,712/215,1,1,020-729-265-206-090,10.1109/12.48865,"Gurindar Sohi, Instruction Issue Logic for High Performance, Interruptible, Multiplt Functional Unit, Pipelined Computers, IEEE Transactions On Computers, vol. 39, No. 3 pp. 349 359, Mar. 1990.",EXPIRED
239,US,B2,US 6788481 B2,135-167-299-471-579,2004-09-07,2004,US 10442202 A,2002-03-21,US 10442202 A,2002-03-21,Process for measuring nonlinear transition shift (NLTS) at high recording densities with a giant magetoresistive (GMR) head,"
    A nonlinear transition shift (NLTS) measurement procedure for read/write heads employing a giant magnetoresistive (GMR) merged heads. The method of this invention includes the pulse-shape distortion effects on recording nonlinearity, which can significantly affect the existing theoretical formulae for calculating nonlinearity correction factor from measured partial erasure values, and second-order approximation of equation of NLTS and nonlinearity correction factor. Transition broadening effects (TBE) and partial erasure (PE) are incorporated in the NLTS measurement procedure to permit accurate isolation of the NLTS from the unrelated TBE/PE and GMR nonlinear transfer characteristic (NTC). First, a fifth harmonic elimination (5HE) test is performed at bit period T to measure a first nonlinearity value X. Then two partial erasure (PE) tests are done at two different densities, one below the PE threshold to measure a second nonlinearity value X _{ S } and the other at the same density as the 5HE test to measure a third nonlinearity value X _{ h } . Finally, the NLTS is computed by combining the first, second and third nonlinearity values. 
",IBM,FANG PETER CHEN-I;;FENG XIANGJUN;;LAM TERENCE TIN-LOK;;LIN ZHONG-HENG,INTERNATIONAL BUSINESS MACHINES CORPORATION (2002-03-19);;HITACHI GLOBAL STORAGE TECHNOLOGIES NETHERLANDS B.V (2002-12-31),https://lens.org/135-167-299-471-579,Granted Patent,yes,9,41,2,2,0,B82Y10/00;;B82Y25/00;;G11B5/09;;G11B20/10009;;G11B27/36;;G11B2005/001;;G11B2005/3996;;Y10S977/934;;B82Y25/00;;G11B20/10009;;G11B2005/001;;B82Y10/00;;G11B2005/3996;;G11B27/36;;G11B5/09;;Y10S977/934,G11B5/00;;G11B5/09;;G11B5/39;;G11B20/10;;G11B27/36,360/31;;360/45;;360/53;;360/51,11,8,086-072-934-757-078;;119-093-317-646-661;;008-942-815-155-514;;000-307-313-959-826;;020-628-532-794-702;;036-636-120-829-068;;053-890-318-080-451;;123-821-761-200-057,10.1109/20.617449;;10.1109/20.281360;;10.1109/20.809148;;10.1109/20.490257;;10.1109/20.334046;;10.1109/20.706755;;10.1109/20.809147;;10.1109/20.334047,"Non-Linear Transition Shift, LeCroy, Apr. 24, 2001 (from ""lecroy.com/applications"").;;IEICE Trans. Electronics, vol. E80-C, No. 9, Sep. 1997, ""An Improved Technique to Measure Nonlinear Phase Shift and Amplitude Distortion"".;;IEEE Trans. on Magnetics, vol. 33, No. 5, Sep. 1997, ""Novel Method for Real-Time Monitoring of Non-Linear Transition Shift"".;;IEEE Trans. on Magnetics, vol. 29,No. 6,Nov. 1993, ""Studies of Nonlinear Bit Shift and Partial Erasure Using Pseudo-Random Sequence"".;;IEEE Trans. on Magnetics, vol. 35,No. 6, Nov. 1999, ""New Frequency-Domain Technique for Joint Measurement of Nonlinear Transition Shift and Partial Erasure"".;;IEEE Trans. on Magnetics, vol. 31, No. 6, Nov. 1995, ""Nonlinearity Measurements and Write Precompensation Studies for a PRML Recording Channel"".;;IEEE Trans. on Magnetics, vol. 30, No. 6, Nov. 1994, ""A Generalized Frequency Domain Nonlinearity Measurement Method"".;;IEEE Trans. on Magnetics, vol. 34, No. 4, Jul. 1998, ""A Theoretical Study of Nonlinear Transition Shift"".;;IEEE Trans. on Magnetics, vol. 35, No. 6, Nov. 1999, ""Magnetoresistive Read Nonlinearity Correction by a Frequency-Domain Approach"".;;IEEE Trans. on Magnetics, vol. 30, No. 6, Nov. 1994, ""A Time-Correlation Method of Calculating Nonlinearities Utilizing Pseudorandom Sequences"".;;IEEE Trans. on Magnetics, vol. 33, No. 5, pt. 1, Sep. 1997, ""Experimental and theoretical studies of nonlinear transition shift in metal evaporated tape"".",EXPIRED
240,CN,U,CN 204947243 U,025-011-498-005-803,2016-01-06,2016,CN 201520491671 U,2015-04-28,US 201462002934 P;;US 201462021066 P;;US 201462026046 P;;CN 201520262338 U,2014-05-26,Socket connector,"The utility model provides a socket connector which includes insulator, the two rows of terminals, set up at insulator's masking shield and surround insulator and form the metal casing in butt joint chamber. Insulator includes basal portion and butt joint hyoplastron, and the definition of butt joint hyoplastron has two relative surfaces. Two rows of terminals are including arranging respectively at contact site that docks the hyoplastron and the pin that extends the basal portion. The masking shield is including setting up at the butt joint hyoplastron and being located first shielding portion and the second shielding portion between two rows of terminal contact sites, and the second shielding portion is located between the pin of two rows of terminals. The overlap joint arm is extended to the horizontal both sides of first shielding portion, the contact of overlap joint arm the metal casing. The utility model discloses a second shielding portion can both effectually improve the electromagnetic interference problem that high frequency signal transmits with the overlap joint arm.",FOXCONN KUNSHAN COMPUTER CONNECTOR CO LTD,TERENCE F LITTLE;;ZHENG ZHIPI;;CHEN ZHAOJIE;;XIAO XUELONG;;ZHANG YUAN;;STEPHEN SEDIO,,https://lens.org/025-011-498-005-803,Limited Patent,no,0,8,16,270,0,,H01R13/658;;H01R12/70;;H01R13/502,,0,0,,,,ACTIVE
241,US,B2,US 8620899 B2,085-776-513-211-279,2013-12-31,2013,US 70238410 A,2010-02-09,US 70238410 A,2010-02-09,Generating materialized query table candidates,"Techniques for generating a set of one or more materialized query table (MQT) candidates for a workload are provided. The techniques include receiving a workload, wherein the workload comprises a set of one or more queries, generating one or more best matching MQTs (BMQTs) based on one or more query blocks of the one or more queries by removing syntax that is not qualified for a MQT re-write, determining one or more frequently used multi-joins in the workload, using the one or more BMQTs and the one or more frequently used multi-joins to generate a set of one or more workload MQTs (WMQTs), and grouping one or more WMQTs and one or more BMQTs into one or more groups to merge into a set of a smaller number of MQTs and to cover the workload.",CHEN DONGSHENG;;MIN HONG;;PURCELL TERENCE P;;SHUF YEFIM;;WANG XIAOBO;;ZHANG ZHONGLIANG;;IBM,CHEN DONGSHENG;;MIN HONG;;PURCELL TERENCE P;;SHUF YEFIM;;WANG XIAOBO;;ZHANG ZHONGLIANG,INTERNATIONAL BUSINESS MACHINES CORPORATION (2010-02-03),https://lens.org/085-776-513-211-279,Granted Patent,yes,28,2,2,2,0,G06F16/24539;;G06F16/24539,G06F7/00;;G06F17/30,707/714;;707/717,11,5,130-642-113-024-577;;094-603-801-004-996;;038-968-042-457-37X;;094-603-801-004-996;;038-968-042-457-37X,10.1109/icde.2001.914852;;10.1109/icde.2008.4497452;;10.1109/coopis.1996.555007;;10.1109/icde.2008.4497452;;10.1109/coopis.1996.555007,"Lehner et al., ""fAST Refresh using Mass Query Optimization,"" 17th International Conference on Data Engineering (ICDE'01), 2001.;;Bello et al. ""Materialized Views in Oracle"", Proc of the 24th VLDB Conference, New York, USA, 1998.;;Gao et al.; Provisioning Deployment of Materialized Views and Indices for Data Warehouse Operation Schedule.;;Phan et al.; ""Dynamic Materialization of Query Views for Data Warehouse Workloads."";;Xie et al.; Adaptive Query Correlation Aware Workload Execution Ordering.;;Scheuermann et al.; ""Dynamic Integration and Query Processing with Ranked Role Sets."";;Jiang et al.; ""Exploiting Correlation and Parallelism of Materialized View Recommendation for Distributed Data Warehouse,"" IEEE 23rd Inter. Conf.Apr. 15-20, 2007, pp. 276-285.;;D. Gao et al., ""Provisioning Deployment of Materialized Views and Indices for Data Warehouse Operation Schedule,"" ip.com, IPCOM000176163D, Nov. 2008, 10 pages.;;T. Phan et al., ""Dynamic Materialization of Query Views for Data Warehouse Workloads,"" IEEE 24th International Conference on Data Engineering, Apr. 2008, pp. 436-334.;;J. Xie et al., ""Adaptive Query Correlation Aware Workload Execution Ordering,"" ip.com, IPCOM000176156D, Nov. 2008, 14 pages.;;P. Scheuermann et al., ""Dynamic Integration and Query Processing with Ranked Role Sets,"" IEEE, First International Conference on Cooperative Information Systems (IFCIS), Jun. 1996, pp. 157-166.",INACTIVE
242,US,A1,US 2004/0127483 A1,146-547-536-986-271,2004-07-01,2004,US 66574003 A,2003-09-19,US 66574003 A;;US 11771799 A;;EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,Pyrazolopyrimidines as CRF receptor antagonists,"
    This invention concerns compounds of formula 

    including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R ¹ is NR ⁴ R ⁵ or OR ⁵ ; R ² is C ₁₋₆ alkyl, C ₁₋₆ alkyloxy or C ₁₋₆ alkylthio; R ³ is hydrogen, C ₁₋₆ alkyl, C ₁₋₆ alkylsulfonyl, C ₁₋₆ alkylsulfoxy or C ₁₋₆ alkylthio; R ⁴ is hydrogen, C ₁₋₆ alkyl, mono- or di(C ₃₋₆ cycloalkyl)methyl, C ₃₋₆ cycloalkyl, C ₃₋₆ alkenyl, hydroxyC ₁₋₆ alkyl, C ₁₋₆ alkylcarbonyloxyC ₁₋₆ alkyl or C ₁₋₆ alkyloxyC ₁₋₆ alkyl; R ⁵ is C ₁₋₈ alkyl, mono- or di(C ₃₋₆ cycloalkyl)methyl, A ¹ CH ₂ , C ₁₋₆ alkyloxyC ₁₋₆ alkyl, hydroxyC ₁₋₆ alkyl, C ₃₋₆ alkenyl, thienylmethyl, furanylmethyl, C ₁₋₆ alkylthioC ₁₋₆ alkyl, morpholinyl, mono- or di(C ₁₋₆ alkyl)aminoC ₁₋₆ alkyl, di(C ₁₋₆ alkyl)amino, C ₁₋₆ alkylcarbonylC ₁₋₆ alkyl, C ₁₋₆ alkyl substituted with imidazolyl; or a radical of formula AlkOCOAr ¹ ; or R ⁴ and R ⁵ taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I). 
",NEUROCRINE BIOSCIENCES INC,CHEN CHEN;;WEBB THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M;;HUANG CHARLES Q,,https://lens.org/146-547-536-986-271,Patent Application,yes,13,2,5,52,0,C07D487/04;;C07D487/04,C07D487/04,514/217.06;;514/234.5;;514/259.3;;X5406;;544/117;;544/281,0,0,,,,EXPIRED
243,CN,A,CN 112313255 A,129-846-501-100-622,2021-02-02,2021,CN 201880094720 A,2018-07-10,CN 2018095099 W,2018-07-10,Aqueous Dispersion of Multistage Polymer Particles and Process of Making the Same,An aqueous dispersion of multistage polymer particles comprising a specific oligomer prepared from polymerization of monomers comprising an alkoxylated (meth) acrylate providing aqueous coating compositions with both good flow-and-leveling property and extended open time.,DOW GLOBAL TECHNOLOGIES INC;;ROHM & HAAS,LI YAN;;WONG TERENCE;;CHEN JUNYU;;WANG TAO;;BOHLING JAMES;;GONG ZHIJUAN;;HU YUEHAN,,https://lens.org/129-846-501-100-622,Patent Application,no,7,1,12,12,0,C08F220/14;;C09D133/12;;C08F265/06;;C08F265/00;;C08F285/00;;C09D151/003;;C08F220/286;;C08F220/06;;C08F220/14;;C08F220/365;;C08F220/14;;C09D133/12;;C08F265/00;;C08F265/06,C08F220/10;;C08F220/02;;C08F220/04;;C08F220/56,,0,0,,,,ACTIVE
244,EP,A2,EP 2643000 A2,164-028-188-181-191,2013-10-02,2013,EP 11827395 A,2011-09-21,US 88792010 A;;US 2011/0052441 W,2010-09-22,THERAPEUTIC PIPERAZINES,,DART NEUROSCIENCE CAYMAN LTD,KAPLAN ALAN;;KEENAN TERENCE;;WEINHOUSE MICHAEL;;WILSON MARK;;LINDSTROM ANDREW;;RIPKA WILLIAM;;CHEN MI,,https://lens.org/164-028-188-181-191,Patent Application,yes,0,0,8,8,0,A61K31/495;;A61K31/495;;A61K31/496;;A61K31/496;;A61K31/5377;;A61K31/5377;;A61K31/551;;A61K31/551;;A61K45/06;;A61K45/06;;A61P25/00;;A61P25/28;;C07D403/06;;C07D403/06;;C07D241/04;;C07D241/04;;C07D243/08;;C07D243/08;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/14;;C07D401/14;;C07D403/04;;C07D403/04;;C07D403/14;;C07D403/14;;C07D409/06;;C07D409/06;;C07D413/06;;C07D413/06;;C07D413/14;;C07D413/14;;C07D417/06;;C07D417/06;;C07D417/14;;C07D417/14,A61K31/496,,0,0,,,,DISCONTINUED
245,US,B2,US 7895185 B2,074-944-236-895-983,2011-02-22,2011,US 53640006 A,2006-09-28,US 53640006 A,2006-09-28,Row-identifier list processing management,"A method, computer program product, and system for managing row identifier (RID) list processing on an index are provided. The method, computer program product, and system provide for accessing one or more key values in the index based on one or more keys specified in a query, retrieving a plurality of row identifiers corresponding to the one or more key values from the index, and predicting an actual number of row identifiers to be retrieved from the index based on the one or more key values accessed and the plurality of row identifiers retrieved.",IBM,CHEN YING-LIN;;FUH YOU-CHIN;;LIN FEN-LING;;PURCELL TERENCE PATRICK;;ZENG YING,INTERNATIONAL BUSINESS MACHINES CORPORATION (2006-09-26),https://lens.org/074-944-236-895-983,Granted Patent,yes,21,5,2,2,0,G06F16/2228;;G06F16/24557;;G06F16/24557;;G06F16/2228,G06F17/30,707/711;;707/742,1,0,,,"Chong et al., B+-Tree Indexes with Hybrid Row Identifier in Oracle8i, 2001, pp. 341-348, Oracle Corporation, New Hampshire USA.",INACTIVE
246,TW,B,TW I246117 B,141-694-678-804-734,2005-12-21,2005,TW 92100521 A,2003-01-10,US 4796402 A,2002-01-15,Bilayer HDP CVD/PE CVD cap in advanced BEOL interconnect structures and method thereof,"An advanced back-end-of-line (BEOL) metallization structure is disclosed. The structure includes a bilayer diffusion barrier or cap, where the first cap layer is formed of a dielectric material preferably deposited by a high density plasma chemical vapor deposition (HDP CVD) process, and the second cap layer is formed of a dielectric material preferably deposited by a plasma-enhanced chemical vapor deposition (PE CVD) process. A method for forming the BEOL metallization structure is also disclosed. The invention is particularly useful in interconnect structures comprising low-k dielectric material for the inter-layer dielectric (ILD) and copper for the conductors.",IBM;;INFINEON TECHNOLOGIES AG,CHEN TZE-CHIANG;;ENGEL BRETT H;;FITZSIMMONS JOHN A;;KANE TERENCE;;LUSTIG NAFTALI E,,https://lens.org/141-694-678-804-734,Granted Patent,no,0,0,22,22,0,H01L21/76807;;H01L21/76832;;H01L21/76834;;H01L23/5226;;H01L23/53228;;H01L23/53295;;H01L2924/0002;;H01L21/768;;H01L21/76834;;H01L23/53295;;H01L21/76832;;H01L23/53228;;H01L23/5226;;H01L21/76807;;H01L21/76801;;H01L2924/0002,H01L21/768;;H01L23/522;;H01L23/532,,0,0,,,,EXPIRED
247,US,A1,US 2008/0082489 A1,051-299-107-696-271,2008-04-03,2008,US 53640006 A,2006-09-28,US 53640006 A,2006-09-28,Row Identifier List Processing Management,"A method, computer program product, and system for managing row identifier (RID) list processing on an index are provided. The method, computer program product, and system provide for accessing one or more key values in the index based on one or more keys specified in a query, retrieving a plurality of row identifiers corresponding to the one or more key values from the index, and predicting an actual number of row identifiers to be retrieved from the index based on the one or more key values accessed and the plurality of row identifiers retrieved.",IBM,CHEN YING-LIN;;FUH YOU-CHIN;;LIN FEN-LING;;PURCELL TERENCE PATRICK;;ZENG YING,INTERNATIONAL BUSINESS MACHINES CORPORATION (2006-09-26),https://lens.org/051-299-107-696-271,Patent Application,yes,21,22,2,2,0,G06F16/2228;;G06F16/24557;;G06F16/24557;;G06F16/2228,G06F17/30,707/3,0,0,,,,INACTIVE
248,WO,A2,WO 2012/040258 A2,002-962-740-529-250,2012-03-29,2012,US 2011/0052441 W,2011-09-21,US 88792010 A,2010-09-22,THERAPEUTIC PIPERAZINES,"The invention includes a compound of formula I... wherein R 1 , Y, A, n, R 4 and Z have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function and/or treating cognitive disorders or impariment, traumatic and/or ischemic injuries of the central and peripheral nervous system and/or psychiatric disorders in animals, especially humans.",HELICON THERAPEUTICS INC;;KAPLAN ALAN;;KEENAN TERENCE;;WEINHOUSE MICHAEL;;WILSON MARK;;LINDSTROM ANDREW;;RIPKA WILLIAM;;CHEN MI,KAPLAN ALAN;;KEENAN TERENCE;;WEINHOUSE MICHAEL;;WILSON MARK;;LINDSTROM ANDREW;;RIPKA WILLIAM;;CHEN MI,,https://lens.org/002-962-740-529-250,Patent Application,yes,0,11,8,8,0,A61K31/495;;A61K31/495;;A61K31/496;;A61K31/496;;A61K31/5377;;A61K31/5377;;A61K31/551;;A61K31/551;;A61K45/06;;A61K45/06;;A61P25/00;;A61P25/28;;C07D403/06;;C07D403/06;;C07D241/04;;C07D241/04;;C07D243/08;;C07D243/08;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/14;;C07D401/14;;C07D403/04;;C07D403/04;;C07D403/14;;C07D403/14;;C07D409/06;;C07D409/06;;C07D413/06;;C07D413/06;;C07D413/14;;C07D413/14;;C07D417/06;;C07D417/06;;C07D417/14;;C07D417/14,A61K31/551;;A61K31/495;;A61K31/496;;A61K31/5377;;A61P25/00;;A61P25/28;;C07D241/04;;C07D243/08;;C07D401/06;;C07D403/04;;C07D403/06;;C07D413/06;;C07D413/14;;C07D417/06;;C12N5/07,,1,0,,,See references of EP 2643000A4,PENDING
249,WO,A3,WO 2012/040258 A3,170-838-903-477-04X,2012-06-07,2012,US 2011/0052441 W,2011-09-21,US 88792010 A,2010-09-22,THERAPEUTIC PIPERAZINES,"The invention includes a compound of formula I... wherein R 1 , Y, A, n, R 4 and Z have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function and/or treating cognitive disorders or impariment, traumatic and/or ischemic injuries of the central and peripheral nervous system and/or psychiatric disorders in animals, especially humans.",HELICON THERAPEUTICS INC;;KAPLAN ALAN;;KEENAN TERENCE;;WEINHOUSE MICHAEL;;WILSON MARK;;LINDSTROM ANDREW;;RIPKA WILLIAM;;CHEN MI,KAPLAN ALAN;;KEENAN TERENCE;;WEINHOUSE MICHAEL;;WILSON MARK;;LINDSTROM ANDREW;;RIPKA WILLIAM;;CHEN MI,,https://lens.org/170-838-903-477-04X,Search Report,yes,2,0,8,8,0,A61K31/495;;A61K31/495;;A61K31/496;;A61K31/496;;A61K31/5377;;A61K31/5377;;A61K31/551;;A61K31/551;;A61K45/06;;A61K45/06;;A61P25/00;;A61P25/28;;C07D403/06;;C07D403/06;;C07D241/04;;C07D241/04;;C07D243/08;;C07D243/08;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/14;;C07D401/14;;C07D403/04;;C07D403/04;;C07D403/14;;C07D403/14;;C07D409/06;;C07D409/06;;C07D413/06;;C07D413/06;;C07D413/14;;C07D413/14;;C07D417/06;;C07D417/06;;C07D417/14;;C07D417/14,A61K31/496,,2,1,028-531-017-402-399,10.1124/mol.61.1.20;;11752202,"DYM ET AL.: ""Molecular Docking of Competitive Phosphodiesterase Inhibitors"", MOL PHARMACOL, vol. 61, no. 20, 2002, pages 20 - 25, XP055081424, Retrieved from the Internet <URL:http://molpharm.aspetjournals.org/content/61/1/20.full.pdf>;;See also references of EP 2643000A4",PENDING
250,EP,A4,EP 2643000 A4,128-867-781-917-704,2014-05-21,2014,EP 11827395 A,2011-09-21,US 88792010 A;;US 2011/0052441 W,2010-09-22,THERAPEUTIC PIPERAZINES,,DART NEUROSCIENCE CAYMAN LTD,KAPLAN ALAN;;KEENAN TERENCE;;WEINHOUSE MICHAEL;;WILSON MARK;;LINDSTROM ANDREW;;RIPKA WILLIAM;;CHEN MI,,https://lens.org/128-867-781-917-704,Search Report,no,6,0,8,8,0,A61K31/495;;A61K31/495;;A61K31/496;;A61K31/496;;A61K31/5377;;A61K31/5377;;A61K31/551;;A61K31/551;;A61K45/06;;A61K45/06;;A61P25/00;;A61P25/28;;C07D403/06;;C07D403/06;;C07D241/04;;C07D241/04;;C07D243/08;;C07D243/08;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/14;;C07D401/14;;C07D403/04;;C07D403/04;;C07D403/14;;C07D403/14;;C07D409/06;;C07D409/06;;C07D413/06;;C07D413/06;;C07D413/14;;C07D413/14;;C07D417/06;;C07D417/06;;C07D417/14;;C07D417/14,A61K31/496,,0,0,,,,DISCONTINUED
251,JP,A,JP 2016029056 A,097-980-124-465-025,2016-03-03,2016,JP 2015180082 A,2015-09-11,US 74164005 P;;US 82259706 P,2005-12-02,COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH CYTOKINE SIGNALING INVOLVING ANTIBODIES BINDING TO IL-22 AND ANTIBODIES BINDING TO IL-22R,"PROBLEM TO BE SOLVED: To provide compositions and methods for the diagnosis or treatment of inflammation and autoimmune disorders, such as psoriasis.SOLUTION: There are provided compositions such as antibodies that bind to IL-22 and IL-22R for modulating IL-23 or IL-22 signaling. A method of treating an autoimmune disorder using the antibody compositions is provided, where the autoimmune disorder is not arthritis, comprising administering to a mammal an effective amount of a pharmaceutical formulation comprising an antagonist of IL-22. A method of treating inflammation is provided, where the inflammation is not arthritic inflammation but inflammatory bowel disease or psoriasis, comprising administering to a mammal an effective amount of a pharmaceutical formulation comprising an antagonist of IL-22.SELECTED DRAWING: None",GENENTECH INC,CHEN YVONNE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;CHEN YAN,,https://lens.org/097-980-124-465-025,Patent Application,no,2,0,36,39,4,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,C07K16/24;;A61K39/395;;A61K45/00;;A61P1/04;;A61P17/00;;A61P17/06;;A61P29/00;;A61P35/00;;A61P37/02;;A61P43/00;;C07K16/28;;C07K16/46;;C12N5/0783;;C12N15/02,,0,0,,,,INACTIVE
252,JP,A,JP 2013060443 A,189-260-109-037-137,2013-04-04,2013,JP 2012226023 A,2012-10-11,US 74164005 P;;US 82259706 P,2005-12-02,COMPOSITION AND METHOD FOR TREATMENT OF DISEASE AND DISORDER ASSOCIATED WITH CYTOKINE SIGNALING INVOLVING ANTIBODY THAT BINDS TO IL-22 AND ANTIBODY THAT BINDS TO IL-22R,"PROBLEM TO BE SOLVED: To provide compositions and methods useful for the diagnosis and treatment of diseases or disorders associated with cytokine signaling.SOLUTION: There are provided antibodies that bind to IL-22 and IL-22R for modulating IL-23 signaling or IL-22 signaling, and compositions containing the antibodies. A method for treating an autoimmune disorder includes administering to a mammal an effective amount of a pharmaceutical formulation comprising an antagonist of IL-22. A method of treating inflammation includes administering to a mammal an effective amount of a pharmaceutical formulation comprising an antagonist of IL-22.",GENENTECH INC,CHEN YVONNE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;CHEN YAN,,https://lens.org/189-260-109-037-137,Patent Application,no,2,0,36,39,4,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,A61K39/395;;C07K16/24;;A61P1/04;;A61P3/10;;A61P5/14;;A61P11/00;;A61P17/00;;A61P17/06;;A61P19/02;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P35/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C12N5/10;;C12N15/02;;C12N15/09;;C12P21/08,,0,0,,,,INACTIVE
253,EP,A2,EP 2959284 A2,076-433-944-586-135,2015-12-30,2015,EP 14709128 A,2014-02-24,US 201361768367 P;;US 2014/0018110 W,2013-02-22,OPTICAL SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,,LIFE TECHNOLOGIES CORP,CHEN MINGSONG;;AGUANNO MAURO;;BOO KUAN MOON;;SOH WOON LIANG TERENCE;;FREUDENTHAL JACOB;;MARKS JEFFREY,LIFE TECHNOLOGIES CORPORATION (2016-11-23),https://lens.org/076-433-944-586-135,Patent Application,yes,0,0,11,11,0,G01N21/274;;G01N21/645;;G01N21/6452;;G01N2201/0627;;G01N2201/0624;;G01N2201/121;;G01N21/274;;G01N21/645;;G01N21/6452;;G01N2201/0624;;G01N2201/0627;;G01N2201/121;;G01N2201/0624;;G01N21/6452;;G01N2201/0627;;G01N2201/121;;G01N21/274;;G01N21/645;;G01N21/0332;;G01N21/6486;;G01N2201/061,G01N21/27,,0,0,,,,PENDING
254,WO,A1,WO 2012/008929 A1,020-712-424-938-950,2012-01-19,2012,SG 2011000254 W,2011-07-15,SG 201005144 A,2010-07-16,"SENSOR AND METHOD OF MANUFACTURING THE SAME, AND SYSTEM FOR DETECTING A PARTIAL DISCHARGE SIGNAL AND A METHOD OF FORMING THE SAME","According to various embodiments, a sensor is provided. The sensor includes an antenna configured to receive a partial discharge signal, and a vertical-cavity surface-emitting laser coupled to the antenna, wherein the vertical-cavity surface-emitting laser is configured to convert the received partial discharge signal into an optical signal. Further embodiments provide a method of manufacturing a sensor, a system for detecting a partial discharge signal, a method of forming a system for detecting a partial discharge signal and a method of detecting a partial discharge signal.",AGENCY SCIENCE TECH & RES;;HOESTAR INSPECTION INTERNAT PTE LTD;;CHEN ZHIHAO;;NG JUN HONG;;SEE SHIE PING TERENCE;;LEONG WENG HOE;;KOH YONG KWEE,CHEN ZHIHAO;;NG JUN HONG;;SEE SHIE PING TERENCE;;LEONG WENG HOE;;KOH YONG KWEE,,https://lens.org/020-712-424-938-950,Patent Application,yes,3,8,2,2,0,G01R29/0878;;G01R15/22;;G01R31/1218;;G01R31/1227;;H01S5/0028;;H01S5/183,G01R31/12;;H01S5/183,,0,0,,,,PENDING
255,SG,A,SG 11201506481Q A,118-394-201-885-487,2015-09-29,2015,SG 11201506481Q A,2014-02-24,US 201361768367 P;;US 2014/0018110 W,2013-02-22,OPTICAL SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,,LIFE TECHNOLOGIES CORP,CHEN MINGSONG;;AGUANNO MAURO;;BOO KUAN MOON;;SOH WOON LIANG TERENCE;;FREUDENTHAL JACOB;;MARKS JEFFREY,,https://lens.org/118-394-201-885-487,Unknown,no,0,0,11,11,0,G01N21/274;;G01N21/645;;G01N21/6452;;G01N2201/0627;;G01N2201/0624;;G01N2201/121;;G01N21/274;;G01N21/645;;G01N21/6452;;G01N2201/0624;;G01N2201/0627;;G01N2201/121;;G01N2201/0624;;G01N21/6452;;G01N2201/0627;;G01N2201/121;;G01N21/274;;G01N21/645;;G01N21/0332;;G01N21/6486;;G01N2201/061,G01N21/27,,0,0,,,,PENDING
256,CN,A,CN 102954936 A,146-193-076-618-99X,2013-03-06,2013,CN 201110271134 A,2011-08-18,CN 201110271134 A,2011-08-18,Test system and test method,"The invention provides a test system and a test method. The test system comprises a tester and a checker, wherein the tester is configured to apply a predetermined load to a predetermined position on a tested component, the predetermined load simulates a load which is applied to the component when a user uses the component, and the predetermined position is limited through structural analysis on the component, so that the maximum stress is generated at the joint of the component when the predetermined load is applied; and the checker is configured to check the tested component to as to judge whether the tested component is acceptable or not.",APPLE INC,JAY KEVIN OSBORNE;;KIM SANG-HA;;TERENCE JOHNSON CHEN;;CAO JINHE;;SUN GUOHUA;;EDWARD NABIGIAN,,https://lens.org/146-193-076-618-99X,Patent Application,no,5,0,2,2,0,,G01N19/04,,0,0,,,,ACTIVE
257,WO,A3,WO 2014/130970 A3,019-632-131-674-378,2015-12-03,2015,US 2014/0018110 W,2014-02-24,US 201361768367 P,2013-02-22,OPTICAL SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,"An instrument for processing and/or measuring a biological process contains a sample processing system, an excitation source, an excitation optical system, an optical sensor, and an emission optical system. The sample processing system is configured to retain a first sample holder and a second sample holder, wherein the number of sample cells is different for each sample holder or a characteristic dimension for the first sample cells is different from that of the second sample holder. The instrument also includes an excitation source temperature controller comprising a temperature sensor that is coupled to the excitation source. The temperature controller is configured to produce a first target temperature when the first sample holder is retained by the instrument and to produce a second target temperature when the second sample holder is retained by the instrument.",LIFE TECHNOLOGIES CORP,CHEN MINGSONG;;AGUANNO MAURO;;BOO KUAN MOON;;SOH WOON LIANG TERENCE;;FREUDENTHAL JACOB;;MARKS JEFFREY,,https://lens.org/019-632-131-674-378,Search Report,yes,3,0,11,11,0,G01N21/274;;G01N21/645;;G01N21/6452;;G01N2201/0627;;G01N2201/0624;;G01N2201/121;;G01N21/274;;G01N21/645;;G01N21/6452;;G01N2201/0624;;G01N2201/0627;;G01N2201/121;;G01N2201/0624;;G01N21/6452;;G01N2201/0627;;G01N2201/121;;G01N21/274;;G01N21/645;;G01N21/0332;;G01N21/6486;;G01N2201/061,G01N21/27;;G01N21/64,,0,0,,,,PENDING
258,SG,A1,SG 187096 A1,124-034-083-082-066,2013-02-28,2013,SG 2013003363 A,2011-07-15,SG 201005144 A;;SG 2011000254 W;;SG 2013003363 A,2010-07-16,"SENSOR AND METHOD OF MANUFACTURING THE SAME, AND SYSTEM FOR DETECTING A PARTIAL DISCHARGE SIGNAL AND A METHOD OF FORMING THE SAME","According to various embodiments, a sensor is provided. The sensor includes an antenna configured to receive a partial discharge signal, and a vertical-cavity surface-emitting laser coupled to the antenna, wherein the vertical-cavity surface-emitting laser is configured to convert the received partial discharge signal into an optical signal. Further embodiments provide a method of manufacturing a sensor, a system for detecting a partial discharge signal, a method of forming a system for detecting a partial discharge signal and a method of detecting a partial discharge signal.",AGENCY SCIENCE TECH & RES;;HOESTAR INSPECTION INTERNAT PTE LTD,CHEN ZHIHAO;;NG JUN HONG;;SEE SHIE PING TERENCE;;LEONG WENG HOE;;KOH YONG KWEE,,https://lens.org/124-034-083-082-066,Patent Application,no,0,1,2,2,0,G01R29/0878;;G01R15/22;;G01R31/1218;;G01R31/1227;;H01S5/0028;;H01S5/183,,,0,0,,,,PENDING
259,WO,A2,WO 2014/130970 A2,172-539-494-451-406,2014-08-28,2014,US 2014/0018110 W,2014-02-24,US 201361768367 P,2013-02-22,OPTICAL SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,"An instrument for processing and/or measuring a biological process contains a sample processing system, an excitation source, an excitation optical system, an optical sensor, and an emission optical system. The sample processing system is configured to retain a first sample holder and a second sample holder, wherein the number of sample cells is different for each sample holder or a characteristic dimension for the first sample cells is different from that of the second sample holder. The instrument also includes an excitation source temperature controller comprising a temperature sensor that is coupled to the excitation source. The temperature controller is configured to produce a first target temperature when the first sample holder is retained by the instrument and to produce a second target temperature when the second sample holder is retained by the instrument.",LIFE TECHNOLOGIES CORP,CHEN MINGSONG;;AGUANNO MAURO;;BOO KUAN MOON;;SOH WOON LIANG TERENCE;;FREUDENTHAL JACOB;;MARKS JEFFREY,,https://lens.org/172-539-494-451-406,Patent Application,yes,0,0,11,11,0,G01N21/274;;G01N21/645;;G01N21/6452;;G01N2201/0627;;G01N2201/0624;;G01N2201/121;;G01N21/274;;G01N21/645;;G01N21/6452;;G01N2201/0624;;G01N2201/0627;;G01N2201/121;;G01N2201/0624;;G01N21/6452;;G01N2201/0627;;G01N2201/121;;G01N21/274;;G01N21/645;;G01N21/0332;;G01N21/6486;;G01N2201/061,G01N21/27,,0,0,,,,PENDING
260,AU,A1,AU 2014/215990 A1,010-202-334-662-054,2014-09-11,2014,AU 2014/215990 A,2014-08-21,AU 2008/228778 A;;AU 2014/215990 A,2008-03-21,Apoptotic anti-IgE antibodies binding the membrane-bound IgE,"Abstract of the Disclosure The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated 5 disorders. 5693062_1 (GHMatters) P81939.AU.1 LEOWNR",GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/010-202-334-662-054,Patent Application,no,0,0,1,1,0,,C07K16/42;;A61P37/06,,0,0,,,,DISCONTINUED
261,US,A1,US 2012/0177635 A1,031-709-187-603-381,2012-07-12,2012,US 201113281209 A,2011-10-25,US 201113281209 A;;US 5306308 A;;US 89633907 P,2007-03-22,METHODS OF USING APOPTOTIC ANTI-IGE ANTIBODIES,"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.",WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDY;;CHEN YVONNE;;CHUNTHARAPAL ANAN;;DENNIS MARK;;WONG TERENCE;;GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDY;;CHEN YVONNE;;CHUNTHARAPAL ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/031-709-187-603-381,Patent Application,yes,2,1,56,56,112,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,A61K39/395,424/131.1,0,0,,,,INACTIVE
262,US,A1,US 2011/0196857 A1,055-001-447-743-135,2011-08-11,2011,US 70238410 A,2010-02-09,US 70238410 A,2010-02-09,Generating Materialized Query Table Candidates,"Techniques for generating a set of one or more materialized query table (MQT) candidates for a workload are provided. The techniques include receiving a workload, wherein the workload comprises a set of one or more queries, generating one or more best matching MQTs (BMQTs) based on one or more query blocks of the one or more queries by removing syntax that is not qualified for a MQT re-write, determining one or more frequently used multi-joins in the workload, using the one or more BMQTs and the one or more frequently used multi-joins to generate a set of one or more workload MQTs (WMQTs), and grouping one or more WMQTs and one or more BMQTs into one or more groups to merge into a set of a smaller number of MQTs and to cover the workload.",IBM,CHEN DONG SHENG;;MIN HONG;;PURCELL TERENCE P;;SHUF YEFIM;;WANG XIAO BO;;ZHANG ZHONG LIANG,INTERNATIONAL BUSINESS MACHINES CORPORATION (2010-02-03),https://lens.org/055-001-447-743-135,Patent Application,yes,28,68,2,2,0,G06F16/24539;;G06F16/24539,G06F17/30,707/714;;707/717;;X707E17017;;X707E17005;;X707E17044;;707/803;;707/737;;X707E17089;;707/752,0,0,,,,INACTIVE
263,SI,T1,SI 2132230 T1,057-849-421-319-978,2014-07-31,2014,SI 200831219 T,2008-03-21,US 89633907 P;;US 2008/0057819 W;;EP 08744179 A,2007-03-22,APOPTOTIC ANTI-IGE ANTIBODIES BINDING THE MEMBRANE-BOUND IGE,,GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/057-849-421-319-978,Granted Patent,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/00;;A01K67/00;;A61P37/00,,0,0,,,,ACTIVE
264,CN,A,CN 116439930 A,135-247-318-999-652,2023-07-18,2023,CN 202310450086 A,2023-04-25,CN 202310450086 A,2023-04-25,Nursing bed and method,"The invention provides a nursing bed and a method. The nursing bed comprises a bed frame, a hip bed board, a back raising unit and a leg bending unit, wherein the hip bed board, the back raising unit and the leg bending unit are mounted on the bed frame, and the back raising unit and the leg bending unit are located on the two sides of the hip bed board respectively; the leg bending unit comprises a thigh bed board, a shank bed board, a linear pull rod and a leg bending mechanism, the thigh bed board is rotationally connected with the shank bed board, the shank bed board is rotationally connected with the linear pull rod, and the leg bending mechanism comprises a leg bending motor, a leg bending rotating arm, a leg bending circular shaft, a leg bending supporting arm, a leg bending connecting rod and a leg bending roller; and the leg bending rotating arm is fixedly connected with the leg bending circular shaft. According to the nursing bed, the pressure feeling of a patient on the buttocks in the back raising process can be reduced, the pressure feeling of the patient on the thigh roots in the leg bending process is reduced, and the comfort level is high.",MAIFU SHANDONG SCIENT INSTRUMENT CO LTD,CHEN XUEYIN;;ZHOU ZHEN;;DONG CHUNGENG;;ZHAO SHANSHAN;;WONG KA CHEONG TERENCE;;CHANG SHENGYU;;ZHU GUANXU,,https://lens.org/135-247-318-999-652,Patent Application,no,0,0,1,1,0,A61G7/015;;A61G7/05;;A61G7/0573;;Y02A50/30,A61G7/015;;A61G7/05;;A61G7/057,,0,0,,,,PENDING
265,TW,B,TW I464178 B,085-285-589-932-527,2014-12-11,2014,TW 97110305 A,2008-03-21,US 89633907 P,2007-03-22,Apoptotic anti-ige antibodies,,GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/085-285-589-932-527,Granted Patent,no,1,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,,,1,0,,,"Chen, et al., Monoclonal Antibodies against the CεmX Domain of Human Membrane-Bound IgE and Their Potential Use for Targeting IgE-Expressing B Cells, Int. Arch. Allergy Immunol., 128, 315-324, 2002. Chang TW. Developing antibodies for targeting immunoglobulin and membrane-bound immunoglobulin E. Allergy Asthma Proc. 2006 Mar-Apr;27(2 Suppl 1):S7-14.",INACTIVE
266,TW,A,TW 200848432 A,085-981-717-793-808,2008-12-16,2008,TW 97110305 A,2008-03-21,US 89633907 P,2007-03-22,Apoptotic anti-IGE antibodies,"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.",GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/085-981-717-793-808,Patent of Addition,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A61K39/395;;C07K14/47,,0,0,,,,INACTIVE
267,PL,T3,PL 2132230 T3,153-035-845-685-67X,2014-09-30,2014,PL 08744179 T,2008-03-21,US 89633907 P;;EP 08744179 A;;US 2008/0057819 W,2007-03-22,APOPTOTIC ANTI-IGE ANTIBODIES BINDING THE MEMBRANE-BOUND IGE,,GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/153-035-845-685-67X,Patent Application,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A01K67/027;;A61P37/06,,0,0,,,,PENDING
268,BR,A,BR 9707391 A,034-069-104-997-01X,1999-07-20,1999,BR 9707391 A,1997-01-30,EP 9700459 W;;US 1127996 P;;US 2768896 P,1996-02-07,Pirazolpirimidinas como antagonistas de receptor de crf,,JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHENG CHEN;;WEGG THOMAS R;;MCCARTHY JAMES R;;MORAN TERENCE J;;WILCOXEN KEITH M;;HUANG CHARLES,NEUROCRINE BIOSCIENCES INC. (US) (2006-08-08),https://lens.org/034-069-104-997-01X,Patent Application,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,DISCONTINUED
269,KR,A,KR 20100015754 A,055-209-305-265-871,2010-02-12,2010,KR 20097021946 A,2008-03-21,US 89633907 P,2007-03-22,APOPTOTIC ANTI-IGE ANTIBODIES BINDING THE MEMBRANE-BOUND IGE,"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.",GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/055-209-305-265-871,Patent Application,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,A61K39/395;;A61P37/06,,0,0,,,,ACTIVE
270,MX,A,MX 2009010092 A,104-161-518-705-848,2010-02-09,2010,MX 2009010092 A,2008-03-21,US 89633907 P;;US 2008/0057819 W,2007-03-22,APOPTOTIC ANTI- IGE ANTIBODIES BINDING THE MEMBRANE-BOUND IGE.,"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.",GENENTECH INC,CHUNTHARAPAI ANAN;;WU LAWREN;;DENNIS MARK;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;WONG TERENCE,,https://lens.org/104-161-518-705-848,Patent Application,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A61P37/06,,0,0,,,,ACTIVE
271,RS,B,RS 53402 B,111-240-499-343-181,2014-10-31,2014,RS P20140360 A,2008-03-21,US 89633907 P;;US 2008/0057819 W,2007-03-22,APOPTOTIC ANTI-IGE ANTIBODIES BINDING THE MEMBRANE-BOUND IGE,Anti-IgE/M1' antitelo koje specifično vezuje epitop u M1' segmentu IgE definisanom ostacima 317 do 351 SEQ ID NO:1 i koje indukuje apoptozu u IgE eksprimirajućim B ćelijama.Prijava sadrži još 32 patentna zahteva.,GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/111-240-499-343-181,Granted Patent,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A01K67/027;;A61P37/06,,0,0,,,,ACTIVE
272,US,A1,US 2012/0178127 A1,160-284-811-474-250,2012-07-12,2012,US 201113281224 A,2011-10-25,US 201113281224 A;;US 5306308 A;;US 89633907 P,2007-03-22,Nucleic acid encoding apoptotic anti-ige antibodies,"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.",WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE;;GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/160-284-811-474-250,Patent Application,yes,2,1,56,56,112,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C12P21/06;;C07H21/04;;C12N5/10;;C12N15/63,435/69.6;;435/325;;435/358;;435/320.1;;536/23.53,4,2,027-477-313-726-928;;015-239-659-590-870,10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.4049/jimmunol.150.3.880;;8423344,"Janeway et al., Immunobiology, 3rd edition, 1997, Garland Press, pages 3:1-3:11;;Rudikoff et al., Proc Natl Acad Sci USA, 1982, 79:1979-1983.;;Portolano et al., J. Immunol., 1993, 150:880-887.;;FUNDAMENTAL IMMUNOLOGY, William E. Paul, M.D. ed., 3d ed. 1993, page 242.",INACTIVE
273,JP,A,JP 2015017103 A,010-710-990-176-848,2015-01-29,2015,JP 2014169311 A,2014-08-22,US 89633907 P,2007-03-22,APOPTOTIC ANTI-IGE ANTIBODIES,"PROBLEM TO BE SOLVED: To provide apoptotic anti-IgE antibodies usable for treating IgE-mediated disorders, nucleic acids encoding them and therapeutic compositions thereof.SOLUTION: The present invention provides an anti-IgE/Ml' antibody that specifically binds the Ml' segment of IgE and induces apoptosis in IgE-producing B-cells. In a specific aspect, the antibody specifically depletes IgE-producing B-cells. In another specific aspect, the antibody reduces total serum IgE. In yet another specific aspect, the antibody reduces both total serum and serum-free IgE. In a still further specific aspect, the antibody binds to IgE that is human, rhesus monkey and cynomolgus monkey in origin. In a still further specific aspect, the antibody is chimeric. In a still further specific aspect, the antibody is humanized. In a still further aspect, the antibody is human.",GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;HANS BRIGHTBILL;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/010-710-990-176-848,Patent Application,no,0,0,56,56,112,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A01K67/027;;A61K39/395;;A61K45/00;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P19/00;;A61P33/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/02,,0,0,,,,DISCONTINUED
274,CY,T1,CY 1115257 T1,165-261-239-664-132,2017-01-04,2017,CY 141100511 T,2014-07-08,EP 08744179 A;;US 89633907 P,2007-03-22,ΑΠΟΠΤΩΤΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΙgE ΠΟΥ ΔΕΣΜΕΥΟΝΤΑΙ ΜΕ ΙgE ΔΕΣΜΕΥΜΕΝΗ ΣΕ ΜΕΜΒΡΑΝΗ,"Η παρούσα αίτηση σχετίζεται με αποπτωτικά αντισώματα αντι-IgE, με νουκλεϊκά οξέα που τα κωδικοποιούν, με θεραπευτικές συνθέσεις αυτών, και με την χρήση τους στην θεραπευτική αγωγή IgE-διαμεσολαβούμενων διαταραχών.",GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/165-261-239-664-132,Granted Patent,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A01K67/027;;A61P37/06,,0,0,,,,ACTIVE
275,US,A1,US 2012/0144512 A1,180-518-127-026-384,2012-06-07,2012,US 201113281158 A,2011-10-25,US 201113281158 A;;US 5306308 A;;US 89633907 P,2007-03-22,TRANSGENIC ANIMALS EXPRESSING HUMAN IGE-M1',"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.",WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE;;GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/180-518-127-026-384,Patent Application,yes,0,1,56,56,112,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,A01K67/027,800/18;;800/13,9,7,138-157-823-727-156;;023-154-204-899-879;;134-958-999-769-59X;;002-305-399-176-585;;051-508-475-126-991;;014-330-136-504-946;;029-062-984-888-15X,10.1016/s0378-1119(98)00607-6;;9931414;;10.1161/01.atv.20.6.1425;;10845854;;15699570;;10.1385/mb:29:2:153;;10.1007/s00429-009-0230-8;;19937345;;10.1016/s0168-1656(02)00105-0;;pmc7252021;;12204554;;15809359;;10.1161/01.hyp.0000161995.64192.2b;;17943232;;10.1007/s12026-007-8008-7,"Kolb et al, (Gene, 227: 21031, 1999) .;;Sigmund (Arterioscler Throm Vasc Biol 20: 1425-1429, 2000) .;;Ristevski et al (Molecular Biotechnology, 29: 153-163, 2005) .;;Gama Sosa et al (Brain Struct Funct, 214: 91-109, 2010);;Smith et al (Journal of Biotechnology, 99: 1-22, 2002).;;Qi et al (Hypertension, 45: 1004-1011, 2005) .;;Ravirajan et al (Lupus, 11(2): 20202-Abstract) .;;Kumar et al (Immunol Res, 40: 208-223, 2008).;;Chang et al (Allergy and Asthma Proc, 27: S70 S14, 2006) .",DISCONTINUED
276,HK,A1,HK 1194743 A1,049-258-432-163-070,2014-10-24,2014,HK 14107981 A,2014-08-05,US 89633907 P,2007-03-22,APOPTOTIC ANTI- IGE ANTIBODIES BINDING THE MEMBRANE-BOUND IGE IGE IGE,,GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/049-258-432-163-070,Patent Application,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K/;;A61K/;;A61P/,,0,0,,,,DISCONTINUED
277,PT,E,PT 2132230 E,074-616-396-580-005,2014-07-17,2014,PT 08744179 T,2008-03-21,US 89633907 P,2007-03-22,APOPTOTIC ANTI-IGE ANTIBODIES BINDING THE MEMBRANE-BOUND IGE,,GENENTECH INC,CHUNTHARAPAI ANAN;;DENNIS MARK;;CHEN YVONNE;;WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;WONG TERENCE,,https://lens.org/074-616-396-580-005,Granted Patent,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A61P37/06,,0,0,,,,ACTIVE
278,CN,A,CN 103554263 A,083-398-832-018-697,2014-02-05,2014,CN 201310472607 A,2008-03-21,US 89633907 P;;CN 200880016908 A,2007-03-22,Apoptotic anti- IgE antibodies binding the membrane-bound IgE,"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.",GENENTECH INC,CHAN ANDREW;;DENNIS MARK;;BALAZS MERCEDESZ;;WONG TERENCE;;CHEN YVONNE;;BRIGHTBILL HANS;;CHUNTHARAPAI ANAN;;WU LAWREN,,https://lens.org/083-398-832-018-697,Patent Application,no,0,1,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A61K39/395;;A61P37/06,,0,0,,,,INACTIVE
279,EP,B1,EP 2644621 B1,146-536-223-101-379,2017-12-13,2017,EP 13165235 A,2008-03-21,US 89633907 P;;EP 08744179 A,2007-03-22,Apoptotic anti-IgE antibodies,,GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/146-536-223-101-379,Granted Patent,yes,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A01K67/027;;A61P37/06,,7,0,,,"CHEN HUAN YUAN ET AL: ""Monoclonal antibodies against the C(epsilon)mX domain of human membrane-bound IgE and their potential use for targeting IgE-expressing B cells."", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY AUG 2002, vol. 128, no. 4, August 2002 (2002-08), pages 315-324, XP008083849, ISSN: 1018-2438;;CHANG TSE WEN: ""Developing antibodies for targeting immunoglobulin and membrane-bound immunoglobulin E."", ALLERGY AND ASTHMA PROCEEDINGS : THE OFFICIAL JOURNAL OF REGIONAL AND STATE ALLERGY SOCIETIES 2006 MAR-APR, vol. 27, no. 2 Suppl 1, March 2006 (2006-03), pages S7-14, XP008083904, ISSN: 1088-5412;;CHEN HUAN YUAN ET AL: ""Generation and characterization of monoclonal antibodies against a segment (epsilonm67) uniquely present in membrane-bound IgE"", FASEB JOURNAL, vol. 15, no. 5, 8 March 2001 (2001-03-08), page A1018, XP008095920, & ANNUAL MEETING OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY ON EXPERIMENTAL BIOL; ORLANDO, FLORIDA, USA; MARCH 31-APRIL 04, 2001 ISSN: 0892-6638;;POGGIANELLA MONICA ET AL: ""The extracellular membrane-proximal domain of human membrane IgE controls apoptotic signaling of the B cell receptor in the mature B cell line A20."", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 SEP 2006, vol. 177, no. 6, 15 September 2006 (2006-09-15), pages 3597-3605, XP002494041, ISSN: 0022-1767;;TUMAS D B ET AL: ""Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitization."", THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY JUN 2001, vol. 107, no. 6, June 2001 (2001-06), pages 1025-1033, XP002494042, ISSN: 0091-6749;;INFÜHR D ET AL: ""Molecular and cellular targets of anti-IgE antibodies."", ALLERGY AUG 2005, vol. 60, no. 8, August 2005 (2005-08), pages 977-985, XP002494043, ISSN: 0105-4538;;FEICHTNER STEFAN ET AL: ""Targeting the extracellular membrane-proximal domain of membrane-bound IgE by passive immunization blocks IgE synthesis in vivo."", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 APR 2008, vol. 180, no. 8, 15 April 2008 (2008-04-15), pages 5499-5505, XP002494044, ISSN: 0022-1767",ACTIVE
280,WO,A2,WO 2008/116149 A2,113-861-901-771-147,2008-09-25,2008,US 2008/0057819 W,2008-03-21,US 89633907 P,2007-03-22,APOPTOTIC ANTI-IGE ANTIBODIES,"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.",GENENTECH INC;;WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/113-861-901-771-147,Patent Application,yes,0,49,56,56,112,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A61P37/06,,0,0,,,,PENDING
281,MA,B1,MA 31312 B1,128-854-270-812-596,2010-04-01,2010,MA 32281 A,2009-10-15,US 89633907 P;;US 2008/0057819 W,2007-03-22,الأجسام المضادة مضاد- ig المفكرة.,"La présente invention concerne des anticorps anti-ige apoptopiques, des acides nucléiques codant ceux-ci, leurs compositions thérapeutiques, et leur utilisation dans le traitement de désordres à médiation par l'ige.",GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/128-854-270-812-596,Granted Patent,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A61P37/06,,0,0,,,,ACTIVE
282,EP,B1,EP 2132230 B1,176-301-212-229-424,2014-04-16,2014,EP 08744179 A,2008-03-21,US 2008/0057819 W;;US 89633907 P,2007-03-22,APOPTOTIC ANTI-IGE ANTIBODIES BINDING THE MEMBRANE-BOUND IGE,,GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/176-301-212-229-424,Granted Patent,yes,0,1,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A01K67/027;;A61P37/06,,7,0,,,"CHEN HUAN YUAN ET AL: ""Monoclonal antibodies against the C(epsilon)mX domain of human membrane-bound IgE and their potential use for targeting IgE-expressing B cells."" INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY AUG 2002, vol. 128, no. 4, August 2002 (2002-08), pages 315-324, XP008083849 ISSN: 1018-2438;;CHANG TSE WEN: ""Developing antibodies for targeting immunoglobulin and membrane-bound immunoglobulin E."" ALLERGY AND ASTHMA PROCEEDINGS : THE OFFICIAL JOURNAL OF REGIONAL AND STATE ALLERGY SOCIETIES 2006 MAR-APR, vol. 27, no. 2 Suppl 1, March 2006 (2006-03), pages S7-14, XP008083904 ISSN: 1088-5412;;CHEN HUAN YUAN ET AL: ""Generation and characterization of monoclonal antibodies against a segment (epsilonm67) uniquely present in membrane-bound IgE"" FASEB JOURNAL, vol. 15, no. 5, 8 March 2001 (2001-03-08), page A1018, XP008095920 & ANNUAL MEETING OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY ON EXPERIMENTAL BIOL; ORLANDO, FLORIDA, USA; MARCH 31-APRIL 04, 2001 ISSN: 0892-6638;;POGGIANELLA MONICA ET AL: ""The extracellular membrane-proximal domain of human membrane IgE controls apoptotic signaling of the B cell receptor in the mature B cell line A20."" JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 SEP 2006, vol. 177, no. 6, 15 September 2006 (2006-09-15), pages 3597-3605, XP002494041 ISSN: 0022-1767;;TUMAS D B ET AL: ""Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitization."" THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY JUN 2001, vol. 107, no. 6, June 2001 (2001-06), pages 1025-1033, XP002494042 ISSN: 0091-6749;;INFÜHR D ET AL: ""Molecular and cellular targets of anti-IgE antibodies."" ALLERGY AUG 2005, vol. 60, no. 8, August 2005 (2005-08), pages 977-985, XP002494043 ISSN: 0105-4538;;FEICHTNER STEFAN ET AL: ""Targeting the extracellular membrane-proximal domain of membrane-bound IgE by passive immunization blocks IgE synthesis in vivo."" JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 APR 2008, vol. 180, no. 8, 15 April 2008 (2008-04-15), pages 5499-5505, XP002494044 ISSN: 0022-1767",ACTIVE
283,CA,A1,CA 2681341 A1,169-030-267-386-632,2008-09-25,2008,CA 2681341 A,2008-03-21,US 89633907 P;;US 2008/0057819 W,2007-03-22,APOPTOTIC ANTI-IGE ANTIBODIES,"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.",GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;CHEN YVONNE;;BRIGHTBILL HANS;;CHAN ANDREW;;DENNIS MARK;;CHUNTHARAPAI ANAN;;WONG TERENCE,,https://lens.org/169-030-267-386-632,Patent Application,no,0,2,56,56,112,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A61P37/06,,0,0,,,,DISCONTINUED
284,DK,T3,DK 2132230 T3,041-408-866-000-463,2014-06-30,2014,DK 08744179 T,2008-03-21,US 89633907 P;;US 2008/0057819 W,2007-03-22,"APOPTOTISKE ANTI-IGE-ANTISTOFFER, DER BINDER DET MEMBRANBUNDNE IGE",,GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/041-408-866-000-463,Granted Patent,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A01K67/027;;A61P37/06,,0,0,,,,ACTIVE
285,AU,A1,AU 2008/228778 A1,139-340-592-408-861,2008-09-25,2008,AU 2008/228778 A,2008-03-21,US 89633907 P;;US 2008/0057819 W,2007-03-22,Apoptotic anti- IgE antibodies binding the membrane-bound IgE,,GENENTECH INC,CHAN ANDREW;;DENNIS MARK;;BALAZS MERCEDESZ;;WONG TERENCE;;CHEN YVONNE;;BRIGHTBILL HANS;;CHUNTHARAPAI ANAN;;WU LAWREN,,https://lens.org/139-340-592-408-861,Patent Application,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A61P37/06,,0,0,,,,INACTIVE
286,US,B2,US 8586040 B2,181-276-584-127-209,2013-11-19,2013,US 201113281209 A,2011-10-25,US 201113281209 A;;US 5306308 A;;US 89633907 P,2007-03-22,Methods of using apoptotic anti-IGE antibodies,"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.",WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDY;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE;;GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDY;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/181-276-584-127-209,Granted Patent,yes,35,4,56,56,112,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,A61K39/00,424/139.1;;424/133.1;;424/144.1;;424/153.1;;424/805;;424/810,52,41,079-641-458-974-955;;012-766-659-499-706;;026-394-549-918-010;;031-155-990-917-687;;169-898-528-890-498;;016-159-131-505-996;;098-430-732-762-189;;005-288-963-505-077;;049-134-753-209-354;;047-666-521-157-692;;037-250-999-819-307;;125-421-571-646-808;;081-796-381-766-573;;014-120-339-887-224;;011-664-260-437-411;;037-018-511-164-049;;086-096-098-843-89X;;050-959-366-576-084;;102-239-156-414-748;;043-856-845-093-906;;104-370-350-200-141;;002-348-443-531-16X;;067-287-661-835-147;;087-297-425-142-95X;;011-174-345-245-142;;014-190-984-734-267;;098-563-753-507-901;;008-757-580-600-622;;045-556-293-127-132;;031-816-544-752-97X;;149-540-380-570-946;;002-305-399-176-585;;138-157-823-727-156;;029-062-984-888-15X;;015-239-659-590-870;;014-330-136-504-946;;008-783-229-055-363;;134-958-999-769-59X;;027-477-313-726-928;;023-154-204-899-879;;051-508-475-126-991,9188850;;10.1016/s0161-5890(96)00110-1;;pmc2196392;;8976175;;10.1084/jem.184.6.2197;;pmc1555307;;6807838;;10.1016/s0091-6749(97)70202-1;;9257795;;16722326;;10.1016/s0065-2776(06)93002-8;;17383539;;12218370;;10.1159/000063860;;20083663;;10.4049/jimmunol.0902437;;10.1016/0022-2836(87)90412-8;;3681981;;pmc507895;;9062345;;10.1172/jci119252;;10.1016/j.ejphar.2005.12.045;;16464445;;10.1038/nbt0191-53;;1370037;;18390733;;10.4049/jimmunol.180.8.5499;;pmc2959155;;pmc1414812;;7927502;;2185467;;pmc53900;;10.1073/pnas.87.9.3363;;8254205;;pmc42997;;10.1073/pnas.91.2.604;;7507250;;10.1038/363446a0;;8502296;;1937909;;10.1159/000235333;;15969677;;10.1111/j.1398-9995.2005.00832.x;;10.1111/1523-1747.ep12286482;;9036935;;16219319;;10.1016/j.jim.2005.08.009;;1727861;;10.4049/jimmunol.177.6.3597;;16951319;;8784342;;10.1038/nsb0996-733;;7522164;;10.1002/eji.1830240934;;1701791;;10.1067/mai.2001.115625;;11398080;;10.1016/s1074-7613(00)00006-6;;10933393;;2369921;;10.1002/eji.1830200630;;12700943;;10.1007/s00262-002-0347-6;;10.1007/s00429-009-0230-8;;19937345;;10.1016/s0378-1119(98)00607-6;;9931414;;17943232;;10.1007/s12026-007-8008-7;;10.4049/jimmunol.150.3.880;;8423344;;15809359;;10.1161/01.hyp.0000161995.64192.2b;;10.1191/0961203302lu305rr;;12529049;;15699570;;10.1385/mb:29:2:153;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1161/01.atv.20.6.1425;;10845854;;10.1016/s0168-1656(02)00105-0;;pmc7252021;;12204554,"Anand, S. et al., ""Multiple transcripts of the murine immunoglobulin epsilon membrane locus are generated by alternative splicing and differential usage of two polyadenylation sites"" Molecular Immunology 34(2):175-183 (1997).;;Austrian Search Report GCC/P/2008/10423, mailing date Sep. 9, 2011, pp. 1-14 (Sep. 9, 2011).;;Batista, F. et al., ""The two membrane isoforms of human IgE assemble into functionally distinct B cell antigen receptors"" Journal of Experimental Medicine 184:2197-2205 (Dec. 1996).;;Bozelka, B. et al., ""IgE isotype suppression in anti-epsilon-treated mice"" Immunology 46:527-532 (1982).;;Casale, T. et al., ""Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis"" J. Allergy Clin. Immunol. 100(1):110-121 (Jul. 1997).;;Chang, T.W., ""Developing Antibodies for Targeting Immunoglobulin and Membrane-Bound Immunoglobulin E"" Allergy and Asthma Proceedings: The Official Journal of Regional and State Allergy Societies 2006 27(2):S7-S14 (Mar. 2006).;;Chang, Tse Wen et al., ""Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases"" Advances in Immunol. 93:63-119 (2007).;;Chen, H. Y. et al., ""Generation and Characterization of Monoclonal Antibodies Against a Segment (epsilonm67) Uniquely Present in Membrane-Bound IgE"" FASEB Journal 15(5):A1018 (Mar. 8, 2001).;;Chen, H. Y. et al., ""Monoclonal Antibodies Against the C(epsilon)mX Domain of Human Membrane-Bound IgE and Their Potential Use for Targeting IgE-Expressing B Cells"" Int. Arch Allergy Immunology 128(4):315-324 (Aug. 2002).;;Chen, Jiun-Bo et al., ""Unique Epitopes on CepsilonmX in IgE-B Cell Receptors Are Potentially Applicable for Targeting IgE-Committed B Cells"" The Journal of Immunology 184:1748-1756 (Jan. 2010).;;Chothia and Lesk, ""Canonical structures for the hypervariable regions of immunoglobulins"" J. Mol. Biol. 196:901-917 (1987).;;Corne, J. et al., ""The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety and pharmacokinetics"" J. Clin. Invest. 99(5):879-887 (Mar. 1997).;;Crestani, E. et al., ""In Vivo Association of Cytokine Production and IgE Levels in Infants and Adults"" J Allergy Clin Immunol 113(2):S87 (Feb. 2004).;;D'Amato, Gennaro ""Role of anti-IgE monoclonal antibody (omalizumab in the treatment of bronchial asthma and allergic respiratory diseases"" European Journal of Pharmacology 533:302-307 (Feb. 7, 2006).;;Davis, F. et al., ""An epitope on membrane-bound but not secreted IgE: implications in isotype-specific regulation"" Bio/Technology 9:53-56 (Jan. 1991).;;Feichtner, S. et al., ""Targeting the Extracellular Membrane-Proximal Domain of Membrane-Bound IgE by Passive Immunization Blocks IgE Synthesis in Vivo"" Journal of Immunology 180(8):5499-5505 (Apr. 15, 2008).;;Haak-Frendscho et al., ""Administration of an anti-IgE antibody inhhibits CD23 expression and IgE production in vivo"" Immunology 82:306-313 (1994).;;Haba and Nisinoff, ""Inhibition of IgE synthesis by anti-IgE: Role in long-term inhibition of IgE synthesis by neonatally administered soluble IgE"" Proc. Natl. Acad. Sci. USA 87:3363-3367 (May 1990).;;Haba and Nisonoff, ""Effects of syngeneic anti-IgE antibodies on the development of IgE memory and on the secondary IgE response"" J. Immunol. 152:51-57 (1994).;;Haba and Nisonoff, ""Role of antibody and T cells in the long-term inhibition of IgE synthesis"" Proc. Natl. Acad. Sci. USA 91:604-608 (Jan. 1994).;;Hamers-Casterman et al., ""Naturally occurring antibodies devoid of light chains"" Nature 363:446-448 (Jun. 3, 1993).;;Heusser, Ch.H. et al., ""New concepts of IgE regulation"" Int. Arch. Allergy Appl. Immunol. 94:87-90 (1991).;;Infuhr, D. et al., ""Molecular and Cellular Targets of Anti-IgE Antibodies"" Allergy 60(8):977-985 (Aug. 2005).;;Johansson, S.G.O., ""IgE in allergic diseases"" Proc. roy. Soc. Med. 62:37-38 (975-976) (Sep. 1969).;;Johnson and Wu Methods in Molecular Biology ""The Kabat Database and a Bioinformatics Example"" Lo ed., Totowa, NJ:Human Press, vol. 248:11-25 (2003).;;Klubal, R. et al., ""The high-affinity receptor for IgE is the predominant IgE-binding structure in lesional skin of atopic dermatitis patients"" J. Invest. Dermatol. 108:336-342 (1997).;;Niwa, Rinpei et al., ""IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked Oligosaccharides"" Immunological Mathods 306:151-160 (Aug. 10, 2005).;;Peng, C. et al., ""A new isoform of human membrane-bound IgE"" J. Immunol. 148:129-136 (Jan. 1, 1992).;;Poggianella, M. et al., ""The Extracellular Membrane-Proximal Domain of Human Membrane IgE Controls Apoptotic Signaling of the B Cell Receptor in the Mature B Cell Line A20"" Journal of Immunology 177(6):3597-3605 (Sep. 15, 2006).;;Sheriff and Constantine, ""Redefining the minimal antigen-binding fragment"" Nature Struct Biol 3(9):733-736 (Sep. 1996).;;Stampfli, M. et al., ""Inhibition of human IgE synthesis by anti-IgE antibodies requires divalent recognition"" Eur. J. of Immunol. 24:2161-2167 (1994).;;Sun, L. K. et al., ""Transfectomas expressing both secreted and membrane-bound forms of chimeric IgE with anti-viral specificity"" J. Immunol. 146(1):199-205 (Jan. 1, 1991).;;Terr, A.I., ""The Atopic Diseases"" Med. Immunol., Stites et al., 9th edition, Stamford, Connecticut:Appleton & Lange, Chapter 27, (1997).;;Tumas, D.B. et al., ""Anti-IgE Efficacy in Murine Asthma Models is Dependent on the Method of Allergen Sensitization"" The Journal of Allergy and Clinical Immunology 107(6):1025-1033 (Jun. 2001).;;Xu and Davis, ""Diversity in the CDR3 region of V H is sufficient for most antibody specificities"" Immunity 13:37-45 (Jul. 2000).;;Benhamou et al., ""Anti-immunoglobulins induce death by apoptosis in WEHI-231 B lymphoma cells"" Eur. J. Immunol 20:1405-1407 ( 1990).;;Chinn et al., ""Antibody therapy of non-Hodgkin's B-cell lymphoma"" Cancer Immunol Immunother 52:257-280 ( 2003).;;Janeway, Jr. et al. ImmunoBiology: the immune system in health and disease 6th edition, New York:Garland Science,:352, 353, 401, 402 ( 2005).;;Rituxan ® (Rituximab) Proposed Mechanism of Action, pp. 1-3 (Internet Retrieval Date Oct. 5, 2012).;;Fundamental Immunology Paul, W. ed., Third edition, New York:Raven Press,:242 ( 1993).;;Gama Sosa et al., ""Animal transgenesis: an overview"" Brain Struct Funct 214:91-109 ( 2010).;;Janeway et al. Immunobiology Third edition,Garland Press,:3:1 - 3:11 ( 1997).;;Kolb et al., ""Insertion of a foreign gene into the Beta-casein locus by Cre-mediated site-specific recombination"" Gene 227:21-31 ( 1999).;;Kumar et al., ""Understanding B-cell tolerance through the use of immunoglobulin transgenic models"" Immunol Res 40:208-223 ( 2008).;;Portolano et al., ""Lack of promiscuity in autoantigen-specific H and L chain combinations as revealed by human H and L chain 'Roulette""' J Immunol 150(3):880-887 (Feb. 1993).;;Qi et al., ""A New Transgenic Rat Model of Hepatic Steatosis and the Metabolic Syndrome"" Hypertension 45:1004-1011 ( 2005).;;Ravirajan et al., ""Transgenic models of tolerance and autoimmunity: with special reference to systemic lupus erythematosus"" Lupus 11:843-849 ( 2002).;;Ristevski, ""Making Better Transgenic Models"" Molecular Biotechnology 29:153-163 ( 2005).;;Rudikoff et al., ""Single amino acid substitution altering antigen-binding specificity"" P Natl Acad Sci USA 79:1979-1983 (Mar. 1982).;;Sigmund, Arteroscler Throm Vasc Biol 20:1425-1429 ( 2000).;;Smith et al., ""Gene Transfer in higher animals: theoretical considerations and key concepts"" J Biotechnol 99(1):1-22 ( 2002).;;Third Party Submission under 37 CFR 1.290 filed Oct. 23, 2012.",INACTIVE
287,CR,A,CR 11035 A,193-646-878-592-393,2009-12-03,2009,CR 11035 A,2009-09-18,US 89633907 P,2007-03-22,ANTICUERPOS ANTI-IGE APOPTOTICOS LIGANDO LA MEMBRANA- ATADA IGE,"La presente solicitud guarda relacion con anti-IgE apoptoticos, con el acido nucleico que los codifica, con composiciones terapeuticas de estos y con su uso en el tratamiento de trastornos mediados por IgE.",GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/193-646-878-592-393,Patent Application,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,A61P37/06;;C07K16/42,,0,0,,,,PENDING
288,JP,A,JP 2001273607 A,197-169-204-095-717,2001-10-05,2001,JP 2001055070 A,2001-02-28,US 51916000 A,2000-03-06,"MAGNETIC HEAD, ITS MANUFACTURING METHOD, AND HARD DISK DRIVE","PROBLEM TO BE SOLVED: To provide a magnetic head wherein the leakage of a magnetic flux passed through a surface gap is extremely small, and its manufacturing method, and a hard disk drive having the magnetic head loaded. SOLUTION: A magnetic head 38 has a first magnetic pole composed of double layers. This first magnetic pole has a first magnetic pole layer formed on a reading head element, and a second magnetic pole layer formed on the first magnetic pole layer. The second magnetic pole layer is formed to be a pattern so as to have an opening formed in the vicinity of the upper end position of a substantially formed second magnetic pole tip part 76. A surface gap distance between the upper end of a second magnetic pole tip part and the first magnetic pole layer 68 is increased, and the leakage of a magnetic flux crossing a surface gap 72 is reduced. According to one embodiment, the second magnetic pole layer, is provided as a single integrated formed layer having an opening. According to another embodiment, the second magnetic pole layer is formed as two independent parts having openings.",IBM,WEN-CHEN DAVID SHIAO;;TERENCE TIN-LOCK LAMB;;LEE EDWARD HINPONG;;YANSHEN RUO;;YUAN SAMUEL WONDER,,https://lens.org/197-169-204-095-717,Patent Application,no,0,0,2,2,0,,G11B5/31;;G11B5/187;;G11B5/23;;G11B5/245,,0,0,,,,PENDING
289,US,A1,US 2014/0115729 A1,024-075-095-051-190,2014-04-24,2014,US 201314137927 A,2013-12-20,US 201314137927 A;;US 201113281126 A;;US 5306308 A;;US 89633907 P,2007-03-22,APOPTOTIC ANTI-IGE ANTIBODIES,"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.",GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/024-075-095-051-190,Patent Application,yes,7,1,56,56,112,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42,800/18;;530/387.2;;530/326;;530/327;;424/131.1;;536/23.53;;435/320.1;;435/327;;435/69.6,0,0,,,,DISCONTINUED
290,NZ,A,NZ 580553 A,061-481-678-152-044,2012-05-25,2012,NZ 58055308 A,2008-03-21,US 89633907 P;;US 2008/0057819 W,2007-03-22,APOPTOTIC ANTI- IGE ANTIBODIES BINDING THE MEMBRANE-BOUND IGE,"Provided is an anti-IgE/M1' antibody that specifically binds an epitope in the M1' segment of IgE defined by residues 317 to 352 of SEQ ID NO:1 and which induces apoptosis in IgE-expressing B-cells. Further provided are deposited murine hybridomas expressing such antibodies, methods of antibody production and use of the antibodies against IgE mediated disorders, including allergies, asthma and IgE myeloma.",GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,"GENENTECH, INC., US (2012-03-30)",https://lens.org/061-481-678-152-044,Patent Application,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A61P37/06,,0,0,,,,DISCONTINUED
291,EP,A1,EP 2644621 A1,103-600-514-471-912,2013-10-02,2013,EP 13165235 A,2008-03-21,US 89633907 P;;EP 08744179 A,2007-03-22,Apoptotic anti-IgE antibodies,"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.
",GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/103-600-514-471-912,Patent Application,yes,0,0,56,56,112,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A01K67/027;;A61P37/06,,7,7,098-430-732-762-189;;169-898-528-890-498;;106-725-365-736-38X;;087-297-425-142-95X;;008-757-580-600-622;;043-856-845-093-906;;081-796-381-766-573,12218370;;10.1159/000063860;;16722326;;10.1096/fasebj.15.3.855;;10.4049/jimmunol.177.6.3597;;16951319;;10.1067/mai.2001.115625;;11398080;;15969677;;10.1111/j.1398-9995.2005.00832.x;;18390733;;10.4049/jimmunol.180.8.5499;;pmc2959155,"CHEN HUAN YUAN ET AL: ""Monoclonal antibodies against the C(epsilon)mX domain of human membrane-bound IgE and their potential use for targeting IgE-expressing B cells."", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY AUG 2002, vol. 128, no. 4, August 2002 (2002-08-01), pages 315 - 324, XP008083849, ISSN: 1018-2438;;CHANG TSE WEN: ""Developing antibodies for targeting immunoglobulin and membrane-bound immunoglobulin E."", ALLERGY AND ASTHMA PROCEEDINGS : THE OFFICIAL JOURNAL OF REGIONAL AND STATE ALLERGY SOCIETIES 2006 MAR-APR, vol. 27, no. 2 Suppl 1, March 2006 (2006-03-01), pages S7 - 14, XP008083904, ISSN: 1088-5412;;CHEN HUAN YUAN ET AL: ""Generation and characterization of monoclonal antibodies against a segment (epsilonm67) uniquely present in membrane-bound IgE"", FASEB JOURNAL, vol. 15, no. 5, 8 March 2001 (2001-03-08), & ANNUAL MEETING OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY ON EXPERIMENTAL BIOL; ORLANDO, FLORIDA, USA; MARCH 31-APRIL 04, 2001, pages A1018, XP008095920, ISSN: 0892-6638;;POGGIANELLA MONICA ET AL: ""The extracellular membrane-proximal domain of human membrane IgE controls apoptotic signaling of the B cell receptor in the mature B cell line A20."", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 SEP 2006, vol. 177, no. 6, 15 September 2006 (2006-09-15), pages 3597 - 3605, XP002494041, ISSN: 0022-1767;;TUMAS D B ET AL: ""Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitization."", THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY JUN 2001, vol. 107, no. 6, June 2001 (2001-06-01), pages 1025 - 1033, XP002494042, ISSN: 0091-6749;;INFÜHR D ET AL: ""Molecular and cellular targets of anti-IgE antibodies."", ALLERGY AUG 2005, vol. 60, no. 8, August 2005 (2005-08-01), pages 977 - 985, XP002494043, ISSN: 0105-4538;;FEICHTNER STEFAN ET AL: ""Targeting the extracellular membrane-proximal domain of membrane-bound IgE by passive immunization blocks IgE synthesis in vivo."", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 APR 2008, vol. 180, no. 8, 15 April 2008 (2008-04-15), pages 5499 - 5505, XP002494044, ISSN: 0022-1767",ACTIVE
292,ES,T3,ES 2478242 T3,107-978-972-674-880,2014-07-21,2014,ES 08744179 T,2008-03-21,US 89633907 P;;US 2008/0057819 W,2007-03-22,Anticuerpos anti IgE apoptóticos que se unen con el IgE unido a membrana,Un anticuerpo anti IgE/M1' que se une específicamente con un epítopo en el segmento M1' de IgE definido por los restos 317 a 351 de SEC ID Nº: 1 y que induce apoptosis en linfocitos B que expresan IgE.,GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/107-978-972-674-880,Granted Patent,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A01K67/027;;A61P37/06,,0,0,,,,ACTIVE
293,CN,A,CN 101679528 A,145-410-085-331-706,2010-03-24,2010,CN 200880016908 A,2008-03-21,US 2008/0057819 W;;US 89633907 P,2007-03-22,Apoptotic anti-ige antibodies,"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.",GENENTECH INC,LAWREN WU;;MERCEDESZ BALAZS;;HANS BRIGHTBILL;;ANDREW CHAN;;YVONNE CHEN;;ANAN CHUNTHARAPAI;;MARK DENNIS;;TERENCE WONG,,https://lens.org/145-410-085-331-706,Patent Application,no,0,1,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A61P37/06,,0,0,,,,INACTIVE
294,AU,B2,AU 2008/228778 B2,158-866-731-522-230,2014-05-22,2014,AU 2008/228778 A,2008-03-21,US 89633907 P;;US 2008/0057819 W,2007-03-22,Apoptotic anti- IgE antibodies binding the membrane-bound IgE,"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.",GENENTECH INC,BALAZS MERCEDESZ;;CHUNTHARAPAI ANAN;;BRIGHTBILL HANS;;WONG TERENCE;;WU LAWREN;;CHAN ANDREW;;CHEN YVONNE;;DENNIS MARK,,https://lens.org/158-866-731-522-230,Granted Patent,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A61P37/06,,3,2,169-898-528-890-498;;098-430-732-762-189,16722326;;12218370;;10.1159/000063860,"Chen, H. et al. 2001 Faseb J. 15(5):A1018, Ab 778.1;;Chang, T. 2006 Allergy Asthma Proc. 27:S7-S14;;Chen, H. et al. 2002 Int. Arch. Allergy Immunol;128:315-324",INACTIVE
295,PE,A1,PE 20140771 A1,000-315-885-551-017,2014-07-07,2014,PE 2013000851 A,2008-03-24,US 89633907 P,2007-03-22,ANTICUERPOS ANTI-IGE APOPTOTICOS,"SE REFIERE HA ANTICUERPOS ANTI-IGE, DONDE: EL HVR-L1 COMPRENDE RESIDUOS 24-34 DE LA SEQ ID NOS: 21, 22, 23 ENTRE OTROS;EL HVR-L2 COMPRENDE RESIDUOS 50-56 DE SEQ ID NOS: 21,22,23, ENTRE OTROS; EL HVR-L3 COMPRENDE RESIDUOS 89-97 DE SEQ ID NOS: 24,25,26, ENTRE OTROS; EL HVR-H1 COMPRENDE RESIDUOS 26-35 DE SEQ ID NOS: 33,34,35, ENTRE OTROS; EL HVR-H2 COMPRENDE RESIDUOS 49-65 DE SEQ ID NO: 36,,37,38 ENTRE OTRSO; EL HVR-H3 COMPRENDE RESIDUOS 93-102 DE SEQ ID NO: 33,34, ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA QUE SON UTILES EN EL TRATAMIENTO DE TRASTORNOS MEDIADO POR IgE.",GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/000-315-885-551-017,Patent Application,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A61P37/06,,0,0,,,,DISCONTINUED
296,JP,A,JP 2017048190 A,027-778-681-703-155,2017-03-09,2017,JP 2016178023 A,2016-09-12,US 89633907 P,2007-03-22,APOPTOTIC ANTI-IGE ANTIBODY,"PROBLEM TO BE SOLVED: To provide a novel therapeutic approach to allergy.SOLUTION: The present invention provides an apoptosis-inducible anti-IgEM1' antibody, a nucleic acid encoding the antibody, a therapeutic composition thereof, and the use thereof in treatment of IgE-mediated disorder through the use of a fact that targeting the M1' segment of IgE with anti-IgE antibodies can result in inducing apoptosis of the B-cell.SELECTED DRAWING: None",GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;HANS BRIGHTBILL;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/027-778-681-703-155,Patent Application,no,0,0,56,56,112,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A01K67/027;;A61K39/395;;A61K45/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/06;;A61P37/08;;A61P43/00;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/00;;C12N5/20;;C12N15/09;;C12P21/08,,0,0,,,,PENDING
297,US,A1,US 2009/0010924 A1,020-565-345-004-570,2009-01-08,2009,US 5306308 A,2008-03-21,US 5306308 A;;US 89633907 P,2007-03-22,Apoptotic Anti-IgE Antibodies,"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.",GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,GENENTECH INC (2008-07-24),https://lens.org/020-565-345-004-570,Patent Application,yes,23,56,56,56,112,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,A61K39/395;;A01K67/00;;C07H21/04;;C07K7/08;;C07K16/00;;C07K16/42;;C12N5/00;;C12N5/10;;C12N15/63;;C12P21/04,424/131.1;;530/387.2;;530/387.9;;530/326;;530/327;;424/133.1;;536/23.53;;435/320.1;;435/358;;435/69.6;;435/346;;800/13,0,0,,,,INACTIVE
298,US,B2,US 8618274 B2,160-328-580-448-160,2013-12-31,2013,US 201113281224 A,2011-10-25,US 201113281224 A;;US 5306308 A;;US 89633907 P,2007-03-22,Nucleic acid encoding apoptotic anti-IgE antibodies,"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.",WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDY;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE;;GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDY;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/160-328-580-448-160,Granted Patent,yes,34,4,56,56,112,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07H21/04,536/23.53;;424/139.1;;424/141.1;;424/144.1;;424/805;;424/810;;435/331;;435/343.1,52,41,027-477-313-726-928;;015-239-659-590-870;;079-641-458-974-955;;012-766-659-499-706;;026-394-549-918-010;;031-155-990-917-687;;169-898-528-890-498;;016-159-131-505-996;;098-430-732-762-189;;005-288-963-505-077;;049-134-753-209-354;;047-666-521-157-692;;037-250-999-819-307;;125-421-571-646-808;;081-796-381-766-573;;014-120-339-887-224;;011-664-260-437-411;;037-018-511-164-049;;086-096-098-843-89X;;050-959-366-576-084;;102-239-156-414-748;;043-856-845-093-906;;104-370-350-200-141;;002-348-443-531-16X;;067-287-661-835-147;;087-297-425-142-95X;;011-174-345-245-142;;014-190-984-734-267;;098-563-753-507-901;;008-757-580-600-622;;045-556-293-127-132;;031-816-544-752-97X;;149-540-380-570-946;;002-305-399-176-585;;138-157-823-727-156;;029-062-984-888-15X;;014-330-136-504-946;;008-783-229-055-363;;134-958-999-769-59X;;023-154-204-899-879;;051-508-475-126-991,10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.4049/jimmunol.150.3.880;;8423344;;9188850;;10.1016/s0161-5890(96)00110-1;;pmc2196392;;8976175;;10.1084/jem.184.6.2197;;pmc1555307;;6807838;;10.1016/s0091-6749(97)70202-1;;9257795;;16722326;;10.1016/s0065-2776(06)93002-8;;17383539;;12218370;;10.1159/000063860;;20083663;;10.4049/jimmunol.0902437;;10.1016/0022-2836(87)90412-8;;3681981;;pmc507895;;9062345;;10.1172/jci119252;;10.1016/j.ejphar.2005.12.045;;16464445;;10.1038/nbt0191-53;;1370037;;18390733;;10.4049/jimmunol.180.8.5499;;pmc2959155;;pmc1414812;;7927502;;2185467;;pmc53900;;10.1073/pnas.87.9.3363;;8254205;;pmc42997;;10.1073/pnas.91.2.604;;7507250;;10.1038/363446a0;;8502296;;1937909;;10.1159/000235333;;15969677;;10.1111/j.1398-9995.2005.00832.x;;10.1111/1523-1747.ep12286482;;9036935;;16219319;;10.1016/j.jim.2005.08.009;;1727861;;10.4049/jimmunol.177.6.3597;;16951319;;8784342;;10.1038/nsb0996-733;;7522164;;10.1002/eji.1830240934;;1701791;;10.1067/mai.2001.115625;;11398080;;10.1016/s1074-7613(00)00006-6;;10933393;;2369921;;10.1002/eji.1830200630;;12700943;;10.1007/s00262-002-0347-6;;10.1007/s00429-009-0230-8;;19937345;;10.1016/s0378-1119(98)00607-6;;9931414;;17943232;;10.1007/s12026-007-8008-7;;15809359;;10.1161/01.hyp.0000161995.64192.2b;;10.1191/0961203302lu305rr;;12529049;;15699570;;10.1385/mb:29:2:153;;10.1161/01.atv.20.6.1425;;10845854;;10.1016/s0168-1656(02)00105-0;;pmc7252021;;12204554,"Janeway et al., Immunobiology, 3rd edition, 1997, Garland Press, pp. 3:1-3:11.;;Rudikoff et al., Proc Natl Acad Sci USA, 1982, 79:1979-1983.;;Portolano et al., J. Immunol., 1993, 150:880-887.;;Fundamental Immunology, William E. Paul, M.D. ed., 3d ed. 1993, p. 242.;;Anand, S. et al., ""Multiple transcripts of the murine immunoglobulin epsilon membrane locus are generated by alternative splicing and differential usage of two polyadenylation sites"" Molecular Immunology 34(2):175-183 (1997).;;Austrian Search Report GCC/P/2008/10423, mailing date Sep. 9, 2011, pp. 1-14.;;Batista, F. et al., ""The two membrane isoforms of human IgE assemble into functionally distinct B cell antigen receptors"" Journal of Experimental Medicine 184:2197-2205 (Dec. 1996).;;Bozelka, B. et al., ""IgE isotype suppression in anti-epsilon-treated mice"" Immunology 46:527-532 (1982).;;Casale, T. et al., ""Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis"" J. Allergy Clin. Immunol. 100(1):110-121 (Jul. 1997).;;Chang, T.W., ""Developing Antibodies for Targeting Immunoglobulin and Membrane-Bound Immunoglobulin E"" Allergy and Asthma Proceedings: The Official Journal of Regional and State Allergy Societies 2006 27(2):S7-S14 (Mar. 2006).;;Chang, Tse Wen et al., ""Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases"" Advances in Immunol 93:63-119 (2007).;;Chen, H. Y. et al., ""Generation and Characterization of Monoclonal Antibodies Against a Segment (epsilonm67) Uniquely Present in Membrane-Bound IgE"" FASEB Journal 15(5):A1018 (Mar. 8, 2001).;;Chen, H. Y. et al., ""Monoclonal Antibodies Against the C(epsilon)mX Domain of Human Membrane-Bound IgE and Their Potential Use for Targeting IgE-Expressing B Cells"" Int. Arch !Allergy Immunology 128(4):315-324 (Aug. 2002).;;Chen, Jiun-Bo et al., ""Unique Epitopes on CepsilonmX in IgE-B Cell Receptors Are Potentially Applicable for Targeting IgE-Committed B Cells"" The Journal of Immunology 184:1748-1756 (Jan. 2010).;;Chothia and Lesk, ""Canonical structures for the hypervariable regions of immunoglobulins"" J. Mol. Biol. 196:901-917 (1987).;;Corne, J. et al., ""The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety and pharmacokinetics"" J. Clin. Invest. 99(5):879-887 (Mar. 1997).;;Crestani, E. et al., ""In Vivo Association of Cytokine Production and IgE Levels in Infants and Adults"" J Allergy Clin Immunol 113(2):S87 (Feb. 2004).;;D'Amato, Gennaro ""Role of anti-IgE monoclonal antibody (omalizumab in the treatment of bronchial asthma and allergic respiratory diseases"" European Journal of Pharmacology 533:305-307 (Feb. 7, 2006).;;Davis, F. et al., ""An epitope on membrane-bound but not secreted IgE: implications in isotype-specific regulation"" Bio/Technology 9:53-56 (Jan. 1991).;;Feichtner, S. et al., ""Targeting the Extracellular Membrane-Proximal Domain of Membrane-Bound IgE by Passive Immunization Blocks IgE Synthesis in Vivo"" Journal of Immunology 180(8):5499-5505 (Apr. 15, 2008).;;Haak-Frendscho et al., ""Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo"" Immunology 82:306-313 (1994).;;Haba and Nisinoff, ""Inhibition of IgE synthesis by anti-IgE: Role in long-term inhibition of IgE synthesis by neonatally administered soluble IgE"" Proc. Natl. Acad. Sci. USA 87:3363-3367 (May 1990).;;Haba and Nisonoff, ""Effects of syngeneic anti-IgE antibodies on the development of IgE memory and on the secondary IgE response"" J. Immunol. 152:51-57 (1994.);;Haba and Nisonoff, ""Role of antibody and T cells in the long-term inhibition of IgE synthesis"" Proc. Natl. Acad. Sci. USA 91:604-608 (Jan. 1994).;;Hamers-Casterman et al., ""Naturally occurring antibodies devoid of light chains"" Nature 363:446-448 (Jun. 3, 1993).;;Heusser, Ch.H. et al., ""New concepts of IgE regulation"" Int. Arch. Allergy Appl. Immunol. 94:87-90 (1991).;;Infuhr, D. et al., ""Molecular and Cellular Targets of Anti-IgE Antibodies"" Allergy 60(8):977-985 (Aug. 2005).;;Johansson, S.G.O., ""IgE in allergic diseases"" Proc. roy. Soc. Med. 62:37-38(975-976) (Sep. 1969).;;Johnson and Wu Methods in Molecular Biology ""The Kabat Database and a Bioinformatics Example"" Lo ed., Totowa, NJ:Human Press, vol. 248:11-25 ( 2003).;;Klubal, R. et al., ""The high-affinity receptor for IgE is the predominant IgE-binding structure in lesional skin of atopic dermatitis patients"" J. Invest. Dermatol. 108:336-342 (1997).;;Niwa, Rinpei et al., ""IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked Oligosaccharides"" Immunological Mathods 306:151-160 (Aug. 10, 2005).;;Peng, C. et al., ""A new isoform of human membrane-bound IgE"" J. Immunol. 148:129-136 (Jan. 1, 1992).;;Poggianella, M. et al., ""The Extracellular Membrane-Proximal Domain of Human Membrane IgE Controls Apoptotic Signaling of the B Cell Receptor in the Mature B Cell Line A20"" Journal of Immunology 177(6):3597-3605 (Sep. 15, 2006).;;Sheriff and Constantine, ""Redefining the minimal antigen-binding fragment"" Nature Struct Biol 3(9):733-736 (Sep. 1996).;;Stampfli, M. et al., ""Inhibition of human IgE synthesis by anti-IgE antibodies requires divalent recognition"" Eur. J. of Immunol. 24:2161-2167 (1994).;;Sun, L. K. et al., ""Transfectomas expressing both secreted and membrane-bound forms of chimeric IgE with anti-viral specificity"" J. Immunol. 146(1):199-205 (Jan. 1, 1991).;;Terr. A.I., ""The Atopic Diseases"" Med. Immunol., Stites et al., 9th edition, Stamford, Connecticut:Appleton & Lange, Chapter 27, (1997).;;Tumas, D.B. et al., ""Anti-IgE Efficacy in Murine Asthma Models is Dependent on the Method of Allergen Sensitization"" The Journal of Allergy and Clinical Immunology 107(6):1025-1033 (Jun. 2001).;;Xu and Davis, ""Diversity in the CDR3 region ofV H is sufficient for most antibody specificites"" Immunity 13:37-45 (Jul. 2000).;;Benhamou et al., ""Anti-immunoglobulins induce death by apoptosis in WEHI-231 B lymphoma cells"" Eur. J. Immunol 20:1405-1407 ( 1990).;;Chinn et al., ""Antibody therapy of non-Hodgkin's B-cell lymphoma"" Cancer Immunol Immunother 52:257-280 ( 2003).;;Janeway, Jr. et al. ImmunoBiology: the immune system in health and disease 6th edition, New York:Garland Science,:352, 353, 401, 402 ( 2005).;;Rituxan® (Rituximab) Proposed Mechanism of Action, pp. 1-3 (Internet Retrieval Date Oct 5, 2012).;;Gama Sosa et al., ""Animal Transgenesis: an overview"" Brain Struct Funct 214:91-109 (2010).;;Kolb et al., ""Insertion of a foreign gene into the Beta-casein locus by Cre-mediated site-specific recombination"" Gene 227:21-31 (1999).;;Kumar et al., ""Understanding B-cell tolerance through the use of immunoglobin transgenic models"" Immunol Res 40:208-223 (2008).;;Qi et al., ""A New Transgenic Rat Model of Hepatic Steatosis and the Metabolic Syndrome"" Hypertension 45:1004-1011 (2005).;;Ravirajan et al., ""Transgenic models of tolerance and autoimmunity: with spatial reference to systematic lupus erythematosus"" Lupus 11:843-849 (2002).;;Ristevski, ""Making Better Transgenic Models"" Molecular Biotechnology 29:153-163 (2005).;;Sigmund, Arteroscler Throm Vasc Biol 20:1425-1429 (2000).;;Smith et al., ""Gene Transfer in higher animals: theoretical considerations and key concepts"" J Biotechnol 99(1):1-22 (2002).;;Third Party Submission under 37 CFR 1.290 filed Oct. 23, 2012 in related U.S. Appl. No. 13/281,126.",INACTIVE
299,EP,A2,EP 2132230 A2,009-737-401-371-173,2009-12-16,2009,EP 08744179 A,2008-03-21,US 2008/0057819 W;;US 89633907 P,2007-03-22,APOPTOTIC ANTI-IGE ANTIBODIES BINDING THE MEMBRANE-BOUND IGE,,GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/009-737-401-371-173,Patent Application,yes,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A01K67/027;;A61P37/06,,0,0,,,,ACTIVE
300,HR,T1,HR P20140661 T1,016-322-838-001-684,2014-10-10,2014,HR P20140661 T,2014-07-11,US 89633907 P;;US 2008/0057819 W,2007-03-22,APOPTOTIC ANTI-IGE ANTIBODIES BINDING THE MEMBRANE-BOUND IGE,,GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/016-322-838-001-684,Granted Patent,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A01K67/027;;A61P37/06,,0,0,,,,ACTIVE
301,US,B2,US 8632775 B2,173-231-626-399-589,2014-01-21,2014,US 201113281126 A,2011-10-25,US 201113281126 A;;US 5306308 A;;US 89633907 P,2007-03-22,Apoptotic anti-IgE antibodies,"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.",WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE;;GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/173-231-626-399-589,Granted Patent,yes,35,3,56,56,112,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,A61K39/00,424/139.1;;424/141.1;;424/144.1;;424/153.1;;424/805;;424/810;;530/387.9;;530/388.22;;530/388.7;;530/862;;530/868,55,43,079-641-458-974-955;;012-766-659-499-706;;026-394-549-918-010;;031-155-990-917-687;;169-898-528-890-498;;016-159-131-505-996;;098-430-732-762-189;;005-288-963-505-077;;049-134-753-209-354;;047-666-521-157-692;;037-250-999-819-307;;125-421-571-646-808;;081-796-381-766-573;;014-120-339-887-224;;011-664-260-437-411;;037-018-511-164-049;;086-096-098-843-89X;;050-959-366-576-084;;102-239-156-414-748;;043-856-845-093-906;;104-370-350-200-141;;002-348-443-531-16X;;067-287-661-835-147;;087-297-425-142-95X;;011-174-345-245-142;;014-190-984-734-267;;098-563-753-507-901;;008-757-580-600-622;;045-556-293-127-132;;031-816-544-752-97X;;149-540-380-570-946;;149-540-380-570-946;;031-816-544-752-97X;;002-305-399-176-585;;138-157-823-727-156;;029-062-984-888-15X;;015-239-659-590-870;;014-330-136-504-946;;008-783-229-055-363;;134-958-999-769-59X;;027-477-313-726-928;;023-154-204-899-879;;051-508-475-126-991,9188850;;10.1016/s0161-5890(96)00110-1;;pmc2196392;;8976175;;10.1084/jem.184.6.2197;;pmc1555307;;6807838;;10.1016/s0091-6749(97)70202-1;;9257795;;16722326;;10.1016/s0065-2776(06)93002-8;;17383539;;12218370;;10.1159/000063860;;20083663;;10.4049/jimmunol.0902437;;10.1016/0022-2836(87)90412-8;;3681981;;pmc507895;;9062345;;10.1172/jci119252;;10.1016/j.ejphar.2005.12.045;;16464445;;10.1038/nbt0191-53;;1370037;;18390733;;10.4049/jimmunol.180.8.5499;;pmc2959155;;pmc1414812;;7927502;;2185467;;pmc53900;;10.1073/pnas.87.9.3363;;8254205;;pmc42997;;10.1073/pnas.91.2.604;;7507250;;10.1038/363446a0;;8502296;;1937909;;10.1159/000235333;;15969677;;10.1111/j.1398-9995.2005.00832.x;;10.1111/1523-1747.ep12286482;;9036935;;16219319;;10.1016/j.jim.2005.08.009;;1727861;;10.4049/jimmunol.177.6.3597;;16951319;;8784342;;10.1038/nsb0996-733;;7522164;;10.1002/eji.1830240934;;1701791;;10.1067/mai.2001.115625;;11398080;;10.1016/s1074-7613(00)00006-6;;10933393;;2369921;;10.1002/eji.1830200630;;12700943;;10.1007/s00262-002-0347-6;;12700943;;10.1007/s00262-002-0347-6;;2369921;;10.1002/eji.1830200630;;10.1007/s00429-009-0230-8;;19937345;;10.1016/s0378-1119(98)00607-6;;9931414;;17943232;;10.1007/s12026-007-8008-7;;10.4049/jimmunol.150.3.880;;8423344;;15809359;;10.1161/01.hyp.0000161995.64192.2b;;10.1191/0961203302lu305rr;;12529049;;15699570;;10.1385/mb:29:2:153;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1161/01.atv.20.6.1425;;10845854;;10.1016/s0168-1656(02)00105-0;;pmc7252021;;12204554,"Anand, S. et al., ""Multiple transcripts of the murine immunoglobulin epsilon membrane locus are generated by alternative splicing and differential usage of two polyadenylation sites,"" Molecular Immunology 34(2):175-183 (1997).;;Austrian Search Report GCC/P/2008/10423, mailing date Sep. 9, 2011, pp. 1-14 (Sep. 9, 2011).;;Batista, F. et al., ""The two membrane isoforms of human IgE assemble into functionally distinct B cell antigen receptors"" Journal of Experimental Medicine 184:2197-2205 (Dec. 1996).;;Bozelka, B. et al., ""IgE isotype suppression in anti-epsilon-treated mice"" Immunology 46:527-532 (1982).;;Casale, T. et al., ""Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis"" J. Allergy Clin. Immunol. 100(1):110-121 (Jul. 1997).;;Chang, T.W., ""Developing Antibodies for Targeting Immunoglobulin and Membrane-Bound Immunoglobulin E"" Allergy and Asthma Proceedings: The Official Journal of Regional and State Allergy Societies 2006 27(2):S7-S14 (Mar. 2006).;;Chang, Tse Wen et al., ""Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases"" Advances In Immunol. 93:63-119 (2007).;;Chen, H. Y. et al., ""Generation and Characterization of Monoclonal Antibodies Against a Segment (epsilonm67) Uniquely Present in Membrane-Bound IgE"" FASEB Journal 15(5):A1018 (Mar. 8, 2001).;;Chen, H. Y. et al., ""Monoclonal Antibodies Against the C(epsilon)mX Domain of Human Membrane-Bound IgE and Their Potential Use for Targeting IgE-Expressing B Cells"" Int. Arch Allergy Immunology 128(4):315-324 (Aug. 2002).;;Chen, Jiun-Bo et al., ""Unique Epitopes on CepsilonmX in IgE-B Cell Receptors Are Potentially Applicable for Targeting IgE-Committed B Cells"" The Journal of Immunology 184:1748-1756 (Jan. 2010).;;Chothia and Lesk, ""Canonical structures for the hypervariable regions of immunoglobulins"" J. Mol. Biol. 196:901-917 (1987).;;Corne, J. et al., ""The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety and pharmacokinetics"" J. Clin. Invest. 99(5):879-887 (Mar. 1997).;;Crestani, E. et al., ""In Vivo Association of Cytokine Production and IgE Levels in Infants and Adults"" J Allergy Clin Immunol 113(2):S87 (Feb. 2004).;;D'Amato, Gennaro ""Role of anti-IgE monoclonal antibody (omalizumab in the treatment of bronchial asthma and allergic respiratory diseases"" European Journal of Pharmacology 533:302-307 (Feb. 7, 2006).;;Davis, F. et al., ""An epitope on membrane-bound but not secreted IgE: implications in isotype-specific regulation"" Bio/Technology 9:53-56 (Jan. 1991).;;Feichtner, S. et al., ""Targeting the Extracellular Membrane-Proximal Domain of Membrane-Bound IgE by Passive Immunization Blocks IgE Synthesis in Vivo"" Journal of Immunology 180(8):5499-5505 (Apr. 15, 2008).;;Haak-Frendscho et al., ""Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo"" Immunology 82:306-313 (1994).;;Haba and Nisinoff, ""Inhibition of IgE synthesis by anti-IgE: Role in long-term inhibition of IgE synthesis by neonatally administered soluble IgE"" Proc. Natl. Acad. Sci. USA 87:3363-3367 (May 1990).;;Haba and Nisonoff, ""Effects of syngeneic anti-IgE antibodies on the development of IgE memory and on the secondary IgE response"" J. Immunol. 152:51-57 (1994).;;Haba and Nisonoff, ""Role of antibody and T cells in the long-term inhibition of IgE synthesis"" Proc. Natl. Acad. Sci. USA 91:604-608 (Jan. 1994).;;Hamers-Casterman et al., ""Naturally occurring antibodies devoid of light chains"" NATURE 363:446-448 (Jun. 3, 1993).;;Heusser, Ch.H. et al., ""New concepts of IgE regulation"" Int. Arch. Allergy Appl. Immunol. 94:87-90 (1991).;;Infuhr, D. et al., ""Molecular and Cellular Targets of Anti-IgE Antibodies"" Allergy 60(8):977-985 (Aug. 2005).;;Johansson, S.G.O., ""IgE in allergic diseases"" Proc. roy. Soc. Med. 62:37-38 (975-976) (Sep. 1969).;;Johnson and Wu Methods in Molecular Biology ""The Kabat Database and a Bioinformatics Example"" Lo ed., Totowa, NJ:Human Press, vol. 248:11-25 ( 2003).;;Klubal, R. et al., ""The high-affinity receptor for IgE is the predominant IgE-binding structure in lesional skin of atopic dermatitis patients"" J. Invest. Dermatol. 108:336-342 (1997).;;Niwa, Rinpei et al., ""IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked Oligosaccharides"" Immunological Mathods 306:151-160 (Aug. 10, 2005).;;Peng, C. et al., ""A new isoform of human membrane-bound IgE"" J. Immunol 148:129-136 (Jan. 1, 1992).;;Poggianella, M. et al., ""The Extracellular Membrane-Proximal Domain of Human Membrane IgE Controls Apoptotic Signaling of the B Cell Receptor in the Mature B Cell Line A20"" Journal of Immunology 177(6):3597-3605 (Sep. 15, 2006).;;Sheriff and Constantine, ""Redefining the minimal antigen-binding fragment"" Nature Struct Biol 3(9):733-736 (Sep. 1996).;;Stampfli, M. et al., ""Inhibition of human IgE synthesis by anti-IgE antibodies requires divalent recognition"" Eur. J. of Immunol. 24:2161-2167 (1994).;;Sun, L. K. et al., ""Transfectomas expressing both secreted and membrane-bound forms of chimeric IgE with anti-viral specificity"" J. Immunol. 146(1):199-205 (Jan. 1, 1991).;;Terr, A.I., ""The Atopic Diseases"" Med. Immunol., Stites et al., 9th edition, Stamford, Connecticut:Appleton & Lange, Chapter 27, (1997).;;Tumas, D.B. et al., ""Anti-IgE Efficacy in Murine Asthma Models is Dependent on the Method of Allergen Sensitization"" The Journal of Allergy and Clinical Immunology 107(6):1025-1033 (Jun. 2001).;;Xu and Davis, ""Diversity in the CDR3 region V H sufficient for most antibody specificities"" IMMUNITY 13:37-45 (Jul. 2000).;;Benhamou et al., ""Anti-immunoglobulins induce death by apoptosis in WEHI-231 B lymphoma cells"" Eur. J. Immunol 20:1405-1407 ( 1990).;;Chinn et al., ""Antibody therapy of non-Hodgkin's B-cell lymphoma"" Cancer Immunol Immunother 52:257-280 ( 2003).;;Janeway, Jr. et al. ImmunoBiology: the immune system in health and disease 6th edition, New York:Garland Science,:352, 353, 401, 402 ( 2005).;;RITUXAN® (Rituximab) Proposed Mechanism of Action , pp. 1-3 (Internet Retrieval Date Oct. 5, 2012).;;Rituxan® (Rituximab) Proposed Mechanism of Action, http://www.rituxan.com/hem/hcp/mechanism-action/index.html, retrieved on line at least as of Oct. 5, 2012 (Document 5).;;Chinn P., Braslawsky G., White C., and Hanna N.,Antibody therapy of non-Hodgkin's B-cell lymphoma, Cancer Immunol. Immunother., 2003, 52:257-280 (Document 4).;;Benhamou L, Cazenve P-A., and Sarthou P., Anti-immunoglobulins induce death by apoptosis in WEHI-231 B lymphoma cells. Eur. J. Immunol. 1990, 20:1405-1407 (Document 3).;;Janeway et al., Immunobiology, the immune system in health and disease, 6th ed., 2005, Garland Science, pp. 352-353 and 401-402 (Document 2).;;Fundamental Immunology Paul, W. ed., Third edition, New York:Raven Press,:242 (1993).;;Gama Sosa et al., ""Animal transgenesis: an overview"" Brain Struct Funct 214:91-109 (2010).;;Janeway et al. Immunobiology Third edition,Garland Press,:3:1-3:11 (1997).;;Kolb et al., ""Insertion of a foreign gene into the Beta-casein locus by Cre-mediated site-specific recombination"" Gene 227:21-31 (1999).;;Kumar et al., ""Understanding B-cell tolerance through the use of immunoglobulin transgenic models"" Immunol Res 40:208-223 (2008).;;Portolano et al., ""Lack of promiscuity in autoantigen-specific H and L chain combinations as revealed by human H and L chain 'Roulette'"" J Immunol 150(3):880-887 (Feb. 1993).;;Qi et al., ""A New Transgenic Rat Model of Hepatic Steatosis and the Metabolic Syndrome"" Hypertension 45:1004-1011 (2005).;;Ravirajan et al., ""Transgenic models of tolerance and autoimmunity: with special reference to systemic lupus erythematosus"" Lupus 11:843-849 ( 2002).;;Ristevski, ""Making Better Transgenic Models"" Molecular Biotechnology 29:153-163 ( 2005).;;Rudikoff et al., ""Single amino acid substitution altering antigen-binding specificity"" P Natl Acad Sci USA 79:1979-1983 (Mar. 1982).;;Sigmund, Arteroscler Throm Vasc Biol 20:1425-1429 (2000).;;Smith et al., ""Gene Transfer in higher animals: theoretical considerations and key concepts"" J Biotechnol 99(1):1-22 (2002).",INACTIVE
302,UA,C2,UA 102994 C2,051-319-707-760-703,2013-09-10,2013,UA A200910649 A,2008-03-21,US 89633907 P;;US 2008/0057819 W,2007-03-22,ANTIBODY THAT SPECIFICALLY BINDS TO IgE/M1' AND INDUCES APOPTOSIS IN IgE-EXPRESSING B-CELLS,"The invention relates to antibody that specifically binds an epitope in the M1' segment of IgE and induces apoptosis in IgE-expressing B-cells. The invention further relates to an isolated nucleic acid encoding the antibody, expression vector, host cell, process for producing the antibody, composition for the treatment of IgE-mediated disorders, method for preventing allergen-induced IgE production etc.",GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/051-319-707-760-703,Limited Patent,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A61K39/395;;A61P37/00;;C12N15/13,,0,0,,,,EXPIRED
303,CN,B,CN 101679528 B,107-651-954-912-748,2013-11-06,2013,CN 200880016908 A,2008-03-21,US 2008/0057819 W;;US 89633907 P,2007-03-22,Apoptotic anti-IGE antibodies,,GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/107-651-954-912-748,Granted Patent,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A61P37/06,,0,0,,,,INACTIVE
304,WO,A3,WO 2008/116149 A3,143-596-904-776-721,2008-11-06,2008,US 2008/0057819 W,2008-03-21,US 89633907 P,2007-03-22,APOPTOTIC ANTI- IGE ANTIBODIES BINDING THE MEMBRANE-BOUND IGE,"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.",GENENTECH INC;;WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/143-596-904-776-721,Search Report,yes,0,0,56,56,112,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A61P37/06,,7,7,098-430-732-762-189;;169-898-528-890-498;;106-725-365-736-38X;;087-297-425-142-95X;;008-757-580-600-622;;043-856-845-093-906;;081-796-381-766-573,12218370;;10.1159/000063860;;16722326;;10.1096/fasebj.15.3.855;;10.4049/jimmunol.177.6.3597;;16951319;;10.1067/mai.2001.115625;;11398080;;15969677;;10.1111/j.1398-9995.2005.00832.x;;18390733;;10.4049/jimmunol.180.8.5499;;pmc2959155,"CHEN HUAN YUAN ET AL: ""Monoclonal antibodies against the C(epsilon)mX domain of human membrane-bound IgE and their potential use for targeting IgE-expressing B cells."", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY AUG 2002, vol. 128, no. 4, August 2002 (2002-08-01), pages 315 - 324, XP008083849, ISSN: 1018-2438;;CHANG TSE WEN: ""Developing antibodies for targeting immunoglobulin and membrane-bound immunoglobulin E."", ALLERGY AND ASTHMA PROCEEDINGS : THE OFFICIAL JOURNAL OF REGIONAL AND STATE ALLERGY SOCIETIES 2006 MAR-APR, vol. 27, no. 2 Suppl 1, March 2006 (2006-03-01), pages S7 - 14, XP008083904, ISSN: 1088-5412;;CHEN HUAN YUAN ET AL: ""Generation and characterization of monoclonal antibodies against a segment (epsilonm67) uniquely present in membrane-bound IgE"", FASEB JOURNAL, vol. 15, no. 5, 8 March 2001 (2001-03-08), & ANNUAL MEETING OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY ON EXPERIMENTAL BIOL; ORLANDO, FLORIDA, USA; MARCH 31-APRIL 04, 2001, pages A1018, XP008095920, ISSN: 0892-6638;;POGGIANELLA MONICA ET AL: ""The extracellular membrane-proximal domain of human membrane IgE controls apoptotic signaling of the B cell receptor in the mature B cell line A20."", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 SEP 2006, vol. 177, no. 6, 15 September 2006 (2006-09-15), pages 3597 - 3605, XP002494041, ISSN: 0022-1767;;TUMAS D B ET AL: ""Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitization."", THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY JUN 2001, vol. 107, no. 6, June 2001 (2001-06-01), pages 1025 - 1033, XP002494042, ISSN: 0091-6749;;INFÜHR D ET AL: ""Molecular and cellular targets of anti-IgE antibodies."", ALLERGY AUG 2005, vol. 60, no. 8, August 2005 (2005-08-01), pages 977 - 985, XP002494043, ISSN: 0105-4538;;FEICHTNER STEFAN ET AL: ""Targeting the extracellular membrane-proximal domain of membrane-bound IgE by passive immunization blocks IgE synthesis in vivo."", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 APR 2008, vol. 180, no. 8, 15 April 2008 (2008-04-15), pages 5499 - 5505, XP002494044, ISSN: 0022-1767",PENDING
305,US,B2,US 8071097 B2,147-126-570-290-519,2011-12-06,2011,US 5306308 A,2008-03-21,US 5306308 A;;US 89633907 P,2007-03-22,Apoptotic anti-IgE antibodies,"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.",WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE;;GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,GENENTECH INC (2008-07-24),https://lens.org/147-126-570-290-519,Granted Patent,yes,31,29,56,56,112,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,A61K39/395,424/144.1;;424/133.1;;424/139.1;;424/141.1;;424/143.1;;424/178.1;;514/1.7;;530/387.3;;530/387.9;;530/388.22;;435/331;;435/343.1,32,27,169-898-528-890-498;;098-430-732-762-189;;081-796-381-766-573;;043-856-845-093-906;;087-297-425-142-95X;;008-757-580-600-622;;079-641-458-974-955;;012-766-659-499-706;;026-394-549-918-010;;031-155-990-917-687;;016-159-131-505-996;;049-134-753-209-354;;047-666-521-157-692;;125-421-571-646-808;;014-120-339-887-224;;011-664-260-437-411;;037-018-511-164-049;;086-096-098-843-89X;;050-959-366-576-084;;102-239-156-414-748;;104-370-350-200-141;;067-287-661-835-147;;011-174-345-245-142;;014-190-984-734-267;;098-563-753-507-901;;045-556-293-127-132;;005-288-963-505-077,16722326;;12218370;;10.1159/000063860;;18390733;;10.4049/jimmunol.180.8.5499;;pmc2959155;;15969677;;10.1111/j.1398-9995.2005.00832.x;;10.4049/jimmunol.177.6.3597;;16951319;;10.1067/mai.2001.115625;;11398080;;9188850;;10.1016/s0161-5890(96)00110-1;;pmc2196392;;8976175;;10.1084/jem.184.6.2197;;pmc1555307;;6807838;;10.1016/s0091-6749(97)70202-1;;9257795;;10.1016/s0065-2776(06)93002-8;;17383539;;10.1016/0022-2836(87)90412-8;;3681981;;pmc507895;;9062345;;10.1172/jci119252;;10.1038/nbt0191-53;;1370037;;pmc1414812;;7927502;;2185467;;pmc53900;;10.1073/pnas.87.9.3363;;8254205;;pmc42997;;10.1073/pnas.91.2.604;;7507250;;10.1038/363446a0;;8502296;;1937909;;10.1159/000235333;;10.1111/1523-1747.ep12286482;;9036935;;1727861;;8784342;;10.1038/nsb0996-733;;7522164;;10.1002/eji.1830240934;;1701791;;10.1016/s1074-7613(00)00006-6;;10933393;;20083663;;10.4049/jimmunol.0902437,"Chang, T.W., ""Developing Antibodies for Targeting Immunoglobulin and Membrane-Bound Immunoglobulin E"" Allergy and Asthma Proceedings: The Official Journal of Regional and State Allergy Societies 2006 27(2):S7-S14 (Mar. 2006).;;Chen, H. Y. et al., ""Generation and Characterization of Monoclonal Antibodies Against a Segment (epsilonm67) Uniquely Present in Membrane-Bound IgE"" FASEB Journal 15(5):A1018 (Mar. 8, 2001).;;Chen, H. Y. et al., ""Monoclonal Antibodies Against the C(epsilon)mX Domain of Human Membrane-Bound IgE and Their Potential Use for Targeting IgE-Expressing B Cells"" Int. Arch Allergy Immunology 128 (4):315-324 (Aug. 2002).;;Feichtner, S. et al., ""Targeting the Extracellular Membrane-Proximal Domain of Membrane-Bound IgE by Passive Immunization Blocks IgE Synthesis in Vivo"" Journal of Immunology 180(8):5499-5505 (Apr. 15, 2008).;;Infuhr, D. et al., ""Molecular and Cellular Targets of Anti-IgE Antibodies"" Allergy 60(8):977-985 (Aug. 2005).;;Poggianella, M. et al., ""The Extracellular Membrane-Proximal Domain of Human Membrane IgE Controls Apoptotic Signaling of the B Cell Receptor in the Mature B Cell Line A20"" Journal of Immunology 177 (6):3597-3605 (Sep. 15, 2006).;;Tumas, D.B. et al., ""Anti-IgE Efficacy in Murine Asthma Models is Dependent on the Method of Allergen Sensitization"" The Journal of Allergy and Clinical Immunology 107 (6):1025-1033 (Jun. 2001).;;Anand, S. et al., ""Multiple transcripts of the murine immunoglobulin epsilon membrane locus are generated by alternative splicing and differential usage of two polyadenylation sites"" Molecular Immunology 34 (2):175-183 (1997).;;Batista, F. et al., ""The two membrane isoforms of human IgE assemble into functionally distinct B cell antigen receptors"" Journal of Experimental Medicine 184:2197-2205 (Dec. 1996).;;Bozelka, B. et al., ""IgE isotype suppression in anti-epsilon-treated mice"" Immunology 46:527-532 (1982).;;Casale, T. et al., ""Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis"" J. Allergy Clin. Immunol. 100(1):110-121 (Jul. 1997).;;Chang, Tse Wen et al., ""Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases"" Advances In Immunol. 93:63-119 (2007).;;Chothia and Lesk, ""Canonical structures for the hypervariable regions of immunoglobulins"" J. Mol. Biol. 196:901-917 (1987).;;Corne, J. et al., ""The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety and pharmacokinetics"" J. Clin. Invest. 99(5):879-887 (Mar. 1997).;;Davis, F. et al., ""An epitope on membrane-bound but not secreted IgE: implications in isotype-specific regulation"" Bio/Technology 9:53-56 (Jan. 1991).;;Haak-Frendscho et al., ""Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo"" Immunology 82:306-313 (1994).;;Haba and Nisinoff, ""Inhibition of IgE synthesis by anti-IgE: Role in long-term inhibition of IgE synthesis by neonatally administered soluble IgE"" Proc. Natl. Acad. Sci. USA 87:3363-3367 (May 1990).;;Haba and Nisonoff, ""Effects of syngeneic anti-IgE antibodies on the development of IgE memory and on the secondary IgE response"" J. Immunol. 152:51-57 (1994).;;Haba and Nisonoff, ""Role of antibody and T cells in the long-term inhibition of IgE synthesis"" Proc. Natl. Acad. Sci. USA 91:604-608 (Jan. 1994).;;Hamers-Casterman et al., ""Naturally occurring antibodies devoid of light chains"" Nature 363:446-448 (Jun. 3, 1993).;;Heusser, Ch.H. et al., ""New concepts of IgE regulation"" Int. Arch. Allergy Appl. Immunol. 94:87-90 (1991).;;Johansson, S.G.O., ""IgE in allergic diseases"" Proc. roy. Soc. Med. 62:37-38 (975-976) (Sep. 1969).;;Johnson and Wu, ""The Kabat Database and a Bioinformatics Example"" Methods in Molecular Biology, Lo ed., Totowa, NJ:Human Press vol. 248:11-25 (2003).;;Klubal, R. et al., ""The high-affinity receptor for IgE is the predominant IgE-binding structure in lesional skin of atopic dermatitis patients"" J. Invest. Dermatol. 108:336-342 (1997).;;Peng, C. et al., ""A new isoform of human membrane-bound IgE"" J. Immunol. 148:129-136 (Jan. 1, 1992).;;Sheriff and Constantine, ""Redefining the minimal antigen-binding fragment"" Nature Struct. Biol. 3(9):733-736 (Sep. 1996).;;Stampfli, M. et al., ""Inhibition of human IgE synthesis by anti-IgE antibodies requires divalent recognition"" Eur. J. of Immunol. 24:2161-2167 (1994).;;Sun, L. K. et al., ""Transfectomas expressing both secreted and membrane-bound forms of chimeric IgE with anti-viral specificity"" J. Immunol. 146(1):199-205 (Jan. 1, 1991).;;Terr, A.I., ""The Atopic Diseases"" Med. Immunol., Stites et al., 9th edition, Stamford, Connecticut:Appleton & Lange, Chapter 27, (1997).;;Xu and Davis, ""Diversity in the CDR3 region of VH is sufficient for most antibody specificities"" Immunity 13:37-45 (Jul. 2000).;;Chen, Jiun-Bo et al., ""Unique Epitopes on CepsilonmX in IgE-B Cell Receptors Are Potentially Applicable for Targeting IgE-Committed B Cells"" The Journal of Immunology 184:1748-1756 (Jan. 2010).;;Crestani, E. et al., ""In Vivo Association of Cytokine Production and IgE Levels in Infants and Adults"" J Allergy Clin Immunol 113 (2) :S87 (Feb. 2004).",INACTIVE
306,US,A1,US 2012/0149881 A1,192-612-825-572-24X,2012-06-14,2012,US 201113281126 A,2011-10-25,US 201113281126 A;;US 5306308 A;;US 89633907 P,2007-03-22,APOPTOTIC ANTI-IGE ANTIBODIES,"The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.",WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE;;GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/192-612-825-572-24X,Patent Application,yes,2,1,56,56,112,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42,530/387.9;;530/389.1,0,0,,,,INACTIVE
307,CN,A,CN 113743615 A,011-658-383-364-768,2021-12-03,2021,CN 202110585014 A,2021-05-27,US 202016886316 A,2020-05-28,FEATURE REMOVAL FRAMEWORK TO STREAMLINE MACHINE LEARNING,"The disclosed embodiments provide a system for streamlining machine learning. During operation, the system determines a resource overhead for a baseline version of a machine learning model that uses a set of features to produce entity rankings and a number of features to be removed to lower the resource overhead to a target resource overhead. Next, the system calculates importance scores for the features, wherein each importance score represents an impact of a corresponding feature on the entity rankings. The system then identifies a first subset of the features to be removed as the number of features with lowest importance scores and trains a simplified version of the machine learning model using a second subset of the features that excludes the first subset of the features. Finally, the system executes the simplified version to produce new entity rankings.",MICROSOFT TECHNOLOGY LICENSING LLC,CHANG YEN-JUNG;;MENG YUNSONG;;WONG TERENCE;;Y YOUNG;;LONG BRANDON;;CHEN BRYANT;;JIANG YANBIN;;LI ZHE,,https://lens.org/011-658-383-364-768,Patent Application,no,0,0,3,3,0,G06N20/00;;G06N20/00;;G06N20/00;;G06N5/04,G06N20/00,,0,0,,,,PENDING
308,EC,A,EC SP099645 A,084-823-876-140-10X,2009-10-30,2009,EC SP099645 A,2009-09-22,US 89633907 P,2007-03-22,ANTICUERPOS ANTI IGE APOPTÓTICOS,"La presente solicitud guarda relación con anticuerpos anti IgE apoptóticos, con el ácido nucleico que los codifica, con composiciones terapéuticas de éstos y con su uso en el tratamiento de trastornos mediados por IgE.",GENENTECH INC,CHAN ANDREW C;;DENNIS MARK;;CHUNTHARAPAI ANAN;;BALAZS MERCEDESZ;;WU LAWREN;;BRIGHTBILL HANS;;CHEN YVONNE;;WONG TERENCE,,https://lens.org/084-823-876-140-10X,Patent Application,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,A61P37/06;;C07K16/42,,0,0,,,,PENDING
309,ZA,B,ZA 201205868 B,162-830-010-601-457,2014-04-30,2014,ZA 201205868 A,2012-08-03,US 89633907 P,2007-03-22,APOPTOTIC ANTI-IGE ANTIBODIES BINDING THE MEMBRANE-BOUND IGE,,GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW C;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK;;WONG TERENCE,,https://lens.org/162-830-010-601-457,Granted Patent,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,A61P/;;C07K/,,0,0,,,,ACTIVE
310,US,A1,US 2023/0106558 A1,199-561-344-245-931,2023-04-06,2023,US 202217962123 A,2022-10-07,US 202217962123 A;;US 202016797561 A;;US 201514766725 A;;US 2014/0018110 W;;US 201361768367 P,2013-02-22,OPTICAL SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,"An instrument for processing and/or measuring a biological process comprises a sample processing system and an excitation source exhibiting a spectral function of output power or intensity verses wavelength of output power or intensity. The spectral function has a minima wavelength corresponding to a local minima value of the output power or intensity; a first maxima wavelength corresponding to a first local maxima of output power or intensity, the output power or intensity at the first local maxima being greater than the output power or intensity at any wavelength less than the minima wavelength; a second maxima wavelength corresponding to a second local maxima of output power or intensity, the output power or intensity at the second local maxima being greater than the output at any wavelength greater than the minima wavelength; the minima wavelength is between the first maxima wavelength and the second maxima wavelength.",LIFE TECHNOLOGIES CORP,CHEN MINGSONG;;AGUANNO MAURO;;BOO KUAN MOON;;SOH WOON LIANG TERENCE;;FREUDENTHAL JACOB K;;MARKS JEFFREY A,LIFE TECHNOLOGIES CORPORATION (2015-08-21),https://lens.org/199-561-344-245-931,Patent Application,yes,2,0,11,11,0,G01N21/274;;G01N21/645;;G01N21/6452;;G01N2201/0627;;G01N2201/0624;;G01N2201/121;;G01N21/274;;G01N21/645;;G01N21/6452;;G01N2201/0624;;G01N2201/0627;;G01N2201/121;;G01N2201/0624;;G01N21/6452;;G01N2201/0627;;G01N2201/121;;G01N21/274;;G01N21/645;;G01N21/0332;;G01N21/6486;;G01N2201/061,G01N21/64;;G01N21/03;;G01N21/27,,0,0,,,,PENDING
311,PE,A1,PE 20090726 A1,030-243-742-908-267,2009-06-23,2009,PE 2008000526 A,2008-03-24,US 89633907 P,2007-03-22,ANTICUERPOS ANTI-IGE APOPTOTICOS,"REFERIDA A UN ANTICUERPO ANTI-IgE/M1' QUE INDUCE LA APOPTOSIS EN CELULAS B QUE EXPRESAN IgE, DONDE LA IgE ES DE ORIGEN HUMANO, DE MONO RHESUS O DE MONO CYNOMOLGUS. TAMBIEN ESTA REFERIDA A: UN ANTICUERPO ANTI-IgE/M1' QUE SE UNE ESPECIFICAMENTE AL EPITOPO AL QUE SE UNE UN ANTICUERPO SELECCIONADO DE 26A11, 26A11V1-16, 7A6, 7A6V1, 47H4, 47H4V1-6 Y DONDE EL EPITOPO CORRESPONDE A UN PEPTIDO SELECCIONADO DE PEPTIDO 4 (NUM, IDENT. SECUENCIA:8), PEPTIDO 5 (NUM. IDENT. SECUENCIA:9), PEPTIDO 7 (NUM. IDENT. SECUENCIA:11) O PEPTIDO 8 (NUM. IDENT. SECUENCIA:12); UNA COMPOSICION QUE COMPRENDE DICHOS ANTICUERPOS EN COMBINACION CON UN FARMACO TAL COMO ANTIHISTAMINICOS, BRONCODILATADORES, GLUCOCORTICOIDES, ENTRE OTROS; UN ACIDO NUCLEICO QUE CODIFICA EL ANTICUERPO; UN VECTOR; UNA CELULA ANFITRIONA Y UN PROCESO DE PRODUCCION",GENENTECH INC,WU LAWREN;;BALAZS MERCEDESZ;;BRIGHTBILL HANS;;CHAN ANDREW;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK S;;WONG TERENCE,,https://lens.org/030-243-742-908-267,Patent Application,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,A61P37/06;;C07K16/42,,0,0,,,,ACTIVE
312,US,A1,US 2016/0011115 A1,158-923-178-534-778,2016-01-14,2016,US 201414766725 A,2014-02-24,US 201414766725 A;;US 201361768367 P;;US 2014/0018110 W,2013-02-22,Optical Systems and Methods for Biological Analysis,"An instrument for processing and/or measuring a biological process contains a sample processing system, an excitation source, an excitation optical system, an optical sensor, and an emission optical system. The sample processing system is configured to retain a first sample holder and a second sample holder, wherein the number of sample cells is different for each sample holder or a characteristic dimension for the first sample cells is different from that of the second sample holder. The instrument also includes an excitation source temperature controller comprising a temperature sensor that is coupled to the excitation source. The temperature controller is configured to produce a first target temperature when the first sample holder is retained by the instrument and to produce a second target temperature when the second sample holder is retained by the instrument.",LIFE TECHNOLOGIES CORP,CHEN MINGSONG;;AGUANNO MAURO;;BOO KUAN MOON;;SOH WOON LIANG TERENCE;;FREUDENTHAL JACOB K;;MARKS JEFFREY A,LIFE TECHNOLOGIES CORPORATION (2015-08-21),https://lens.org/158-923-178-534-778,Patent Application,yes,58,8,11,11,0,G01N21/274;;G01N21/645;;G01N21/6452;;G01N2201/0627;;G01N2201/0624;;G01N2201/121;;G01N21/274;;G01N21/645;;G01N21/6452;;G01N2201/0624;;G01N2201/0627;;G01N2201/121;;G01N2201/0624;;G01N21/6452;;G01N2201/0627;;G01N2201/121;;G01N21/274;;G01N21/645;;G01N21/0332;;G01N21/6486;;G01N2201/061,G01N21/64;;G01N21/03,,0,0,,,,ACTIVE
313,US,B2,US 11467092 B2,006-258-190-730-414,2022-10-11,2022,US 202016797561 A,2020-02-21,US 202016797561 A;;US 201514766725 A;;US 2014/0018110 W;;US 201361768367 P,2013-02-22,Optical systems and methods for biological analysis,"An instrument for processing and/or measuring a biological process contains a sample processing system, an excitation source, an excitation optical system, an optical sensor, and an emission optical system. The sample processing system is configured to retain a first sample holder and a second sample holder, wherein the number of sample cells is different for each sample holder or a characteristic dimension for the first sample cells is different from that of the second sample holder. The instrument also includes an excitation source temperature controller comprising a temperature sensor that is coupled to the excitation source. The temperature controller is configured to produce a first target temperature when the first sample holder is retained by the instrument and to produce a second target temperature when the second sample holder is retained by the instrument.",LIFE TECHNOLOGIES CORP,CHEN MINGSONG;;AGUANNO MAURO;;BOO KUAN MOON;;SOH WOON LIANG TERENCE;;FREUDENTHAL JACOB K;;MARKS JEFFREY A,LIFE TECHNOLOGIES CORPORATION (2015-08-21),https://lens.org/006-258-190-730-414,Granted Patent,yes,56,0,11,11,0,G01N21/274;;G01N21/645;;G01N21/6452;;G01N2201/0627;;G01N2201/0624;;G01N2201/121;;G01N21/274;;G01N21/645;;G01N21/6452;;G01N2201/0624;;G01N2201/0627;;G01N2201/121;;G01N2201/0624;;G01N21/6452;;G01N2201/0627;;G01N2201/121;;G01N21/274;;G01N21/645;;G01N21/0332;;G01N21/6486;;G01N2201/061,G01N21/64;;G01N21/03;;G01N21/27,,7,0,,,"EP Communication issued in corresponding European Application No. 14 709 128.4, dated Mar. 25, 2020.;;Chinese Third Office Action issued in CN Application No. 201480021532.1, dated Jan. 11, 2019.;;Chinese First Search for Application No. 2014800215321, dated Jun. 22, 2017.;;PCT/US2014/018110, International Preliminary Reporton Patentability dated Oct. 29, 2015, 10 pgs.;;PCT/US2014/018110, International Search Report and Written Opinion dated Oct. 19, 2015, 15 pgs.;;SG11201506481Q, Written Opinion and Search Report dated Jun. 29, 2016, pp. 1-9.;;EP Communication issued in corresponding European Application No. 14 709 128.4, dated Apr. 1, 2022.",ACTIVE
314,BR,A2,BR PI0808291 A2,115-561-543-003-196,2018-12-11,2018,BR PI0808291 A,2008-03-21,US 2008/0057819 W;;US 89633907 P,2007-03-22,"anticorpos anti-ige/ m1, peptideo, composições, ácido nucléico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo anti-ige/m1' apoptótico ou o fragmento funcional, artigo de fabricação, método para depletar espcificamente as células b produtoras de ige, métodos para o tratamento de um doença mediada por ige, para evitar a produção de ige induzida por alérgeno, para reduzir a produção de lge induzida por alérgeno, hibridoma murino, anticorpo e animal transgênico",,GENENTECH INC,ANAN CHUNTHARAPAI;;ANDREW C CHAN;;HANS BRIGHTBILL;;LAWREN WU;;MARK DENNIS;;MERCEDESZ BALAZS;;TERENCE WONG;;YVONNE CHEN,,https://lens.org/115-561-543-003-196,Patent Application,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,C07K16/42;;A61P37/06,,0,0,,,,DISCONTINUED
315,US,A1,US 2020/0191719 A1,130-277-226-916-528,2020-06-18,2020,US 202016797561 A,2020-02-21,US 202016797561 A;;US 201514766725 A;;US 2014/0018110 W;;US 201361768367 P,2013-02-22,OPTICAL SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,"An instrument for processing and/or measuring a biological process contains a sample processing system, an excitation source, an excitation optical system, an optical sensor, and an emission optical system. The sample processing system is configured to retain a first sample holder and a second sample holder, wherein the number of sample cells is different for each sample holder or a characteristic dimension for the first sample cells is different from that of the second sample holder. The instrument also includes an excitation source temperature controller comprising a temperature sensor that is coupled to the excitation source. The temperature controller is configured to produce a first target temperature when the first sample holder is retained by the instrument and to produce a second target temperature when the second sample holder is retained by the instrument.",LIFE TECHNOLOGIES CORP,CHEN MINGSONG;;AGUANNO MAURO;;BOO KUAN MOON;;SOH WOON LIANG TERENCE;;FREUDENTHAL JACOB K;;MARKS JEFFREY A,LIFE TECHNOLOGIES CORPORATION (2015-08-21),https://lens.org/130-277-226-916-528,Patent Application,yes,0,0,11,11,0,G01N21/274;;G01N21/645;;G01N21/6452;;G01N2201/0627;;G01N2201/0624;;G01N2201/121;;G01N21/274;;G01N21/645;;G01N21/6452;;G01N2201/0624;;G01N2201/0627;;G01N2201/121;;G01N2201/0624;;G01N21/6452;;G01N2201/0627;;G01N2201/121;;G01N21/274;;G01N21/645;;G01N21/0332;;G01N21/6486;;G01N2201/061,G01N21/64;;G01N21/03;;G01N21/27,,0,0,,,,ACTIVE
316,US,A1,US 2014/0268420 A1,089-877-878-279-135,2014-09-18,2014,US 201313830567 A,2013-03-14,US 201313830567 A,2013-03-14,MAGNETIC WRITE HEAD HAVING A WRITE POLE WITH A CONSTANT FLARE ANGLE AND MULTIPLE YOKE ANGLES,"A magnetic write head having a write pole with a novel configuration improving write field strength and field gradient while also reducing adjacent track interference and far track interference. The write pole is configured with a pole tip portion that has a narrow track width, preferably 15-30 degrees and a main yoke portion with a larger flare angle of about 45 degrees. The write pole also has an intermediate portion located between the pole tip and main pole portions. The intermediate portion includes a first portion adjacent to the pole tip that has a flare angle greater than the flare angle of the main yoke and has a second portion with a flare angle less than the flare angle of the yoke.",HGST NETHERLANDS BV,CHEN YINGJIAN;;HUANG SHIWEN;;LAM TERENCE T L;;PARK MUN H;;SHIN KYUSIK;;ZHENG YI;;ZHOU YUMING,HGST NETHERLANDS B.V (2013-02-18),https://lens.org/089-877-878-279-135,Patent Application,yes,2,0,1,1,0,G11B5/3116;;G11B5/3163;;Y10T29/49032;;G11B5/187;;Y10T29/49032;;G11B5/3163;;G11B5/3116,G11B5/187;;G11B5/127,360/234.7;;29/603.07,0,0,,,,DISCONTINUED
317,US,B2,US 10591416 B2,097-159-384-905-769,2020-03-17,2020,US 201414766725 A,2014-02-24,US 201414766725 A;;US 201361768367 P;;US 2014/0018110 W,2013-02-22,Optical systems and methods for biological analysis,"An instrument for processing and/or measuring a biological process contains a sample processing system, an excitation source, an excitation optical system, an optical sensor, and an emission optical system. The sample processing system is configured to retain a first sample holder and a second sample holder, wherein the number of sample cells is different for each sample holder or a characteristic dimension for the first sample cells is different from that of the second sample holder. The instrument also includes an excitation source temperature controller comprising a temperature sensor that is coupled to the excitation source. The temperature controller is configured to produce a first target temperature when the first sample holder is retained by the instrument and to produce a second target temperature when the second sample holder is retained by the instrument.",LIFE TECHNOLOGIES CORP,CHEN MINGSONG;;AGUANNO MAURO;;BOO KUAN MOON;;SOH WOON LIANG TERENCE;;FREUDENTHAL JACOB K;;MARKS JEFFREY A,LIFE TECHNOLOGIES CORPORATION (2015-08-21),https://lens.org/097-159-384-905-769,Granted Patent,yes,49,2,11,11,0,G01N21/274;;G01N21/645;;G01N21/6452;;G01N2201/0627;;G01N2201/0624;;G01N2201/121;;G01N21/274;;G01N21/645;;G01N21/6452;;G01N2201/0624;;G01N2201/0627;;G01N2201/121;;G01N2201/0624;;G01N21/6452;;G01N2201/0627;;G01N2201/121;;G01N21/274;;G01N21/645;;G01N21/0332;;G01N21/6486;;G01N2201/061,G01N21/64;;G01N21/03;;G01N21/27,,5,0,,,"PCT/US2014/018110, International Preliminary Report on Patentability dated Oct. 29, 2015, 10 pages.;;PCT/US2014/018110, International Search Report and Written Opinion dated Oct. 19, 2015, 15 pages.;;SG11201506481Q, Written Opinion and Search Report dated Jun. 29, 2016, 1-9.;;Chinese First Search for Application No. 2014800215321, dated Jun. 22, 2017.;;Chinese Third Office Action issued in CN Application No. 201480021532.1, dated Jan. 11, 2019.",ACTIVE
318,EP,A2,EP 2623516 A2,121-751-681-016-395,2013-08-07,2013,EP 13150883 A,2006-11-30,US 74164005 P;;US 82259706 P;;EP 06851192 A,2005-12-02,COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH CYTOKINE SIGNALING INVOLVING ANTIBODIES THAT BIND TO IL-22 AND IL-22R,"Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.
",GENENTECH INC,CHEN YVONNE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;WALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/121-751-681-016-395,Patent Application,yes,144,0,36,39,4,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,A61K39/395;;C07K16/24,,207,159,007-804-874-228-785;;029-265-494-891-698;;106-450-291-507-591;;041-241-834-308-816;;110-088-048-889-302;;107-783-742-795-839;;106-753-778-592-300;;034-331-211-704-877;;020-855-322-534-259;;005-283-943-871-819;;079-666-119-599-514;;039-981-636-470-013;;054-876-950-584-376;;040-428-679-610-399;;089-899-040-309-502;;010-916-105-450-247;;032-820-729-763-323;;130-151-032-772-614;;038-613-711-274-229;;108-171-296-335-638;;043-108-278-056-872;;030-607-398-087-475;;006-574-964-805-278;;042-204-626-457-327;;162-646-650-680-173;;065-608-090-342-50X;;077-495-150-106-187;;010-916-105-450-247;;016-251-721-517-200;;026-048-786-530-595;;085-727-974-637-837;;005-119-615-003-591;;001-779-867-387-972;;044-522-255-085-902;;001-779-867-387-972;;135-513-407-563-622;;033-420-504-339-461;;055-865-733-704-493;;023-864-313-309-782;;076-436-009-754-971;;060-553-606-987-302;;022-444-989-389-180;;026-944-353-804-488;;034-371-894-074-363;;049-083-896-825-798;;106-753-778-592-300;;048-564-471-521-204;;082-670-193-611-235;;034-345-578-106-977;;079-666-119-599-514;;039-118-196-658-356;;005-112-559-456-657;;010-340-295-705-917;;042-204-626-457-327;;045-094-249-115-990;;093-067-181-692-392;;049-134-753-209-354;;009-483-512-107-343;;069-144-826-896-138;;003-984-734-905-938;;040-428-679-610-399;;089-899-040-309-502;;117-775-899-628-564;;031-063-853-127-197;;037-711-371-585-567;;072-064-906-772-096;;104-212-297-137-759;;035-232-534-898-963;;022-375-749-274-329;;018-694-084-068-187;;012-268-510-926-843;;037-445-639-149-821;;011-842-849-963-456;;068-264-897-850-380;;054-717-629-774-351;;060-301-220-665-473;;000-499-911-678-177;;083-019-407-395-691;;015-914-646-829-770;;115-440-304-483-056;;000-346-919-904-207;;053-098-960-981-987;;139-806-732-117-559;;026-623-017-714-89X;;062-812-395-967-77X;;053-478-641-542-076;;078-224-945-072-373;;124-620-210-014-755;;030-677-476-709-748;;024-874-895-840-324;;049-068-325-956-852;;028-252-648-185-958;;051-940-176-386-905;;065-430-968-783-392;;021-430-782-622-770;;015-447-991-049-708;;068-219-938-816-865;;098-782-988-009-907;;019-055-424-431-057;;037-531-283-684-284;;065-684-269-783-203;;068-082-778-319-717;;093-183-016-210-781;;003-280-353-877-595;;017-653-724-773-187;;022-932-029-853-743;;088-507-053-804-367;;023-254-173-733-304;;056-118-200-157-615;;004-272-966-072-139;;002-495-630-767-098;;027-670-963-287-976;;012-830-491-824-205;;001-576-828-082-834;;019-115-775-607-415;;009-406-912-144-89X;;009-186-473-238-939;;083-771-782-040-353;;034-331-211-704-877;;020-855-322-534-259;;103-353-898-106-766;;028-901-227-164-152;;069-413-474-955-853;;029-082-892-809-272;;009-471-901-851-880;;089-633-612-001-004;;034-498-755-334-91X;;100-223-052-747-506;;059-176-157-859-658;;016-347-847-071-941;;018-365-412-976-946;;128-549-225-621-837;;149-123-035-572-142;;012-458-837-416-447;;013-282-459-019-419;;123-753-195-103-479;;001-235-219-615-96X;;037-396-041-244-359;;156-286-546-413-59X;;019-296-445-400-759;;019-152-320-543-606;;121-840-201-888-472;;180-951-241-610-952;;129-555-670-333-881;;029-662-877-505-431;;003-057-557-736-434;;039-746-998-590-127;;039-216-811-420-147;;046-229-024-024-571;;013-815-017-642-288;;127-234-476-612-000;;013-314-082-116-844;;011-488-261-758-663;;060-910-994-589-367;;057-161-083-684-466;;060-910-994-589-367;;115-806-652-196-516;;114-738-893-000-504;;051-687-973-057-614,pmc2803035;;10.1038/nature01322;;12490959;;15999093;;10.1038/nri1648;;15912962;;16688182;;10.1038/nature04808;;10.1007/978-3-642-78432-3_11;;12514726;;10.1038/nm0103-129;;1172191;;10.1038/256495a0;;10.1038/352624a0;;1907718;;1748994;;10.1016/0022-2836(91)90498-u;;15066433;;10.1016/j.jmb.2004.02.050;;15236968;;10.1016/j.jmb.2004.05.051;;15306681;;10.1073/pnas.0401786101;;pmc515084;;14736422;;10.1016/j.jim.2003.11.001;;10.1073/pnas.90.6.2551;;8460171;;pmc46126;;8459850;;10.1038/362255a0;;10.1038/nbt0792-779;;1368267;;8159246;;10.1038/368856a0;;8159237;;10.1038/368812a0;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10.1038/nbt0796-826a;;9631000;;7494109;;10.3109/08830189509061738;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10.1038/321522a0;;3713831;;3127726;;10.1038/332323a0;;10.1016/0959-440x(92)90091-k;;8654676;;10.1042/bst0231035;;10.1016/0958-1669(94)90053-1;;7765176;;10.1038/nbt0792-779;;1368267;;10.1073/pnas.91.9.3809;;pmc43671;;8170992;;10.1016/0378-1119(95)00821-7;;8647439;;7897213;;10.4049/jimmunol.154.7.3310;;10.1016/0022-2836(92)90639-2;;1507232;;10.1006/jmbi.1999.3192;;10543973;;9377574;;10.1006/jmbi.1999.3192;;10543973;;10.1016/0378-1119(85)90140-4;;3891521;;10.1128/mcb.8.5.2159-2165.1988;;10.1128/mcb.8.5.2159;;2455217;;pmc363397;;10.1128/mcb.5.12.3610;;10.1128/mcb.5.12.3610-3616.1985;;pmc369192;;3915782;;2164668;;10.1093/protein/3.6.547;;10.1038/nbt1088-1204;;10.1126/science.1553544;;1553544;;pmc54540;;10.1073/pnas.87.16.6393;;1696729;;10.1021/ja00897a025;;34167191;;10.1016/s1046-2023(05)80150-1;;10.1016/0076-6879(90)82010-y;;6159641;;pmc350025;;10.1073/pnas.77.9.5201;;1172191;;10.1038/256495a0;;10.4049/jimmunol.133.6.3001;;6092464;;6254391;;10.1016/0003-2697(80)90515-1;;11968478;;10.1385/1-59259-240-6:001;;15236968;;10.1016/j.jmb.2004.05.051;;1560176;;10.1016/0165-022x(92)90051-b;;10.1126/science.3925553;;3925553;;1368228;;10.1038/nbt0292-163;;3127726;;10.1038/332323a0;;10.1126/science.2451287;;2451287;;7688398;;10.4049/jimmunol.151.4.2296;;10.1016/0022-2836(87)90412-8;;3681981;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;8360482;;10.4049/jimmunol.151.5.2623;;10.4049/jimmunol.147.1.86;;2051030;;10.1073/pnas.90.6.2551;;8460171;;pmc46126;;8459850;;10.1038/362255a0;;10.1038/305537a0;;6137772;;pmc453097;;1834458;;10.1002/j.1460-2075.1991.tb04932.x;;10.1016/0076-6879(86)21019-8;;3724461;;pmc2119072;;10.1084/jem.175.1.217;;1346155;;10.4049/jimmunol.148.5.1547;;1531669;;10.4049/jimmunol.152.11.5368;;8189055;;1675655;;10.4049/jimmunol.147.1.60;;10.1126/science.2471267;;2471267;;15037082;;10.3410/f.1020100.229441;;10.1016/j.jmb.2004.01.007;;10.1016/0003-9861(86)90031-7;;2428310;;3258649;;10.1038/332738a0;;10.4049/jimmunol.117.2.587;;950463;;10.4049/jimmunol.164.8.4178;;10754313;;16087878;;pmc1187972;;10.1073/pnas.0502680102;;10.1084/jem.176.4.1191;;1402660;;pmc2119390;;10.4049/jimmunol.148.9.2918;;1573276;;8495420;;2930624;;6248238;;10.1016/0092-8674(80)90613-3;;10.1016/0378-1119(95)00018-2;;7622050;;10.1016/1046-2023(92)90047-c;;10.1002/prot.340080405;;1708882;;10.1016/s0022-1759(02)00036-4;;12009210;;10.1074/jbc.274.28.19601;;10391895;;10748200;;10.1074/jbc.m910233199;;10.1074/jbc.m910234199;;10748201;;10.1046/j.1365-2958.2001.02250.x;;11123702;;10.1089/mdr.1996.2.63;;9158724;;10.1038/297598a0;;6178031;;7070530;;10.1038/297017a0;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;10.1095/biolreprod23.1.243;;6774781;;10.1111/j.1749-6632.1982.tb23161.x;;7046561;;6999941;;10.1016/0003-2697(80)90151-7;;3017704;;pmc1166981;;10.1002/j.1460-2075.1986.tb04398.x;;10837540;;10.1016/s0169-409x(97)00032-x;;3317828;;10.1126/science.3317828;;pmc38722;;10.1073/pnas.93.16.8618;;8710920;;1727373;;pmc1185838;;708370;;10.1042/bj1730723;;11709343;;pmc90872;;10.1128/aac.45.12.3580-3584.2001;;9797233;;pmc105973;;10.1128/aac.42.11.2961;;10.1016/b978-1-4832-2819-8.50009-x;;10.1021/ja00196a061;;9627667;;10.1055/s-1996-4296;;10.1039/p19960000859;;10.1038/nbt832;;12778055;;8324745;;9679947;;pmc345355;;6204335;;10.1073/pnas.81.13.3998;;pmc396995;;2578661;;10.1073/pnas.82.1.178;;2443575;;10.1016/0022-1759(87)90085-8;;2447184;;10.4049/jimmunol.140.2.611;;10.1073/pnas.87.16.6378;;2201029;;pmc54537;;10.1021/bi00109a004;;1932005;;10.1038/352624a0;;1907718;;1748994;;10.1016/0022-2836(91)90498-u;;1370065;;10.1016/0958-1669(91)90032-z;;10.4049/jimmunol.166.12.7090;;11390453;;11481447;;10.1073/pnas.171303198;;pmc55483;;15241403;;10.1038/430161a;;pmc47248;;10.1073/pnas.90.16.7889;;8356098;;6933450;;pmc349762;;10.1073/pnas.77.7.4030;;7053372;;10.1016/s0021-9258(19)68359-6;;2778836;;10.1093/jnci/81.19.1484;;15199399;;10.1172/jci22147;;10.1172/jci200422147;;pmc420513;;16138103;;10.1038/nri1689;;10.1111/j.0022-202x.2004.23448.x;;15610511;;7518619;;10.1097/00007890-199407150-00005;;pmc2953379;;10.1097/00007890-199407000-00005;;7930631;;9465487;;10.1016/s0167-5699(97)01186-9;;9018237;;10.1038/nm0297-183;;7887440;;pmc1869187;;10.1084/jem.20031482;;14981113;;pmc2213300;;2822260;;10.1016/0092-8674(87)90646-5;;1606615;;10.1016/0092-8674(92)90611-f;;2547163;;10.1038/340245a0;;10.1073/pnas.88.21.9578;;pmc52761;;1946372;;1631061;;pmc402103;;10.1073/pnas.89.13.5789;;10.1201/9781482242683;;10.1146/annurev.immunol.20.100101.151926;;11861612;;10.1038/nri954;;12461566;;10.1146/annurev.immunol.18.1.451;;10837066;;10802665;;10.1038/75671;;pmc22390;;10097133;;10.1073/pnas.96.7.3888;;10.1046/j.1523-1747.2001.01327.x;;11348449;;10.1111/1523-1747.ep12484041;;1940442;;9693957;;10.1016/s1357-2725(97)00066-6;;10.1159/000249184;;3582707;;11163236;;10.1016/s0092-8674(01)00187-8;;16200070;;10.1038/ni1254;;10.1038/ni1261;;pmc1618871;;16200068;;16200070;;10.1038/ni1254;;16473830;;10.1016/j.immuni.2006.01.001;;012023369;;10.4049/jimmunol.168.11.5699;;12023369;;10.1152/physiolgenomics.00157.2002;;12644634,"COUSSENS ET AL., NATURE, vol. 420, 2002, pages 860 - 867;;HUNTER, NAT. REV. IMMUNOL., vol. 5, 2005, pages 521 - 531;;HOLSCHER, CURR. OPIN. INVEST. DRUGS, vol. 6, 2005, pages 489 - 495;;LANGOWSKI ET AL., NATURE, vol. 442, 2006, pages 461 - 465;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest, Fifth Edition,"", 1991, NATIONAL INSTITUTE OF HEALTH;;ABBAS ET AL.: ""Cellular and Mol. Immunology, 4th ed."", 2000;;PLUCKTHUN: ""The Pharmacology of Monoclonal Antibodies"", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315;;HUDSON ET AL., NAT. MED., vol. 9, 2003, pages 129 - 134;;HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;KOHLER ET AL., NATURE, vol. 256, 1975, pages 495;;HARLOW ET AL.: ""Antibodies: A Laboratory Manual, 2nd ed."", 1988, COLD SPRING HARBOR LABORATORY PRESS;;HAMMERLING ET AL.: ""Monoclonal Antibodies and T-Cell Hybridomas"", 1981, ELSEVIER, pages: 563 - 681;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;MARKS ET AL., J MOL. BIOL., vol. 222, 1992, pages 581 - 597;;SIDHU ET AL., J MOL. BIOL., vol. 338, no. 2, 2004, pages 299 - 310;;LEE ET AL., J MOL. BIOL., vol. 340, no. 5, 2004, pages 1073 - 1093;;FELLOUSE, PROC. AM. ACAD. SCI. USA, vol. 101, no. 34, 2004, pages 12467 - 12472;;LEE ET AL., J. IMMUNOL. METHODS, vol. 284, no. 1-2, 2004, pages 119 - 132;;JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 2551;;JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255 - 258;;BRUGGEMANN ET AL., YEAR IN IMMUNOL, vol. 7, 1993, pages 33;;MARKS ET AL., BIO. TECHNOLOGY, vol. 10, 1992, pages 779 - 783;;LONBERG ET AL., NATURE, vol. 368, 1994, pages 856 - 859;;MORRISON, NATURE, vol. 368, 1994, pages 812 - 813;;FISHWILD ET AL., NATURE BIOTECHNOL., vol. 14, 1996, pages 845 - 851;;NEUBERGER, NATURE BIOTECHNOL., vol. 14, 1996, pages 826;;LONBERG; HUSZAR, INTERN. REV. IMMUNOL, vol. 13, 1995, pages 65 - 93;;MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329;;PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596;;VASWANI; HAMILTON, ANN. ALLERGY, ASTHMA & IMMUNOL, vol. 1, 1998, pages 105 - 115;;HARRIS, BIOCHEM. SOC. TRANSACTIONS, vol. 23, 1995, pages 1035 - 1038;;HURLE; GROSS, CURR. OP. BIOTECH., vol. 5, 1994, pages 428 - 433;;MARKS ET AL., BIOLTECHNOLOGY, vol. 10, 1992, pages 779 - 783;;BARBAS ET AL., PROC NAT. ACAD. SCI. USA, vol. 91, 1994, pages 3809 - 3813;;SCHIER ET AL., GENE, vol. 169, 1995, pages 147 - 155;;YELTON ET AL., J IMMUNOL., vol. 155, 1995, pages 1994 - 2004;;JACKSON ET AL., J IMMUNOL., vol. 154, no. 7, 1995, pages 3310 - 9;;HAWKINS ET AL., J MOL. BIOL., vol. 226, 1992, pages 889 - 896;;CHEN ET AL., J. MOL. BIOL., vol. 293, 1999, pages 865 - 881;;PRESTA ET AL., CANCER RES., vol. 57, 1997, pages 4593 - 4599;;CHEN, Y. ET AL., J MOL. BIOL., vol. 293, 1999, pages 865 - 881;;MURAKAMI ET AL.: ""The Molecular Basis of Cancer"", 1995, WB SAUNDERS, article ""Cell cycle regulation, oncogens, and antineoplastic drugs"", pages: 13;;CARTER ET AL., NUCL. ACIDS RES., vol. 13, 1986, pages 4331;;ZOLLER ET AL., NUCL. ACIDS RES., vol. 10, 1987, pages 6487;;WELLS ET AL., GENE, vol. 34, 1985, pages 315;;WELLS ET AL., PHILOS. TRANS. R. SOC. LONDON SERA, vol. 317, 1986, pages 415;;T.E. CREIGHTON: ""Proteins: Structure and Molecular Properties"", 1983, W.H. FREEMAN & CO., pages: 79 - 86;;FIELD ET AL., MOL. CELL. BIOL., vol. 8, 1988, pages 2159 - 2165;;EVAN ET AL., MOLECULAR AND CELLULAR BIOLOGY, vol. 5, 1985, pages 3610 - 3616;;PABORSKY ET AL., PROTEIN ENGINEERING, vol. 3, no. 6, 1990, pages 547 - 553;;HOPP ET AL., BIOTECHNOLOGY, vol. 6, 1988, pages 1204 - 1210;;MARTIN ET AL., SCIENCE, vol. 255, 1992, pages 192 - 194;;SKINNER ET AL., J. BIOL. CHEM., vol. 266, 1991, pages 15163 - 15166;;LUTZ-FREYERMUTH ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 6393 - 6397;;STEWART ET AL.: ""Solid-Phase Peptide Synthesis"", 1969, W.H. FREEMAN CO.;;MERRIFIELD, J. AM. CHEM. SOC., vol. 85, 1963, pages 2149 - 2154;;DEUTSCHER, METHODS IN ENZYMOLOGY, vol. 182, 1990;;SCOPES: ""Protein Purification: Principles and Practice"", 1982, SPRINGER-VERLAG;;THOMAS, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 5201 - 5205;;KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495;;GODING: ""Monoclonal Antibodies: Principles and Practice"", 1986, ACADEMIC PRESS, pages: 59 - 103;;KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001;;BRODEUR ET AL.: ""Monoclonal Antibody Production Techniques and Applications"", 1987, MARCEL DEKKER, INC., pages: 51 - 63;;MUNSON; POLLARD, ANAL. BIOCHEM., vol. 107, 1980, pages 220;;HOOGENBOOM ET AL.: ""Methods in Molecular Biology"", vol. 178, 2001, HUMAN PRESS, pages: 1 - 37;;LEE ET AL., J MOL. BIOL., vol. 340, 2004, pages 1073 - 1093;;KABAT ET AL.: ""Sequences of Proteins oflmmunological Interest, Fifth Edition,"", 1991, NIH PUBLICATION 91-3242;;MORIMOTO ET AL., JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, vol. 24, 1992, pages 107 - 117;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81;;CARTER ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 163 - 167;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327;;VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536;;SIMS ET AL., J IMMUNOL., vol. 151, 1993, pages 2296;;CHOTHIA ET AL., J MOL. BIOL., vol. 196, 1987, pages 901;;CARTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285;;PRESTA ET AL., J IMMUNOL., vol. 151, 1993, pages 2623;;KOZBOR, J 1MMUNOL., vol. 133, 1984, pages 3001;;BOERNER ET AL., J IMMUNOL., vol. 147, 1991, pages 86;;JAKOBOVITS ET AL., PROC. AM. ACAD. SCI USA, vol. 90, 1993, pages 2551;;JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255;;BRUGGERMANN ET AL., YEAR IN IMMUNOL., vol. 7, no. 33, 1993;;MILSTEIN; CUELLO, NATURE, vol. 305, 1983, pages 537;;TRAUNECKER ET AL., EMBO J, vol. 10, 1991, pages 3655;;SURESH ET AL., METHODS IN ENZYMOLOGY, vol. 121, 1986, pages 210;;SHALABY ET AL., J EXP. MED., vol. 175, 1992, pages 217 - 225;;KOSTELNY ET AL., J 1MMUNOL., vol. 148, no. 5, 1992, pages 1547 - 1553;;HOLLINGER ET AL., PROC. AM. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;GRUBER ET AL., J IMMUNOL., vol. 152, 1994, pages 5368;;TUTT ET AL., J IMMUNOL., vol. 147, 1991, pages 60;;CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085;;OKAZAKI ET AL., J MOL. BIOL., vol. 336, 2004, pages 1239 - 1249;;YAMANE-OHNUKI ET AL., BIOTECH. BIOENG, vol. 87, 2004, pages 614;;RIPKA ET AL., ARCH. BIOCHEM. BIOPHYS, vol. 249, 1986, pages 533 - 545;;DUNCAN; WINTER, NATURE, vol. 322, 1988, pages 738 - 40;;SHIELDS ET AL., J BIOL. CHEM., vol. 9, no. 2, 2001, pages 6591 - 6604;;GUYER ET AL., J. IMMUNOL., vol. 117, 1976, pages 587;;KIM ET AL., J. IMMUNOL., vol. 24, 1994, pages 249;;IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178 - 4184;;KAM ET AL., PROC. NATL. ACAD. SCI., vol. 102, 2005, pages 11600 - 11605;;CARON ET AL., 1. EXP MED., vol. 176, 1992, pages 1191 - 1195;;SHOPES, J. IMMUNOL., vol. 148, 1992, pages 2918 - 2922;;WOLFF ET AL., CANCER RESEARCH, vol. 53, 1993, pages 2560 - 2565;;STEVENSON ET AL., ANTI-CANCER DRUG DESIGN, vol. 3, 1989, pages 219 - 230;;SIEBENLIST ET AL., CELL, vol. 20, 1980, pages 269;;PROBA; PLUCKTHUN, GENE, vol. 159, 1995, pages 203;;YANSURA ET AL., METHODS: A COMPANION TO METHODS IN ENZYMOL, vol. 4, 1992, pages 151 - 158;;BACHMANN, CELLULAR AND MOLECULAR BIOLOGY, vol. 2, 1987, pages 1190 - 1219;;BASS ET AL., PROTEINS, vol. 8, 1990, pages 309 - 314;;SIMMONS ET AL., J. IMMUNOL. METHODS, vol. 263, 2002, pages 133 - 147;;CHEN ET AL., J BIOL. CHEM., vol. 274, 1999, pages 19601 - 19605;;BOTHMANN; PLUCKTHUN, J BIOL. CHEM., vol. 275, 2000, pages 17100 - 17105;;RAMM; PLUCKTHUN, J BIOL. CHEM., vol. 275, 2000, pages 17106 - 17113;;ARIE ET AL., MOL. MICROBIOL., vol. 39, 2001, pages 199 - 210;;HARA ET AL., MICROBIAL DRUG RESISTANCE, vol. 2, 1996, pages 63 - 72;;LINDMARK ET AL., J IMMUNOL. METH., vol. 62, 1983, pages 1 - 13;;REYES ET AL., NATURE, vol. 297, 1982, pages 598 - 601;;YANIV, NATURE, vol. 297, 1982, pages 17 - 18;;J GEN VIROL., vol. 36, 1977, pages 59;;CHO, URLAUB ET AL., PROC. AM. ACAD. SCI. USA, vol. 77, 1980, pages 4216;;MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251;;MATHER ET AL., ANNALS N. Y ACAD. SCI, vol. 383, 1982, pages 44 - 68;;HAM ET AL., METH. ENZ., vol. 58, 1979, pages 44;;BARNES ET AL., ANAL. BIOCHEM., vol. 102, 1980, pages 255;;LINDMARK ET AL., J IMMUNOL. METHODS, vol. 62, 1983, pages 1 - 13;;GUSS ET AL., EMBO J., vol. 5, 1986, pages 15671575;;SYRIGOS ET AL., ANTICANCER RESEARCH, vol. 19, 1999, pages 605 - 614;;NICULESCU-DUVAZ ET AL., ADV. DRUG DELIV. REV., vol. 26, 1997, pages 151 - 172;;BALDWIN ET AL., LANCET, 15 March 1986 (1986-03-15), pages 603 - 05;;THORPE ET AL.: ""Monoclonal Antibodies '84: Biological and Clinical Applications"", 1985, article ""Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review"", pages: 475 - 506;;VITETTA ET AL., SCIENCE, vol. 238, 1987, pages 1098;;LIU ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 8618 - 8623;;CHARI ET AL., CANCER RESEARCH, vol. 52, 1992, pages 127 - 131;;CARLSSON ET AL., BIOCHEM. J., vol. 173, 1978, pages 723 - 737;;WOYKE ET AL., ANTIMICROB. AGENTS AND CHEMOTHER, vol. 45, no. 12, 2001, pages 3580 - 3584;;PETTIT ET AL., ANTIMICROB. AGENTS CHEMOTHER, vol. 42, 1998, pages 2961 - 2965;;E. SCHRODER; K. LUBKE: ""The Peptides"", vol. 1, 1965, ACADEMIC PRESS, pages: 76 - 136;;PETTIT ET AL., J. AM. CHEM. SOC., vol. 111, 1989, pages 5463 - 5465;;PETTIT ET AL., ANTI-CANCER DRUG DESIGN, vol. 13, 1998, pages 243 - 277;;PETTIT, G.R. ET AL., SYNTHESIS, 1996, pages 719 - 725;;PETTIT ET AL., J. CHEM. SOC. PERKIN TRANS., vol. 1, no. 5, 1996, pages 859 - 863;;DORONINA, NAT. BIOTECHNOL., vol. 21, no. 7, 2003, pages 778 - 784;;HINMAN ET AL., CANCER RESEARCH, vol. 53, 1993, pages 3336 - 3342;;LODE ET AL., CANCER RESEARCH, vol. 58, 1998, pages 2925 - 2928;;FRAKER ET AL., BIOCHEM. BIOPHYS. RES. COMMUN, vol. 80, 1978, pages 49 - 57;;CHATAL: ""Monoclonal Antibodies in Immunoscintigraphy"", 1989, CRC PRESS;;GEYSEN ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 81, 1984, pages 3998 - 4002;;GEYSEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 178 - 182;;GEYSEN ET AL., SYNTHETIC PEPTIDES AS ANTIGENS, 1986, pages 130 - 149;;GEYSEN ET AL., J. IMMUNOL. METH., vol. 102, 1987, pages 259 - 274;;SCHOOFS ET AL., J. IMMUNOL., vol. 140, 1988, pages 611 - 616;;CWIRLA, S. E. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 6378;;LOWMAN, H.B. ET AL., BIOCHEMISTRY, vol. 30, 1991, pages 10832;;CLACKSON, T. ET AL., NATURE, vol. 352, 1991, pages 624;;MARKS, J. D. ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581;;KANG, A.S. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 8363;;SMITH, G. P., CURRENT OPIN. BIOTECHNOL., vol. 2, 1991, pages 668;;DUMOUTIER L. ET AL.: ""Cloning and characterization of IL-22 binding protein, a natural antagonist of IL- 1 0-related T cell-derived inducible factor/IL-22"", J. IMMUNOL., vol. 166, 2001, pages 7090 - 7095, XP002206182;;XU W. ET AL.: ""A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist"", PROC. NATL. ACAD. SCI. U.S.A., vol. 98, 2001, pages 9511 - 9516, XP002206183, DOI: doi:10.1073/pnas.171303198;;NOVINA ET AL., NATURE, vol. 430, 2004, pages 161 - 164;;OSOL, A.: ""Remington's Pharmaceutical Sciences 16th edition,"", 1980;;MARASCO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 7889 - 7893;;EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, no. 3688, 1985;;HWANG ET AL., PROC. NATL ACAD. SCI. USA, vol. 77, 1980, pages 4030;;MARTIN ET AL., J. BIOL. CHEM., vol. 257, 1982, pages 286 - 288;;GABIZON ET AL., J. NATIONAL CANCER INST., vol. 81, no. 19, 1989, pages 1484;;NICKOLOFF ET AL., JCLIN. INVEST, vol. 113, 2004, pages 1664 - 1675;;BOWCOCK ET AL., NAT. REV. IMMUNOL., vol. 5, 2005, pages 699 - 711;;KAUFFMAN ET AL., J INVEST. DERMATOL., vol. 123, 2004, pages 1037 - 1044;;NICKOLOFF ET AL., J CLIN. INVEST., vol. 113, 2004, pages 1664 - 1675;;KAUFFMAN ET AL., J INVEST. DERMATOL, vol. 123, 2004, pages 1037 - 1044;;M.C. PERRY,: ""Chemotherapy Service"", 1992, WILLIAMS & WILKINS;;AUCHINCLOSS, H. JR.; SACHS, D. H.: ""Fundamental Immunology, 2nd ed.,"", 1989, RAVEN PRESS, pages: 889 - 992;;TANABE, M. ET AL., TRANSPLANTATION, vol. 58, 1994, pages 23;;TINUBU, S. A. ET AL., J IMMUNOL., 1994, pages 4330 - 4338;;J. E. COLOGAN, A. M. KRUISBEEK, D. H. MARGULIES, E. M. SHEVACH AND W. STROBER,: ""Current Protocols in Immunology"", 1994, JOHN WILEY & SONS, INC.;;GRABBE, S.; SCHWARZ, T, IMMUN. TODAY, vol. 19, no. 1, 1998, pages 37 - 44;;SCHON, M. P. ET AL., NAT. MED., vol. 3, 1997, pages 183;;NICKOLOFF, B. J. ET AL., AM. J PATH., vol. 146, 1995, pages 580;;BOYMAN ET AL., J EXP MED., vol. 199, no. 5, 2004, pages 731 - 6;;THOMAS; CAPECCHI, CELL, vol. 51, 1987, pages 503;;LI ET AL., CELL, vol. 69, 1992, pages 915;;BRADLEY: ""Teratocarcinomas and Embryonic Stem Cells: A Practical Approach"", 1987, IRL, pages: 113 - 152;;FIELDS; SONG, NATURE (LONDON, vol. 340, 1989, pages 245 - 246;;CHIEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 9578 - 9582;;CHEVRAY; NATHANS, PROC. NATL. ACAD. SCI. USA, vol. 89, 1991, pages 5789 - 5793;;ZOLA: ""Monoclonal Antibodies: A Manual of Techniques"", 1987, CRC PRESS, INC., pages: 147 - L58;;SPRENT ET AL., ANNU REV IMMUNOL., vol. 20, 2002, pages 551 - 79;;SPRENT ET AL., ANNU REV IMMUNOL, vol. 20, 2002, pages 551 - 79;;MURPHY ET AL., NAT REV IMMUNOL., vol. 2, no. 12, December 2002 (2002-12-01), pages 933 - 44;;MURPHY ET AL., ANNU REV IMMUNOL., vol. 18, 2000, pages 451 - 94;;ROGGE ET AL., NATURE GENETICS, vol. 25, 2000, pages 96 - 101;;OUYANG ET AL., PROC NATL ACAD SCI USA., vol. 96, no. 7, 30 March 1999 (1999-03-30), pages 3888 - 93;;FREEDBERG ET AL., SOC. INVEST. DERM., vol. 116, 2001, pages 633 - 640;;MADSEN P. ET AL., J. INVEST. DERM., vol. 97, 1991, pages 701 - 712;;WATSON ET AL., INT. J. OF BIOCHEM. AND CELL BIO., vol. 30, 1998, pages 567 - 571;;P. C. VAN DE KERKHOF ET AL., DERMATOLOGICA, vol. 174, 1987, pages 224;;P. R. MANGAN ET AL., NATURE, vol. 441, 2006, pages 235;;BLUMBERG ET AL., CELL, vol. 104, 2001, pages 9;;L. E. HARRINGTON., NAT. IMMUNOL, vol. 6, 2005, pages 1123;;H. PARK., NAT. IMMUNOL., vol. 6, 2005, pages 1133;;L. E. HARRINGTON ET AL., NAT. IMMUNOL, vol. 6, 2005, pages 1123;;M. VELDHOEN ET AL., IMMUNITY, vol. 24, 2006, pages 179;;L. E. HARRINGTON ET AL., NAT IMMUNOL, vol. 6, 2005, pages 1123;;C. PARHAM ET AL., J IMMUNOL, vol. 168, 2002, pages 5699;;ZHOU ET AL., PHYSIOL. GENOMICS, vol. 13, 2003, pages 69 - 78",ACTIVE
319,ES,T3,ES 2547689 T3,192-706-695-557-830,2015-10-08,2015,ES 13150883 T,2006-11-30,US 74164005 P;;US 82259706 P,2005-12-02,Composiciones y métodos para el tratamiento de enfermedades y trastornos asociados con la señalización de citocinas que implican anticuerpos que se unen a IL-22 y a IL-22R,"Un anticuerpo que se une específicamente a IL-22, siendo el anticuerpo: (a) un anticuerpo producido a partir de un hibridoma seleccionado entre 8E11.9 (Nº de Referencia ATCC PTA-7319) y 3F11.3 (Nº de Referencia ATCC PTA-7312); (b) una forma madurada por afinidad del anticuerpo de (a); (c) un fragmento de unión a antígeno del anticuerpo de (a) o (b); o (d) una forma humanizada del anticuerpo de (a), (b), o (c)",GENENTECH INC,CHEN YVONNE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;WALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/192-706-695-557-830,Granted Patent,no,0,0,36,39,0,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,A61K39/395;;C07K16/24,,0,0,,,,ACTIVE
320,CA,A1,CA 2631961 A1,031-617-230-513-595,2007-11-08,2007,CA 2631961 A,2006-11-30,US 74164005 P;;US 82259706 P;;US 2006/0061418 W,2005-12-02,COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH CYTOKINE SIGNALING INVOLVING ANTIBODIES THAT BIND TO IL-22 AND IL-22R,,GENENTECH INC,OUYANG WENJUN;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;WU JIANFENG;;CHEN YVONNE;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;ZHENG YAN,,https://lens.org/031-617-230-513-595,Patent Application,no,0,0,36,39,4,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,C07K16/24;;A61K38/20;;A61K39/00;;C07K16/28,,0,0,,,,DISCONTINUED
321,EP,A2,EP 3006466 A2,096-612-234-568-898,2016-04-13,2016,EP 15176159 A,2006-11-30,US 74164005 P;;US 82259706 P;;EP 13150883 A;;EP 06851192 A;;US 2006/0061418 W,2005-12-02,COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH CYTOKINE SIGNALING INVOLVING ANTIBODIES THAT BIND TO IL-22 AND IL-22R,"Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.
",GENENTECH INC,CHEN YVONNE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/096-612-234-568-898,Patent Application,yes,143,0,36,39,4,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,C07K16/24;;A61K38/17;;A61K38/20;;A61K39/00;;A61K39/395;;C07K16/28,,205,155,007-804-874-228-785;;029-265-494-891-698;;106-450-291-507-591;;041-241-834-308-816;;107-783-742-795-839;;106-753-778-592-300;;034-331-211-704-877;;020-855-322-534-259;;005-283-943-871-819;;079-666-119-599-514;;039-981-636-470-013;;054-876-950-584-376;;040-428-679-610-399;;089-899-040-309-502;;010-916-105-450-247;;032-820-729-763-323;;130-151-032-772-614;;038-613-711-274-229;;108-171-296-335-638;;043-108-278-056-872;;030-607-398-087-475;;006-574-964-805-278;;042-204-626-457-327;;162-646-650-680-173;;065-608-090-342-50X;;077-495-150-106-187;;016-251-721-517-200;;026-048-786-530-595;;085-727-974-637-837;;005-119-615-003-591;;001-779-867-387-972;;044-522-255-085-902;;001-779-867-387-972;;135-513-407-563-622;;033-420-504-339-461;;055-865-733-704-493;;023-864-313-309-782;;076-436-009-754-971;;060-553-606-987-302;;022-444-989-389-180;;026-944-353-804-488;;034-371-894-074-363;;049-083-896-825-798;;106-753-778-592-300;;048-564-471-521-204;;082-670-193-611-235;;079-666-119-599-514;;039-118-196-658-356;;005-112-559-456-657;;010-340-295-705-917;;042-204-626-457-327;;045-094-249-115-990;;093-067-181-692-392;;049-134-753-209-354;;009-483-512-107-343;;069-144-826-896-138;;003-984-734-905-938;;089-899-040-309-502;;117-775-899-628-564;;031-063-853-127-197;;037-711-371-585-567;;072-064-906-772-096;;104-212-297-137-759;;035-232-534-898-963;;022-375-749-274-329;;018-694-084-068-187;;012-268-510-926-843;;037-445-639-149-821;;011-842-849-963-456;;068-264-897-850-380;;054-717-629-774-351;;060-301-220-665-473;;000-499-911-678-177;;083-019-407-395-691;;015-914-646-829-770;;115-440-304-483-056;;000-346-919-904-207;;053-098-960-981-987;;139-806-732-117-559;;026-623-017-714-89X;;062-812-395-967-77X;;053-478-641-542-076;;078-224-945-072-373;;124-620-210-014-755;;030-677-476-709-748;;024-874-895-840-324;;049-068-325-956-852;;028-252-648-185-958;;008-587-496-850-953;;051-940-176-386-905;;065-430-968-783-392;;021-430-782-622-770;;015-447-991-049-708;;068-219-938-816-865;;098-782-988-009-907;;019-055-424-431-057;;037-531-283-684-284;;065-684-269-783-203;;068-082-778-319-717;;093-183-016-210-781;;003-280-353-877-595;;017-653-724-773-187;;022-932-029-853-743;;088-507-053-804-367;;023-254-173-733-304;;056-118-200-157-615;;004-272-966-072-139;;002-495-630-767-098;;027-670-963-287-976;;012-830-491-824-205;;001-576-828-082-834;;019-115-775-607-415;;009-406-912-144-89X;;009-186-473-238-939;;083-771-782-040-353;;034-331-211-704-877;;020-855-322-534-259;;103-353-898-106-766;;028-901-227-164-152;;069-413-474-955-853;;029-082-892-809-272;;009-471-901-851-880;;089-633-612-001-004;;034-498-755-334-91X;;100-223-052-747-506;;059-176-157-859-658;;016-347-847-071-941;;018-365-412-976-946;;128-549-225-621-837;;149-123-035-572-142;;012-458-837-416-447;;013-282-459-019-419;;123-753-195-103-479;;001-235-219-615-96X;;037-396-041-244-359;;156-286-546-413-59X;;019-296-445-400-759;;019-152-320-543-606;;121-840-201-888-472;;129-555-670-333-881;;029-662-877-505-431;;003-057-557-736-434;;039-746-998-590-127;;039-216-811-420-147;;046-229-024-024-571;;013-815-017-642-288;;127-234-476-612-000;;013-314-082-116-844;;011-488-261-758-663;;060-910-994-589-367;;057-161-083-684-466;;060-910-994-589-367;;115-806-652-196-516;;114-738-893-000-504;;051-687-973-057-614,pmc2803035;;10.1038/nature01322;;12490959;;15999093;;10.1038/nri1648;;15912962;;16688182;;10.1038/nature04808;;12514726;;10.1038/nm0103-129;;1172191;;10.1038/256495a0;;10.1038/352624a0;;1907718;;1748994;;10.1016/0022-2836(91)90498-u;;15066433;;10.1016/j.jmb.2004.02.050;;15236968;;10.1016/j.jmb.2004.05.051;;15306681;;10.1073/pnas.0401786101;;pmc515084;;14736422;;10.1016/j.jim.2003.11.001;;10.1073/pnas.90.6.2551;;8460171;;pmc46126;;8459850;;10.1038/362255a0;;10.1038/nbt0792-779;;1368267;;8159246;;10.1038/368856a0;;8159237;;10.1038/368812a0;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;10.1038/nbt0796-826a;;9631000;;7494109;;10.3109/08830189509061738;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10.1038/321522a0;;3713831;;3127726;;10.1038/332323a0;;10.1016/0959-440x(92)90091-k;;8654676;;10.1042/bst0231035;;10.1016/0958-1669(94)90053-1;;7765176;;10.1073/pnas.91.9.3809;;pmc43671;;8170992;;10.1016/0378-1119(95)00821-7;;8647439;;7897213;;10.4049/jimmunol.154.7.3310;;10.1016/0022-2836(92)90639-2;;1507232;;10.1006/jmbi.1999.3192;;10543973;;9377574;;10.1006/jmbi.1999.3192;;10543973;;10.1016/0378-1119(85)90140-4;;3891521;;10.1128/mcb.8.5.2159-2165.1988;;10.1128/mcb.8.5.2159;;2455217;;pmc363397;;10.1128/mcb.5.12.3610;;10.1128/mcb.5.12.3610-3616.1985;;pmc369192;;3915782;;2164668;;10.1093/protein/3.6.547;;10.1038/nbt1088-1204;;10.1126/science.1553544;;1553544;;pmc54540;;10.1073/pnas.87.16.6393;;1696729;;10.1021/ja00897a025;;34167191;;10.1016/s1046-2023(05)80150-1;;10.1016/0076-6879(90)82010-y;;6159641;;pmc350025;;10.1073/pnas.77.9.5201;;1172191;;10.1038/256495a0;;10.4049/jimmunol.133.6.3001;;6092464;;6254391;;10.1016/0003-2697(80)90515-1;;15236968;;10.1016/j.jmb.2004.05.051;;1560176;;10.1016/0165-022x(92)90051-b;;10.1126/science.3925553;;3925553;;1368228;;10.1038/nbt0292-163;;3127726;;10.1038/332323a0;;10.1126/science.2451287;;2451287;;7688398;;10.4049/jimmunol.151.4.2296;;10.1016/0022-2836(87)90412-8;;3681981;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;8360482;;10.4049/jimmunol.151.5.2623;;10.4049/jimmunol.147.1.86;;2051030;;8459850;;10.1038/362255a0;;10.1038/305537a0;;6137772;;pmc453097;;1834458;;10.1002/j.1460-2075.1991.tb04932.x;;10.1016/0076-6879(86)21019-8;;3724461;;pmc2119072;;10.1084/jem.175.1.217;;1346155;;10.4049/jimmunol.148.5.1547;;1531669;;10.4049/jimmunol.152.11.5368;;8189055;;1675655;;10.4049/jimmunol.147.1.60;;10.1126/science.2471267;;2471267;;15037082;;10.3410/f.1020100.229441;;10.1016/j.jmb.2004.01.007;;10.1016/0003-9861(86)90031-7;;2428310;;3258649;;10.1038/332738a0;;10.4049/jimmunol.117.2.587;;950463;;10.4049/jimmunol.164.8.4178;;10754313;;16087878;;pmc1187972;;10.1073/pnas.0502680102;;10.1084/jem.176.4.1191;;1402660;;pmc2119390;;10.4049/jimmunol.148.9.2918;;1573276;;8495420;;2930624;;6248238;;10.1016/0092-8674(80)90613-3;;10.1016/0378-1119(95)00018-2;;7622050;;10.1016/1046-2023(92)90047-c;;10.1002/prot.340080405;;1708882;;10.1016/s0022-1759(02)00036-4;;12009210;;10.1074/jbc.274.28.19601;;10391895;;10748200;;10.1074/jbc.m910233199;;10.1074/jbc.m910234199;;10748201;;10.1046/j.1365-2958.2001.02250.x;;11123702;;10.1089/mdr.1996.2.63;;9158724;;10.1038/297598a0;;6178031;;7070530;;10.1038/297017a0;;886304;;10.1099/0022-1317-36-1-59;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;10.1095/biolreprod23.1.243;;6774781;;10.1111/j.1749-6632.1982.tb23161.x;;7046561;;6999941;;10.1016/0003-2697(80)90151-7;;3017704;;pmc1166981;;10.1002/j.1460-2075.1986.tb04398.x;;10837540;;10.1016/s0169-409x(97)00032-x;;3317828;;10.1126/science.3317828;;pmc38722;;10.1073/pnas.93.16.8618;;8710920;;1727373;;pmc1185838;;708370;;10.1042/bj1730723;;11709343;;pmc90872;;10.1128/aac.45.12.3580-3584.2001;;9797233;;pmc105973;;10.1128/aac.42.11.2961;;10.1016/b978-1-4832-2819-8.50009-x;;10.1021/ja00196a061;;9627667;;10.1055/s-1996-4296;;10.1039/p19960000859;;10.1038/nbt832;;12778055;;8324745;;9679947;;pmc345355;;6204335;;10.1073/pnas.81.13.3998;;pmc396995;;2578661;;10.1073/pnas.82.1.178;;2443575;;10.1016/0022-1759(87)90085-8;;2447184;;10.4049/jimmunol.140.2.611;;10.1073/pnas.87.16.6378;;2201029;;pmc54537;;10.1021/bi00109a004;;1932005;;10.1038/352624a0;;1907718;;1748994;;10.1016/0022-2836(91)90498-u;;1370065;;10.1016/0958-1669(91)90032-z;;10.4049/jimmunol.166.12.7090;;11390453;;11481447;;10.1073/pnas.171303198;;pmc55483;;15241403;;10.1038/430161a;;pmc47248;;10.1073/pnas.90.16.7889;;8356098;;6933450;;pmc349762;;10.1073/pnas.77.7.4030;;7053372;;10.1016/s0021-9258(19)68359-6;;2778836;;10.1093/jnci/81.19.1484;;15199399;;10.1172/jci22147;;10.1172/jci200422147;;pmc420513;;16138103;;10.1038/nri1689;;10.1111/j.0022-202x.2004.23448.x;;15610511;;7518619;;10.1097/00007890-199407150-00005;;pmc2953379;;10.1097/00007890-199407000-00005;;7930631;;9465487;;10.1016/s0167-5699(97)01186-9;;9018237;;10.1038/nm0297-183;;7887440;;pmc1869187;;10.1084/jem.20031482;;14981113;;pmc2213300;;2822260;;10.1016/0092-8674(87)90646-5;;1606615;;10.1016/0092-8674(92)90611-f;;2547163;;10.1038/340245a0;;10.1073/pnas.88.21.9578;;pmc52761;;1946372;;1631061;;pmc402103;;10.1073/pnas.89.13.5789;;10.1146/annurev.immunol.20.100101.151926;;11861612;;10.1038/nri954;;12461566;;10.1146/annurev.immunol.18.1.451;;10837066;;10802665;;10.1038/75671;;pmc22390;;10097133;;10.1073/pnas.96.7.3888;;10.1046/j.1523-1747.2001.01327.x;;11348449;;10.1111/1523-1747.ep12484041;;1940442;;9693957;;10.1016/s1357-2725(97)00066-6;;10.1159/000249184;;3582707;;11163236;;10.1016/s0092-8674(01)00187-8;;16200070;;10.1038/ni1254;;10.1038/ni1261;;pmc1618871;;16200068;;16200070;;10.1038/ni1254;;16473830;;10.1016/j.immuni.2006.01.001;;012023369;;10.4049/jimmunol.168.11.5699;;12023369;;10.1152/physiolgenomics.00157.2002;;12644634,"COUSSENS ET AL., NATURE, vol. 420, 2002, pages 860 - 867;;HUNTER, NAT. REV. IMMUNOL., vol. 5, 2005, pages 521 - 531;;HOLSCHER, CURR. OPIN. INVEST. DRUGS, vol. 6, 2005, pages 489 - 495;;LANGOWSKI ET AL., NATURE, vol. 442, 2006, pages 461 - 465;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest, 5th ed."", 1991, NATIONAL INSTITUTE OF HEALTH, BETHESDA, MD;;ABBAS ET AL.: ""Cellular and Mol. Immunology, 4th ed."", 2000;;ROSENBURG AND MOORE: ""The Pharmacology of Monoclonal Antibodies"", vol. 113, 1994, SPRINGER-VERLAG, article PLUCKTHUN, pages: 269 - 315;;HUDSON ET AL., NAT. MED., vol. 9, 2003, pages 129 - 134;;HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;KOHLER ET AL., NATURE, vol. 256, 1975, pages 495;;HARLOW ET AL.: ""Antibodies: A Laboratory Manual, 2nd ed."", 1988, COLD SPRING HARBOR LABORATORY PRESS;;HAMMERLING ET AL.: ""Monoclonal Antibodies and T-Cell Hybridomas"", 1981, ELSEVIER, pages: 563 - 681;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;MARKS ET AL., J. MOL. BIOL., vol. 222, 1992, pages 581 - 597;;SIDHU ET AL., J. MOL. BIOL., vol. 338, no. 2, 2004, pages 299 - 310;;LEE ET AL., J. MOL. BIOL., vol. 340, no. 5, 2004, pages 1073 - 1093;;FELLOUSE, PROC. NATL. ACAD. SCI. USA, vol. 101, no. 34, 2004, pages 12467 - 12472;;LEE ET AL., J IMMUNOL. METHODS, vol. 284, no. 1-2, 2004, pages 119 - 132;;JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 2551;;JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255 - 258;;BRUGGEMANN ET AL., YEAR IN IMMUNOL., vol. 7, 1993, pages 33;;MARKS ET AL., BIO.TECHNOLOGY, vol. 10, 1992, pages 779 - 783;;LONBERG ET AL., NATURE, vol. 368, 1994, pages 856 - 859;;MORRISON, NATURE, vol. 368, 1994, pages 812 - 813;;FISHWILD ET AL., NATURE BIOTECHNOL., vol. 14, 1996, pages 845 - 851;;NEUBERGER, NATURE BIOTECHNOL., vol. 14, 1996, pages 826;;LONBERG; HUSZAR, INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93;;MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329;;PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596;;HAMILTON, ANN. ALLERGY, ASTHMA & IMMUNOL., vol. 1, 1998, pages 105 - 115;;HARRIS, BIOCHEM. SOC. TRANSACTIONS, vol. 23, 1995, pages 1035 - 1038;;HURLE; GROSS, CURR. OP. BIOTECH., vol. 5, 1994, pages 428 - 433;;MARKS ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 779 - 783;;BARBAS ET AL., PROC NAT. ACAD. SCI. USA, vol. 91, 1994, pages 3809 - 3813;;SCHIER ET AL., GENE, vol. 169, 1995, pages 147 - 155;;YELTON ET AL., J. IMMUNOL., vol. 155, 1995, pages 1994 - 2004;;JACKSON ET AL., J. IMMUNOL., vol. 154, no. 7, 1995, pages 3310 - 9;;HAWKINS ET AL., J. MOL. BIOL., vol. 226, 1992, pages 889 - 896;;CHEN ET AL., J. MOL. BIOL., vol. 293, 1999, pages 865 - 881;;PRESTA ET AL., CANCER RES., vol. 57, 1997, pages 4593 - 4599;;CHEN, Y. ET AL., J. MOL. BIOL., vol. 293, 1999, pages 865 - 881;;MENDELSOHN AND ISRAEL: ""The Molecular Basis of Cancer"", 1995, WB SAUNDERS, article MURAKAMI ET AL.: ""Cell cycle regulation, oncogens, and antineoplastic drugs (chapter 1)"", pages: 13;;CARTER ET AL., NUCL. ACIDS RES, vol. 13, 1986, pages 4331;;ZOLLER ET AL., NUCL. ACIDS RES., vol. 10, 1987, pages 6487;;WELLS ET AL., GENE, vol. 34, 1985, pages 315;;WELLS ET AL., PHILOS. TRANS. R. SOC. LONDON SERA., vol. 317, 1986, pages 415;;T.E. CREIGHTON: ""Proteins: Structure and Molecular Properties"", 1983, W.H. FREEMAN & CO., pages: 79 - 86;;FIELD ET AL., MOL. CELL. BIOL., vol. 8, 1988, pages 2159 - 2165;;EVAN ET AL., MOLECULAR AND CELLULAR BIOLOGY., vol. 5, 1985, pages 3610 - 3616;;PABORSKY ET AL., PROTEIN ENGINEERING., vol. 3, no. 6, 1990, pages 547 - 553;;HOPP ET AL., BIOTECHNOLOGY, vol. 6, 1988, pages 1204 - 1210;;MARTIN ET AL., SCIENCE, vol. 255, 1992, pages 192 - 194;;SKINNER ET AL., J. BIOL. CHEM., vol. 266, 1991, pages 15163 - 15166;;LUTZ-FREYERMUTH ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 6393 - 6397;;STEWART ET AL.: ""Solid-Phase Peptide Synthesis"", 1969, W.H. FREEMAN CO.;;MERRIFIELD, J. AM. CHEM. SOC., vol. 85, 1963, pages 2149 - 2154;;DEUTSCHER, METHODS IN ENZVMOLOGV, vol. 182, 1990;;SCOPES: ""Protein Purification: Principles and Practice"", 1982, SPRINGER-VERLAG;;THOMAS, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 5201 - 5205;;KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495;;GODING: ""Monoclonal Antibodies: Principles and Practice"", 1986, ACADEMIC PRESS, pages: 59 - 103;;KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001;;BRODEUR ET AL.: ""Monoclonal Antibody Production Techniques and Applications"", 1987, MARCEL DEKKER, INC., pages: 51 - 63;;MUNSON; POLLARD, ANAL. BIOCHEM., vol. 107, 1980, pages 220;;O'BRIEN ET AL.: ""Methods in Molecular Biology"", vol. 178, 2001, HUMAN PRESS, article HOOGENBOOM ET AL., pages: 1 - 37;;LEE ET AL., J. MOL. BIOL., vol. 340, 2004, pages 1073 - 1093;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest, 5TH ED."", vol. 1-3, 1991, NIH PUBLICATION 91-3242;;MORIMOTO ET AL., JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, vol. 24, 1992, pages 107 - 117;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81;;CARTER ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 163 - 167;;BORREBAECK: ""Antibody Engineering"", .;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327;;VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536;;SIMS ET AL., J. IMMUNOL., vol. 151, 1993, pages 2296;;CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901;;CARTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285;;PRESTA ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623;;KOZBOR, J IMMUNOL., vol. 133, 1984, pages 3001;;BOERNER ET AL., J. IMMUNOL., vol. 147, 1991, pages 86;;JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI USA, vol. 90, 1993, pages 2551;;JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255;;BRUGGERMANN ET AL., YEAR IN IMMUNOL., vol. 7, 1993, pages 33;;MILSTEIN; CUELLO, NATURE, vol. 305, 1983, pages 537;;TRAUNECKER ET AL., EMBO J, vol. 10, 1991, pages 3655;;SURESH ET AL., METHODS IN ENZYMOLOGY, vol. 121, 1986, pages 210;;SHALABY ET AL., J. EXP. MED., vol. 175, 1992, pages 217 - 225;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, no. 5, 1992, pages 1547 - 1553;;GRUBER ET AL., J. IMMUNOL., vol. 152, 1994, pages 5368;;TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60;;CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085;;OKAZAKI ET AL., J. MOL. BIOL., vol. 336, 2004, pages 1239 - 1249;;YAMANE-OHNUKI ET AL., BIOTECH. BIOENG., vol. 87, 2004, pages 614;;RIPKA ET AL., ARCH. BIOCHEM. BIOPHYS., vol. 249, 1986, pages 533 - 545;;DUNCAN; WINTER, NATURE, vol. 322, 1988, pages 738 - 40;;SHIELDS ET AL., J. BIOL. CHEM., vol. 9, no. 2, 2001, pages 6591 - 6604;;GUYER ET AL., J. IMMUNOL., vol. 117, 1976, pages 587;;KIM ET AL., J. IMMUNOL., vol. 24, 1994, pages 249;;IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178 - 4184;;KAM ET AL., PROC. NATL. ACAD. SCI., vol. 102, 2005, pages 11600 - 11605;;CARON ET AL., J. EXP MED., vol. 176, 1992, pages 1191 - 1195;;SHOPES, J. IMMUNOL., vol. 148, 1992, pages 2918 - 2922;;WOLFF ET AL., CANCER RESEARCH, vol. 53, 1993, pages 2560 - 2565;;STEVENSON ET AL., ANTI-CANCER DRUG DESIGN, vol. 3, 1989, pages 219 - 230;;SIEBENLIST ET AL., CELL, vol. 20, 1980, pages 269;;PROBA; PLUCKTHUN, GENE, vol. 159, 1995, pages 203;;YANSURA ET AL., METHODS: A COMPANION TO METHODS IN ENZYMOL., vol. 4, 1992, pages 151 - 158;;BACHMANN: ""Cellular and Molecular Biology"", vol. 2, 1987, AMERICAN SOCIETY FOR MICROBIOLOGY, pages: 1190 - 1219;;BASS ET AL., PROTEINS, vol. 8, 1990, pages 309 - 314;;SIMMONS ET AL., J. IMMUNOL. METHODS, vol. 263, 2002, pages 133 - 147;;CHEN ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 19601 - 19605;;BOTHMANN; PLUCKTHUN, J. BIOL. CHEM., vol. 275, 2000, pages 17100 - 17105;;RAMM; PLUCKTHUN, J. BIOL. CHEM., vol. 275, 2000, pages 17106 - 17113;;ARIE ET AL., MOL. MICROBIOL., vol. 39, 2001, pages 199 - 210;;HARA ET AL., MICROBIAL DRUG RESISTANCE, vol. 2, 1996, pages 63 - 72;;LINDMARK ET AL., J. IMMUNOL. METH., vol. 62, 1983, pages 1 - 13;;REYES ET AL., NATURE, vol. 297, 1982, pages 598 - 601;;YANIV, NATURE, vol. 297, 1982, pages 17 - 18;;GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59;;URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216;;MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251;;MATHER ET AL.: ""Annals N.Y. Acad. Sci."", vol. 383, 1982, pages: 44 - 68;;HAM ET AL., METH. ENZ., vol. 58, 1979, pages 44;;BARNES ET AL., ANAL. BIOCHEM., vol. 102, 1980, pages 255;;LINDMARK ET AL., J. IMMUNOL. METHODS, vol. 62, 1983, pages 1 - 13;;GUSS ET AL., EMBO J., vol. 5, 1986, pages 1567 - 1575;;SYRIGOS ET AL., ANTICANCER RESEARCH, vol. 19, 1999, pages 605 - 614;;NICULESCU-DUVAZ ET AL., ADV. DRUG DELIV. REV., vol. 26, 1997, pages 151 - 172;;BALDWIN ET AL., LANCET, 15 March 1986 (1986-03-15), pages 603 - 05;;A. PINCHERA ET AL.: ""Monoclonal Antibodies '84: Biological and Clinical Applications"", 1985, article THORPE ET AL.: ""Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review"", pages: 475 - 506;;VITETTA ET AL., SCIENCE, vol. 238, 1987, pages 1098;;LIU ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 8618 - 8623;;CHARI ET AL., CANCER RESEARCH, vol. 52, 1992, pages 127 - 131;;CARLSSON ET AL., BIOCHEM. J., vol. 173, 1978, pages 723 - 737;;WOYKE ET AL., ANTIMICROB AGENTS AND CHEMOTHER, vol. 45, no. 12, 2001, pages 3580 - 3584;;PETTIT ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 42, 1998, pages 2961 - 2965;;E. SCHRODER; K. LUBKE: ""The Peptides"", vol. 1, 1965, ACADEMIC PRESS, pages: 76 - 136;;PETTIT ET AL., J. AM. CHEM. SOC., vol. 111, 1989, pages 5463 - 5465;;PETTIT ET AL., ANTI-CANCER DRUG DESIGN, vol. 13, 1998, pages 243 - 277;;PETTIT, G.R. ET AL., SYNTHESIS, 1996, pages 719 - 725;;PETTIT ET AL., J. CHEM. SOC. PERKIN TRANS., vol. 1 5, 1996, pages 859 - 863;;DORONINA, NAT. BIOTECHNOL., vol. 21, no. 7, 2003, pages 778 - 784;;HINMAN ET AL., CANCER RESEARCH, vol. 53, 1993, pages 3336 - 3342;;LODE ET AL., CANCER RESEARCH, vol. 58, 1998, pages 2925 - 2928;;FRAKER ET AL., BIOCHEM. BIOPHVS. RES. COMMUN., vol. 80, 1978, pages 49 - 57;;CHATAL: ""Monoclonal Antibodies in Immunoscintigraphy"", 1989, CRC PRESS;;GEYSEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 3998 - 4002;;GEYSEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 178 - 182;;GEYSEN ET AL., SYNTHETIC PEPTIDES AS ANTIGENS, 1986, pages 130 - 149;;GEYSEN ET AL., J. IMMUNOL. METH., vol. 102, 1987, pages 259 - 274;;SCHOOFS ET AL., J. IMMUNOL., vol. 140, 1988, pages 611 - 616;;CWIRLA, S. E. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 6378;;LOWMAN, H.B. ET AL., BIOCHEMISTRV, vol. 30, 1991, pages 10832;;CLACKSON, T. ET AL., NATURE, vol. 352, 1991, pages 624;;MARKS, J. D. ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581;;KANG, A.S. ET AL., PROC. NATL. ACAD. SCI. USA., vol. 88, 1991, pages 8363;;SMITH, G. P., CURRENT OPIN. BIOTECHNOL., vol. 2, 1991, pages 668;;DUMOUTIER L. ET AL.: ""Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22"", J. IMMUNOL., vol. 166, 2001, pages 7090 - 7095, XP002206182;;XU W. ET AL.: ""A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist"", PROC. NATL. ACAD. SCI. U.S.A., vol. 98, 2001, pages 9511 - 9516, XP002206183, DOI: doi:10.1073/pnas.171303198;;NOVINA ET AL., NATURE, vol. 430, 2004, pages 161 - 164;;OSOL, A.: ""Remington's Pharmaceutical Sciences, 16th ed."", 1980;;MARASCO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 7889 - 7893;;EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA., vol. 82, 1985, pages 3688;;HWANG ET AL., PROC. NATL ACAD. SCI. USA., vol. 77, 1980, pages 4030;;MARTIN ET AL., J. BIOL. CHEM., vol. 257, 1982, pages 286 - 288;;GABIZON ET AL., J. NATIONAL CANCER INST., vol. 81, no. 19, 1989, pages 1484;;NICKOLOFF ET AL., J.CLIN. INVEST., vol. 113, 2004, pages 1664 - 1675;;BOWCOCK ET AL., NAT. REV. IMMUNOL., vol. 5, 2005, pages 699 - 711;;KAUFFMAN ET AL., J. INVEST. DERMATOL., vol. 123, 2004, pages 1037 - 1044;;NICKOLOFF ET AL., J. CLIN. INVEST., vol. 113, 2004, pages 1664 - 1675;;M.C. PERRY: ""Chemotherapy Service"", 1992, WILLIAMS & WILKINS;;W. E. PAUL: ""Fundamental Immunology, 2nd ed."", 1989, RAVEN PRESS, article AUCHINCLOSS, H. JR.; SACHS, D. H., pages: 889 - 992;;TANABE, M. ET AL., TRANSPLANTATION, vol. 58, 1994, pages 23;;TINUBU, S. A. ET AL., J. IMMUNOL., 1994, pages 4330 - 4338;;J. E. COLOGAN, A. M. KRUISBEEK, D. H. MARGULIES, E. M. SHEVACH AND W. STROBER: ""Current Protocols in Immunology"", 1994, JOHN WILEY & SONS, INC., article ""unit 4.2."";;GRABBE, S.; SCHWARZ, T, IMMUN. TODAY, vol. 19, no. 1, 1998, pages 37 - 44;;SCHON, M. P. ET AL., NAT. MED., vol. 3, 1997, pages 183;;NICKOLOFF, B. J. ET AL., AM. J. PATH., vol. 146, 1995, pages 580;;BOYMAN ET AL., J EXP MED., vol. 199, no. 5, 2004, pages 731 - 6;;THOMAS; CAPECCHI, CELL, vol. 51, 1987, pages 503;;LI ET AL., CELL, vol. 69, 1992, pages 915;;E. J. ROBERTSON: ""Teratocarcinomas and Embryonic Stem Cells: A Practical Approach"", 1987, IRL, article BRADLEY, pages: 113 - 152;;FIELDS; SONG, NATURE (LONDON, vol. 340, 1989, pages 245 - 246;;CHIEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 9578 - 9582;;CHEVRAY; NATHANS, PROC. NATL. ACAD. SCI. USA, vol. 89, 1991, pages 5789 - 5793;;ZOLA: ""Monoclonal Antibodies: A Manual of Techniques"", 1987, CRC PRESS, INC., pages: 147 - 158;;SPRENT ET AL., ANNU REV IMMUNOL., vol. 20, 2002, pages 551 - 79;;MURPHY ET AL., NAT REV IMMUNOL., vol. 2, no. 12, December 2002 (2002-12-01), pages 933 - 44;;MURPHY ET AL., ANNU REV IMMUNOL., vol. 18, 2000, pages 451 - 94;;ROGGE ET AL., NATURE GENETICS, vol. 25, 2000, pages 96 - 101;;OUYANG ET AL., PROC NATL ACAD SCI USA., vol. 96, no. 7, 30 March 1999 (1999-03-30), pages 3888 - 93;;FREEDBERG ET AL., SOC. INVEST. DERM., vol. 116, 2001, pages 633 - 640;;MADSEN P. ET AL., J. INVEST. DERM., vol. 97, 1991, pages 701 - 712;;WATSON ET AL., INT. J. OF BIOCHEM. AND CELL BIO., vol. 30, 1998, pages 567 - 571;;P. C. VAN DE KERKHOF ET AL., DERMATOLOGICA, vol. 174, 1987, pages 224;;P. R. MANGAN ET AL., NATURE, vol. 441, 2006, pages 235;;BLUMBERG ET AL., CELL, vol. 104, 2001, pages 9;;L. E. HARRINGTON, NAT. IMMUNOL., vol. 6, 2005, pages 1123;;H. PARK., NAT. IMMUNOL., vol. 6, 2005, pages 1133;;L. E. HARRINGTON ET AL., NAT. IMMUNOL., vol. 6, 2005, pages 1123;;M. VELDHOEN ET AL., IMMUNITY, vol. 24, 2006, pages 179;;L. E. HARRINGTON ET AL., NAT IMMUNOL, vol. 6, 2005, pages 1123;;C. PARHAM ET AL., J IMMUNOL, vol. 168, 2002, pages 5699;;ZHOU ET AL., PHYSIOL. GENOMICS, vol. 13, 2003, pages 69 - 78",ACTIVE
322,KR,A,KR 20080077247 A,151-858-719-424-22X,2008-08-21,2008,KR 20087016113 A,2006-11-30,US 74164005 P;;US 82259706 P;;US 2006/0061418 W,2005-12-02,COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH CYTOKINE SIGNALING INVOLVING ANTIBODIES THAT BIND TO IL-22 AND IL-22R,"Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.",GENENTECH INC,CHEN YVONNE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/151-858-719-424-22X,Patent Application,no,0,0,36,39,0,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,C07K16/24;;A61K38/20;;A61K39/00;;C07K16/28,,0,0,,,,INACTIVE
323,EP,A3,EP 3006466 A3,042-193-025-824-709,2016-07-27,2016,EP 15176159 A,2006-11-30,US 74164005 P;;US 82259706 P;;EP 13150883 A;;EP 06851192 A;;US 2006/0061418 W,2005-12-02,COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH CYTOKINE SIGNALING INVOLVING ANTIBODIES THAT BIND TO IL-22 AND IL-22R,"Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.
",GENENTECH INC,CHEN YVONNE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/042-193-025-824-709,Search Report,yes,4,0,36,39,0,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,C07K16/24;;A61K38/17;;A61K38/20;;A61K39/00;;A61K39/395;;C07K16/28,,9,9,024-774-135-892-49X;;017-290-745-989-446;;039-055-037-316-441;;031-582-333-134-996;;073-164-139-424-502;;006-608-058-804-372;;025-969-152-076-888;;001-144-618-215-249;;118-344-042-969-88X,11390454;;10.4049/jimmunol.166.12.7096;;11197690;;10.1038/sj.gene.6363716;;10.4049/jimmunol.174.6.3695;;15749908;;15122762;;10.1002/hep.20184;;15039135;;10.1165/rcmb.2003-0285oc;;16982811;;10.1084/jem.20061308;;pmc2118116;;17187052;;10.1038/nature05505;;10.4049/jimmunol.179.12.8098;;18056351;;pmc2149911;;17919941;;10.1016/j.immuni.2007.07.023,"KOTENKO S V ET AL: ""Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity"", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 166, no. 12, 15 June 2001 (2001-06-15), pages 7096 - 7103, XP002186668, ISSN: 0022-1767;;DUMOUTIER L ET AL: ""IL-TIF/IL-22: GENOMIC ORGANIZATION AND MAPPING OF THE HUMAN AND MOUSE GENES"", GENES AND IMMUNITY, NATURE PUBLISHING GROUP, GB, vol. 1, 2000, pages 488 - 494, XP008003465, ISSN: 1466-4879;;BONIFACE KATIA ET AL: ""IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes."", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 MAR 2005, vol. 174, no. 6, 15 March 2005 (2005-03-15), pages 3695 - 3702, XP002456794, ISSN: 0022-1767;;RADAEVA S ET AL: ""INTERLEUKIN 22 (IL-22) PLAYS A PROTECTIVE ROLE IN T CELL-MEDIATED MURINE HEPATITIS: IL-22 IS A SURVIVAL FACTOR FOR HEPATOCYTES VIA STAT3 ACTIVATION"", HEPATOLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 39, no. 5, May 2004 (2004-05-01), pages 1332 - 1342, XP009040550, ISSN: 0270-9139;;WHITTINGTON HAYLEY A ET AL: ""Interleukin-22: a potential immunomodulatory molecule in the lung."", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY AUG 2004, vol. 31, no. 2, August 2004 (2004-08-01), pages 220 - 226, XP002472106, ISSN: 1044-1549;;LIANG SPENCER C ET AL: ""Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides"", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 203, no. 10, 1 October 2006 (2006-10-01), pages 2271 - 2279, XP002454989, ISSN: 0022-1007, DOI: 10.1084/JEM.20061308;;ZHENG YAN ET AL: ""Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis."", NATURE 8 FEB 2007, vol. 445, no. 7128, 8 February 2007 (2007-02-08), pages 648 - 651, XP002455693, ISSN: 1476-4687;;KREYMBORG KATHARINA ET AL: ""IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis."", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 DEC 2007, vol. 179, no. 12, 15 December 2007 (2007-12-15), pages 8098 - 8104, XP002750928, ISSN: 0022-1767;;ZENEWICZ LAUREN A ET AL: ""Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation."", IMMUNITY OCT 2007, vol. 27, no. 4, October 2007 (2007-10-01), pages 647 - 659, XP002750929, ISSN: 1074-7613",ACTIVE
324,AU,B2,AU 2013/200914 B2,076-113-002-134-925,2016-01-14,2016,AU 2013/200914 A,2013-02-19,AU 2006/342792 A;;AU 2013/200914 A,2006-11-30,Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R,"Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided. 4080117_1 (GHMatters) P77078.AU.1",GENENTECH INC,CHEN YVONNE;;CHUTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/076-113-002-134-925,Granted Patent,no,1,0,3,3,0,,C07K16/24;;A61K38/20;;A61K39/00;;A61K39/395;;A61P29/00;;A61P35/00;;A61P37/00;;C07K16/28,,0,0,,,,INACTIVE
325,AU,A1,AU 2006/342792 A1,016-124-751-627-791,2007-11-08,2007,AU 2006/342792 A,2006-11-30,US 74164005 P;;US 82259706 P;;US 2006/0061418 W,2005-12-02,Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R,,GENENTECH INC,WU JIANFENG;;CHUNTHARAPAI ANAN;;ZHENG YAN;;OUYANG WENJUN;;CHEN YVONNE;;WONG TERENCE;;VALDEZ PATRICIA;;SA SUSAN;;DANILENKO DIMITRY,,https://lens.org/016-124-751-627-791,Patent Application,no,0,0,36,39,0,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,C07K16/24;;A61K39/395;;A61P29/00;;A61P35/00;;A61P37/00;;C07K16/28,,0,0,,,,DISCONTINUED
326,WO,A3,WO 2007/126439 A3,009-256-748-289-411,2008-05-22,2008,US 2006/0061418 W,2006-11-30,US 74164005 P;;US 82259706 P,2005-12-02,COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH CYTOKINE SIGNALING INVOLVING ANTIBODIES THAT BIND TO IL-22 AND IL-22R,"Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided, including antibodies that bind to IL-22 and IL-22R.",GENENTECH INC;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,CHEN YVONNE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/009-256-748-289-411,Search Report,yes,13,0,36,39,0,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,C07K16/24;;A61K38/20;;A61K39/00;;C07K16/28,,34,34,024-774-135-892-49X;;017-290-745-989-446;;060-910-994-589-367;;029-265-494-891-698;;118-959-492-088-765;;039-055-037-316-441;;069-413-474-955-853;;046-845-561-202-870;;025-969-152-076-888;;031-582-333-134-996;;073-164-139-424-502;;019-361-130-866-392;;050-182-807-494-608;;018-409-678-212-654;;028-901-227-164-152;;082-156-536-633-654;;045-742-941-589-95X;;113-167-467-883-751;;051-984-618-807-258;;024-234-866-423-833;;020-759-695-485-058;;106-450-291-507-591;;038-011-063-251-943;;027-030-197-775-202;;087-807-940-683-002;;029-833-309-321-558;;078-208-633-946-764;;035-586-215-470-490;;057-161-083-684-466;;006-608-058-804-372;;128-710-566-954-152;;051-097-128-786-019;;029-944-018-971-659;;154-897-296-289-193,11390454;;10.4049/jimmunol.166.12.7096;;11197690;;10.1038/sj.gene.6363716;;16200070;;10.1038/ni1254;;15999093;;10.1038/nri1648;;10.1038/sj.gene.6364104;;15201862;;10.4049/jimmunol.174.6.3695;;15749908;;11481447;;10.1073/pnas.171303198;;pmc55483;;10.1016/j.intimp.2004.01.010;;15120653;;17187052;;10.1038/nature05505;;15122762;;10.1002/hep.20184;;15039135;;10.1165/rcmb.2003-0285oc;;10.1189/jlb.0204117;;15123776;;10.1111/j.0300-9475.2004.01504.x;;15541036;;16212920;;10.4049/jimmunol.166.12.7090;;11390453;;10.4049/jimmunol.177.11.8266;;17114505;;12087100;;10.1074/jbc.m204204200;;10875937;;10.1074/jbc.m005304200;;10.1016/s1074-7613(03)00296-6;;14614851;;12707317;;pmc2841978;;10.4049/jimmunol.170.9.4432;;12525561;;10.1189/jlb.0602326;;15912962;;16404147;;10.1016/s1016-8478(23)13236-5;;16116186;;10.4049/jimmunol.175.5.2994;;15005873;;10.1211/0022357022962;;14768061;;10.1002/eji.200324714;;10.1074/jbc.m207577200;;12417590;;pmc2212798;;10.1084/jem.20041257;;15657292;;10.1038/ni1261;;pmc1618871;;16200068;;16982811;;10.1084/jem.20061308;;pmc2118116;;16648837;;10.1038/nature04754;;10.1590/s0074-02762006000900052;;17308791;;pmc2118338;;10.1084/jem.20060285;;16818675;;10.1038/ni1497;;17676044,"KOTENKO S V ET AL: ""Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity"", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 166, no. 12, 15 June 2001 (2001-06-15), pages 7096 - 7103, XP002186668, ISSN: 0022-1767;;DUMOUTIER L ET AL: ""IL-TIF/IL-22: GENOMIC ORGANIZATION AND MAPPING OF THE HUMAN AND MOUSE GENES"", GENES AND IMMUNITY, NATURE PUBLISHING GROUP, GB, vol. 1, 2000, pages 488 - 494, XP008003465, ISSN: 1466-4879;;HARRINGTON LAURIE E ET AL: ""Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages."", NATURE IMMUNOLOGY NOV 2005, vol. 6, no. 11, November 2005 (2005-11-01), pages 1123 - 1132, XP002455690, ISSN: 1529-2908;;HUNTER CHRISTOPHER A: ""New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions."", NATURE REVIEWS. IMMUNOLOGY JUL 2005, vol. 5, no. 7, July 2005 (2005-07-01), pages 521 - 531, XP002455691, ISSN: 1474-1733;;WEISS B ET AL: ""Cloning of murine IL-22 receptor alpha 2 and comparison with its human counterpart."", GENES AND IMMUNITY AUG 2004, vol. 5, no. 5, August 2004 (2004-08-01), pages 330 - 336, XP002455692, ISSN: 1466-4879;;BONIFACE KATIA ET AL: ""IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes."", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 MAR 2005, vol. 174, no. 6, 15 March 2005 (2005-03-15), pages 3695 - 3702, XP002456794, ISSN: 0022-1767;;XU WENFENG ET AL: ""A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 98, no. 17, 14 August 2001 (2001-08-14), pages 9511 - 9516, XP002186667, ISSN: 0027-8424;;LI J ET AL: ""TEMPORAL ASSOCIATIONS BETWEEN INTERLEUKIN 22 AND THE EXTRACELLULAR DOMAINS OF IL-22R AND IL-10R2"", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 4, no. 5, May 2004 (2004-05-01), pages 693 - 708, XP001182318, ISSN: 1567-5769;;ZHENG YAN ET AL: ""Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis."", NATURE 8 FEB 2007, vol. 445, no. 7128, 8 February 2007 (2007-02-08), pages 648 - 651, XP002455693, ISSN: 1476-4687;;RADAEVA S ET AL: ""INTERLEUKIN 22 (IL-22) PLAYS A PROTECTIVE ROLE IN T CELL-MEDIATED MURINE HEPATITIS: IL-22 IS A SURVIVAL FACTOR FOR HEPATOCYTES VIA STAT3 ACTIVATION"", HEPATOLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 39, no. 5, May 2004 (2004-05-01), pages 1332 - 1342, XP009040550, ISSN: 0270-9139;;WHITTINGTON HAYLEY A ET AL: ""Interleukin-22: a potential immunomodulatory molecule in the lung."", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY AUG 2004, vol. 31, no. 2, August 2004 (2004-08-01), pages 220 - 226, XP002472106, ISSN: 1044-1549;;DONNELLY R P ET AL: ""THE EXPANDED FAMILY OF CLASS II CYTOKINES THAT SHARE THE IL-10 RECEPTOR-2 (IL-10R2) CHAIN"", JOURNAL OF LEUKOCYTE BIOLOGY, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL, US, vol. 76, 3 May 2004 (2004-05-03), pages 314 - 321, XP008045024, ISSN: 0741-5400;;NAGAKAWA H ET AL: ""Expression of interleukin-22 in murine carcinoma cells did not influence tumour growth in vivo but did improve survival of the inoculated hosts."", SCANDINAVIAN JOURNAL OF IMMUNOLOGY NOV 2004, vol. 60, no. 5, November 2004 (2004-11-01), pages 449 - 454, XP002472107, ISSN: 0300-9475;;PAN HONGNA ET AL: ""Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3."", CELLULAR & MOLECULAR IMMUNOLOGY FEB 2004, vol. 1, no. 1, February 2004 (2004-02-01), pages 43 - 49, XP002472108, ISSN: 1672-7681;;DUMOUTIER L ET AL: ""Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22"", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 166, no. 12, 15 June 2001 (2001-06-15), pages 7090 - 7095, XP002206182, ISSN: 0022-1767;;WEBER GEORG F ET AL: ""IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase."", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 DEC 2006, vol. 177, no. 11, 1 December 2006 (2006-12-01), pages 8266 - 8272, XP002472109, ISSN: 0022-1767;;LEJEUNE DIANE ET AL: ""Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10."", THE JOURNAL OF BIOLOGICAL CHEMISTRY 13 SEP 2002, vol. 277, no. 37, 13 September 2002 (2002-09-13), pages 33676 - 33682, XP002472683, ISSN: 0021-9258;;XIE M-H ET AL: ""Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R"", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 275, no. 40, 6 October 2000 (2000-10-06), pages 31335 - 31339, XP002164307, ISSN: 0021-9258;;TRINCHIERI GIORGIO ET AL: ""The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses."", IMMUNITY NOV 2003, vol. 19, no. 5, November 2003 (2003-11-01), pages 641 - 644, XP002472680, ISSN: 1074-7613;;HAPPEL KYLE I ET AL: ""Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection."", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 MAY 2003, vol. 170, no. 9, 1 May 2003 (2003-05-01), pages 4432 - 4436, XP002472681, ISSN: 0022-1767;;LANKFORD CARLA S R ET AL: ""A unique role for IL-23 in promoting cellular immunity."", JOURNAL OF LEUKOCYTE BIOLOGY JAN 2003, vol. 73, no. 1, January 2003 (2003-01-01), pages 49 - 56, XP002472682, ISSN: 0741-5400;;HÖLSCHER CHRISTOPH: ""Targeting IL-23 in autoimmunity"", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, vol. 6, no. 5, May 2005 (2005-05-01), pages 489 - 495, XP008085031, ISSN: 1472-4472;;LIU XIKUI K ET AL: ""Signaling through the murine T cell receptor induces IL-17 production in the absence of costimulation, IL-23 or dendritic cells."", MOLECULES AND CELLS 31 DEC 2005, vol. 20, no. 3, 31 December 2005 (2005-12-31), pages 339 - 347, XP002472684, ISSN: 1016-8478;;LA SALA ANDREA ET AL: ""G(i)-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and JNK."", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 SEP 2005, vol. 175, no. 5, 1 September 2005 (2005-09-01), pages 2994 - 2999, XP002472686, ISSN: 0022-1767;;VANDENBROECK K ET AL: ""INHIBITING CYTOKINES OF THE INTERLEUKIN-12 FAMILY: RECENT ADVANCES AND NOVEL CHALLENGES"", JOURNAL OF PHARMACY AND PHARMACOLOGY, LONDON, GB, vol. 56, 2004, pages 145 - 160, XP008074541, ISSN: 0022-3573;;WEIGHARDT HEIKE ET AL: ""Identification of a TLR4- and TRIF-dependent activation program of dendritic cells."", EUROPEAN JOURNAL OF IMMUNOLOGY FEB 2004, vol. 34, no. 2, February 2004 (2004-02-01), pages 558 - 564, XP002472687, ISSN: 0014-2980;;AGGARWAL S ET AL: ""Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17"", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 278, no. 3, 17 January 2003 (2003-01-17), pages 1910 - 1914, XP002294203, ISSN: 0021-9258;;LANGRISH C L ET AL: ""IL-23 DRIVES A PATHOGENIC T CELL POPULATION THAT INDUCES AUTOIMMUNE INFLAMMATION"", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 201, no. 2, 17 January 2005 (2005-01-17), pages 233 - 240, XP001206021, ISSN: 0022-1007;;PARK HEON ET AL: ""A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17."", NATURE IMMUNOLOGY NOV 2005, vol. 6, no. 11, November 2005 (2005-11-01), pages 1133 - 1141, XP002472833, ISSN: 1529-2908;;LIANG SPENCER C ET AL: ""Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides"", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 203, no. 10, October 2006 (2006-10-01), pages 2271 - 2279, XP002454989, ISSN: 0022-1007;;MANGAN PAUL R ET AL: ""Transforming growth factor-beta induces development of the T(H)17 lineage."", NATURE 11 MAY 2006, vol. 441, no. 7090, 11 May 2006 (2006-05-11), pages 231 - 234, XP002472834, ISSN: 1476-4687;;RUTITZKY LAURA I ET AL: ""CD4 T cells producing pro-inflammatory interleukin-17 mediate high pathology in schistosomiasis."", MEMÓRIAS DO INSTITUTO OSWALDO CRUZ SEP 2006, vol. 101 Suppl 1, September 2006 (2006-09-01), pages 327 - 330, XP002472835, ISSN: 0074-0276;;SUTTON CAROLINE ET AL: ""A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis."", THE JOURNAL OF EXPERIMENTAL MEDICINE 10 JUL 2006, vol. 203, no. 7, 10 July 2006 (2006-07-10), pages 1685 - 1691, XP002472836, ISSN: 0022-1007;;WILSON NICHOLAS J ET AL: ""Development, cytokine profile and function of human interleukin 17-producing helper T cells."", NATURE IMMUNOLOGY SEP 2007, vol. 8, no. 9, September 2007 (2007-09-01), pages 950 - 957, XP002472837, ISSN: 1529-2908",PENDING
327,HK,A1,HK 1222870 A1,026-352-626-267-894,2017-07-14,2017,HK 16111098 A,2016-09-21,US 74164005 P;;US 82259706 P,2005-12-02,COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH CYTOKINE SIGNALING INVOLVING ANTIBODIES THAT BIND TO IL-22 AND IL-22R IL-22 IL-22R,,GENENTECH INC,CHEN YVONNE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/026-352-626-267-894,Patent Application,no,0,0,36,39,0,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,C07K/;;A61K/,,0,0,,,,DISCONTINUED
328,CN,A,CN 101379087 A,049-740-577-582-327,2009-03-04,2009,CN 200680052270 A,2006-11-30,US 2006/0061418 W;;US 74164005 P;;US 82259706 P,2005-12-02,Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling,"Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided, including antibodies that bind to IL-22 and IL-22R.",GENENTECH INC,YVONNE CHEN;;ANAN CHUNTHARAPAI;;DIMITRY DANILENKO;;WENJUN OUYANG;;SUSAN SA;;PATRICIA VALDEZ;;TERENCE WONG;;JIANFENG WU;;YAN ZHENG,,https://lens.org/049-740-577-582-327,Patent Application,no,0,2,3,39,0,,C07K16/24;;A61K38/20;;A61K39/00;;C07K16/28,,0,0,,,,INACTIVE
329,ZA,B,ZA 200805051 B,061-108-155-528-668,2009-08-26,2009,ZA 200805051 A,2006-11-30,US 74164005 P,2005-12-02,Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL22R,,GENENTECH INC,YVONNE CHEN;;ANAN CHUNTHARAPAI;;DIMITRY DANILENKO;;WENJUN OUYANG;;SUSAN SA;;PATRICIA VALDEZ;;TERENCE WONG;;JIANFENG WU;;YAN ZHENG,,https://lens.org/061-108-155-528-668,Granted Patent,no,0,0,3,39,0,,A61K/;;C07K/,,0,0,,,,ACTIVE
330,EP,A3,EP 2623516 A3,183-766-208-646-843,2013-10-16,2013,EP 13150883 A,2006-11-30,US 74164005 P;;US 82259706 P;;EP 06851192 A,2005-12-02,Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R,"Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.
",GENENTECH INC,CHEN YVONNE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;WALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/183-766-208-646-843,Search Report,yes,5,0,36,39,0,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,C07K16/24;;A61K38/17;;A61K38/20;;A61K39/00;;C07K16/28,,4,4,024-774-135-892-49X;;017-290-745-989-446;;073-164-139-424-502;;025-969-152-076-888,11390454;;10.4049/jimmunol.166.12.7096;;11197690;;10.1038/sj.gene.6363716;;15039135;;10.1165/rcmb.2003-0285oc;;17187052;;10.1038/nature05505,"KOTENKO S V ET AL: ""Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity"", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 166, no. 12, 15 June 2001 (2001-06-15), pages 7096 - 7103, XP002186668, ISSN: 0022-1767;;DUMOUTIER L ET AL: ""IL-TIF/IL-22: GENOMIC ORGANIZATION AND MAPPING OF THE HUMAN AND MOUSE GENES"", GENES AND IMMUNITY, NATURE PUBLISHING GROUP, GB, vol. 1, 2000, pages 488 - 494, XP008003465, ISSN: 1466-4879;;WHITTINGTON HAYLEY A ET AL: ""Interleukin-22: a potential immunomodulatory molecule in the lung."", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY AUG 2004, vol. 31, no. 2, August 2004 (2004-08-01), pages 220 - 226, XP002472106, ISSN: 1044-1549;;ZHENG YAN ET AL: ""Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis."", NATURE 8 FEB 2007, vol. 445, no. 7128, 8 February 2007 (2007-02-08), pages 648 - 651, XP002455693, ISSN: 1476-4687",ACTIVE
331,US,A1,US 2010/0039263 A1,078-353-413-416-252,2010-02-18,2010,US 45837009 A,2009-07-09,US 45837009 A;;US 12965708 P,2008-07-10,System and method for utilization of smart meter infrastructure,"A system and method for tracking household assets that takes advantage of a home area network and neighborhood smart meter infrastructure. The system uses an asset tracking module comprising a microcontroller unit, motion sensor unit, and communication unit may be registered to a home area network and attached to a household asset. A home management system may be used to track the location of the module and alert a user if the module is moved.",CHEN CHRISTOPHER WAY-FUNG;;MOHN MICHAEL TERENCE;;AYBAR FATIH;;LOPEZ SAUL VASQUEZ;;DU WANZHU STELLA;;PANDYA NIMIT KANDARP,CHEN CHRISTOPHER WAY-FUNG;;MOHN MICHAEL TERENCE;;AYBAR FATIH;;LOPEZ SAUL VASQUEZ;;DU WANZHU STELLA;;PANDYA NIMIT KANDARP,SEMPRA ENERGY LAW DEPARTMENT (2009-08-28),https://lens.org/078-353-413-416-252,Patent Application,yes,23,48,1,1,0,G08B13/1427;;H04L12/2827;;G08B13/1427;;H04L12/2827;;Y02B70/30;;Y04S20/20,G08B5/22;;G08B13/14,340/572.1;;340/825.49,0,0,,,,DISCONTINUED
332,HK,A1,HK 1185895 A1,180-565-951-553-379,2014-02-28,2014,HK 13113820 A,2008-08-22,US 74164005 P;;US 82259706 P,2005-12-02,COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH CYTOKINE SIGNALING INVOLVING ANTIBODIES THAT BIND TO IL-22 AND IL-22R IL-22 IL-22R,,GENENTECH INC,CHEN YVONNE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;WALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/180-565-951-553-379,Patent Application,no,0,0,36,39,0,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,A61K/;;C07K/,,0,0,,,,DISCONTINUED
333,CO,A2,CO 6241138 A2,030-393-013-407-079,2011-01-20,2011,CO 09118682 A,2009-10-22,US 89633907 P,2007-03-22,ANTICUERPOS ANTI-IGE APOPTOPICOS UNIENDO IGE UNIDA A LA MEMBRANA,"1.- Un anticuerpo anti-IgE/M1' que se une específicamente al segmento M1' de IgE y que induce la apoptosis en células B que expresan IgE.2.- El anticuerpo de la reivindicación 1, en que el anticuerpo se una a IgE que es de origen humano, de mono rhesus y de mono cynomolgus.3.- Un anticuerpo anti-IgE/M1' que se une específicamente al segmento M1' de IgE y elimina específicamente las células B productoras de IgE cuando se administra in vivo una cantidad terapéuticamente efectiva a un mamífero.4.- El anticuerpo de la reivindicación 3, que reduce el IgE serico total.5.- El anticuerpo de la reivindicación 4, que reduce el IgE sérico libre.6.- El anticuerpo de la reivindicación 4, en que el IgE es específico al alergeno.7.- El anticuerpo de la reivindicación 3 que es quimérico.8.- El anticuerpo de la reivindicación 3 que es humanizado.9.- El anticuerpo de la reivindicación 3 que es humano.10.- Un anticuerpo anti-IgE/M1' que se una específicamente al mismo epítopo al que se une un anticuerpo seleccionado del grupo que comprende: 47H4, 7A6, 26A11, 47H4v5, 7A6v1 y 26A11v6.11.- El anticuerpo de la reivindicación 10, en que el epítopo corresponde a un péptido que se selecciona del grupo que comprende: péptido 4 (Núm. ident. secuencia:8), péptido 5 (Núm. ident. secuencia:9), péptido 7 (Núm. ident. secuencia: 11) o péptido 8 (Núm. ident. secuencia: 12).12.- El anticuerpo de la reivindicación 11, en que el epítopo corresponde al péptido 4 (Núm. ident. secuencia:8).13.- Un péptido seleccionado del grupo que comprende: péptido 4 (Núm. ident. secuencia:8), péptido 5 (Núm. ident. secuencia:9), péptido 7 (Núm. ident. secuencia:11) o péptido 8 (Núm. ident. secuencia:12).",GENENTECH INC,WU LAWREN;;BALAZS MERCEDES;;BRIGHTBILL HANS;;CHAN ANDREW C;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DENNIS MARK S;;WONG TERENCE,,https://lens.org/030-393-013-407-079,Patent Application,no,0,0,56,56,0,A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/0387;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/41;;C07K2317/73;;C07K16/4291;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/10;;A61P17/00;;A61P17/04;;A61P19/00;;A61P31/10;;A61P33/00;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07K16/42;;A61K39/395;;A01K2267/0387;;C07K2317/41;;A01K67/0278;;A01K2217/072;;A01K2227/105;;C07K2317/21;;C07K2317/24;;A61K2039/505;;C07K2317/73;;C07K16/4291,A61P37/06;;C07K16/42,,0,0,,,,ACTIVE
334,EP,A2,EP 1954719 A2,026-864-491-479-214,2008-08-13,2008,EP 06851192 A,2006-11-30,US 2006/0061418 W;;US 74164005 P;;US 82259706 P,2005-12-02,COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH CYTOKINE SIGNALING INVOLVING ANTIBODIES THAT BIND TO IL-22 AND IL-22R,,GENENTECH INC,CHEN YVONNE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/026-864-491-479-214,Patent Application,yes,0,0,36,39,0,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,C07K16/28;;A61K38/17;;A61K38/20;;C07K16/24,,7,6,006-608-058-804-372;;118-344-042-969-88X;;031-582-333-134-996;;067-950-652-336-686;;001-144-618-215-249;;005-844-854-175-771,16982811;;10.1084/jem.20061308;;pmc2118116;;pmc2149911;;17919941;;10.1016/j.immuni.2007.07.023;;15122762;;10.1002/hep.20184;;10.1172/jci33194;;pmc2157567;;18172556;;10.4049/jimmunol.179.12.8098;;18056351;;10.1016/b978-0-12-381300-8.00001-0;;21034969,"LIANG SPENCER C ET AL: ""Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides."", THE JOURNAL OF EXPERIMENTAL MEDICINE 2 OCT 2006 LNKD- PUBMED:16982811, vol. 203, no. 10, 2 October 2006 (2006-10-02), pages 2271 - 2279, ISSN: 0022-1007;;ZENEWICZ LAUREN A ET AL: ""Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation."", IMMUNITY OCT 2007 LNKD- PUBMED:17919941, vol. 27, no. 4, October 2007 (2007-10-01), pages 647 - 659, ISSN: 1074-7613;;RADAEVA SVETLANA ET AL: ""Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation."", HEPATOLOGY (BALTIMORE, MD.) MAY 2004 LNKD- PUBMED:15122762, vol. 39, no. 5, May 2004 (2004-05-01), pages 1332 - 1342, ISSN: 0270-9139;;SUGIMOTO KEN ET AL: ""IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis."", THE JOURNAL OF CLINICAL INVESTIGATION FEB 2008 LNKD- PUBMED:18172556, vol. 118, no. 2, February 2008 (2008-02-01), pages 534 - 544, ISSN: 0021-9738;;KREYMBORG KATHARINA ET AL: ""IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis."", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 DEC 2007 LNKD- PUBMED:18056351, vol. 179, no. 12, 15 December 2007 (2007-12-15), pages 8098 - 8104, ISSN: 0022-1767;;SONNENBERG GREGORY F ET AL: ""Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces."", ADVANCES IN IMMUNOLOGY 2010 LNKD- PUBMED:21034969, vol. 107, 2010, pages 1 - 29, ISSN: 1557-8445;;See also references of WO 2007126439A2",DISCONTINUED
335,EP,B1,EP 2623516 B1,164-789-570-505-050,2015-07-15,2015,EP 13150883 A,2006-11-30,US 74164005 P;;US 82259706 P;;EP 06851192 A,2005-12-02,COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH CYTOKINE SIGNALING INVOLVING ANTIBODIES THAT BIND TO IL-22 AND IL-22R,,GENENTECH INC,CHEN YVONNE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;WALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/164-789-570-505-050,Granted Patent,yes,5,0,36,39,0,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,A61K39/395;;C07K16/24,,4,0,,,"KOTENKO S V ET AL: ""Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity"", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 166, no. 12, 15 June 2001 (2001-06-15), pages 7096-7103, XP002186668, ISSN: 0022-1767;;DUMOUTIER L ET AL: ""IL-TIF/IL-22: GENOMIC ORGANIZATION AND MAPPING OF THE HUMAN AND MOUSE GENES"", GENES AND IMMUNITY, NATURE PUBLISHING GROUP, GB, vol. 1, 2000, pages 488-494, XP008003465, ISSN: 1466-4879;;WHITTINGTON HAYLEY A ET AL: ""Interleukin-22: a potential immunomodulatory molecule in the lung."", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY AUG 2004, vol. 31, no. 2, August 2004 (2004-08), pages 220-226, XP002472106, ISSN: 1044-1549;;ZHENG YAN ET AL: ""Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis."", NATURE 8 FEB 2007, vol. 445, no. 7128, 8 February 2007 (2007-02-08), pages 648-651, XP002455693, ISSN: 1476-4687",ACTIVE
336,CN,A,CN 105859886 A,067-236-536-761-003,2016-08-17,2016,CN 201610078240 A,2006-11-30,US 74164005 P;;US 82259706 P;;CN 200680052270 A,2005-12-02,Compositions and methods associated with antibodies that bind to IL-22 and IL-22R,"Compositions and methods are provided for the diagnosis and treatment of diseases related to cytokines signal transduction, and associated with antibodies that bind to IL-22 and IL-22R; the method and composition can diagnosis and treat inflammation and autoimmune disorders, such as psoriasis. The compositions and methods can modulate IL-23 or IL-22 signaling, and comprise the antibodies that bind to IL-22 and IL-22R.",GENENTECH INC,CHEN YVONNE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/067-236-536-761-003,Patent Application,no,3,2,36,39,0,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,C07K16/24;;A61K45/00;;A61P29/00;;A61P35/00;;A61P37/02;;A61P43/00;;C07K16/28;;G01N33/68,,0,0,,,,DISCONTINUED
337,AU,B2,AU 2016/202280 B2,021-025-760-857-916,2017-08-24,2017,AU 2016/202280 A,2016-04-12,AU 2016/202280 A;;AU 2013/200914 A;;AU 2006/342792 A,2006-11-30,Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R,"Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided. 7625904_1 (GHMatters) P77978.AU.2",GENENTECH INC,CHEN YVONNE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/021-025-760-857-916,Granted Patent,no,1,1,3,3,0,,C07K16/24;;A61K38/20;;A61K39/00;;A61K39/395;;A61P29/00;;A61P35/00;;A61P37/00;;C07K16/28,,0,0,,,,INACTIVE
338,AU,A1,AU 2013/200914 A1,198-057-534-251-858,2013-03-07,2013,AU 2013/200914 A,2013-02-19,AU 2006/342792 A;;AU 2013/200914 A,2006-11-30,Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R,"Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided. 4080117_1 (GHMatters) P77078.AU.1",GENENTECH INC,CHEN YVONNE;;CHUTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/198-057-534-251-858,Patent Application,no,0,3,3,3,0,,C07K16/24;;A61K38/20;;A61K39/00;;A61K39/395;;A61P29/00;;A61P35/00;;A61P37/00;;C07K16/28,,0,0,,,,INACTIVE
339,NZ,A,NZ 712762 A,000-857-625-042-298,2017-03-31,2017,NZ 71276206 A,2006-11-30,US 82259706 P;;US 74164005 P;;NZ 62148306 A,2005-12-02,Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r,"Disclosed is an antibody that specifically binds to IL-22, wherein the antibody is (a) an antibody produced by a hybridoma selected from 7E9.10.8 (ATCC Accession No. PTA-7313), hybridoma 8A12.32 (ATCC Accession No. PTA-7318), and hybridoma 8H11.32.28 (ATCC 5 Accession No. PTA-7317); (b) an affinity matured form of the antibody of (a); (c) an antigen-binding fragment of the antibody of (a) or (b); or (d) a humanised form of the antibody of (a), (b), or (c). Also disclosed is a method of treating an autoimmune disorder, wherein the autoimmune disorder is not arthritis, the method comprising administering to a mammal an effective amount of a pharmaceutical formulation comprising an antagonist of IL-22.",GENENTECH INC,CHUNTHARAPAI ANAN;;WONG TERENCE;;OUYANG WENJUN;;VALDEZ PATRICIA;;DANILENKO DIMITRY;;SA SUSAN;;WU JIANFENG;;ZHENG YAN;;CHEN YVONNE,,https://lens.org/000-857-625-042-298,Patent Application,no,0,0,36,39,0,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,C07K16/28;;A61K38/20;;A61K39/00;;C07K16/24,,0,0,,,,DISCONTINUED
340,NZ,A,NZ 601871 A,058-586-782-942-17X,2014-10-31,2014,NZ 60187106 A,2006-11-30,US 82259706 P;;US 74164005 P;;NZ 56877706 A,2005-12-02,Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r,"Disclosed is an antibody that specifically binds to IL-22, wherein the antibody is: (a) an antibody produced by a hybridoma selected from 3F11.3 (ATCC Accession No. PTA-7312), and hybridoma 8E11.9 (ATCC Accession No. PTA-7319); (b) an affinity matured form of the antibody of (a); (c) an antigen-binding fragment of the antibody of (a) or (b); or (d) a humanised form of the antibody of (a), (b), or (c). Also disclosed is the use of said antibody in the preparation of a pharmaceutical composition for alleviating a disorder characterised by skin inflammation.",GENENTECH INC,CHUNTHARAPAI ANAN;;WONG TERENCE;;OUYANG WENJUN;;ZHENG YAN;;CHEN YVONNE;;SA SUSAN;;WU JIANFENG;;VALDEZ PATRICIA;;DANILENKO DIMITRY,,https://lens.org/058-586-782-942-17X,Patent Application,no,0,0,1,1,0,,C07K16/28;;A61K38/20;;A61K39/00;;C07K16/24,,0,0,,,,DISCONTINUED
341,EP,B1,EP 3006466 B1,137-575-142-989-463,2018-08-01,2018,EP 15176159 A,2006-11-30,US 74164005 P;;US 82259706 P;;EP 13150883 A;;EP 06851192 A;;US 2006/0061418 W,2005-12-02,COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH CYTOKINE SIGNALING INVOLVING ANTIBODIES THAT BIND TO IL-22 AND IL-22R,,GENENTECH INC,CHEN YVONNE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/137-575-142-989-463,Granted Patent,yes,4,0,36,39,0,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,C07K16/24;;A61K38/17;;A61K38/20;;A61K39/00;;A61K39/395;;C07K16/28,,9,0,,,"KOTENKO S V ET AL: ""Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity"", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 166, no. 12, 15 June 2001 (2001-06-15), pages 7096-7103, XP002186668, ISSN: 0022-1767;;DUMOUTIER L ET AL: ""IL-TIF/IL-22: GENOMIC ORGANIZATION AND MAPPING OF THE HUMAN AND MOUSE GENES"", GENES AND IMMUNITY, NATURE PUBLISHING GROUP, GB, vol. 1, 2000, pages 488-494, XP008003465, ISSN: 1466-4879;;BONIFACE KATIA ET AL: ""IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes."", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 MAR 2005, vol. 174, no. 6, 15 March 2005 (2005-03-15), pages 3695-3702, XP002456794, ISSN: 0022-1767;;RADAEVA S ET AL: ""INTERLEUKIN 22 (IL-22) PLAYS A PROTECTIVE ROLE IN T CELL-MEDIATED MURINE HEPATITIS: IL-22 IS A SURVIVAL FACTOR FOR HEPATOCYTES VIA STAT3 ACTIVATION"", HEPATOLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 39, no. 5, May 2004 (2004-05), pages 1332-1342, XP009040550, ISSN: 0270-9139;;WHITTINGTON HAYLEY A ET AL: ""Interleukin-22: a potential immunomodulatory molecule in the lung."", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY AUG 2004, vol. 31, no. 2, August 2004 (2004-08), pages 220-226, XP002472106, ISSN: 1044-1549;;LIANG SPENCER C ET AL: ""Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides"", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 203, no. 10, 1 October 2006 (2006-10-01), pages 2271-2279, XP002454989, ISSN: 0022-1007, DOI: 10.1084/JEM.20061308;;ZHENG YAN ET AL: ""Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis."", NATURE 8 FEB 2007, vol. 445, no. 7128, 8 February 2007 (2007-02-08), pages 648-651, XP002455693, ISSN: 1476-4687;;KREYMBORG KATHARINA ET AL: ""IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis."", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 DEC 2007, vol. 179, no. 12, 15 December 2007 (2007-12-15), pages 8098-8104, XP002750928, ISSN: 0022-1767;;ZENEWICZ LAUREN A ET AL: ""Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation."", IMMUNITY OCT 2007, vol. 27, no. 4, October 2007 (2007-10), pages 647-659, XP002750929, ISSN: 1074-7613",ACTIVE
342,NZ,A,NZ 621483 A,166-000-733-272-59X,2015-10-30,2015,NZ 62148306 A,2006-11-30,US 82259706 P;;US 74164005 P;;NZ 60187106 A,2005-12-02,Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r,"Disclosed is an antibody that specifically binds to IL-22, wherein the antibody is (a) an antibody produced by hybridoma 11H4.4 (ATCC Accession No. PTA-7315) (b) an affinity matured form of the antibody of (a); (c) an antigen-binding fragment of the antibody of (a) or (b); or (d) a humanised form of the antibody of (a), (b), or (c).",GENENTECH INC,CHUNTHARAPAI ANAN;;WONG TERENCE;;OUYANG WENJUN;;VALDEZ PATRICIA;;DANILENKO DIMITRY;;SA SUSAN;;WU JIANFENG;;ZHENG YAN;;CHEN YVONNE,,https://lens.org/166-000-733-272-59X,Patent Application,no,0,0,36,39,0,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,C07K16/28;;A61K38/20;;A61K39/00;;C07K16/24,,0,0,,,,DISCONTINUED
343,WO,A2,WO 2007/126439 A2,109-079-627-377-889,2007-11-08,2007,US 2006/0061418 W,2006-11-30,US 74164005 P;;US 82259706 P,2005-12-02,COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH CYTOKINE SIGNALING,"Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.",GENENTECH INC;;CHEN YVONNE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,CHEN YVONNE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/109-079-627-377-889,Patent Application,yes,18,13,36,39,4,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,A61K39/395;;C07K16/24;;A61P29/00;;A61P35/00;;A61P37/00;;C07K16/28,,25,13,012-830-491-824-205;;001-576-828-082-834;;019-115-775-607-415;;009-406-912-144-89X;;009-186-473-238-939;;083-771-782-040-353;;034-331-211-704-877;;020-855-322-534-259;;103-353-898-106-766;;034-498-755-334-91X;;100-223-052-747-506;;059-176-157-859-658;;018-365-412-976-946,pmc345355;;6204335;;10.1073/pnas.81.13.3998;;pmc396995;;2578661;;10.1073/pnas.82.1.178;;2443575;;10.1016/0022-1759(87)90085-8;;2447184;;10.4049/jimmunol.140.2.611;;10.1073/pnas.87.16.6378;;2201029;;pmc54537;;10.1021/bi00109a004;;1932005;;10.1038/352624a0;;1907718;;1748994;;10.1016/0022-2836(91)90498-u;;1370065;;10.1016/0958-1669(91)90032-z;;7053372;;10.1016/s0021-9258(19)68359-6;;2778836;;10.1093/jnci/81.19.1484;;15199399;;10.1172/jci22147;;10.1172/jci200422147;;pmc420513;;10.1111/j.0022-202x.2004.23448.x;;15610511,"FRAKER ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 80, 1978, pages 49 - 57;;CHATAL: ""Monoclonal Antibodies in Immunoscintigraphy"", 1989, CRC PRESS;;GEYSEN ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 81, 1984, pages 3998 - 4002;;GEYSEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 178 - 182;;GEYSCN ET AL., SYNTHETIC PEPTIDES AS ANTIGENS, 1986, pages 130 - 149;;GEYSEN ET AL., J. IMMUNOL. METH., vol. 102, 1987, pages 259 - 274;;SCHOOFS ET AL., J. IMMUNOL., vol. 140, 1988, pages 611 - 616;;CWIRLA, S. E. ET AL., PROC. NATL, ACAD. SCI. USA, vol. 87, 1990, pages 6378;;LOWMAN, H.B. ET AL., BIOCHEMISTRY, vol. 30, 1991, pages 10832;;CLACKSON, T. ET AL., NATURE, vol. 352, 1991, pages 624;;MARKS, J. D. ET AL., J. MOL. BIOL, vol. 222, 1991, pages 581;;KANG, A.S. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 8363;;SMITH, G. P., CURRENT OPIN. BIOTECHNOL, vol. 2, 1991, pages 668;;""Retningion's Pharmaceutical Sciences"", 1980;;MARASCO ET AL., PROC, NETL. ACAD. SCI. USA, vol. 90, 1993, pages 7899 - 7893;;EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 3688;;WANG ET AL., PROC. NATL ACAD. SCI. USA, vol. 77, 1980, pages 4030;;MARTIN ET AL., J. BIOL. CHEM., vol. 257, 1982, pages 286 - 288;;GABIZOU ET AL., J. NATIONAL CANCER INST., vol. 81, no. 19, 1989, pages 1484;;""Reiningion Pharmaceutical Sciences"", 1980;;NICKOLOFF ET AL., J. CLIN. INVEST., vol. 113, 2004, pages 1664 - 1675;;BOWCOCK ET AL., NAT. REV. IMMUNOL., vol. 3, 2005, pages 699 - 711;;KAUFFMAN ET AL., J. INVEST. DERMATOL., vol. 123, 2004, pages 1037 - I044;;""Chemotherapy Service"", 1992, WILLIAMS & WILKINS;;See also references of EP 1954719A2",PENDING
344,ES,T1,ES 2168237 T1,071-964-780-235-654,2002-06-16,2002,ES 97902295 T,1997-01-30,US 1127996 P;;US 2768896 P,1996-02-07,PIRAZOLOPIRIMIDINAS QUE ACTUAN COMO ANTAGONISTAS DEL RECEPTOR DEL CRF.,"ESTA INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I), INCLUIDOS ESTEREOISOMEROS Y LAS FORMAS DE SALES DE ADICION ACIDAS FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, EN LA QUE R 1 ES NR 4 R 5 U OR 5 ; R 2 ES ALQUILO C 1-6 , ALQUILOXI C 1-6 O ALQUILTIO C 1-6 ; R 3 ES HIDROGENO, ALQUILO C 1-6 , ALQUILSULFONILO C 1-6 , ALQUILSULFOXI C 1-6 O ALQUILTIO C 1-6 ; R 4 ES HIDR OGENO, ALQUILO C 1-6 , MONO - O DI(CICLOALQUIL C 36 ) METILO, CICLOALQUILO C 3-6 , ALQUENILO C 3-6 , HIDROXIALQUILO C 3-6 , ALQUILCARBONILOXI C 1-6 ALQUILO C SUB ,1-6 O ALQUILOXI C 1-6 ALQUILO C 1-6 ; R 5 ES ALQUILO C 1-8 , MONO - O DI(CICLOALQUIL C 3-6 )METILO, AR 1 CH 2 , ALQUILOXI C 1-6 ALQUILO C 1-6 , HIDROXIALQUILO C 1-6 , ALQUENILO C 3-6 , TIENILMETILO, FURANILMETILO, ALQUILTIO C 1-6 ALQUILO C 1-6 , MORFOLINILO, MONO - O DI(ALQUIL C 1-6 )AMINOALQUILO C 16 , D I(ALQUIL C 1-6 )AMINO, ALQUILCARBONIL C 1-6 ALQUILO C1-6 , ALQUILO C 1-6 SUSTITUIDO CON IMIDAZOLILO; O UN RADICAL DE LA FORMULA - ALK - O - CO - AR 1 ; O R 4 O R 5 TOMADOS JUNTO CON EL ATOMO DE NITROGENO AL QUE ESTAN UNIDOS PUEDEN FORMAR UN GRUPO PIRROLIDINILO, PIPERIDINILO, HOMOPIPERIDINILO O MORFOLINILO OPCIONALMENTE SUSTITUIDO; QUE POSEEN PROPIEDADES ANTAGONISTICAS AL RECEPTOR DEL CRF; A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN TALES COMPUESTOS COMO INGREDIENTES ACTIVOS; METODO PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA HIPERSECRECION DE CRF TALES COMO LA DEPRESION, ANSIEDAD, ABUSO DE SUSTANCIAS, MEDIANTE LA ADMINISTRACION DE UNA CANTIDAD EFECTIVA DE UN COMPUESTO DE FORMULA (I).",JANSSEN PHARMACEUTICA NV;;NEUROCRINE BIOSCIENCES INC,CHEN CHEN-NEUROCRINE BIOSCIENC;;WEBB THOMAS R-NEUROCRINE BIOSC;;MCCARTHY JAMES R-NEUROCRINE BI;;MORAN TERENCE J-NEUROCRINE BIO;;WILCOXEN KEITH M-NEUROCRINE BI,,https://lens.org/071-964-780-235-654,Patent Application,no,0,0,43,52,0,C07D487/04;;C07D471/10;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/00;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P3/00;;A61P3/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/00;;A61P9/00;;A61P9/12;;C07D487/04;;A61K31/495,A61K31/00;;A61K31/435;;A61K31/439;;A61K31/485;;A61K31/495;;A61K31/496;;A61K31/505;;A61K31/519;;A61K31/529;;A61K31/535;;A61K31/5375;;A61K31/5377;;A61K31/55;;A61P1/00;;A61P1/04;;A61P1/12;;A61P1/14;;A61P3/00;;A61P3/04;;A61P9/00;;A61P9/12;;A61P11/00;;A61P11/06;;A61P11/14;;A61P13/12;;A61P19/02;;A61P25/08;;A61P25/18;;A61P25/22;;A61P25/24;;A61P25/30;;A61P25/32;;A61P29/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;C07D471/08;;C07D471/10;;C07D487/04;;C07D489/09;;C07D491/18;;C07D491/20;;C07D495/22,,0,0,,,,EXPIRED
345,SI,T1,SI 0880523 T1,064-976-340-392-87X,2007-04-30,2007,SI 9730753 T,1997-01-30,US 1127996 P;;US 2768896 P;;EP 9700459 W;;EP 97902295 A,1996-02-07,PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS,,NEUROCRINE BIOSCIENCES INC,CHEN CHEN-NEUROCRINE BIOSCIENC;;WEBB THOMAS R-NEUROCRINE BIOSC;;MCCARTHY JAMES R-NEUROCRINE BI;;MORAN TERENCE J-NEUROCRINE BIO;;WILCOXEN KEITH M-NEUROCRINE BI,,https://lens.org/064-976-340-392-87X,Granted Patent,no,0,0,1,52,0,,C07D487/00;;A61K31/00,,0,0,,,,EXPIRED
346,US,A1,US 2007/0212356 A1,175-021-101-021-230,2007-09-13,2007,US 56539506 A,2006-11-30,US 56539506 A;;US 82259706 P;;US 74164005 P,2005-12-02,COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH CYTOKINE SIGNALING,"Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.",CHEN YVONNE M;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,CHEN YVONNE M;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,GENENTECH INC (2007-02-02),https://lens.org/175-021-101-021-230,Patent Application,yes,36,42,36,39,4,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,A61K39/395;;C07K16/24,424/145.1;;530/388.23,0,0,,,,INACTIVE
347,US,B2,US 7737259 B2,178-243-106-226-895,2010-06-15,2010,US 56539506 A,2006-11-30,US 56539506 A;;US 82259706 P;;US 74164005 P,2005-12-02,Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling,"Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.",GENENTECH INC,CHEN YVONNE M;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,GENENTECH INC (2007-02-02),https://lens.org/178-243-106-226-895,Granted Patent,yes,51,13,36,39,4,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,C07K16/24,530/388.23,47,47,019-361-130-866-392;;028-901-227-164-152;;017-290-745-989-446;;024-234-866-423-833;;060-910-994-589-367;;106-450-291-507-591;;024-774-135-892-49X;;035-586-215-470-490;;020-759-695-485-058;;045-742-941-589-95X;;046-845-561-202-870;;006-608-058-804-372;;038-011-063-251-943;;128-710-566-954-152;;050-182-807-494-608;;018-409-678-212-654;;057-161-083-684-466;;031-582-333-134-996;;051-097-128-786-019;;027-030-197-775-202;;029-944-018-971-659;;051-984-618-807-258;;087-807-940-683-002;;082-156-536-633-654;;029-833-309-321-558;;118-959-492-088-765;;073-164-139-424-502;;154-897-296-289-193;;113-167-467-883-751;;069-413-474-955-853;;078-208-633-946-764;;011-488-261-758-663;;039-055-037-316-441;;010-808-085-430-282;;007-804-874-228-785;;132-817-119-508-278;;059-766-301-817-277;;106-450-291-507-591;;029-265-494-891-698;;092-787-602-337-946;;041-241-834-308-816;;034-849-028-103-586;;002-123-394-403-657;;011-118-124-045-116;;115-806-652-196-516;;015-376-605-232-403;;025-969-152-076-888,10.1189/jlb.0204117;;15123776;;10.4049/jimmunol.166.12.7090;;11390453;;11197690;;10.1038/sj.gene.6363716;;12707317;;pmc2841978;;10.4049/jimmunol.170.9.4432;;16200070;;10.1038/ni1254;;15912962;;11390454;;10.4049/jimmunol.166.12.7096;;pmc2212798;;10.1084/jem.20041257;;15657292;;12525561;;10.1189/jlb.0602326;;12087100;;10.1074/jbc.m204204200;;10.1016/j.intimp.2004.01.010;;15120653;;16982811;;10.1084/jem.20061308;;pmc2118116;;16404147;;10.1016/s1016-8478(23)13236-5;;16648837;;10.1038/nature04754;;10.1111/j.0300-9475.2004.01504.x;;15541036;;16212920;;10.1038/ni1261;;pmc1618871;;16200068;;15122762;;10.1002/hep.20184;;10.1590/s0074-02762006000900052;;17308791;;16116186;;10.4049/jimmunol.175.5.2994;;pmc2118338;;10.1084/jem.20060285;;16818675;;10.1016/s1074-7613(03)00296-6;;14614851;;15005873;;10.1211/0022357022962;;10.4049/jimmunol.177.11.8266;;17114505;;14768061;;10.1002/eji.200324714;;10.1038/sj.gene.6364104;;15201862;;15039135;;10.1165/rcmb.2003-0285oc;;10.1038/ni1497;;17676044;;10875937;;10.1074/jbc.m005304200;;11481447;;10.1073/pnas.171303198;;pmc55483;;10.1074/jbc.m207577200;;12417590;;11163236;;10.1016/s0092-8674(01)00187-8;;10.4049/jimmunol.174.6.3695;;15749908;;pmc1785338;;17236132;;10.1086/511051;;pmc2803035;;10.1038/nature01322;;12490959;;10.1111/j.0022-202x.2004.22719.x;;15191538;;10.1016/s1471-4906(01)02149-4;;11929132;;15912962;;15999093;;10.1038/nri1648;;10.4049/jimmunol.165.11.6107;;11086043;;16688182;;10.1038/nature04808;;10.4049/jimmunol.176.3.1908;;16424222;;10.1038/nri1153;;12974481;;16510278;;10.1016/j.ejca.2006.01.002;;16473830;;10.1016/j.immuni.2006.01.001;;10.1182/blood-2002-12-3793;;12649136;;17187052;;10.1038/nature05505,"Donnelly, et al., ""The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain"", Journal of Leukocyte Biology, vol. 76, pp. 314-321, (2004).;;Dumoutier, et al., ""Cloning and Characterization of II-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor /IL-22"", Journal of Immunology, vol. 166, No. 12, pp. 7090-7095, (2001).;;Dumoutier, et al., ""IL-TIF/IL-22: Genomic Organization and Mapping of the Human and Mouse Genes"", Genes and Immunity, vol. 1, pp. 488-494, (2000).;;Happel, et al., ""Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection"", Journal of Immunology, vol. 170, No. 9, pp. 4432-4436, (2003).;;Harrington, et al., ""Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages"", Nature Immunology, vol. 6, No. 11, pp. 1123-1132, (2005).;;Holscher, et al., ""Targeting IL-23 in autoimmunity"", Current Opinion in Investigational Drugs, vol. 6, No. 5, pp. 489-495, (2005).;;Kotenko, et al., ""Identification, cloning and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity"", Journal of Immunology, vol. 166, No. 12, pp. 7096-7103, (2001).;;Langrish, et al., ""IL-23 Drives a pathogenic T cell population that induces autoimmune Inflammation"", Journal of Experimental Medicine, vol. 201, No. 2, pp. 233-240, (2005).;;Lankford, et al., ""A unique role for IL-23 in promoting cellular immunity"", Journal of Leukocyte Biology, vol. 73, No. 1, pp. 49-56, (2003).;;Lejeune, et al., ""Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10"", The Journal of Biological Chemistry, vol. 277, No. 37, pp. 33676-33682, (2002).;;Li, et al., ""Temporal associations between interleukin 22 and the extracellular domains of IL-22R and IL-10R2"", International Immunopharmacology, vol. 4, No. 5, pp. 693-708, (2004).;;Liang, et al., ""Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides"", vol. 203, No. 10, pp. 2271-2279, (2006).;;Liu, et al., ""Signaling through the murine T cell receptor induces IL-17 production in the absence of costimulation, IL-23 or dendritic cells"", Molecules and Cells, vol. 20, No. 3, pp. 339-347, (2005).;;Mangan, et al., ""Transforming growth factor-beta induces development of the T(H)17 lineage"", Nature, vol. 441, No. 7090, pp. 231-234, (2006).;;Nagakawa, et al., ""Expression of interleukin-22 in murine carcinoma cells did not influence tumor growth in vivo but did improve survival of the inoculated hosts"", Scandinavian Journal of Immunology, vol. 60, No. 5, pp. 449-454, (2004).;;Pan, et al., ""Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3"", Cellular & Molecular. Immunology, vol. 1, No. 1, pp. 43-49, (2004).;;Park, et al., A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17, Nature Immunology, vol. 6, No. 11, pp. 1133-1141, (2005).;;Radaeva, et al., ""Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via stat3 activation"", Hepatology, vol. 39, No. 5, pp. 1332-1342, (2004).;;Rutitzky, et al., ""CD4 T cells producing pro-inflammatory interleukin-17 mediate high pathology in schistosomiasis"", Mem'orias do instituto oswaldo cruz, vol. 101, Suppl. 1, pp. 327-330, (2006).;;Sala, et al., ""G(i)-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and JNK"", Journal of Immunology, vol. 175, No. 5, pp. 2994-2999, (2005).;;Sutton, et al., ""A crucial role for leukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis"", The Journal of Experimental Medicine, vol. 203, No. 7, pp. 1685-1691, (2006).;;Trinchieri, et al., ""The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses"", Immunity, vol. 19, No. 5, pp. 641-644, (2003).;;Vandenbroeck, et al., ""Inhibiting Cytokines of the Interleukin-12 Family: Recent Advances and Novel Challenges"", Journal of Pharmacy and Pharmacology, vol. 56, pp. 145-160, (2004).;;Weber, et al., ""IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase"", Journal of Immunology, vol. 177, No. 11, pp. 8266-8272, (2006).;;Weighardt, et al., Identification of a TLR4- and TRIF-dependent activation program of dendritic cells, European Journal of Immunology, vol, 34, No. 2, pp. 558-564, (2004).;;Weiss, et al., ""Cloning and murine IL-22 receptor alpha 2 and comparison with its human counterpart"", Genes and Immunity, vol. 5, No. 5, pp. 330-336, (2004).;;Whittington, et al., """"Interleukin-22: a potential immunomodulatory molecule in the lung"", American Journal of Respiratory Cell and Molecular Biology"", vol. 31, No. 2, pp. 220-226, (2004).;;Wilson, et al., ""Development, cytokine profile and function of human interleukin 17-producing helper T cells"", Nature Immunology, vol. 8, No. 9, pp. 950-957, (2007).;;Xie, et al., ""Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R"", Journal of Biological Chemistry, vol. 275, No. 40, pp. 31335-31339, (2000).;;Xu, et al., ""A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist"", Proceedings of the National Academy of Sciences, vol. 98, No. 17, pp. 9511-9516, (2001).;;Aggarwal et al., ""Interleukin-23 Promotes a Distinct CD4 T Cell Activation State Characterized by the Production of Interleukin-17"" Journal of Biological Chemistry 278:1910-1914 (2003).;;Blumberg et al., ""Interleukin 20: Discovery, Receptor Identification, and Role in Epidermal Function"" Cell 104:9-19 (Jan. 12, 2001).;;Boniface et al., ""IL-22 Inhibits Epidermal Differentiation and Induces Proinflammatory Gene Expression and Migration of Human Keratinocytes"" The Journal of Immunology 174:3695-3702 (2005).;;Cargill et al., ""A Large-Scale Genetic Association Study Confirms IL1 2B and Leads to the Identification of IL23R as Psoriasis-Risk Genes"" The American Journal of Human Genetics 80:273-290 (Feb. 2007).;;Coussens et al., ""Inflammation and Cancer"" Nature 420:860-867 (Dec. 2002).;;Eckert et al., ""S100 Proteins in the Epidermis"" The Journal of Investigative Dermatology 123:23-33 (Jul. 1, 2004).;;Fickenscher et al., ""The Interleukin-10 Family of Cytokines"" Trends in Immunology 23(2):89-96 (Feb. 2002).;;Holscher, Christoph, ""Targeting IL-23 in Autoimmunity"" Current Opinion in Investigational Drugs 6(5):489-495 (2005).;;Hunter et al., ""New IL-12-Family Members: IL-23 and IL-27, Cytokines with Divergent Functions"" Nature Reviews: Immunology 5:521-531 (Jul. 2005).;;Infante-Duarte, ""Microbial Lipopeptides Induce the production of IL-17 in Th cells"" The Journal of Immunology 165:6107-6115 (2000).;;Langowski et al., ""IL-23 Promotes Tumour Incidence and Growth"" Nature 442:461-465 (Jul. 2006).;;Piskin et al., ""In Vitro and In Situ Expression of IL-23 by Keratinocytes in Healthy Skin and Psoriasis Lesions: Enhanced Expression in Psoriatic Skin"" The Journal of Immunology 176:1908-1915 (2006).;;Renauld, Jean-Christophe, ""Class II Cytokine Receptors and Their Ligands: Key Antiviral and Inflammatory Modulators"" Nature Reviews/Immunology 3:667-676 (Aug. 2003).;;Rollins, Barrett J., ""Inflammatory Chemokines in Cancer Growth and Progression"" European Journal of Cancer 42:760-767 (2006).;;Veldhoen et al., ""TGF in the Context of an Inflammatory Cytokine Milieu Supports De Novo Differentiation of IL-17-Producing T Cells"" Immunity 24:179-189 (Feb. 2006).;;Xia et al., ""Transgenic Delivery of VEGF to Mouse Skin Leads to an Inflammatory Condition Resembling Human Psoriasis"" Blood 102(1):161-168 (Jul. 1, 2003).;;Zheng et al., ""Interleukin-22, a TH17 Cytokine, Mediates IL-23-Induced Dermal Inflammation and Acanthosis"" Nature 445(7128):648-651 (Feb. 8, 2007).",INACTIVE
348,US,B2,US 9555107 B2,051-072-068-856-511,2017-01-31,2017,US 201213404241 A,2012-02-24,US 201213404241 A;;US 75949610 A;;US 56539506 A;;US 74164005 P;;US 82259706 P,2005-12-02,Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling,"Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.",CHEN YVONNE M;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN;;GENENTECH INC,CHEN YVONNE M;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/051-072-068-856-511,Granted Patent,yes,58,0,36,39,4,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,A61K39/395;;A61K38/17;;A61K38/20;;A61K39/00;;C07K16/24;;C07K16/28,,52,52,078-888-763-252-869;;006-608-058-804-372;;078-208-633-946-764;;011-488-261-758-663;;039-055-037-316-441;;010-808-085-430-282;;007-804-874-228-785;;019-361-130-866-392;;028-901-227-164-152;;017-290-745-989-446;;132-817-119-508-278;;059-766-301-817-277;;024-234-866-423-833;;060-910-994-589-367;;106-450-291-507-591;;029-265-494-891-698;;092-787-602-337-946;;024-774-135-892-49X;;041-241-834-308-816;;035-586-215-470-490;;020-759-695-485-058;;045-742-941-589-95X;;046-845-561-202-870;;006-608-058-804-372;;038-011-063-251-943;;128-710-566-954-152;;050-182-807-494-608;;018-409-678-212-654;;057-161-083-684-466;;034-849-028-103-586;;031-582-333-134-996;;002-123-394-403-657;;011-118-124-045-116;;051-097-128-786-019;;027-030-197-775-202;;029-944-018-971-659;;051-984-618-807-258;;087-807-940-683-002;;115-806-652-196-516;;082-156-536-633-654;;029-833-309-321-558;;118-959-492-088-765;;073-164-139-424-502;;154-897-296-289-193;;015-376-605-232-403;;113-167-467-883-751;;069-413-474-955-853;;025-969-152-076-888;;001-144-618-215-249;;005-844-854-175-771;;067-950-652-336-686;;118-344-042-969-88X,18021898;;10.1016/j.clindermatol.2007.08.014;;16982811;;10.1084/jem.20061308;;pmc2118116;;10.1074/jbc.m207577200;;12417590;;11163236;;10.1016/s0092-8674(01)00187-8;;10.4049/jimmunol.174.6.3695;;15749908;;pmc1785338;;17236132;;10.1086/511051;;pmc2803035;;10.1038/nature01322;;12490959;;10.1189/jlb.0204117;;15123776;;10.4049/jimmunol.166.12.7090;;11390453;;11197690;;10.1038/sj.gene.6363716;;10.1111/j.0022-202x.2004.22719.x;;15191538;;10.1016/s1471-4906(01)02149-4;;11929132;;12707317;;pmc2841978;;10.4049/jimmunol.170.9.4432;;16200070;;10.1038/ni1254;;15912962;;15999093;;10.1038/nri1648;;10.4049/jimmunol.165.11.6107;;11086043;;11390454;;10.4049/jimmunol.166.12.7096;;16688182;;10.1038/nature04808;;pmc2212798;;10.1084/jem.20041257;;15657292;;12525561;;10.1189/jlb.0602326;;12087100;;10.1074/jbc.m204204200;;10.1016/j.intimp.2004.01.010;;15120653;;16982811;;10.1084/jem.20061308;;pmc2118116;;16404147;;10.1016/s1016-8478(23)13236-5;;16648837;;10.1038/nature04754;;10.1111/j.0300-9475.2004.01504.x;;15541036;;16212920;;10.1038/ni1261;;pmc1618871;;16200068;;10.4049/jimmunol.176.3.1908;;16424222;;15122762;;10.1002/hep.20184;;10.1038/nri1153;;12974481;;16510278;;10.1016/j.ejca.2006.01.002;;10.1590/s0074-02762006000900052;;17308791;;16116186;;10.4049/jimmunol.175.5.2994;;pmc2118338;;10.1084/jem.20060285;;16818675;;10.1016/s1074-7613(03)00296-6;;14614851;;15005873;;10.1211/0022357022962;;16473830;;10.1016/j.immuni.2006.01.001;;10.4049/jimmunol.177.11.8266;;17114505;;14768061;;10.1002/eji.200324714;;10.1038/sj.gene.6364104;;15201862;;15039135;;10.1165/rcmb.2003-0285oc;;10.1038/ni1497;;17676044;;10.1182/blood-2002-12-3793;;12649136;;10875937;;10.1074/jbc.m005304200;;11481447;;10.1073/pnas.171303198;;pmc55483;;17187052;;10.1038/nature05505;;10.4049/jimmunol.179.12.8098;;18056351;;10.1016/b978-0-12-381300-8.00001-0;;21034969;;10.1172/jci33194;;pmc2157567;;18172556;;pmc2149911;;17919941;;10.1016/j.immuni.2007.07.023,"Boehncke et al., Clinics in Dermatology, 25(6):596-605, Nov.-Dec. 2007.;;Liang, et al. ""Interleukin (IL)-22 and IL-17 are coexpressed by TH17 cells and cooperatively enhance expression of antimicrobial peptides"", J. Exp. Med. 203(10):2271-2279, 2006.;;Aggarwal, et al., ""Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17"", Journal of Biological Chemistry, 278: 1910-1914, (2003).;;Blumberg, et al., ""Interleukin 20: Discovery, receptor identification and role in epidermal function"", Cell, 104: 9-19, (2001).;;Boniface, et al., ""IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes"", The Journal of Immunology, 174: 3695-3702, (2005).;;Cargill, et al., ""A large-scale genetic association study confirms IL1 2B and leads to the identification of IL23R as psoriasis-risk genes"", The American Journal of human genetics, 80: 273-290, (2007).;;Coussens, et al., ""Inflammation and cancer"", Nature, 420: 860-867, (2002).;;Donnelly, et al., ""The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain"", Journal of Leukocyte Biology, vol. 76, pp. 314-321, (2004).;;Dumoutier, et al., ""Cloning and Characterization of Il-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor /IL-22"", Journal of Immunology, vol. 166, No. 12, pp. 7090-7095, (2001).;;Dumoutier, et al., ""IL-TIF/IL-22: Genomic Organization and Mapping of the Human and Mouse Genes"", Genes and Immunity, vol. 1, pp. 488-494, (2000).;;Eckert, et al., ""S100 proteins in the epidermis"", The Journal of Investigative Dermatology, 123: 23-33, (2004).;;Fickenscher, et al., ""The interleukin-10 family of cytokines"", Trends in Immunology, 23(2): 89-96, (2002).;;Happel, et al., ""Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection"", Journal of Immunology, vol. 170, No. 9, pp. 4432-4436, (2003).;;Harrington, et al., ""Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages"", Nature Immunology, vol. 6, No. 11, pp. 1123-1132, (2005).;;Holscher, et al., ""Targeting IL-23 in autoimmunity"", Current Opinion in Investigational Drugs, vol. 6, No. 5, pp. 489-495, (2005).;;Hunter, et al., ""New IL-12-Family members: IL-23 and IL-27, cytokines with divergent functions"", Nature Reviews,: Immunology, 5: 521-531, (2005).;;Infante-Duarte, ""Microbial lipopeptides induce the production of IL-17 in Th cells"", The Journal of Immunology, 165: 6107-6115, (2000).;;Kotenko, et al., ""Identification, cloning and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity"", Journal of Immunology, vol. 166, No. 12, pp. 7096-7103, (2001).;;Langowski, et al., ""IL-23 promotes tumor incidence and growth"", Nature, 442: 461-465, (2006).;;Langrish, et al., ""IL-23 Drives a pathogenic T cell population that induces autoimmune Inflammation"", Journal of Experimental Medicine, vol. 201, No. 2, pp. 233-240, (2005).;;Lankford, et al., ""A unique role for IL-23 in promoting cellular immunity"", Journal of Leukocyte Biology, vol. 73, No. 1, pp. 49-56, (2003).;;Lejeune, et al., ""Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10"", The Journal of Biological Chemistry, vol. 277, No. 37, pp. 33676-33682, (2002).;;Li, et al., ""Temporal associations between interleukin 22 and the extracellular domains of IL-22R and IL-10R2"", International Immunopharmacology, vol. 4, No. 5, pp. 693-708, (2004).;;Liang, et al., ""Interleukin (IL)-22 and IL-17 are co expressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides"", vol. 203, No. 10, pp. 2271-2279, (2006).;;Liu, et al., ""Signaling through the murine T cell receptor induces IL-17 production in the absence of co stimulation, IL-23 or dendritic cells"", Molecules and Cells, vol. 20, No. 3, pp. 339-347, (2005).;;Mangan, et al., ""Transforming growth factor-beta induces development of the T(H)17 lineage"", Nature, vol. 441, No. 7090, pp. 231-234, (2006).;;Nagakawa, et al., ""Expression of interleukin-22 in murine carcinoma cells did not influence tumor growth in vivo but did improve survival of the inoculated hosts"", Scandinavian Journal of Immunology, vol. 60, No. 5, pp. 449-454, (2004).;;Pan, et al., ""Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3"", Cellular & Molecular Immunology, vol. 1, No. 1, pp. 43-49, (2004).;;Park, et al., A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17, Nature Immunology, vol. 6, No. 11, pp. 1133-1141, (2005).;;Piskin, et al., ""In vitro and in situ expression of IL-23 by Keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin"", The Journal of Immunology, 176: 1908-1915, (2006).;;Radaeva, et al., ""Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via stat3 activation"", Hepatology, vol. 39, No. 5, pp. 1332-1342, (2004).;;Renauld, et al., ""Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators"", Nature Reviews/Immunology, 3: 667-676, (2003).;;Rollins, et al., ""Inflammatory chemokines in cancer growth and progression"", European Journal of Cancer, 42: 760-767, (2006).;;Rutitzky, et al., ""CD4 T cells producing pro-inflammatory interleukin-17 mediate high pathology in schistosomiasis"", Mem'orias do instituto oswaldo cruz, vol. 101, Suppl. 1, pp. 327-330, (2006).;;La Sala, et al., ""G(i)-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and JNK"", Journal of Immunology, vol. 175, No. 5, pp. 2994-2999, (2005).;;Sutton, et al., ""A crucial role for leukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis"", The Journal of Experimental Medicine, vol. 203, No. 7, pp. 1685-1691, (2006).;;Trinchieri, et al., ""The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses"", Immunity, vol. 19, No. 5, pp. 641-644, (2003).;;Vandenbroeck, et al., ""Inhibiting Cytokines of the Interleukin-12 Family: Recent Advances and Novel Challenges"", Journal of Pharmacy and Pharmacology, vol. 56, pp. 145-160, (2004).;;Veldhoen, et al., ""TGF in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17 producing T cells"", Immunity, 24: 179-189, (2006).;;Weber, et al., ""IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase"", Journal of Immunology, vol. 177, No. 11, pp. 8266-8272, (2006).;;Weighardt, et al., Identification of a TLR4- and TRIF-dependent activation program of dendritic cells, European Journal of Immunology, vol. 34, No. 2, pp. 558-564, (2004).;;Weiss, et al., ""Cloning and murine IL-22 receptor alpha 2 and comparison with its human counterpart"", Genes and Immunity, vol. 5, No. 5, pp. 330-336, (2004).;;Whittington, et al., ""Interleukin-22: a potential immunomodulatory molecule in the lung"", American Journal of Respiratory Cell and Molecular Biology, vol. 31, No. 2, pp. 220-226, (2004).;;Wilson, et al., ""Development, cytokine profile and function of human interleukin 17-producing helper T cells"", Nature Immunology, vol. 8, No. 9, pp. 950-957, (2007).;;Xia, et al., ""Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis"", Blood, 102(1): 161-168, (2003).;;Xie, et al., ""Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R"", Journal of Biological Chemistry, vol. 275, No. 40, pp. 31335-31339, (2000).;;Xu, et al., ""A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist"", Proceedings of the National Academy of Sciences, vol. 98, No. 17, pp. 9511-9516, (2001).;;Zheng, et al., ""Interleukin-22, a TH17 cytokine mediates Il-23 induced dermal inflammatory and Acanthosis"", Nature, 445(7128): 648-651, (2007).;;Kreymborg, et al., ""IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis"", The Journal of Immunology, 179: 8098-8104, (2007).;;Sonnenberg, et al., ""Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces"", Advances in Immunology, vol. 107, Chapter 1, pp. 1-29, (2010).;;Sugimoto, et al., ""IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis"", The Journal of Clinical Investigation, vol. 118, No. 2, pp. 534-544, (2008).;;Zenewicz, et al., ""IL-22 but not IL-17 provides protection to hepatocytes during acute liver inflammation"", Immunity, 27(4): 647-659, (2007).",ACTIVE
349,US,A1,US 2023/0317802 A1,008-893-638-546-144,2023-10-05,2023,US 202217657006 A,2022-03-29,US 202217657006 A,2022-03-29,HIGH ASPECT RATIO CONTACT STRUCTURE WITH MULTIPLE METAL STACKS,A high aspect ratio contact structure formed within a dielectric material includes a top portion and a bottom portion. The top portion of the contact structure includes a tapering profile towards the bottom portion. A first metal stack surrounded by an inner spacer is located within the top portion of the contact structure and a second metal stack is located within the bottom portion of the contact structure. A width of the bottom portion of the contact structure is greater than a minimum width of the top portion of the contact structure.,IBM,WANG JUNLI;;ANDERSON BRENT A;;HOOK TERENCE;;SESHADRI INDIRA;;YOUNG ALBERT M;;SIEG STUART;;FAN SU CHEN;;MOCHIZUKI SHOGO,INFINITE COMPUTER SOLUTIONS INC (2022-03-29);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2022-03-25),https://lens.org/008-893-638-546-144,Patent Application,yes,0,0,1,1,0,H01L23/52;;H01L29/401;;H01L27/088;;H01L21/823475;;H01L29/401;;H01L29/41725,H01L29/417;;H01L29/40,,0,0,,,,PENDING
350,US,A1,US 2010/0316596 A1,081-640-229-201-534,2010-12-16,2010,US 75949610 A,2010-04-13,US 75949610 A;;US 56539506 A;;US 74164005 P;;US 82259706 P,2005-12-02,COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH CYTOKINE SIGNALING,"Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.",CHEN YVONNE M;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,CHEN YVONNE M;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/081-640-229-201-534,Patent Application,yes,36,0,36,39,4,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,A61K39/395;;A61K38/17;;A61K38/20;;A61P1/00;;A61P17/06;;A61P29/00;;A61P35/00;;A61P37/02;;C12N5/0783,424/85.2;;424/158.1;;424/133.1;;514/21.2;;424/172.1;;435/375,0,0,,,,DISCONTINUED
351,US,A1,US 2013/0224146 A1,169-679-873-003-714,2013-08-29,2013,US 201213404241 A,2012-02-24,US 201213404241 A;;US 75949610 A;;US 56539506 A;;US 74164005 P;;US 82259706 P,2005-12-02,COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH CYTOKINE SIGNALING,"Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.",CHEN YVONNE M;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,CHEN YVONNE M;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/169-679-873-003-714,Patent Application,yes,2,0,36,39,4,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,A61K39/395;;A61K38/17;;A61K38/20,424/85.2;;424/158.1;;424/133.1;;424/172.1;;514/21.2;;435/375,1,1,078-888-763-252-869,18021898;;10.1016/j.clindermatol.2007.08.014,"Boehncke et al., Clinics in Dermatology, 25(6):596-605, Nov.-Dec. 2007.",ACTIVE
352,US,A1,US 2013/0175594 A1,067-234-737-319-597,2013-07-11,2013,US 201213551714 A,2012-07-18,US 201213551714 A;;US 201213344885 A,2012-01-06,INTEGRATED CIRCUIT INCLUDING DRAM AND SRAM/LOGIC,"An integrated circuit comprising an N+ type layer, a buffer layer arranged on the N+ type layer; a P type region formed on with the buffer layer; an insulator layer overlying the N+ type layer, a silicon layer overlying the insulator layer, an embedded RAM FET formed in the silicon layer and connected with a conductive node of a trench capacitor that extends into the N+ type layer, the N+ type layer forming a plate electrode of the trench capacitor, a first contact through the silicon layer and the insulating layer and electrically connecting to the N+ type layer, a first logic RAM FET formed in the silicon layer above the P type region, the P type region functional as a P-type back gate of the first logic RAM FET, and a second contact through the silicon layer and the insulating layer and electrically connecting to the P type region.",BASKER VEERARAGHAVAN S;;CHENG KANGGUO;;DORIS BRUCE B;;HOOK TERENCE B;;KHAKIFIROOZ ALI;;KULKARNI PRANITA;;YAMASHITA TENKO;;YEH CHUN-CHEN;;IBM,BASKER VEERARAGHAVAN S;;CHENG KANGGUO;;DORIS BRUCE B;;HOOK TERENCE B;;KHAKIFIROOZ ALI;;KULKARNI PRANITA;;YAMASHITA TENKO;;YEH CHUN-CHEN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2012-07-10);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/067-234-737-319-597,Patent Application,yes,1,31,4,8,0,H01L29/945;;H01L27/1203;;H01L21/84;;H10B12/0387;;H10B12/50;;H10B10/125;;H10B10/18;;H10B12/09;;H01L29/945;;H01L27/1203;;H10B10/18;;H10B10/125;;H10B12/05;;H10B12/09;;H10B12/038;;H10B12/50;;H10B12/0387;;H01L21/84,H01L21/782;;H01L27/12,257/301;;438/155;;X257E27112;;X257E217,0,0,,,,INACTIVE
353,KR,A,KR 20140067165 A,063-005-395-570-612,2014-06-03,2014,KR 20147011915 A,2012-09-28,US 201161541453 P;;US 201161541495 P;;US 2012/0058107 W,2011-09-30,OPTICAL SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,,LIFE TECHNOLOGIES CORP,MAHER KEVIN;;CHEN MINGSONG;;FREUDENTHAL JACOB;;BOO KUAN MOON;;LAU SOO YONG;;FORTESCUE DAVID;;SHEN MING;;SOH WOON LIANG TERENCE,,https://lens.org/063-005-395-570-612,Patent Application,no,4,4,14,45,0,G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6428;;G01N21/6486,G01N21/64,,0,0,,,,ACTIVE
354,US,B2,US 8994085 B2,114-570-130-896-289,2015-03-31,2015,US 201213551714 A,2012-07-18,US 201213551714 A;;US 201213344885 A,2012-01-06,Integrated circuit including DRAM and SRAM/logic,"An integrated circuit comprising an N+ type layer, a buffer layer arranged on the N+ type layer; a P type region formed on with the buffer layer; an insulator layer overlying the N+ type layer, a silicon layer overlying the insulator layer, an embedded RAM FET formed in the silicon layer and connected with a conductive node of a trench capacitor that extends into the N+ type layer, the N+ type layer forming a plate electrode of the trench capacitor, a first contact through the silicon layer and the insulating layer and electrically connecting to the N+ type layer, a first logic RAM FET formed in the silicon layer above the P type region, the P type region functional as a P-type back gate of the first logic RAM FET, and a second contact through the silicon layer and the insulating layer and electrically connecting to the P type region.",BASKER VEERARAGHAVAN S;;CHENG KANGGUO;;DORIS BRUCE B;;HOOK TERENCE B;;KHAKIFIROOZ ALI;;KULKARNI PRANITA;;YAMASHITA TENKO;;YEH CHUN-CHEN;;IBM,BASKER VEERARAGHAVAN S;;CHENG KANGGUO;;DORIS BRUCE B;;HOOK TERENCE B;;KHAKIFIROOZ ALI;;KULKARNI PRANITA;;YAMASHITA TENKO;;YEH CHUN-CHEN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2012-07-10);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/114-570-130-896-289,Granted Patent,yes,40,1,4,8,0,H01L29/945;;H01L27/1203;;H01L21/84;;H10B12/0387;;H10B12/50;;H10B10/125;;H10B10/18;;H10B12/09;;H01L29/945;;H01L27/1203;;H10B10/18;;H10B10/125;;H10B12/05;;H10B12/09;;H10B12/038;;H10B12/50;;H10B12/0387;;H01L21/84,H01L27/108;;H01L21/84;;H01L27/11;;H01L27/12;;H01L29/76;;H01L29/94;;H01L31/119,257/301;;257/347;;257/296,6,1,004-976-128-533-077,10.1093/ietele/e90-c.4.735,"U.S. Appl. No. 13/088,376, filed Apr. 17, 2011, entitled ""SOI Device with DTI and STI,"" inventors: K. Cheng et al., (not yet published).;;U.S. Appl. No. 13/106,349, filed May 12, 2011 entitled ""Suppression of Diffusion in Epitaxial Buried Plate for Deep Trenches,"" , inventors: Pei et al., (not yet published).;;Kawahara ""Low-voltage embedded RAMs in the nanometer era"", IEEE Trans. Electron. vol. E90-C, No. 4, Apr. 2007; pp. 333-338.;;Iyer et al., ""45-nm silicon-on-insulator CMOS technology integrating embedded DRAM for high-performance server and ASIC applications,"" IBM J. Res. & Dev., vol. 55, No. 3, Paper 5, May/Jun. 2011, Copyright 2011 by International Business Machines Corporation; pp. 5:1-5:14.;;Disclosed Anonymously, ""Simultaneously forming deep trench isolation and deep trench capacitor on the same chip,"" IPCOM000198808D, IP.com electronic Publication, Aug. 17, 2010, pp. 1-4.;;R.E. Burger, et al., ""Process for Simultaneously Forming Poly/EPI Silicon Filled Deep And Shallow Isolation Trenches Having a CVD Oxide Cap,"" IBM Technical Disclosure Bulletin, IP.Com, IPCOM000102683D, vol. 33, No. 7, Dec. 1990, pp. 388-392.",INACTIVE
355,EP,A1,EP 2761277 A1,139-107-342-021-241,2014-08-06,2014,EP 12783710 A,2012-09-28,US 201161541453 P;;US 201161541495 P;;US 2012/0058107 W,2011-09-30,OPTICAL SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,,LIFE TECHNOLOGIES CORP,MAHER KEVIN;;CHEN MINGSONG;;FREUDENTHAL JACOB;;BOO KUAN MOON;;LAU SOO YONG;;FORTESCUE DAVID;;SHEN MING;;SOH WOON LIANG TERENCE,LIFE TECHNOLOGIES CORPORATION (2016-11-23),https://lens.org/139-107-342-021-241,Patent Application,yes,0,0,14,45,0,G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6428;;G01N21/6486,G01N21/64,,0,0,,,,ACTIVE
356,US,B2,US 9624200 B2,176-985-853-391-827,2017-04-18,2017,US 201414508970 A,2014-10-07,US 201414508970 A;;US 88792010 A;;US 67978207 A;;US 77729106 P,2006-02-28,Therapeutic piperazines,"The invention includes a compound of formula I: wherein R 1 , Y, A, n, R 4 and Z have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function and/or treating cognitive disorders or impairment, traumatic and/or ischemic injuries of the central and peripheral nervous system and/or psychiatric disorders in animals, especially humans.",DART NEUROSCIENCE (CAYMAN) LTD,KAPLAN ALAN P;;KEENAN TERENCE P;;WEINHOUSE MICHAEL I;;WILSON MARK E;;LINDSTROM ANDREW K;;RIPKA WILLIAM C;;CHEN MI,DART NEUROSCIENCE (CAYMAN) LTD (2012-06-28);;HELICON THERAPEUTICS INC (2010-10-28);;DART NEUROSCIENCE LLC (2011-12-30),https://lens.org/176-985-853-391-827,Granted Patent,yes,35,0,8,8,0,A61K31/495;;A61K31/495;;A61K31/496;;A61K31/496;;A61K31/5377;;A61K31/5377;;A61K31/551;;A61K31/551;;A61K45/06;;A61K45/06;;A61P25/00;;A61P25/28;;C07D403/06;;C07D403/06;;C07D241/04;;C07D241/04;;C07D243/08;;C07D243/08;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/14;;C07D401/14;;C07D403/04;;C07D403/04;;C07D403/14;;C07D403/14;;C07D409/06;;C07D409/06;;C07D413/06;;C07D413/06;;C07D413/14;;C07D413/14;;C07D417/06;;C07D417/06;;C07D417/14;;C07D417/14,A61K31/551;;A61K31/495;;A61K31/496;;A61K31/5377;;A61K45/06;;C07D241/04;;C07D243/08;;C07D401/04;;C07D401/06;;C07D401/14;;C07D403/04;;C07D403/06;;C07D403/14;;C07D409/06;;C07D413/06;;C07D413/14;;C07D417/06;;C07D417/14,,26,22,108-605-194-152-131;;093-674-871-031-959;;033-660-961-454-927;;045-002-094-764-206;;018-780-045-695-197;;125-991-068-689-362;;056-417-136-720-521;;011-207-430-571-688;;062-057-738-144-200;;058-879-081-315-674;;001-904-605-776-580;;134-385-808-907-123;;050-371-857-335-464;;043-285-525-958-492;;035-389-807-214-72X;;050-311-732-114-815;;075-741-591-325-228;;045-009-036-718-65X;;062-039-586-104-437;;016-853-477-345-15X;;010-820-688-541-426;;012-082-660-480-298,9054501;;10.1016/s0092-8674(00)81904-2;;9844008;;pmc24568;;10.1073/pnas.95.25.15020;;10.1016/0092-8674(94)90400-6;;7923378;;pmc311273;;10.1101/lm.5.4.365;;10454361;;pmc193593;;12930888;;10.1073/pnas.1834280100;;10.1016/s0957-4166(98)00432-7;;10.1016/s0166-4328(97)02297-3;;9404627;;12802255;;10.1097/00001199-200210000-00007;;10.1021/jm040792y;;15341483;;10.1037/0735-7044.107.6.1093;;8136063;;10.1037//0735-7044.107.6.1093;;10.1016/s0960-9822(06)00022-4;;8999994;;10.1037//0735-7044.111.1.104;;9109628;;10.1016/s0166-4328(98)00032-1;;9867236;;10.1016/s0166-4328(01)00367-9;;11718890;;10837506;;pmc311331;;10.1101/lm.7.3.170;;10.1037//0735-7044.106.2.274;;1590953;;10.1037/0735-7044.106.2.274;;10.1016/s0896-6273(02)00684-0;;11988175;;8939606;;10.1016/s0960-9822(96)00756-7;;1335058;;10804225;;pmc6772685;;10.1523/jneurosci.20-10-03853.2000;;12669026;;10.1038/nrd1061;;11472206;;10.1021/jm010838c,"http://onlinelibrary.wiley.com/doi/10.1002/iub.1104/pdf.;;Abel et al., “Genetic Demonstration of a Role for PKA in the Late Phase of LTP and in Hippocampus-Based Long-Term Memory,” Cell, 88(5): 615-626 (1997).;;Barad et al., “Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory,” Proc. Natl. Acad. Sci., 95(25): 15020-15025 (1998).;;Bose et al., “Synthesis and antidepressant activity of 5-(1-aryl-4-piperazino)methyl-2-amino-2-oxazolines,” Eur. J. Med. Chem., 27(5): 437-442 (1992).;;Bourtchouladze et al., Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein, Cell, 79(1): 59-68 (1994).;;Bourtchouladze et al., “Different Training Procedures Recruit Either One or Two Critical Periods for Contextual Memory Consolidation, Each of Which Requires Protein Synthesis and PKA,” Learn. Mem., 5(4): 365-374 (1998).;;Bourtchouladze et al., “A mouse model of Rubinstein-Taybi syndrome: Defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4,” Proc. Natl. Acad. Sci., 100(8): 10518-10522 (2003).;;D'Arrigo et al., “Chemo-enzymatic synthesis of the active enantiomer of the anorressant 2-benzylmorpholine,” Tetrahedron: Asymmetry, 9(22): 4021-402 (1998).;;Ennaceur, “The effects of neurotoxic lesions of the perirhinal cortex combined to fornix transection on object recognition memory in the rat,” Behav. Brain Res., 88: 181-193 (1997).;;Erlanger et al., “Development and Validation of a Web-Based Screening Tool for Monitoring Cognitive Status,” J. Head Trauma Rehabil., 17: 458-476 (2002).;;Ferrand et al., “Synthesis of new 1,2,3-triazin-4-ones as potential anti-depressants,” Eur. J. Med. Chem., 22(4): 337-345 (1987).;;Giese et al., “Autophosphorylation at Thr286 of the α Calcium-Calmodulin Kinase II in LTP and Learning,” Science, 279(5352): 870-873 (1998).;;Heinrich et al., “Indolebutylamines as Selective 5-HT1A Agonists,” J. Med. Chem., 47(19): 4677-4683 (2004).;;Kim et al., “Effects of Amygdala, Hippocampus, and Periaqueductal Gray Lesions on Short- and Long-Term Contextual Fear,” Behav. Neurosci., 107(6): 1093-1098 (1993).;;Kogan et al., “Spaced training induces normal long-term memory in CREB mutant mice,” Curr. Biol., 7(1): 1-11 (1997).;;Logue et al., “Hippocampal lesions cause learning deficits in inbred mice in the Morris water maze and conditioned-fear task,” Behav. Neurosci., 111(1): 104-113 (1997).;;Mitchell, “The medial frontal cortex and temporal memory: tests using spontaneous exploratory behaviour in the rat,” Behav. Brain Res., 97(1-2): 107-113 (1998).;;Mumby, “Perspectives on object-recognition memory following hippocampal damage: lessons from studies in rats,” Brain Res., 127(1-2): 159-181 (2001).;;Nguyen et al., “Strain-dependent Differences in LTP and Hippocampus-dependent Memory in Inbred Mice,” Learn. Mem., 7: 170-179 (2000).;;Phillips, “Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning,” Behav. Neurosci., 106: 274-285 (1992).;;Pittenger et al., “Reversible Inhibition of CREB/ATF Transcription Factors in Region CA1 of the Dorsal Hippocampus Disrupts Hippocampus-Dependent Spatial Memory,” Neuron, 34(3): 447-462 (2002).;;Silva et al. “Impaired learning in mice with abnormal short-lived plasticity,” Curr. Biol., 6(11): 1509-1518 (1996).;;T.J. Torphy, et al., “Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity,” J. Pharmacol. Exp. Ther., 263(3): 1195-1205 (1992).;;Tang et al., “Contrasting Effects on Discrimination Learning after Hippocampal Lesions and Conjoint Hippocampal-Caudate Lesions in Monkeys” J. Neurosci., 20(10): 3853-3863 (2000).;;Tully et al., “Targeting the CREB pathway for memory enhancers,” Nature Reviews Drug Discovery, 2: 267-277 (2003).;;Van der Mey et al., “Novel Selective PDE4 Inhibitors. 2. Synthesis and Structure—Activity Relationships of 4-Aryl-Substituted cis-Tetra- and cis-Hexahydrophthalazinones,” J. Med. Chem., 44: 2523-2535 (2001).",INACTIVE
357,US,A1,US 2015/0087645 A1,022-728-569-375-844,2015-03-26,2015,US 201414508970 A,2014-10-07,US 201414508970 A;;US 88792010 A;;US 67978207 A;;US 77729106 P,2006-02-28,THERAPEUTIC PIPERAZINES,"The invention includes a compound of formula I: wherein R 1 , Y, A, n, R 4 and Z have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function and/or treating cognitive disorders or impairment, traumatic and/or ischemic injuries of the central and peripheral nervous system and/or psychiatric disorders in animals, especially humans.",DART NEUROSCIENCE CAYMAN LTD,KAPLAN ALAN P;;KEENAN TERENCE P;;WEINHOUSE MICHAEL I;;WILSON MARK E;;LINDSTROM ANDREW K;;RIPKA WILLIAM C;;CHEN MI,DART NEUROSCIENCE (CAYMAN) LTD (2012-06-28);;HELICON THERAPEUTICS INC (2010-10-28);;DART NEUROSCIENCE LLC (2011-12-30),https://lens.org/022-728-569-375-844,Patent Application,yes,1,0,8,8,0,A61K31/495;;A61K31/495;;A61K31/496;;A61K31/496;;A61K31/5377;;A61K31/5377;;A61K31/551;;A61K31/551;;A61K45/06;;A61K45/06;;A61P25/00;;A61P25/28;;C07D403/06;;C07D403/06;;C07D241/04;;C07D241/04;;C07D243/08;;C07D243/08;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/14;;C07D401/14;;C07D403/04;;C07D403/04;;C07D403/14;;C07D403/14;;C07D409/06;;C07D409/06;;C07D413/06;;C07D413/06;;C07D413/14;;C07D413/14;;C07D417/06;;C07D417/06;;C07D417/14;;C07D417/14,C07D403/06;;C07D241/04;;C07D401/04;;C07D401/14;;C07D403/04;;C07D403/14;;C07D409/06;;C07D413/06;;C07D417/14,514/235.2;;514/254.01;;514/255.01;;514/254.05;;514/253.06;;514/254.02;;514/252.11;;514/252.14,1,0,,,http://onlinelibrary.wiley.com/doi/10.1002/iub.1104/pdf,INACTIVE
358,BR,A2,BR PI0619118 A2,104-636-367-607-12X,2011-09-13,2011,BR PI0619118 A,2006-11-30,US 74164005 P;;US 82259706 P;;US 2006/0061418 W,2005-12-02,composições e métodos para o tratamento de doenças e desordens associadas com a sinalização de citocina,"COMPOSIçõES E MéTODOS PARA O TRATAMENTO DE DOENçAS E DESORDENS ASSOCIADAS COM A SINALIZAçãO DE CITOCINA. A presente invenção refere-se a composições e métodos são fornecidos para o diagnóstico e tratamento de inflamação e desordens auto-imunes, tal como psoríase. Composições e métodos para modular a sinalização de IL-23 ou IL-22 são fornecidos.",GENENTECH INC,CHEN YVONNE MAN-YEE;;CHUNTHARAPAI ANAN;;DANILENKO DIMITRY;;OUYANG WENJUN;;SA SUSAN;;VALDEZ PATRICIA;;WONG TERENCE;;WU JIANFENG;;ZHENG YAN,,https://lens.org/104-636-367-607-12X,Patent Application,no,0,0,36,39,0,A61K45/00;;C07K16/244;;C07K16/2866;;G01N33/6869;;G01N2333/54;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;C07K2317/76;;A61K38/17;;A61P1/00;;A61P1/04;;A61P11/00;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/06;;A61P21/04;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P43/00;;A61P5/14;;A61P5/18;;A61P3/10;;C07K16/24;;C07K16/28;;A61K38/20;;A61K39/00;;C07K2317/76;;A61K38/1793;;A61K38/20;;A61K2039/505;;A61K2039/57;;C07K16/244;;C07K16/2866;;C07K2317/92;;A61K38/17;;A61K39/3955,C07K16/24;;A61K38/20;;A61K39/00;;C07K16/28,,0,0,,,,DISCONTINUED
359,SG,A,SG 11201401919T A,060-715-193-132-937,2014-10-30,2014,SG 11201401919T A,2012-09-28,US 201161541453 P;;US 201161541495 P;;US 2012/0058107 W,2011-09-30,OPTICAL SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,,LIFE TECHNOLOGIES CORP,MAHER KEVIN;;CHEN MINGSONG;;FREUDENTHAL JACOB;;BOO KUAN MOON;;LAU SOO YONG;;FORTESCUE DAVID;;SHEN MING;;SOH WOON LIANG TERENCE,,https://lens.org/060-715-193-132-937,Unknown,no,0,0,14,45,0,G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6428;;G01N21/6486,G01N21/64,,0,0,,,,PENDING
360,CN,A,CN 116415796 A,080-212-489-094-440,2023-07-11,2023,CN 202310420411 A,2023-04-14,CN 202310420411 A,2023-04-14,"Parallel reservoir flood control optimal scheduling method, system, medium and equipment","The invention relates to a parallel reservoir flood control optimal scheduling method, system, medium and equipment, and the parallel reservoir flood control optimal scheduling method comprises the following steps: based on the water level of a parallel reservoir at the t moment and the flow of a downstream control section at the t moment, determining the flow of the downstream control section at the t moment; constructing an optimal value function by taking the minimum peak discharge of the downstream control section and the minimum highest water level reached by the reservoir flood storage as scheduling targets; on the basis of the optimal value function, sequentially performing water level discretization, final stage optimization, middle stage optimization and time period recursion to obtain an optimal drainage strategy of one reservoir in the parallel reservoirs, and taking the optimal drainage strategy as a single reservoir flood control optimization strategy; and taking the obtained single reservoir flood control optimization strategy as an initial solution, solving the optimal discharge strategy of the next reservoir in the parallel reservoirs based on an optimal value function, and repeatedly executing the step to obtain the discharge flow and the corresponding water level of each reservoir in the parallel reservoirs.",UNIV SHANDONG;;SHANDONG HYDROLOGY CENTER,WANG JUN;;LIU YANG;;JIA JINGJING;;WANG HAIJUN;;LIU WEI;;CHEN CUIYING;;CAO SHENGLE;;WONG KA CHEONG TERENCE;;GUO CHENG,,https://lens.org/080-212-489-094-440,Patent Application,no,0,0,1,1,0,G06Q10/06313;;G06Q50/06;;G06Q50/26;;Y02A10/40,G06Q10/0631;;G06Q50/06;;G06Q50/26,,0,0,,,,PENDING
361,CN,A,CN 104105957 A,092-816-693-954-383,2014-10-15,2014,CN 201280059369 A,2012-09-28,US 2012/0058107 W;;US 201161541453 P;;US 201161541495 P,2011-09-30,Optical systems and methods for biological analysis,"An instrument (1000) for processing and/or measuring a biological process contains an excitation source (110), a sample holder (204), an optical sensor (118), an excitation optical system (120), and an emission optical system (125). The sample holder (204) is configured to receive a plurality of biological samples. The optical sensor (118) is configured to receive an emission from the biological samples. The excitation optical system (120) is disposed along an excitation optical path (126) and is configured to direct the electromagnetic radiation from the excitation source (110) to the biological samples. The emission optical system (125) is disposed along an emission optical path (128) and is configured to direct electromagnetic emissions from the biological samples to the optical sensor (118). The instrument further contains a plurality of filter assemblies (130, 132) configured to be interchangeably located along at least one of the optical paths. The plurality of filter components (131) includes a first filter component (138) characterized by a first optical power and a first filter (140) having a first filter function, the first filter function characterized by at least one of a first low-pass wavelength or a first high-pass wavelength. The second filter assembly (142) is characterized by a second optical power and a second filter (145) having a second filter function, the second filter function comprising at least one of a second low-pass wavelength that is different than the first low-pass wavelength or a second high-pass wavelength that is different than the first high-pass wavelength. The second optical power differs from the first optical power by an amount sufficient to at least partially compensate for an aberration introduced by the second filter (145) relative to the first filter (140).",LIFE TECHNOLOGIES CORP,MAHER KEVIN;;CHEN MINGSONG;;FREUDENTHAL JACOB;;BOO KUAN MOON;;LAU SOO YONG;;FORTESCUE DAVID;;SHEN MING;;SOH WOON LIANG TERENCE,,https://lens.org/092-816-693-954-383,Patent Application,no,11,10,14,45,0,G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6428;;G01N21/6486,G01N21/64,,0,0,,,,ACTIVE
362,US,B2,US 8927546 B2,161-488-125-686-588,2015-01-06,2015,US 88792010 A,2010-09-22,US 88792010 A;;US 67978207 A;;US 77729106 P,2006-02-28,Therapeutic piperazines,"The invention includes a compound of formula I: wherein R 1 , Y, A, n, R 4 and Z have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function and/or treating cognitive disorders or impairment, traumatic and/or ischemic injuries of the central and peripheral nervous system and/or psychiatric disorders in animals, especially humans.",KAPLAN ALAN P;;KEENAN TERENCE P;;WEINHOUSE MICHAEL I;;WILSON MARK E;;LINDSTROM ANDREW K;;RIPKA WILLIAM C;;CHEN MI;;DART NEUROSCIENCE CAYMAN LTD,KAPLAN ALAN P;;KEENAN TERENCE P;;WEINHOUSE MICHAEL I;;WILSON MARK E;;LINDSTROM ANDREW K;;RIPKA WILLIAM C;;CHEN MI,DART NEUROSCIENCE (CAYMAN) LTD (2012-06-28);;HELICON THERAPEUTICS INC (2010-10-28);;DART NEUROSCIENCE LLC (2011-12-30),https://lens.org/161-488-125-686-588,Granted Patent,yes,37,0,8,8,0,A61K31/495;;A61K31/495;;A61K31/496;;A61K31/496;;A61K31/5377;;A61K31/5377;;A61K31/551;;A61K31/551;;A61K45/06;;A61K45/06;;A61P25/00;;A61P25/28;;C07D403/06;;C07D403/06;;C07D241/04;;C07D241/04;;C07D243/08;;C07D243/08;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/14;;C07D401/14;;C07D403/04;;C07D403/04;;C07D403/14;;C07D403/14;;C07D409/06;;C07D409/06;;C07D413/06;;C07D413/06;;C07D413/14;;C07D413/14;;C07D417/06;;C07D417/06;;C07D417/14;;C07D417/14,A61K31/55;;A61K31/495;;A61K31/496;;A61K31/4965;;A61K31/497;;A61K31/535;;A61K31/5377;;A61K31/551;;A61K45/06;;C07D241/04;;C07D243/08;;C07D295/092;;C07D401/06;;C07D403/06;;C07D413/06;;C07D413/14;;C07D417/06,514/235.8;;514/218;;514/255.02;;514/255.03;;514/254.09;;514/253.06;;514/254.05;;540/575;;544/121;;544/295;;544/363;;544/369;;544/373;;544/383;;544/392,25,24,087-048-103-864-960;;151-086-999-389-598;;062-057-738-144-200;;010-820-688-541-426;;093-674-871-031-959;;018-780-045-695-197;;050-311-732-114-815;;058-879-081-315-674;;045-002-094-764-206;;045-009-036-718-65X;;001-904-605-776-580;;108-605-194-152-131;;096-839-599-846-084;;134-385-808-907-123;;035-389-807-214-72X;;050-371-857-335-464;;016-853-477-345-15X;;043-285-525-958-492;;075-741-591-325-228;;056-417-136-720-521;;011-207-430-571-688;;062-039-586-104-437;;012-082-660-480-298;;125-991-068-689-362,10.1016/0223-5234(87)90272-8;;10.1016/0223-5234(92)90177-3;;10.1021/jm040792y;;15341483;;12669026;;10.1038/nrd1061;;9844008;;pmc24568;;10.1073/pnas.95.25.15020;;pmc193593;;12930888;;10.1073/pnas.1834280100;;10.1037//0735-7044.106.2.274;;1590953;;10.1037/0735-7044.106.2.274;;10.1037/0735-7044.107.6.1093;;8136063;;10.1037//0735-7044.107.6.1093;;pmc311273;;10.1101/lm.5.4.365;;10454361;;8939606;;10.1016/s0960-9822(96)00756-7;;10.1016/s0960-9822(06)00022-4;;8999994;;9054501;;10.1016/s0092-8674(00)81904-2;;9452388;;10.1126/science.279.5352.870;;10.1037//0735-7044.111.1.104;;9109628;;10837506;;pmc311331;;10.1101/lm.7.3.170;;10.1016/s0166-4328(98)00032-1;;9867236;;10804225;;pmc6772685;;10.1523/jneurosci.20-10-03853.2000;;10.1016/s0166-4328(01)00367-9;;11718890;;10.1016/s0896-6273(02)00684-0;;11988175;;10.1016/s0166-4328(97)02297-3;;9404627;;12802255;;10.1097/00001199-200210000-00007;;1335058;;11472206;;10.1021/jm010838c;;10.1016/s0957-4166(98)00432-7,"Ferrand et al., European Journal of Medicinal Chemistry 22(4): 337-345 (1987).;;Bosc et al., European Journal of Medicinal Chemistry 27(5): 437-442 (1992).;;Heinrich et al., Journal of Medicinal Chemistry 47(19): 4677-4683 (2004).;;Tully et. al., Nature Reviews Drug Discovery 2: 267-277 (2003).;;Barad et al., Proc. Natl. Acad. Sci. 95: 15020-15025 (1998).;;Bourtchouladze et al., Proc. Natl. Acad. Sci. 100: 10518-10522 (2003).;;Phillips, Behav. Neurosci. 106: 274-285 (1992).;;Kim et al., Behav. Neurosci. 107: 1093-1098 (1993).;;Bourtchouladze et al., Learn Mem 5: 365-374 (1998).;;Bourtchouladze et al., Cell 79: 59-68 (1994).;;Silva et al., Curr. Biol. 6: 1509-1518 (1996).;;Kogan et al., Curr. Biol. 7: 1-11 (1997).;;Abel et al., Cell 88: 615-626 (1997).;;Giese et al., Science 279: 870-873 (1998).;;Logue et al., Behav. Neurosci. 111: 104-113 (1997).;;Nguyen et al., Learn Mem 7: 170-179 (2000).;;Mitchell, Behav. Brain Res. 97: 107-113 (1998).;;Teng et al., J. Neurosci. 20: 3853-3863 (2000).;;Mumby, Brain Res. 127: 159-181 (2001).;;Pittenger et al., Neuron 34: 447-462 (2002).;;Ennaceur, Behav. Brain Res. 88: 181-193 (1997).;;Erlanger et al., J. Head Trauma Rehabil. 17: 458-476 (2002).;;T.J. Torphy, et al., J. Pharmacol. Exp. Ther. 263: 1195-1205 (1992).;;Van der Mey et. al., Journal of Medicinal Chemistry 44: 2523-2535 (2001).;;D'Arrigo et al., Tetrahedron: Asymmetry 9: 4021-402 (1998).",INACTIVE
363,US,A1,US 2011/0065691 A1,015-033-394-502-551,2011-03-17,2011,US 88792010 A,2010-09-22,US 88792010 A;;US 67978207 A;;US 77729106 P,2006-02-28,THERAPEUTIC PIPERAZINES,"The invention includes a compound of formula I: wherein R 1 , Y, A, n, R 4 and Z have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function and/or treating cognitive disorders or impairment, traumatic and/or ischemic injuries of the central and peripheral nervous system and/or psychiatric disorders in animals, especially humans.",KAPLAN ALAN P;;KEENAN TERENCE P;;WEINHOUSE MICHAEL I;;WILSON MARK E;;LINDSTROM ANDREW K;;RIPKA WILLIAM C;;CHEN MI,KAPLAN ALAN P;;KEENAN TERENCE P;;WEINHOUSE MICHAEL I;;WILSON MARK E;;LINDSTROM ANDREW K;;RIPKA WILLIAM C;;CHEN MI,DART NEUROSCIENCE (CAYMAN) LTD (2012-06-28);;HELICON THERAPEUTICS INC (2010-10-28);;DART NEUROSCIENCE LLC (2011-12-30),https://lens.org/015-033-394-502-551,Patent Application,yes,20,8,8,8,0,A61K31/495;;A61K31/495;;A61K31/496;;A61K31/496;;A61K31/5377;;A61K31/5377;;A61K31/551;;A61K31/551;;A61K45/06;;A61K45/06;;A61P25/00;;A61P25/28;;C07D403/06;;C07D403/06;;C07D241/04;;C07D241/04;;C07D243/08;;C07D243/08;;C07D401/04;;C07D401/04;;C07D401/06;;C07D401/06;;C07D401/14;;C07D401/14;;C07D403/04;;C07D403/04;;C07D403/14;;C07D403/14;;C07D409/06;;C07D409/06;;C07D413/06;;C07D413/06;;C07D413/14;;C07D413/14;;C07D417/06;;C07D417/06;;C07D417/14;;C07D417/14,A61K31/551;;A61K31/495;;A61K31/496;;A61K31/5377;;A61P25/00;;A61P25/28;;C07D241/04;;C07D243/08;;C07D401/06;;C07D403/04;;C07D403/06;;C07D413/06;;C07D413/14;;C07D417/06;;C12N5/07,514/218;;544/392;;514/255.03;;544/383;;514/255.02;;544/373;;514/254.09;;544/121;;514/235.8;;544/363;;514/253.06;;544/371;;514/254.05;;540/575;;544/369;;514/254.02;;544/295;;435/375,0,0,,,,INACTIVE
364,US,B2,US 9702823 B2,090-890-995-187-178,2017-07-11,2017,US 201214348878 A,2012-09-28,US 201214348878 A;;US 201161541453 P;;US 201161541495 P;;US 2012/0058107 W,2011-09-30,Optical systems and methods for biological analysis,"An instrument for processing and/or measuring a biological process contains an excitation source, a sample holder, an optical sensor, an excitation optical system, and an emission optical system. The sample holder is configured to receive a plurality of biological samples. The optical sensor is configured to receive an emission from the biological samples. The excitation optical system is disposed along an excitation optical path and is configured to direct the electromagnetic radiation from the excitation source to the biological samples. The emission optical system is disposed along an emission optical path and is configured to direct electromagnetic emissions from the biological samples to the optical sensor. The instrument further contains a plurality of filter assemblies configured to be interchangeably located along at least one of the optical paths. The plurality of filter components includes a first filter assembly characterized by a first optical power and a first filter having a first filter function, the first filter function characterized by at least one of a first low-pass wavelength or a first high-pass wavelength. The second filter assembly is characterized by a second optical power and a second filter having a second filter function, the second filter function comprising at least one of a second low-pass wavelength that is different than the first low-pass wavelength or a second high-pass wavelength that is different than the first high-pass wavelength.",LIFE TECHNOLOGIES CORP,MAHER KEVIN;;CHEN MINGSONG;;FREUDENTHAL JACOB;;BOO KUAN MOON;;LAU SOO YONG;;FORTESCUE DAVID;;SHEN MING;;SOH WOON LIANG TERENCE,LIFE TECHNOLOGIES CORPORATION (2014-06-10),https://lens.org/090-890-995-187-178,Granted Patent,yes,9,306,14,45,0,G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6428;;G01N21/6486,G01N21/64,,1,0,,,"11201401919T, SG—Search Report and Written Opinion mailed Jan. 28, 2016, 12 pages.",ACTIVE
365,EP,B1,EP 2761277 B1,134-155-916-202-055,2021-02-24,2021,EP 12783710 A,2012-09-28,US 201161541453 P;;US 201161541495 P;;US 2012/0058107 W,2011-09-30,OPTICAL SYSTEMS FOR BIOLOGICAL ANALYSIS,,LIFE TECHNOLOGIES CORP,MAHER KEVIN;;CHEN MINGSONG;;FREUDENTHAL JACOB;;BOO KUAN MOON;;LAU SOO YONG;;FORTESCUE DAVID;;SHEN MING;;SOH WOON LIANG TERENCE,LIFE TECHNOLOGIES CORPORATION (2016-11-23),https://lens.org/134-155-916-202-055,Granted Patent,yes,1,0,14,45,0,G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6428;;G01N21/6486,G01N21/64,,0,0,,,,ACTIVE
366,US,A1,US 2015/0064853 A1,188-821-525-307-168,2015-03-05,2015,US 201414525559 A,2014-10-28,US 201414525559 A;;US 201213551714 A;;US 201213344885 A,2012-01-06,INTEGRATED CIRCUIT INCLUDING DRAM AND SRAM/LOGIC,"An integrated circuit comprising an N+ type layer, a buffer layer arranged on the N+ type layer; a P type region formed on with the buffer layer; an insulator layer overlying the N+ type layer, a silicon layer overlying the insulator layer, an embedded RAM FET formed in the silicon layer and connected with a conductive node of a trench capacitor that extends into the N+ type layer, the N+ type layer forming a plate electrode of the trench capacitor, a first contact through the silicon layer and the insulating layer and electrically connecting to the N+ type layer, a first logic RAM FET formed in the silicon layer above the P type region, the P type region functional as a P-type back gate of the first logic RAM FET, and a second contact through the silicon layer and the insulating layer and electrically connecting to the P type region.",IBM,BASKER VEERARAGHAVAN S;;CHENG KANGGUO;;DORIS BRUCE B;;HOOK TERENCE B;;KHAKIFIROOZ ALI;;KERBER PRANITA;;YAMASHITA TENKO;;YEH CHUN-CHEN,GLOBALFOUNDRIES U.S. INC (2020-10-22);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2014-10-27);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/188-821-525-307-168,Patent Application,yes,0,2,4,8,0,H01L29/945;;H01L27/1203;;H01L21/84;;H10B12/0387;;H10B12/50;;H10B10/125;;H10B10/18;;H10B12/09;;H01L29/945;;H01L27/1203;;H10B10/18;;H10B10/125;;H10B12/05;;H10B12/09;;H10B12/038;;H10B12/50;;H10B12/0387;;H01L21/84,H01L21/84;;H01L27/108;;H01L27/11,438/155,0,0,,,,ACTIVE
367,IN,A,IN 3441DEN2014 A,097-183-110-710-18X,2015-06-05,2015,IN 3441DEN2014 A,2014-04-29,US 201161541453 P;;US 201161541495 P;;US 2012/0058107 W,2011-09-30,OPTICAL SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,An instrument (1000) for processing and/or measuring a biological process contains an excitation source (110) a sample holder (204) an optical sensor (118) an excitation optical system (120) and an emission optical system (125). The sample holder (204) is configured to receive a plurality of biological samples. The optical sensor (118) is configured to receive an emission from the biological samples. The excitation optical system (120) is disposed along an excitation optical path (126) and is configured to direct the electromagnetic radiation from the excitation source (110) to the biological samples. The emission optical system (125) is disposed along an emission optical path (128) and is configured to direct electromagnetic emissions from the biological samples to the optical sensor (118). The instrument further contains a plurality of filter assemblies (130 132) configured to be interchangeably located along at least one of the optical paths. The plurality of filter components (131) includes a first filter component (138) characterized by a first optical power and a first filter (140) having a first filter function the first filter function characterized by at least one of a first low pass wavelength or a first high pass wavelength. The second filter assembly (142) is characterized by a second optical power and a second filter (145) having a second filter function the second filter function comprising at least one of a second low pass wavelength that is different than the first low pass wavelength or a second high pass wavelength that is different than the first high pass wavelength. The second optical power differs from the first optical power by an amount sufficient to at least partially compensate for an aberration introduced by the second filter (145) relative to the first filter (140).,LIFE TECHNOLOGIES CORP,MAHER KEVIN;;CHEN MINGSONG;;FREUDENTHAL JACOB;;BOO KUAN MOON;;LAU SOO YONG;;FORTESCUE DAVID;;SHEN MING;;SOH WOON LIANG TERENCE,,https://lens.org/097-183-110-710-18X,Patent Application,no,0,0,14,45,0,G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6428;;G01N21/6486,G01N21/64,,0,0,,,,PENDING
368,US,B2,US 9018052 B2,137-249-793-047-038,2015-04-28,2015,US 201414525559 A,2014-10-28,US 201414525559 A;;US 201213551714 A;;US 201213344885 A,2012-01-06,Integrated circuit including DRAM and SRAM/logic,"An integrated circuit comprising an N+ type layer, a buffer layer arranged on the N+ type layer; a P type region formed on with the buffer layer; an insulator layer overlying the N+ type layer, a silicon layer overlying the insulator layer, an embedded RAM FET formed in the silicon layer and connected with a conductive node of a trench capacitor that extends into the N+ type layer, the N+ type layer forming a plate electrode of the trench capacitor, a first contact through the silicon layer and the insulating layer and electrically connecting to the N+ type layer, a first logic RAM FET formed in the silicon layer above the P type region, the P type region functional as a P-type back gate of the first logic RAM FET, and a second contact through the silicon layer and the insulating layer and electrically connecting to the P type region.",IBM,BASKER VEERARAGHAVAN S;;CHENG KANGGUO;;DORIS BRUCE B;;HOOK TERENCE B;;KHAKIFIROOZ ALI;;KERBER PRANITA;;YAMASHITA TENKO;;YEH CHUN-CHEN,GLOBALFOUNDRIES U.S. INC (2020-10-22);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2014-10-27);;GLOBALFOUNDRIES U.S. 2 LLC (2015-06-29);;GLOBALFOUNDRIES INC (2015-09-10),https://lens.org/137-249-793-047-038,Granted Patent,yes,44,0,4,8,0,H01L29/945;;H01L27/1203;;H01L21/84;;H10B12/0387;;H10B12/50;;H10B10/125;;H10B10/18;;H10B12/09;;H01L29/945;;H01L27/1203;;H10B10/18;;H10B10/125;;H10B12/05;;H10B12/09;;H10B12/038;;H10B12/50;;H10B12/0387;;H01L21/84,H01L21/00;;H01L21/84;;H01L27/108;;H01L27/11,438/155;;438/149;;438/243;;438/479;;438/151;;438/153,4,1,004-976-128-533-077,10.1093/ietele/e90-c.4.735,"IP.com (Disclosed Anonymously), ""Simultaneously forming deep trench isolation and deep trench capacitor on the same chip,"" IPCOM000198808D, IP.com electronic Publication, Aug. 17, 2010, pp. 1-4.;;Kawahara ""Low-voltage embedded RAMs in the nanometer era"", IEEE Trans. Electron. vol. E90-C, No. 4, Apr. 2007; pp. 333-338.;;R.E. Burger, et al., ""Process for Simultaneously Forming Poly/EPI Silicon Filled Deep and Shallow Isolation Trenches Having a CVD Oxide Cap,"" IBM Technical Disclosure Bulletin, IP.Com, IPCOM000102683D, vol. 33, No. 7, Dec. 1990, pp. 388-392.;;S. S. Iyer et al., ""45-nm silicon-on-insulator CMOS technology integrating embedded DRAM for high-performance server and ASIC applications,"" IBM J. Res. & Dev., vol. 55, No. 3, Paper 5, May/Jun. 2011, pp. 1-14.",ACTIVE
369,US,A1,US 2022/0412890 A1,169-699-490-294-33X,2022-12-29,2022,US 202217825222 A,2022-05-26,US 202217825222 A;;US 201715643626 A;;US 201414348878 A;;US 2012/0058107 W;;US 201161541495 P;;US 201161541453 P,2011-09-30,OPTICAL SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,"An instrument for processing and/or measuring a biological process comprises a plurality of filter assemblies configured to be interchangeably located along at least one of the optical paths. The plurality of filter components includes a first filter assembly characterized by a first optical power and a first filter having a first filter function, the first filter function characterized by at least one of a first low-pass wavelength or a first high-pass wavelength. The second filter assembly is characterized by a second optical power and a second filter having a second filter function, the second filter function comprising at least one of a second low-pass wavelength that is different than the first low-pass wavelength or a second high-pass wavelength that is different than the first high-pass wavelength.",LIFE TECHNOLOGIES CORP,MAHER KEVIN;;CHEN MINGSONG;;FREUDENTHAL JACOB K;;BOO KUAN MOON;;LAU SOO YONG;;FORTESCUE DAVID;;SHEN MING;;SOH WOON LIANG TERENCE,LIFE TECHNOLOGIES CORPORATION (2014-06-10),https://lens.org/169-699-490-294-33X,Patent Application,yes,1,0,14,45,0,G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6428;;G01N21/6486,G01N21/64,,0,0,,,,ACTIVE
370,US,A1,US 2017/0307529 A1,148-243-828-587-766,2017-10-26,2017,US 201715643626 A,2017-07-07,US 201715643626 A;;US 201414348878 A;;US 2012/0058107 W;;US 201161541495 P;;US 201161541453 P,2011-09-30,OPTICAL SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,"An instrument for processing and/or measuring a biological process contains an excitation source, a sample holder, an optical sensor, an excitation optical system, and an emission optical system. The sample holder is configured to receive a plurality of biological samples. The optical sensor is configured to receive an emission from the biological samples. The excitation optical system is disposed along an excitation optical path and is configured to direct the electromagnetic radiation from the excitation source to the biological samples. The emission optical system is disposed along an emission optical path and is configured to direct electromagnetic emissions from the biological samples to the optical sensor. The instrument further contains a plurality of filter assemblies configured to be interchangeably located along at least one of the optical paths. The plurality of filter components includes a first filter assembly characterized by a first optical power and a first filter having a first filter function, the first filter function characterized by at least one of a first low-pass wavelength or a first high-pass wavelength. The second filter assembly is characterized by a second optical power and a second filter having a second filter function, the second filter function comprising at least one of a second low-pass wavelength that is different than the first low-pass wavelength or a second high-pass wavelength that is different than the first high-pass wavelength.",LIFE TECHNOLOGIES CORP,MAHER KEVIN;;CHEN MINGSONG;;FREUDENTHAL JACOB K;;BOO KUAN MOON;;LAU SOO YONG;;FORTESCUE DAVID;;SHEN MING;;SOH WOON LIANG TERENCE,LIFE TECHNOLOGIES CORPORATION (2014-06-10),https://lens.org/148-243-828-587-766,Patent Application,yes,4,1,14,45,0,G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6428;;G01N21/6486,G01N21/64,,0,0,,,,DISCONTINUED
371,US,B2,US 11815460 B2,120-278-041-195-025,2023-11-14,2023,US 202217825222 A,2022-05-26,US 202217825222 A;;US 201715643626 A;;US 201414348878 A;;US 2012/0058107 W;;US 201161541495 P;;US 201161541453 P,2011-09-30,Optical systems and methods for biological analysis,"A method of analyzing a plurality of biological sample volumes comprises emitting, along an excitation optical path toward a sample holder holding the plurality of biological sample volumes, electromagnetic radiation from a broadband LED, wherein the broadband LED emits the electromagnetic radiation across a range of wavelengths at a total output power of at least 5 watts and at a maximum intensity at a wavelength less than 600 nanometers and at an intensity less than 30 percent of the maximum intensity at a wavelength of 650 or 670 nanometers, and receiving, by a sensor, an electromagnetic emission transmitted from the sample holder along an emission optical path.",LIFE TECHNOLOGIES CORP,MAHER KEVIN;;CHEN MINGSONG;;FREUDENTHAL JACOB K;;BOO KUAN MOON;;LAU SOO YONG;;FORTESCUE DAVID;;SHEN MING;;SOH WOON LIANG TERENCE,LIFE TECHNOLOGIES CORPORATION (2014-06-10),https://lens.org/120-278-041-195-025,Granted Patent,yes,21,0,14,45,0,G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6428;;G01N21/6486,G01N21/64;;G01N37/00,,4,0,,,"PhlatLight White LED Illumination Products, CBT-90 White, Product Data Sheet, Luminus Devices, Inc. Jan. 31, 2011.;;KR Notification of Reason for Refusal issued in Application No. 10-2014-7011915, dated Jan. 25, 2019.;;KR Notification of Final Rejection issued in Application No. 10-2014-7011915, dated Jul. 4, 2019.;;PCT/US2014/018110, Written Opinion dated Oct. 19, 2015, 9 pages.",ACTIVE
372,WO,A1,WO 2013/049709 A1,108-455-593-105-614,2013-04-04,2013,US 2012/0058107 W,2012-09-28,US 201161541495 P;;US 201161541453 P,2011-09-30,OPTICAL SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,"An instrument (1000) for processing and/or measuring a biological process contains an excitation source (110), a sample holder (204), an optical sensor (118), an excitation optical system (120), and an emission optical system (125). The sample holder (204) is configured to receive a plurality of biological samples. The optical sensor (118) is configured to receive an emission from the biological samples. The excitation optical system (120) is disposed along an excitation optical path (126) and is configured to direct the electromagnetic radiation from the excitation source (110) to the biological samples. The emission optical system (125) is disposed along an emission optical path (128) and is configured to direct electromagnetic emissions from the biological samples to the optical sensor (118). The instrument further contains a plurality of filter assemblies (130, 132) configured to be interchangeably located along at least one of the optical paths. The plurality of filter components (131) includes a first filter component (138) characterized by a first optical power and a first filter (140) having a first filter function, the first filter function characterized by at least one of a first low-pass wavelength or a first high-pass wavelength. The second filter assembly (142) is characterized by a second optical power and a second filter (145) having a second filter function, the second filter function comprising at least one of a second low-pass wavelength that is different than the first low-pass wavelength or a second high-pass wavelength that is different than the first high-pass wavelength. The second optical power differs from the first optical power by an amount sufficient to at least partially compensate for an aberration introduced by the second filter (145) relative to the first filter (140).",LIFE TECHNOLOGIES CORP,MAHER KEVIN;;CHEN MINGSONG;;FREUDENTHAL JACOB;;BOO KUAN MOON;;LAU SOO YONG;;FORTESCUE DAVID;;SHEN MING;;SOH WOON LIANG TERENCE;;CHENG FRANCIS,,https://lens.org/108-455-593-105-614,Patent Application,yes,11,8,14,45,0,G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6452;;G01N2021/6471;;G01N2021/6478;;G01N2201/062;;G01N21/6428;;G01N21/6486,G01N21/64,,0,0,,,,PENDING
373,AT,T1,AT E539447 T1,172-603-821-602-210,2012-01-15,2012,AT 02784578 T,2002-11-22,US 4796402 A;;US 0237758 W,2002-01-15,VERFAHREN FÜR ZWEISCHICHT-HDP-CVD UND PE-CVD- DECKSCHICHT IN HOCHENTWICKELTEN BEOL- VERBINDUNGSSTRUKTUREN,"An advanced back-end-of-line (BEOL) metallization structure is disclosed. The structure includes a bilayer diffusion barrier or cap, where the first cap layer is formed of a dielectric material preferably deposited by a high density plasma chemical vapor deposition (HDP CVD) process, and the second cap layer is formed of a dielectric material preferably deposited by a plasma-enhanced chemical vapor deposition (PE CVD) process. A method for forming the BEOL metallization structure is also disclosed. The invention is particularly useful in interconnect structure comprising low-k dielectric material for the inter-layer dielectric (ILD) and copper for the conductors.",IBM;;INFINEON TECHNOLOGIES AG,CHEN TZE-CHIANG;;ENGEL BRETT;;FITZSIMMONS JOHN;;KANE TERENCE;;LUSTIG NAFTALI;;MCDONALD ANN;;MCGAHAY VINCENT;;SEO SOON-CHEON;;STAMPER ANTHONY;;WANG YUN;;KALTALIOGLU ERDEM,,https://lens.org/172-603-821-602-210,Granted Patent,no,0,0,22,22,0,H01L21/76807;;H01L21/76832;;H01L21/76834;;H01L23/5226;;H01L23/53228;;H01L23/53295;;H01L2924/0002;;H01L21/768;;H01L21/76834;;H01L23/53295;;H01L21/76832;;H01L23/53228;;H01L23/5226;;H01L21/76807;;H01L21/76801;;H01L2924/0002,H01L21/768;;H01L23/522;;H01L23/532,,0,0,,,,EXPIRED
374,DE,C2,DE 2354120 C2,004-861-911-593-004,1982-09-23,1982,DE 2354120 A,1973-10-29,US 30332772 A,1972-11-03,DE 2354120 C2,,"WESTERN ELECTRIC CO., INC., 10038 NEW YORK, N.Y., US","CHEN, YU-SSU, NEW PROVIDENCE, N.J., US;;GEUSIC, JOSEPH EDWARD, BERKELEY HEIGHTS, N.J., US;;NELSON, TERENCE JOHN, NEW PROVIDENCE, N.J., US;;SHAPIRO, HERBERT MEYER, BRIDGEWATER, N.J., US",,https://lens.org/004-861-911-593-004,Granted Patent,no,0,0,18,18,0,G11C19/0858;;G11C19/0858,G11C11/14;;G11C19/08,,0,0,,,,EXPIRED
375,EP,A4,EP 1641493 A4,011-582-182-696-40X,2007-10-31,2007,EP 04777002 A,2004-06-25,US 2004/0020233 W;;US 48367903 P,2003-06-30,RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS,,MERCK & CO INC,BURNS DONALD H;;CHEN ALEX M;;GIBSON RAYMOND E;;GOULET MARK T;;HAGMANN WILLIAM K;;HAMILL TERENCE G;;JEWELL JAMES P;;LIN LINUS S;;LIU PING;;PERESYPKIN ANDREY V,MERCK SHARP & DOHME CORP. (2010-03-10),https://lens.org/011-582-182-696-40X,Search Report,no,4,0,7,51,0,A61K51/0406;;A61K51/0455;;A61K51/0459;;C07D213/64;;C07D239/34;;A61P43/00;;C07D213/64;;A61K51/0406;;A61K51/0455;;C07D239/34;;A61K51/0459,A61K51/00;;A61K51/04;;A61P43/00;;C07D211/70;;C07D213/00;;C07D213/64;;C07D239/34,,1,0,,,See also references of WO 2005009479A1,DISCONTINUED
376,WO,A1,WO 2003/060983 A1,017-443-142-737-295,2003-07-24,2003,US 0237758 W,2002-11-22,US 4796402 A,2002-01-15,BILAYER HDP CVD / PE CVD CAP IN ADVANCED BEOL INTERCONNECT STRUCTURES AND METHOD THEREOF,"An advanced back-end-of-line (BEOL) metallization structure is disclosed. The structure includes a bilayer diffusion barrier or cap, where the first cap layer (116, 123) is formed of a dielectric material preferably deposited by a high density plasma chemical vapor deposition (HDP CVD) process, and the second cap layer (117, 124) is formed of a dielectric material preferably deposited by a plasma-enhanced chemical vapor deposition (PE CVD) process. A method for forming the BEOL metallization structure is also disclosed. The invention is particularly useful in interconnect structures comprising low-k dielectric material for the inter-layer dielectric (ILD) and copper for the conductors.",IBM;;INFINEON TECHNOLOGIES CORP,CHEN TZE-CHIANG;;ENGEL BRETT H;;FITZSIMMONS JOHN A;;KANE TERENCE;;LUSTIG NAFTALI E;;MCDONALD ANN;;MCGAHAY VINCENT;;SEO SOON-CHEON;;STAMPER ANTHONY K;;WANG YUN YU;;KALTALIOGLU ERDEM,,https://lens.org/017-443-142-737-295,Patent Application,yes,3,0,22,22,0,H01L21/76807;;H01L21/76832;;H01L21/76834;;H01L23/5226;;H01L23/53228;;H01L23/53295;;H01L2924/0002;;H01L21/768;;H01L21/76834;;H01L23/53295;;H01L21/76832;;H01L23/53228;;H01L23/5226;;H01L21/76807;;H01L21/76801;;H01L2924/0002,H01L21/768;;H01L23/522;;H01L23/532,,0,0,,,,PENDING
377,CA,A1,CA 2217073 A1,114-494-779-613-368,1999-04-01,1999,CA 2217073 A,1997-10-01,CA 2217073 A;;US 66726796 A;;US 64502096 A,1996-05-09,MULTIMODE DIGITAL MODEM,"A modem that operates selectively in the voice-band frequency band and at higher frequency bands is provided. This modem supports multiple line codes, like DMT and CAP. The modem uses a Digital Signal Processor (DSP), so that different existing ADSL line codes, such as Discrete MultiTone (DMT) and Carrierless AM/PM (CAP), can be implemented on the same hardware platform. The modem negotiates in real-time, for a desired line transmission rate to accommodate line condition and service-cost requirement. The line code and rate negotiation process may be implemented at the beginning of each communication session through the exchange of tones between the modems. A four-step MDSL modem initialization process is provided for line code and rate compatibility. A new synchronization startup procedure for CAP based MDSL modems is provided. The handshake protocol and receiver algorithm allow reliable modem synchronization over severely amplitude distorted channels such as standard telephone twisted-pair wire. The algorithm makes use of a short length sequence to train a synchronizing equalizer at the receiver. After training to this sequence, a matched filter or correlator is used to detect the inverted sync sequence. The detection of the inverted sequence signals the start of the normal reference training of the CAP demodulation equalizers. The MDSL line connection management process provides a simple, efficient, and flexible interface to manage the line connection between MDSL-C (MDSL in Central Office site) and MDSL-R (MDSL in resident site) in the telecommunication Wide Area Networking environment. An internal state machine in an MDSL modem records and monitors the line status and notifies the state change to the other MDSL and also the host processor. The protocol used for exchanging line connection management messages is a simplified Link Control Protocol (LCP) for MDSL.",TEXAS INSTRUMENTS INC,LU XIAOLIN;;TIMM WILLIAM C;;MANNERING DENNIS G;;CHEN WALTER Y;;RILEY TERENCE J;;POLLEY MICHAEL O;;FRANTZ GENE A;;GARCIA DOMINGO G;;WU SONG S;;SHAVER DONALD P,,https://lens.org/114-494-779-613-368,Patent Application,no,0,0,6,24,0,H04L1/0003;;H04L1/0009;;H04L1/0016;;H04L1/0023;;H04L1/0059;;H04L1/16;;H04L5/1438;;H04L25/03;;H04L25/03343;;H04L25/4921;;H04L27/2647;;H04L2025/03414;;H04L2025/03611;;H04M11/06;;H04M11/062;;H04L27/2675;;Y02D30/50;;H04L1/0023;;H04L25/03343;;H04L2025/03414;;H04L27/2647;;H04L2025/03611;;H04L1/0059;;H04L1/0009;;H04L1/0003;;H04M11/062;;H04L1/0016;;H04L5/1438;;H04L25/03;;H04L25/4921;;H04L1/16;;H04M11/06;;H04L27/2675;;Y02D30/50,H04L29/10;;H04J11/00;;H04L1/00;;H04L1/16;;H04L5/14;;H04L25/03;;H04L25/49;;H04L27/26;;H04M11/00;;H04M11/06,,0,0,,,,EXPIRED
378,EP,A2,EP 0806852 A2,063-457-962-356-231,1997-11-12,1997,EP 97303071 A,1997-05-06,CA 2217073 A;;US 64502096 A;;US 66726796 A,1996-05-09,A multimode digital modem,"A modem that operates selectively in the voice-band frequency band and at higher frequency bands is provided. This modem supports multiple line codes, like DMT and CAP. The modem uses a Digital Signal Processor (DSP), so that different existing ADSL line codes, such as Discrete MultiTone (DMT) and Carrierless AM/PM (CAP), can be implemented on the same hardware platform. The modem negotiates in real-time, for a desired line transmission rate to accommodate line condition and service-cost requirement. The line code and rate negotiation process may be implemented at the beginning of each communication session through the exchange of tones between the modems. A four-step MDSL modem initialization process is provided for line code and rate compatibility. A new synchronization startup procedure for CAP based MDSL modems is provided. The handshake protocol and receiver algorithm allow reliable modem synchronization over severely amplitude distorted channels such as standard telephone twisted-pair wire. the algorithm makes use of a short length sequence to train a synchronizing equalizer at the receiver. After training to this sequence, a matched filter or correlator is used to detect the inverted sync sequence. The detection of the inverted sequence signals the start of the normal reference training o the CAP demodulation equalizers. The MDSL line connection management process provides a simple, efficient, and flexible interface to mange the line connection between MDSL-C (MDSL in Central Office site) and MDSL-R (MDSL in resident site) in the telecommunication Wide Area Networking environment. An internal state machine in an MDSL modem records and monitors the line status and notifies the state change to the other MDSL and also the host processor. The protocol used for exchanging line connection management messages is a simplified Link Control Protocol (LCP) for MDSL.",TEXAS INSTRUMENTS INC,TIMM WILLIAM C;;CHEN WALTER Y;;FRANTZ GENE A;;GARCIA DOMINGO G;;LU XIAOLIN;;MANNERING DENNIS G;;POLLEY MICHAEL O;;RILEY TERENCE J;;SHAVER DONALD P;;WU SONG S,,https://lens.org/063-457-962-356-231,Patent Application,yes,0,94,6,24,0,H04L1/0003;;H04L1/0009;;H04L1/0016;;H04L1/0023;;H04L1/0059;;H04L1/16;;H04L5/1438;;H04L25/03;;H04L25/03343;;H04L25/4921;;H04L27/2647;;H04L2025/03414;;H04L2025/03611;;H04M11/06;;H04M11/062;;H04L27/2675;;Y02D30/50;;H04L1/0023;;H04L25/03343;;H04L2025/03414;;H04L27/2647;;H04L2025/03611;;H04L1/0059;;H04L1/0009;;H04L1/0003;;H04M11/062;;H04L1/0016;;H04L5/1438;;H04L25/03;;H04L25/4921;;H04L1/16;;H04M11/06;;H04L27/2675;;Y02D30/50,H04L29/10;;H04J11/00;;H04L1/00;;H04L1/16;;H04L5/14;;H04L25/03;;H04L25/49;;H04L27/26;;H04M11/00;;H04M11/06,,0,0,,,,DISCONTINUED
379,EP,A3,EP 0806852 A3,062-374-667-340-376,2000-04-12,2000,EP 97303071 A,1997-05-06,CA 2217073 A;;US 64502096 A;;US 66726796 A,1996-05-09,A multimode digital modem,"A modem that operates selectively in the voice-band frequency band and at higher frequency bands is provided. This modem supports multiple line codes, like DMT and CAP. The modem uses a Digital Signal Processor (DSP), so that different existing ADSL line codes, such as Discrete MultiTone (DMT) and Carrierless AM/PM (CAP), can be implemented on the same hardware platform. The modem negotiates in real-time, for a desired line transmission rate to accommodate line condition and service-cost requirement. The line code and rate negotiation process may be implemented at the beginning of each communication session through the exchange of tones between the modems. A four-step MDSL modem initialization process is provided for line code and rate compatibility. A new synchronization startup procedure for CAP based MDSL modems is provided. The handshake protocol and receiver algorithm allow reliable modem synchronization over severely amplitude distorted channels such as standard telephone twisted-pair wire. the algorithm makes use of a short length sequence to train a synchronizing equalizer at the receiver. After training to this sequence, a matched filter or correlator is used to detect the inverted sync sequence. The detection of the inverted sequence signals the start of the normal reference training o the CAP demodulation equalizers. The MDSL line connection management process provides a simple, efficient, and flexible interface to mange the line connection between MDSL-C (MDSL in Central Office site) and MDSL-R (MDSL in resident site) in the telecommunication Wide Area Networking environment. An internal state machine in an MDSL modem records and monitors the line status and notifies the state change to the other MDSL and also the host processor. The protocol used for exchanging line connection management messages is a simplified Link Control Protocol (LCP) for MDSL.",TEXAS INSTRUMENTS INC,TIMM WILLIAM C;;CHEN WALTER Y;;FRANTZ GENE A;;GARCIA DOMINGO G;;LU XIAOLIN;;MANNERING DENNIS G;;POLLEY MICHAEL O;;RILEY TERENCE J;;SHAVER DONALD P;;WU SONG S,,https://lens.org/062-374-667-340-376,Search Report,yes,24,0,6,24,0,H04L1/0003;;H04L1/0009;;H04L1/0016;;H04L1/0023;;H04L1/0059;;H04L1/16;;H04L5/1438;;H04L25/03;;H04L25/03343;;H04L25/4921;;H04L27/2647;;H04L2025/03414;;H04L2025/03611;;H04M11/06;;H04M11/062;;H04L27/2675;;Y02D30/50;;H04L1/0023;;H04L25/03343;;H04L2025/03414;;H04L27/2647;;H04L2025/03611;;H04L1/0059;;H04L1/0009;;H04L1/0003;;H04M11/062;;H04L1/0016;;H04L5/1438;;H04L25/03;;H04L25/4921;;H04L1/16;;H04M11/06;;H04L27/2675;;Y02D30/50,H04L29/10;;H04J11/00;;H04L1/00;;H04L1/16;;H04L5/14;;H04L25/03;;H04L25/49;;H04L27/26;;H04M11/00;;H04M11/06,,7,3,127-860-218-751-081;;075-713-491-754-481;;175-795-202-906-168,10.1109/icwc.1992.200756;;10.1016/0165-1684(83)90013-0;;10.1109/icassp.1997.599597,"JONES D L: ""Fixed wireless access: a cost effective solution for local loop service in underserved areas"", IEEE INTERNATIONAL CONFERENCE ON SELECTED TOPICS IN WIRELESS COMMUNICATIONS, 25 June 1992 (1992-06-25) - 26 June 1992 (1992-06-26), New York, NY, USA, pages 240 - 244, XP002107720;;CROCHIERE R E, RABINER L R: ""Multirate digital signal processing"", 1983, PRENTICE-HALL, ENGLEWOOD CLIFFS, NJ, USA, XP002127495;;ITU: ""Recommendation V.17: A 2-wire modem for facsimile applications with rates up to 14400 bit/s"", CCITT, - February 1991 (1991-02-01), Geneva, CH, XP002129935;;""AMERICAN NATIONAL STANDARD FOR TELECOMMUNICATIONS - NETWORK AND CUSTOMER INSTALLATION INTERFACES - ASYMMETRIC DIGITAL SUBSCRIBER LINE (ADSL) METALLIC INTERFACE"", ANSI, XP000196972;;CHEN W Y: ""A DIRECT EQUALIZATION METHOD"", IEEE INTERNATIONAL CONFERENCE ON ACOUSTICS, SPEECH, AND SIGNAL PROCESSING (ICASSP), vol. 3, 21 April 1997 (1997-04-21) - 24 April 1997 (1997-04-24), pages 2505 - 2508, XP000735068, ISBN: 0-8186-7919-0;;LIN D W ET AL: ""VIDEO ON PHONE LINES: TECHNOLOGY AND APPLICATIONS"", PROCEEDINGS OF THE IEEE,US,IEEE. NEW YORK, vol. 83, no. 2, pages 175-192, XP000501240, ISSN: 0018-9219;;DATABASE TDB January 1982 (1982-01-01), ""Word Processing Display Unit with Means for Indicating Communications Status"", XP002129936",DISCONTINUED
380,US,B2,US 6887783 B2,082-764-416-349-64X,2005-05-03,2005,US 65089003 A,2003-08-28,US 65089003 A;;US 4796402 A,2002-01-15,Bilayer HDP CVD/PE CVD cap in advance BEOL interconnect structures and method thereof,"An advanced back-end-of-line (BEOL) metallization structure is disclosed. The structure includes a bilayer diffusion barrier or cap, where the first cap layer is formed of a dielectric material preferably deposited by a high density plasma chemical vapor deposition (HDP CVD) process, and the second cap layer is formed of a dielectric material preferably deposited by a plasma-enhanced chemical vapor deposition (PE CVD) process. A method for forming the BEOL metallization structure is also disclosed. The invention is particularly useful in interconnect structures comprising low-k dielectric material for the inter-layer dielectric (ILD) and copper for the conductors.",INFINEON TECHNOLOGIES AG,CHEN TZE-CHIANG;;ENGEL BRETT H;;FITZSIMMONS JOHN A;;KANE TERENCE;;LUSTIG NAFTALL E;;MCDONALD ANN;;MCGAHAY VINCENT;;SEO SOON-CHEON;;STAMPER ANTHONY K;;WANG YUN YU;;KALTALIOGLU ERDEM,INFINEON TECHNOLOGIES AG (2004-07-13),https://lens.org/082-764-416-349-64X,Granted Patent,yes,30,26,22,22,0,H01L21/76807;;H01L21/76832;;H01L21/76834;;H01L23/5226;;H01L23/53228;;H01L23/53295;;H01L2924/0002;;H01L21/768;;H01L21/76834;;H01L23/53295;;H01L21/76832;;H01L23/53228;;H01L23/5226;;H01L21/76807;;H01L21/76801;;H01L2924/0002,H01L21/768;;H01L23/522;;H01L23/532,438/631;;438/652;;257/652,3,2,012-795-599-477-38X;;069-694-711-798-462,10.1143/jjap.40.2663;;10.1109/iitc.2000.854287,"Soo Geun Lee et al., ""Low Dielectric Constant 3MS a-SiC:H as Cu Diffusion Barrier Layer in Cu Dual Damascene Process,"" Japanese Journal of Applied Physics, Part 1, vol. 40, No. 4B, pp. 2663-2668, Apr. 2001.;;R.D. Goldblatt et al., "" A High Performance 0.13 um Copper BEOL Technology with Low-k Dielectric,"" Proceedings of the IEEE 2000 International Interconnect Technology Conference, pp. 261-263, Jun. 5-7, 2000.;;J. Yota et al., ""Comparison Between HDP CVD and PECVD Silicon Nitride for Advanced Interconnect Applications,"" Proceedings of the IEEE 2000 International Interconnect Technology Conference, pp. 76-78, Jun. 5-7, 2000.",EXPIRED
381,MY,A,MY 134796 A,104-599-922-808-255,2007-12-31,2007,MY PI20030029 A,2003-01-06,US 4796402 A,2002-01-15,BILAYER HDP CVD / PE CVD CAP IN ADVANCED BEOL INTERCONNECT STRUCTURES AND METHOD THEREOF,"AN ADVANCED BACK-END-OF-LINE (BEOL) METALLIZATION STRUCTURE IS DISCLOSED. THE STRUCTURE INCLUDES A BILAYER DIFFUSION BARRIER OR CAP, WHERE THE FIRST CAP LAYER (116, 123) IS FORMED OF A DIELECTRIC MATERIAL PREFERABLY DEPOSITED BY A HIGH DENSITY PLASMA CHEMICAL VAPOR DEPOSITION (HDP CVD) PROCESS, AND THE SECOND CAP LAYER (117, 124) IS FORMED OF A DIELECTRIC MATERIAL PREFERABLY DEPOSITED BY A PLASMA-ENHANCED CHEMICAL VAPOR DEPOSITION (PE CVD) PROCESS. A METHOD FOR FORMING THE BEOL METALLIZATION STRUCTURE IS ALSO DISCLOSED. THE INVENTION IS PARTICULARLY USEFUL IN INTERCONNECT STRUCTURES COMPRISING LOW-K DIELECTRIC MATERIAL FOR THE INTER-LAYER DIELECTRIC (ILD) AND COPPER FOR THE CONDUCTORS.",IBM;;INFINEON TECHNOLOGIES CORP,CHEN TZE-CHIANG;;WANG YUN YU;;KALTALIOGLU ERDEM;;ENGEL BRETT H;;FITZSIMMONS JOHN A;;KANE TERENCE;;LUSTIG NAFTALI E;;MCDONALD ANN;;MCGAHAY VINCENT;;SEO SOON-CHEON;;STAMPER ANTHONY K,,https://lens.org/104-599-922-808-255,Granted Patent,no,0,0,22,22,0,H01L21/76807;;H01L21/76832;;H01L21/76834;;H01L23/5226;;H01L23/53228;;H01L23/53295;;H01L2924/0002;;H01L21/768;;H01L21/76834;;H01L23/53295;;H01L21/76832;;H01L23/53228;;H01L23/5226;;H01L21/76807;;H01L21/76801;;H01L2924/0002,H01L21/44;;H01L21/768;;H01L23/52;;H01L23/522;;H01L23/532,,0,0,,,,EXPIRED
382,EP,A4,EP 1470580 A4,121-382-183-440-82X,2005-07-20,2005,EP 02784578 A,2002-11-22,US 0237758 W;;US 4796402 A,2002-01-15,BILAYER HDP CVD / PE CVD CAP IN ADVANCED BEOL INTERCONNECT STRUCTURES AND METHOD THEREOF,"An advanced back-end-of-line (BEOL) metallization structure is disclosed. The structure includes a bilayer diffusion barrier or cap, where the first cap layer is formed of a dielectric material preferably deposited by a high density plasma chemical vapor deposition (HDP CVD) process, and the second cap layer is formed of a dielectric material preferably deposited by a plasma-enhanced chemical vapor deposition (PE CVD) process. A method for forming the BEOL metallization structure is also disclosed. The invention is particularly useful in interconnect structure comprising low-k dielectric material for the inter-layer dielectric (ILD) and copper for the conductors.",INFINEON TECHNOLOGIES AG;;INFINEON TECHNOLOGIES CORP,CHEN TZE-CHIANG;;ENGEL BRETT H;;FITZSIMMONS JOHN A;;KANE TERENCE;;LUSTIG NAFTALI E;;MCDONALD ANN;;MCGAHAY VINCENT;;SEO SOON-CHEON;;STAMPER ANTHONY K;;WANG YUN YU;;KALTALIOGLU ERDEM,INFINEON TECHNOLOGIES AG (2010-06-02);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2010-06-02),https://lens.org/121-382-183-440-82X,Search Report,no,2,0,22,22,0,H01L21/76807;;H01L21/76832;;H01L21/76834;;H01L23/5226;;H01L23/53228;;H01L23/53295;;H01L2924/0002;;H01L21/768;;H01L21/76834;;H01L23/53295;;H01L21/76832;;H01L23/53228;;H01L23/5226;;H01L21/76807;;H01L21/76801;;H01L2924/0002,H01L21/768;;H01L23/522;;H01L23/532,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 2000, no. 14 5 March 2001 (2001-03-05)",EXPIRED
383,EP,B1,EP 1470580 B1,167-921-381-189-938,2011-12-28,2011,EP 02784578 A,2002-11-22,US 0237758 W;;US 4796402 A,2002-01-15,Method for bilayer HDP CVD / PE CVD cap in advanced BEOL interconnect structures,"An advanced back-end-of-line (BEOL) metallization structure is disclosed. The structure includes a bilayer diffusion barrier or cap, where the first cap layer is formed of a dielectric material preferably deposited by a high density plasma chemical vapor deposition (HDP CVD) process, and the second cap layer is formed of a dielectric material preferably deposited by a plasma-enhanced chemical vapor deposition (PE CVD) process. A method for forming the BEOL metallization structure is also disclosed. The invention is particularly useful in interconnect structure comprising low-k dielectric material for the inter-layer dielectric (ILD) and copper for the conductors.",IBM;;INFINEON TECHNOLOGIES AG,CHEN TZE-CHIANG;;ENGEL BRETT H;;FITZSIMMONS JOHN A;;KANE TERENCE;;LUSTIG NAFTALI E;;MCDONALD ANN;;MCGAHAY VINCENT;;SEO SOON-CHEON;;STAMPER ANTHONY K;;WANG YUN YU;;KALTALIOGLU ERDEM,INFINEON TECHNOLOGIES AG (2010-06-02);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2010-06-02),https://lens.org/167-921-381-189-938,Granted Patent,yes,4,0,22,22,0,H01L21/76807;;H01L21/76832;;H01L21/76834;;H01L23/5226;;H01L23/53228;;H01L23/53295;;H01L2924/0002;;H01L21/768;;H01L21/76834;;H01L23/53295;;H01L21/76832;;H01L23/53228;;H01L23/5226;;H01L21/76807;;H01L21/76801;;H01L2924/0002,H01L21/768;;H01L23/522;;H01L23/532,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 2000, no. 14, 5 March 2001 (2001-03-05) -& JP 2000 332102 A (NEC CORP), 30 November 2000 (2000-11-30) -& US 6 344 693 B1 (KAWAHARA JUN ET AL) 5 February 2002 (2002-02-05)",EXPIRED
384,CA,A1,CA 2530087 A1,066-130-235-458-56X,2005-02-03,2005,CA 2530087 A,2004-06-25,US 48367903 P;;US 2004/0020233 W,2003-06-30,RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS,"The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly human s. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the process es for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds a re described.",MERCK & CO INC,BURNS DONALD H;;JEWELL JAMES P;;CHEN ALEX M;;GIBSON RAYMOND E;;LIU PING;;LIN LINUS S;;PERESYPKIN ANDREY V;;GOULET MARK T;;HAMILL TERENCE G;;HAGMANN WILLIAM K,,https://lens.org/066-130-235-458-56X,Patent Application,no,0,0,7,51,0,A61K51/0406;;A61K51/0406;;A61K51/0455;;A61K51/0455;;A61K51/0459;;A61K51/0459;;A61P43/00;;C07D213/64;;C07D213/64;;C07D239/34;;C07D239/34,A61K51/00;;A61K51/04;;C07D211/70;;C07D213/00;;C07D213/64;;C07D239/34,,0,0,,,,DISCONTINUED
385,US,B2,US 7754188 B2,121-686-170-103-43X,2010-07-13,2010,US 55922805 A,2005-12-06,US 55922805 A;;US 48367903 P;;US 2004/0020233 W,2003-06-30,Radiolabeled cannabinoid-1 receptor modulators,"The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.",MERCK SHARP & DOHME,BURNS H DONALD;;CHEN ALEX M;;GIBSON RAYMOND E;;GOULET MARK T;;HAGMANN WILLIAM K;;HAMILL TERENCE G;;JEWELL JAMES P;;LIN LINUS S;;LIU PING;;PERESYPKIN ANDREY V,MERCK SHARP & DOHME CORP (2004-06-11),https://lens.org/121-686-170-103-43X,Granted Patent,yes,8,0,7,51,0,A61K51/0406;;A61K51/0406;;A61K51/0455;;A61K51/0455;;A61K51/0459;;A61K51/0459;;A61P43/00;;C07D213/64;;C07D213/64;;C07D239/34;;C07D239/34,A61K51/00;;A61K51/04;;A61M36/14;;C07D213/64;;C07D239/34,424/1.65;;424/1.89,19,18,002-118-695-260-745;;011-418-238-237-321;;115-417-042-272-156;;045-379-519-499-488;;075-637-625-973-259;;030-454-957-682-912;;031-687-469-317-821;;016-837-993-239-724;;000-574-072-545-759;;000-502-354-909-597;;031-104-756-448-392;;134-695-829-186-779;;119-499-508-900-220;;063-249-756-032-037;;102-346-375-032-09X;;002-023-701-824-040;;159-805-998-770-580;;077-500-131-116-893,10.1021/jm020157x;;12570386;;12234592;;10.1016/s0969-8051(02)00308-6;;11150708;;10.1016/s0969-8051(00)00152-9;;10.1016/s0009-3084(02)00148-2;;12505691;;10.1002/(sici)1099-1344(199906)42:6<589::aid-jlcr219>3.3.co;2-2;;9422389;;10.1046/j.1471-4159.1998.70010417.x;;10.1517/13543776.10.10.1529;;10.1016/s0165-6147(00)01482-6;;10838609;;10.1517/13543776.8.3.301;;10.1016/j.bmcl.2004.03.034;;15109619;;15110734;;10.1016/j.biopsych.2004.01.005;;10.1002/(sici)1099-1344(199610)38:10<875::aid-jlcr908>3.3.co;2-7;;10.1002/jlcr.647;;10.1002/jlcr.720;;15878505;;10.1016/j.nucmedbio.2005.02.007;;10.1021/jm050135l;;16190764;;10.1016/s0065-7743(08)60582-5;;16596783;;10.1007/3-540-26573-2_14,"Katoch-Rouse et al., J. Med. Chem., vol. 46 (2003), pp. 642-645, ""Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: . . . "".;;Mathews et al., Nuclear Med. & Biol., vol. 29 (2002), pp. 671-677, ""Carbon-11 labeled radioligands for imaging brain cannabinoid receptors"".;;Mathews et al., Nuclear Med. & Biol., vol. 27 (2000), pp. 757-762, ""Biodistribution of [18F] SR144385 and [18F] SR147963: . . . "".;;Gifford et al., Chem. and Physics of Lipids, vol. 121 (2002), pp. 65-72, ""In vivo imaging of the rain cannabinoid receptor"".;;Mathews et al., J. of Labelled Compounds and Radiopharm., vol. 42 (1999), pp. 589-596, ""Synthesis of [18F] SR144385: . . . "".;;Gatley et al., J. of Neurochem., vol. 70 (1998), pp. 417-423, ""Imaging the brain marijuana receptor: . . . "".;;Goya et al., Exp. Opin. Ther. Patents, vol. 10 (2000), pp. 1529-1538, ""Recent advances in cannabinoid receptor agonists and antagonists"".;;Piomelli et al., TiPS, vol. 21 (2000), pp. 218-224, ""The endocannabinoid system as a target for therapeutic drugs"".;;Barth, Exp. Opin. Ther. Patent, Vo. 8 (1998), pp. 301-313, ""Cannabinoid receptor agonists and antagonists"".;;Kumar et al., Bioorgan. & Med. Chem. Letters, vol. 14 (2004), pp. 2393-2396, ""Synthesis of [O-methyl-11C]1-(2-chloropheny1)-5-(4-methoxypheny1)-4-methyl-1H-pyrazole-3-carboxylic acid . . . "".;;Berding et al., Biol. Psychiatry, vol. 55 (2004), pp. 904-915, ""[123]AM281 Single-photon emission computed tomography imaging of cnetral cannabinoid CB1 receptors before and after delta9-tetrahydrocannabinool . . . "".;;Lan et al., J. of Labelled Compounds and Radiopharm., vol. 38 (1996), pp. 875-881, ""Preparation of iodine-123 labeled AM251: . . . "".;;Katoch-Rouse et al., J.of Labelled Compounds and Radiopharm., vol. 46 (2003), pp. 93-98, ""Synthesis of N-(piperidin-1-yl)-5-(4-methoxyphenyl)-1-(2-chloropheny1)-4[18F]fluoro-1H-pyrazole-3-carboxamide . . . "".;;Willis et al, J. of Labelled Compounds and Radiopharm., vol. 46 (2003), pp. 799-804, ""Regioselective F-18 radiolabeling of AM694, a CB1 cannabinoid receptor ligand"".;;Li et al., Nuclear Med. & Biol., vol. 32 (2005), pp. 361-366, ""Candidate PET radioligands for cannabinoid CB1 receptors: [18F]AM5144 and related pyrazole compounds"".;;Deng et al., J. Med. Chem., vol. 48 (2005), pp. 6386-6392, ""Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor"".;;Xiang et al., Ann. Reports in Med. Chem., vol. 34 (1999), pp. 199-208, ""Chapt. 20. Pharmacology of cannabinoid receptor agonists and antagonists"".;;Mason et al., Ann. Reports in Med. Chem., vol. 40 (2005), pp. 49-61, ""Positron emission tomography agents for central nervous system drug development applications"".;;Lindsey et al., Handbook of Exp. Pharmacol., vol. 168 (2005), pp. 425-443, ""Imaging of the Brain Cannabinoid System"".",INACTIVE
386,US,A1,US 2003/0134499 A1,198-663-293-292-359,2003-07-17,2003,US 4796402 A,2002-01-15,US 4796402 A,2002-01-15,Bilayer HDP CVD / PE CVD cap in advanced BEOL interconnect structures and method thereof,"
   An advanced back-end-of-line (BEOL) metallization structure is disclosed. The structure includes a bilayer diffusion barrier or cap, where the first cap layer is formed of a dielectric material preferably deposited by a high density plasma chemical vapor deposition (HDP CVD) process, and the second cap layer is formed of a dielectric material preferably deposited by a plasma-enhanced chemical vapor deposition (PE CVD) process. A method for forming the BEOL metallization structure is also disclosed. The invention is particularly useful in interconnect structures comprising low-k dielectric material for the inter-layer dielectric (ILD) and copper for the conductors. 
",IBM,CHEN TZE-CHIANG;;ENGEL BRETT H;;FITZSIMMONS JOHN A;;KANE TERENCE;;LUSTIG NAFTALI E;;MCDONALD ANN;;MCGAHAY VINCENT;;SEO SOON-CHEON;;STAMPER ANTHONY K;;WANG YUN YU;;KALTALIOGLU ERDEM,INFINEON TECHNOLOGIES NORTH AMERICA CORP (2002-01-10);;INFINEON TECHNOLOGIES AG (2004-07-13);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2002-01-08),https://lens.org/198-663-293-292-359,Patent Application,yes,0,37,22,22,0,H01L21/76807;;H01L21/76832;;H01L21/76834;;H01L23/5226;;H01L23/53228;;H01L23/53295;;H01L2924/0002;;H01L21/768;;H01L21/76834;;H01L23/53295;;H01L21/76832;;H01L23/53228;;H01L23/5226;;H01L21/76807;;H01L21/76801;;H01L2924/0002,H01L21/768;;H01L23/522;;H01L23/532,438/618,0,0,,,,DISCONTINUED
387,US,A1,US 2004/0115873 A1,110-102-472-075-664,2004-06-17,2004,US 65089003 A,2003-08-28,US 65089003 A;;US 4796402 A,2002-01-15,Bilayer HDP CVD/PE CVD cap in advanced BEOL interconnect structures and method thereof,"
   An advanced back-end-of-line (BEOL) metallization structure is disclosed. The structure includes a bilayer diffusion barrier or cap, where the first cap layer is formed of a dielectric material preferably deposited by a high density plasma chemical vapor deposition (HDP CVD) process, and the second cap layer is formed of a dielectric material preferably deposited by a plasma-enhanced chemical vapor deposition (PE CVD) process. A method for forming the BEOL metallization structure is also disclosed. The invention is particularly useful in interconnect structures comprising low-k dielectric material for the inter-layer dielectric (ILD) and copper for the conductors. 
",CHEN TZE-CHIANG;;ENGEL BRETT H.;;FITZSIMMONS JOHN A.;;KANE TERENCE;;LUSTIG NAFTALL E.;;MCDONALD ANN;;MCGAHAY VINCENT;;SEO SOON-CHEON;;STAMPER ANTHONY K.;;WANG YUN YU;;KALTALIOGLU ERDEM,CHEN TZE-CHIANG;;ENGEL BRETT H;;FITZSIMMONS JOHN A;;KANE TERENCE;;LUSTIG NAFTALL E;;MCDONALD ANN;;MCGAHAY VINCENT;;SEO SOON-CHEON;;STAMPER ANTHONY K;;WANG YUN YU;;KALTALIOGLU ERDEM,INFINEON TECHNOLOGIES AG (2004-07-13),https://lens.org/110-102-472-075-664,Patent Application,yes,21,7,22,22,0,H01L21/76807;;H01L21/76832;;H01L21/76834;;H01L23/5226;;H01L23/53228;;H01L23/53295;;H01L2924/0002;;H01L21/768;;H01L21/76834;;H01L23/53295;;H01L21/76832;;H01L23/53228;;H01L23/5226;;H01L21/76807;;H01L21/76801;;H01L2924/0002,H01L21/768;;H01L23/522;;H01L23/532,4382,0,0,,,,EXPIRED
388,EP,A1,EP 1641493 A1,019-291-561-272-587,2006-04-05,2006,EP 04777002 A,2004-06-25,US 2004/0020233 W;;US 48367903 P,2003-06-30,RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS,,MERCK & CO INC,BURNS DONALD H;;CHEN ALEX M;;GIBSON RAYMOND E;;GOULET MARK T;;HAGMANN WILLIAM K;;HAMILL TERENCE G;;JEWELL JAMES P;;LIN LINUS S;;LIU PING;;PERESYPKIN ANDREY V,MERCK SHARP & DOHME CORP. (2010-03-10),https://lens.org/019-291-561-272-587,Patent Application,yes,0,0,7,51,0,A61K51/0406;;A61K51/0406;;A61K51/0455;;A61K51/0455;;A61K51/0459;;A61K51/0459;;A61P43/00;;C07D213/64;;C07D213/64;;C07D239/34;;C07D239/34,A61K51/00;;A61K51/04;;A61P43/00;;C07D211/70;;C07D213/00;;C07D213/64;;C07D239/34,,0,0,,,,DISCONTINUED
389,US,A1,US 2004/0173907 A1,079-634-542-914-079,2004-09-09,2004,US 80702904 A,2004-03-23,US 80702904 A;;US 65089003 A;;US 4796402 A,2002-01-15,Bilayer HDP CVD / PE CVD cap in advanced BEOL interconnect structures and method thereof,"
   An advanced back-end-of-line (BEOL) metallization structure is disclosed. The structure includes a bilayer diffusion barrier or cap, where the first cap layer is formed of a dielectric material preferably deposited by a high density plasma chemical vapor deposition (HDP CVD) process, and the second cap layer is formed of a dielectric material preferably deposited by a plasma-enhanced chemical vapor deposition (PE CVD) process. A method for forming the BEOL metallization structure is also disclosed. The invention is particularly useful in interconnect structures comprising low-k dielectric material for the inter-layer dielectric (ILD) and copper for the conductors. 
",CHEN TZE-CHIANG;;ENGEL BRETT H.;;FITZSIMMONS JOHN A.;;KANE TERENCE;;LUSTIG NAFTALL E.;;MCDONALD ANN;;MCGAHAY VINCENT;;SEO SOON-CHEON;;STAMPER ANTHONY K.;;WANG YUN YU;;KALTALIOGLU ERDEM,CHEN TZE-CHIANG;;ENGEL BRETT H;;FITZSIMMONS JOHN A;;KANE TERENCE;;LUSTIG NAFTALL E;;MCDONALD ANN;;MCGAHAY VINCENT;;SEO SOON-CHEON;;STAMPER ANTHONY K;;WANG YUN YU;;KALTALIOGLU ERDEM,INFINEON TECHNOLOGIES AG (2004-07-13),https://lens.org/079-634-542-914-079,Patent Application,yes,19,12,22,22,0,H01L21/76807;;H01L21/76832;;H01L21/76834;;H01L23/5226;;H01L23/53228;;H01L23/53295;;H01L2924/0002;;H01L21/768;;H01L21/76834;;H01L23/53295;;H01L21/76832;;H01L23/53228;;H01L23/5226;;H01L21/76807;;H01L21/76801;;H01L2924/0002,H01L21/768;;H01L23/522;;H01L23/532,257/758;;X25775,0,0,,,,EXPIRED
390,CA,C,CA 2217073 C,029-349-347-855-417,2005-08-02,2005,CA 2217073 A,1997-10-01,CA 2217073 A;;US 66726796 A;;US 64502096 A,1996-05-09,MULTIMODE DIGITAL MODEM,"A modem that operates selectively in the voice-band frequency band and at higher frequency bands is provided. This modem supports multiple line codes, like DMT and CAP. The modem uses a Digital Signal Processor (DSP), so that different existing ADSL line codes, such as Discrete MultiTone (DMT) and Carrierless AM/PM (CAP), can be implemented on the same hardware platform. The mode m negotiates in real-time, for a desired line transmission rate to accommodate line condition and service-cost requirement. The line code and rate negotiation process may be implemented at the beginning of each communication session through the exchange of tones between the modems. A four-step MDSL modem initialization process is provided for line code and rate compatibility. A new synchronization startup procedure for CAP based MDSL modems is provided. The handshake protocol and receiver algorithm allow reliable modem synchronization over severely amplitude distorted channels such as standard telephone twisted-pair wire. The algorithm makes use of a short length sequence to train a synchronizing equalizer at the receiver. After training to this sequence, a matched filter or correlator is used to detect the inverted sync sequence. The detection of the inverted sequence signals the start of the normal reference training of the CAP demodulation equalizers. The MDSL line connection management process provides a simple, efficient, and flexible interface to manage the line connection between MDSL-C (MDSL in Central Office site) and MDSL-R (MDSL in resident site) in the telecommunication Wide Area Networking environment. An internal state machine in an MDSL modem records and monitors the line status and notifies the state change to the other MDSL and also the host processor. The protocol used for exchanging line connection management messages is a simplified Link Control Protocol (LCP) for MDSL.",TEXAS INSTRUMENTS INC,WU SONG S;;TIMM WILLIAM C;;CHEN WALTER Y;;SHAVER DONALD P;;MANNERING DENNIS G;;POLLEY MICHAEL O;;RILEY TERENCE J;;LU XIAOLIN;;FRANTZ GENE A;;GARCIA DOMINGO G,,https://lens.org/029-349-347-855-417,Granted Patent,no,0,0,6,24,0,H04L1/0003;;H04L1/0009;;H04L1/0016;;H04L1/0023;;H04L1/0059;;H04L1/16;;H04L5/1438;;H04L25/03;;H04L25/03343;;H04L25/4921;;H04L27/2647;;H04L2025/03414;;H04L2025/03611;;H04M11/06;;H04M11/062;;H04L27/2675;;Y02D30/50;;H04L1/0023;;H04L25/03343;;H04L2025/03414;;H04L27/2647;;H04L2025/03611;;H04L1/0059;;H04L1/0009;;H04L1/0003;;H04M11/062;;H04L1/0016;;H04L5/1438;;H04L25/03;;H04L25/4921;;H04L1/16;;H04M11/06;;H04L27/2675;;Y02D30/50,H04L29/10;;H04J11/00;;H04L1/00;;H04L1/16;;H04L5/14;;H04L25/03;;H04L25/49;;H04L27/26;;H04M11/00;;H04M11/06,,0,0,,,,EXPIRED
391,JP,A,JP H1075279 A,088-588-182-210-124,1998-03-17,1998,JP 15569597 A,1997-05-09,CA 2217073 A;;US 64502096 A;;US 66726796 A,1996-05-09,METHOD AND MODEM FOR DEMODULATING DIGITAL SUBSCRIBER LINE MODEM SIGNAL,"PROBLEM TO BE SOLVED: To prevent the complication of a modem and a cost rise for a high bit transmission speed by using a programmable digital signal processor and running one of the modem softwares of two bands in combination with an analog front end and a common host interface. SOLUTION: This modem 100 performs reception at a frequency within a voice band in a voice band analog front end(VBAFE) 110 and performs transmission and the reception at the frequency of a high voice band higher than the voice band in a digital subscriber line analog front end (DBL AFE) 120 with a subscriber line 140 through a splitter 130. Further, the modem 100 is operated as the high bit transmission speed digital subscriber line modem of the high voice band or a voice band modem by switching a program executed by the programmable digital signal processor(DSP) 150. Thus, the complication of the modem 100 and the cost rise are prevented even for the high bit transmission speed.",TEXAS INSTRUMENTS INC,TIMM WILLIAM C;;CHEN WALTER Y;;FRANTZ GENE A;;GARCIA DOMINGO G;;LU XIAOLIN;;MANNERING DENNIS G;;POLLEY MICHAEL O;;RILEY TERENCE J;;SHAVER DONALD P;;WU SONG S,,https://lens.org/088-588-182-210-124,Patent Application,no,0,31,6,24,0,H04L1/0003;;H04L1/0009;;H04L1/0016;;H04L1/0023;;H04L1/0059;;H04L1/16;;H04L5/1438;;H04L25/03;;H04L25/03343;;H04L25/4921;;H04L27/2647;;H04L2025/03414;;H04L2025/03611;;H04M11/06;;H04M11/062;;H04L27/2675;;Y02D30/50;;H04L1/0023;;H04L25/03343;;H04L2025/03414;;H04L27/2647;;H04L2025/03611;;H04L1/0059;;H04L1/0009;;H04L1/0003;;H04M11/062;;H04L1/0016;;H04L5/1438;;H04L25/03;;H04L25/4921;;H04L1/16;;H04M11/06;;H04L27/2675;;Y02D30/50,H04L29/10;;H04J11/00;;H04L1/00;;H04L1/16;;H04L5/14;;H04L25/03;;H04L25/49;;H04L27/26;;H04M11/00;;H04M11/06,,0,0,,,,PENDING
392,AU,A1,AU 2002/346512 A1,020-004-900-659-120,2003-07-30,2003,AU 2002/346512 A,2002-11-22,US 4796402 A;;US 0237758 W,2002-01-15,BILAYER HDP CVD / PE CVD CAP IN ADVANCED BEOL INTERCONNECT STRUCTURES AND METHOD THEREOF,"An advanced back-end-of-line (BEOL) metallization structure is disclosed. The structure includes a bilayer diffusion barrier or cap, where the first cap layer is formed of a dielectric material preferably deposited by a high density plasma chemical vapor deposition (HDP CVD) process, and the second cap layer is formed of a dielectric material preferably deposited by a plasma-enhanced chemical vapor deposition (PE CVD) process. A method for forming the BEOL metallization structure is also disclosed. The invention is particularly useful in interconnect structure comprising low-k dielectric material for the inter-layer dielectric (ILD) and copper for the conductors.",IBM;;INFINEON TECHNOLOGIES CORP,KANE TERENCE;;LUSTIG NAFTALI E;;MCDONALD ANN;;MCGAHAY VINCENT;;SEO SOON-CHEON;;STAMPER ANTHONY K;;WANG YUN YU;;KALTALIOGLU ERDEM;;CHEN TZE-CHIANG;;ENGEL BRETT H;;FITZSIMMONS JOHN A,,https://lens.org/020-004-900-659-120,Patent Application,no,0,0,22,22,0,H01L21/76807;;H01L21/76832;;H01L21/76834;;H01L23/5226;;H01L23/53228;;H01L23/53295;;H01L2924/0002;;H01L21/768;;H01L21/76834;;H01L23/53295;;H01L21/76832;;H01L23/53228;;H01L23/5226;;H01L21/76807;;H01L21/76801;;H01L2924/0002,H01L21/768;;H01L23/522;;H01L23/532,,0,0,,,,DISCONTINUED
393,US,B2,US 6914320 B2,040-087-187-765-500,2005-07-05,2005,US 80702904 A,2004-03-23,US 80702904 A;;US 65089003 A;;US 4796402 A,2002-01-15,Bilayer HDP CVD/PE CVD cap in advanced BEOL interconnect structures and method thereof,"An advanced back-end-of-line (BEOL) metallization structure is disclosed. The structure includes a bilayer diffusion barrier or cap, where the first cap layer is formed of a dielectric material preferably deposited by a high density plasma chemical vapor deposition (HDP CVD) process, and the second cap layer is formed of a dielectric material preferably deposited by a plasma-enhanced chemical vapor deposition (PE CVD) process. A method for forming the BEOL metallization structure is also disclosed. The invention is particularly useful in interconnect structure comprising low-k dielectric material for the inter-layer dielectric (ILD) and copper for the conductors.",INFINEON TECHNOLOGIES AG,CHEN TZE-CHIANG;;ENGEL BRETT H;;FITZSIMMONS JOHN A;;KANE TERENCE;;LUSTIG NAFTALL E;;MCDONALD ANN;;MCGAHAY VINCENT;;SEO SOON-CHEON;;STAMPER ANTHONY K;;WANG YUN YU;;KALTALIOGLU ERDEM,INFINEON TECHNOLOGIES AG (2004-07-13),https://lens.org/040-087-187-765-500,Granted Patent,yes,24,12,22,22,0,H01L21/76807;;H01L21/76832;;H01L21/76834;;H01L23/5226;;H01L23/53228;;H01L23/53295;;H01L2924/0002;;H01L21/768;;H01L21/76834;;H01L23/53295;;H01L21/76832;;H01L23/53228;;H01L23/5226;;H01L21/76807;;H01L21/76801;;H01L2924/0002,H01L21/768;;H01L23/522;;H01L23/532,257/652;;257/753;;438/631,2,1,012-795-599-477-38X,10.1143/jjap.40.2663,"Soo Geun Lee et al., ""Low Dielectric Constant 3MS a-SiC:H as Cu Diffusion Barrier Layer in Cu Dual Damascene Process,"" Japanese Journal of Applied Physics, Part 1, vol. 40, No. 4B, pp. 2663-2668, Apr. 2001.;;R.D. Goldblatt et al., ""A High Performance 0.13 um Copper BEOL Technology with Low-k Dielectric,"" Proceedings of the IEEE 2000 International Interconnect Technology Conference, pp. 261-263, Jun. 5-7, 2000.",EXPIRED
394,US,A1,US 2006/0115425 A1,055-744-009-762-27X,2006-06-01,2006,US 55922805 A,2005-12-06,US 55922805 A;;US 48367903 P;;US 2004/0020233 W,2003-06-30,Substituted amides,"The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.",BURNS H DONALD;;CHEN ALEX M;;GIBSON RAYMOND E;;GOULET MARK T;;HAGMANN WILLIAM K;;HAMILL TERENCE G;;JEWELL JAMES P;;LIN LINUS S;;LIU PING;;PERESYPKIN ANDREY V,BURNS H DONALD;;CHEN ALEX M;;GIBSON RAYMOND E;;GOULET MARK T;;HAGMANN WILLIAM K;;HAMILL TERENCE G;;JEWELL JAMES P;;LIN LINUS S;;LIU PING;;PERESYPKIN ANDREY V,MERCK SHARP & DOHME CORP (2004-06-11),https://lens.org/055-744-009-762-27X,Patent Application,yes,5,0,7,51,0,A61K51/0406;;A61K51/0406;;A61K51/0455;;A61K51/0455;;A61K51/0459;;A61K51/0459;;A61P43/00;;C07D213/64;;C07D213/64;;C07D239/34;;C07D239/34,A61K51/00;;A61K51/04;;C07D213/64;;C07D213/70;;C07D239/34,424/1.11;;534/11;;546/290,0,0,,,,INACTIVE
395,WO,A1,WO 2005/009479 A1,045-001-089-417-088,2005-02-03,2005,US 2004/0020233 W,2004-06-25,US 48367903 P,2003-06-30,RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS,"The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.",MERCK & CO INC;;BURNS DONALD H;;CHEN ALEX M;;GIBSON RAYMOND E;;GOULET MARK T;;HAGMANN WILLIAM K;;HAMILL TERENCE G;;JEWELL JAMES P;;LIN LINUS S;;LIU PING;;PERESYPKIN ANDREY V,BURNS DONALD H;;CHEN ALEX M;;GIBSON RAYMOND E;;GOULET MARK T;;HAGMANN WILLIAM K;;HAMILL TERENCE G;;JEWELL JAMES P;;LIN LINUS S;;LIU PING;;PERESYPKIN ANDREY V,,https://lens.org/045-001-089-417-088,Patent Application,yes,1,24,7,51,0,A61K51/0406;;A61K51/0406;;A61K51/0455;;A61K51/0455;;A61K51/0459;;A61K51/0459;;A61P43/00;;C07D213/64;;C07D213/64;;C07D239/34;;C07D239/34,A61K51/04;;C07D213/64;;C07D239/34,,1,0,,,See also references of EP 1641493A4,PENDING
396,US,A1,US 2011/0067603 A1,142-003-224-932-249,2011-03-24,2011,US 85726710 A,2010-08-16,US 85726710 A;;US 29181109 P;;US 36082910 P;;US 37160610 P,2009-12-31,Methods and compositions using calcium carbonate,"Provided herein are compositions and methods including hydraulic cement, supplementary cementitious material, and/or self-cementing material. Methods for making the compositions and using the compositions are provided.",CONSTANTZ BRENT R;;FARSAD KASRA;;CAMIRE CHRIS;;PATTERSON JOSHUA;;FERNANDEZ MIGUEL;;YACCATO KARIN;;THATCHER RYAN;;STAGNARO JOHN;;CHEN IRVIN;;OMELON SIDNEY;;HODSON KEITH;;CLODIC LAURENCE;;GERAMITA KATHARINE;;HOLLAND TERENCE C,CONSTANTZ BRENT R;;FARSAD KASRA;;CAMIRE CHRIS;;PATTERSON JOSHUA;;FERNANDEZ MIGUEL;;YACCATO KARIN;;THATCHER RYAN;;STAGNARO JOHN;;CHEN IRVIN;;OMELON SIDNEY;;HODSON KEITH;;CLODIC LAURENCE;;GERAMITA KATHARINE;;HOLLAND TERENCE C,ARELAC INC (2019-09-12);;CALERA CORPORATION (2011-07-28),https://lens.org/142-003-224-932-249,Patent Application,yes,69,47,26,33,0,C04B28/02;;Y10S264/43;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y02C20/40;;Y02P40/10;;C04B28/02;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y10S264/43;;Y02C20/40;;C04B14/28;;C04B28/04,C04B28/04;;B01J19/00;;C04B14/26,106/739;;106/286.6;;422/129,0,0,,,,ACTIVE
397,US,A1,US 2012/0145047 A1,197-480-713-062-712,2012-06-14,2012,US 201213350199 A,2012-01-13,US 201213350199 A;;US 85726710 A;;US 29181109 P;;US 36082910 P;;US 37160610 P,2009-12-31,METHODS AND COMPOSITIONS USING CALCIUM CARBONATE,"Provided herein are compositions and methods including hydraulic cement, supplementary cementitious material, and/or self-cementing material. Methods for making the compositions and using the compositions are provided.",CONSTANTZ BRENT R;;FARSAD KASRA;;CAMIRE CHRIS;;PATTERSON JOSHUA;;FERNANDEZ MIGUEL;;YACCATO KARIN;;THATCHER RYAN;;STAGNARO JOHN;;CHEN IRVIN;;OMELON SIDNEY;;HODSON KEITH;;CLODIC LAURENCE;;GERAMITA KATHARINE;;HOLLAND TERENCE C,CONSTANTZ BRENT R;;FARSAD KASRA;;CAMIRE CHRIS;;PATTERSON JOSHUA;;FERNANDEZ MIGUEL;;YACCATO KARIN;;THATCHER RYAN;;STAGNARO JOHN;;CHEN IRVIN;;OMELON SIDNEY;;HODSON KEITH;;CLODIC LAURENCE;;GERAMITA KATHARINE;;HOLLAND TERENCE C,CALERA CORPORATION (2010-08-19),https://lens.org/197-480-713-062-712,Patent Application,yes,1,9,26,33,0,C04B28/02;;Y10S264/43;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y02C20/40;;Y02P40/10;;C04B28/02;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y10S264/43;;Y02C20/40;;C04B14/28;;C04B28/04,C04B14/28;;C04B28/04,106/738;;106/817,1,0,,,Chloride and Salinity. Water Quality with Vernier. Retrieved on 08-08-2012. Retrieved from http://www.tvdsb.ca/uploads/ScienceProbeware/chloride.pdf,DISCONTINUED
398,PE,A1,PE 20140231 A1,114-804-786-795-316,2014-03-08,2014,PE 2013000885 A,2008-08-22,US 95766807 P;;US 896507 P;;US 1063008 P;;US 8613308 P,2007-08-23,PROTEINAS DE UNION A ANTIGENO CONTRA PROPROTEINA CONVERSTASA SUBTILISINA/KEXINA TIPO 9 (PCSK9),"SE REFIERE A UN ANTICUERPO QUE COMPRENDE: A) UN DOMINIO DE CADENA LIVIANA QUE ES UNA CDR1, CDR2, CDR3 EN SEQ ID NO: 7, SEQ ID NO: 42 ENTRE OTROS, Y B) UN DOMINIO DE CADENA PESADA QUE COMPRENDE UNA SECUENCIA QUE CONSISTE EN CDR1, CDR2 Y CDR3 EN SEQ ID N� 69, SEQ ID 69, SEQ ID DONDE DICHA PROTEINA DE UNION SE UNE SELECTIVAMENTE A PROPROTEINA CONVERSTASA SUBTILISINA/KEXINA TIPO 9 (PCSK9). TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHA PROTEINA DE UNION ES UTIL EN EL TRATAMIENTO DE LA HIPERCOLESTEROLEMIA, ENTRE OTROS.",AMGEN INC,JACKSON SIMON MARK;;WALKER NIGEL PELHAM CLINTON;;PIPER DEREK EVAN;;SHAN BEI;;CHEN WENYAN;;CHAN JOYCE CHI YEE;;KING CHADWICK TERENCE;;KETCHEM RANDAL ROBERT;;MEHLIN CHRISTOPHER;;CARABEO TERESA ARAZAS;;QIONG CAO,,https://lens.org/114-804-786-795-316,Patent Application,no,0,0,176,193,0,A61K31/22;;A61K31/366;;A61K31/40;;A61K31/405;;A61K31/44;;A61K31/47;;A61K31/505;;A61K31/66;;A61K39/395;;A61K39/3955;;A61K45/06;;C07K16/40;;C12N15/1137;;A61K2039/505;;C07K2299/00;;C07K2317/34;;C07K2317/14;;C07K2317/92;;C07K2317/76;;A61K31/22;;A61K31/366;;A61K31/40;;A61K31/405;;A61K31/44;;A61K31/47;;A61K31/505;;A61K31/66;;A61K39/395;;A61K45/06;;A61K2039/505;;C07K2299/00;;C07K2317/92;;A61K39/3955;;C07K2317/34;;C07K2317/76;;C07K16/40;;A61P25/28;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/00;;A61P9/00;;A61P9/10;;C07K16/40;;A61K31/505;;C12N15/1137;;A61K31/405;;A61K31/44;;C07K2299/00;;C07K2317/14;;A61K31/66;;A61K31/40;;A61K2039/505;;A61K31/22;;A61K45/06;;A61K39/3955;;A61K39/395;;A61K31/47;;C07K2317/34;;A61K31/366;;C07K2317/76;;C07K2317/92;;A61K2300/00;;A61P3/06;;A61P7/00;;A61P3/00;;A61P9/10;;A61P43/00;;A61P25/28;;A61P9/00;;C07K16/40;;A61P3/06;;A61K2039/505;;C07K2317/24;;C07K2317/92;;A61K31/22;;A61K31/366;;A61K31/40;;A61K31/405;;A61K31/44;;A61K31/47;;A61K31/505;;A61K31/66;;A61K39/395;;A61K45/06;;A61K2039/505;;C07K2299/00;;C07K2317/92;;A61K39/3955;;C07K2317/34;;C07K2317/76;;C07K16/40;;C12N15/1137;;C07K2317/14,C07K16/18;;A61K39/395;;C12P21/02,,0,0,,,,DISCONTINUED
399,PE,A1,PE 20180173 A1,087-828-578-517-193,2018-01-22,2018,PE 2017002386 A,2008-08-22,US 95766807 P;;US 896507 P;;US 1063008 P;;US 8613308 P,2007-08-23,ANTICUERPOS CONTRA PROPROTEINA CONVERTASA SUBTILISINA/KEXINA TIPO 9 (PCSK9),"Se refiere a un anticuerpo monoclonal aislado que se une especificamente a PCSK9 humano, donde el anticuerpo comprende una region variable de cadena pesada que comprende al menos un aminoacido en la posicion especifica seleccionada del grupo que consiste en T28, S30, S31, Y32, S54, S55, S56, Y57, I58, S59, Y60, N74, A75, R98, Y100, F102, W103, S104, A105, Y106, Y107, D108, A109 y D111 de SEQ ID NO: 67 y una region variable de cadena liviana que comprende al menos un aminoacido en el grupo especifico que consiste en L48, S51, Y93 y S98 de SEQ ID NO: 12. Tambien se refiere a una composicion farmaceutica que comprende dicho anticuerpo. Dichos anticuerpos son utiles en metodos para tratar la hipercolesterolemia y otros trastornos, y para detectar la cantidad de PCSK9 en una muestra",AMGEN INC,JACKSON SIMON MARK;;WALKER NIGEL PELHAM CLINTON;;PIPER DEREK EVAN;;SHAN BEI;;CHEN WENYAN;;CHAN JOYCE CHI YEE;;KING CHADWICK TERENCE;;KETCHEM RANDAL ROBERT;;MEHLIN CHRISTOPHER;;CARABEO TERESA ARAZAS;;QIONG CAO,,https://lens.org/087-828-578-517-193,Patent Application,no,0,0,176,193,0,A61K31/22;;A61K31/366;;A61K31/40;;A61K31/405;;A61K31/44;;A61K31/47;;A61K31/505;;A61K31/66;;A61K39/395;;A61K39/3955;;A61K45/06;;C07K16/40;;C12N15/1137;;A61K2039/505;;C07K2299/00;;C07K2317/34;;C07K2317/14;;C07K2317/92;;C07K2317/76;;A61K31/22;;A61K31/366;;A61K31/40;;A61K31/405;;A61K31/44;;A61K31/47;;A61K31/505;;A61K31/66;;A61K39/395;;A61K45/06;;A61K2039/505;;C07K2299/00;;C07K2317/92;;A61K39/3955;;C07K2317/34;;C07K2317/76;;C07K16/40;;A61P25/28;;A61P3/00;;A61P3/06;;A61P43/00;;A61P7/00;;A61P9/00;;A61P9/10;;C07K16/40;;A61K31/505;;C12N15/1137;;A61K31/405;;A61K31/44;;C07K2299/00;;C07K2317/14;;A61K31/66;;A61K31/40;;A61K2039/505;;A61K31/22;;A61K45/06;;A61K39/3955;;A61K39/395;;A61K31/47;;C07K2317/34;;A61K31/366;;C07K2317/76;;C07K2317/92;;A61K2300/00;;A61P3/06;;A61P7/00;;A61P3/00;;A61P9/10;;A61P43/00;;A61P25/28;;A61P9/00;;C07K16/40;;A61P3/06;;A61K2039/505;;C07K2317/24;;C07K2317/92;;A61K31/22;;A61K31/366;;A61K31/40;;A61K31/405;;A61K31/44;;A61K31/47;;A61K31/505;;A61K31/66;;A61K39/395;;A61K45/06;;A61K2039/505;;C07K2299/00;;C07K2317/92;;A61K39/3955;;C07K2317/34;;C07K2317/76;;C07K16/40;;C12N15/1137;;C07K2317/14,C07K16/40;;A61K39/395;;A61P3/06,,0,0,,,,PENDING
400,US,B2,US 8114214 B2,076-333-267-034-940,2012-02-14,2012,US 85726710 A,2010-08-16,US 85726710 A;;US 29181109 P;;US 36082910 P;;US 37160610 P,2009-12-31,Methods and compositions using calcium carbonate,"Provided herein are compositions and methods including hydraulic cement, supplementary cementitious material, and/or self-cementing material. Methods for making the compositions and using the compositions are provided.",CONSTANTZ BRENT R;;FARSAD KASRA;;CAMIRE CHRIS;;PATTERSON JOSHUA;;FERNANDEZ MIGUEL;;YACCATO KARIN;;THATCHER RYAN;;STAGNARO JOHN;;CHEN IRVIN;;OMELON SIDNEY;;HODSON KEITH;;CLODIC LAURENCE;;GERAMITA KATHARINE;;HOLLAND TERENCE C;;RIES JUSTIN;;CALERA CORP,CONSTANTZ BRENT R;;FARSAD KASRA;;CAMIRE CHRIS;;PATTERSON JOSHUA;;FERNANDEZ MIGUEL;;YACCATO KARIN;;THATCHER RYAN;;STAGNARO JOHN;;CHEN IRVIN;;OMELON SIDNEY;;HODSON KEITH;;CLODIC LAURENCE;;GERAMITA KATHARINE;;HOLLAND TERENCE C;;RIES JUSTIN,ARELAC INC (2019-09-12);;CALERA CORPORATION (2011-07-28),https://lens.org/076-333-267-034-940,Granted Patent,yes,100,91,26,33,0,C04B28/02;;Y10S264/43;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y02C20/40;;Y02P40/10;;C04B28/02;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y10S264/43;;Y02C20/40;;C04B14/28;;C04B28/04,C04B7/00;;B29C65/00;;C01F5/24;;C01F11/18;;C04B9/12;;C04B28/00;;C04B28/04,106/738;;106/713;;423/430;;264/43,36,22,052-437-631-565-015;;106-540-945-715-576;;008-872-683-024-078;;132-766-894-358-39X;;095-461-649-781-832;;003-313-737-686-876;;018-200-596-011-237;;073-457-414-810-416;;071-504-523-967-558;;015-505-724-786-423;;059-908-835-582-979;;083-149-976-326-800;;056-852-006-432-43X;;043-371-287-470-301;;034-438-848-943-058;;068-380-780-571-108;;044-812-723-358-840;;067-783-128-507-009;;126-869-500-266-121;;125-960-056-901-002;;028-753-863-168-638;;048-271-187-553-154,16219345;;10.1016/j.biomaterials.2005.09.026;;10.1021/cg049606f;;3038823;;10.2527/jas1987.651309x;;10.1002/ceat.200500354;;10.1111/j.1151-2916.1965.tb11787.x;;10.1039/a908609i;;10.1016/s0022-0248(96)01128-1;;10.1039/b710895h;;10.1016/s0022-0248(03)01153-9;;10.1016/j.cemconres.2008.01.002;;10.1016/j.cemconres.2006.10.013;;10.1016/0077-7579(86)90043-8;;10.1016/0016-7037(87)90155-4;;10.2307/1543569;;12480717;;16494300;;10.1021/jp055063o;;10.1016/s0022-0248(98)00385-6;;10.1002/crat.200711081;;10.1016/0016-7037(73)90093-8;;10.1016/j.cemconcomp.2004.02.006;;10.1080/03008200390181681;;12952200;;10.1080/713713619;;10.1023/a:1010114131577;;10.1023/a:1011991124181,"C. Combes, Baoji Miao, Reine Bareille, Christian Rey; ""Preparation, physical-chemical characterisation and cytocompatibility of calcium carbonate cements""; Sep. 26, 2005; Biomaterials; vol. 27, Issue 9; p. 1945-1954.;;ACI Manual of Concrete Practice. Part 3-2010. Building Code Requirements for Structural Concrete (ACI 318-08) and Commentary, Chapter 4-Durability Requirements. American Concrete Institute, Farmington Hills, MI. pp. 318-355 to 318-361.;;Ajikumar, P.K. et al. 2005. Synthesis and Characterization of Monodispersed Spheres of Amorphous Calcium Carbonate and Calcite Spherules. Crystal Growth & Design. 5(3): 1129-1134.;;Architecture 2030 Ad Campaign. Think You're Making a Difference? Think Again. Issued by: 2030, Inc. / Architecture 2030 /The 2030 Research Center, http://www.architecture2030.org/news/multimedia.html. Accessed on Mar. 2, 2010.;;ASTM Standard C305-99, 1999. ""Standard Practice for Mechanical Mixing of Hydraulic Cement Pastes and Mortars of Plastic Consistency,"" ASTM International, West Conshohocken, PA, 1999, www.astm.org.;;ASTM Standard C191-04b, 2004, ""Standard Test Methods for Time of Setting of Hydraulic Cement by Vicat Needle,"" ASTM International, West Conshohocken, PA, 2004, www.astm.org.;;ASTM C1437-01, 2001, ""Standard Test Method for Flow of Hydraulic Cement Mortar,"" ASTM International, West Conshohocken, PA, 2001, www.astm.org.;;Boerner, B.J. et al. 1987. Trona and Sodium Bicarbonate in Beef Cattle Diets: Effects on pH and Volatile Fatty Acid Concentrations. Journal of Animal Science. 65: 309-316.;;Cement Association of Canada. 2009. Portland-Limestone Cement. Backgrounder, Aug. 2009. www.cement.ca.;;Constantz, B. 2009. Sequestering CO2 in the Built Environment, Trans. American Geophysical Union Fall Meeting, Poster session 90(52), Fall Meet. Suppl., Abstract U11A-0013 San Francisco.;;Dandeu, A. et al. 2006. Raman Spectroscopy-A Powerful Tool for the Quantitative Determination of the Composition of Polymorph Mixtures: Application to CaCO3 Polymorph Mixtures. Chem. Eng. Technol. 29(2): 221-225.;;Feldman, R.F. et al. 1965. Influence of CaCO3 on the Hydration of 3CaO.Al2O3, Journal of the American Ceramic Society. 48(1): 25-30.;;Hawkins, P. et al. 2003. The Use of Limestone in Portland Cement: A State-of-the-art Review, EB227, Portland Cement Association, Skokie, Illinois, USA, 44 pages.;;Hooton, R.D. et al. 2007. Portland-Limestone Cement: State-of-the-Art Report and Gap Analysis for CSA A 3000. Cement Association of Canada. University of Toronto.;;Kontoyannis, C.G. et al. 2000. Calcium carbonate phase analysis using XRD and FT-Raman spectroscopy. Analyst. 125: 251-255.;;Kralj, D. et al. 1997. Vaterite growth and dissolution in aqueous solution III. Kinetics of transformation. Journal of Crystal Growth. 177: 248-257.;;Lam, R.S.K. et al. 2007. Synthesis-dependant structural variations in amorphous calcium carbonate. CrystEngComm. 9: 1226-1236.;;Loste, E. et al. 2003. The role of magnesium in stabilising amorphous calcium carbonate and controlling calcite morphologies. Journal of Crystal Growth. 254: 206-218.;;Lothenbach, B. et al. 2008. Influence of limestone on the hydration of Portland cements. Cement and Concrete Research. 38: 848-860.;;Matschei, T. et al. 2007. The role of calcium carbonate in cement hydration. Cement and Concrete Research. 37: 551-558.;;Mook, W.G. et al. 1986. 13C in Atmospheric CO2. Netherlands Journal of Sea Research. 20(2/3): 211-223.;;Ogino, T. et al. 1987. The formation and transformation mechanism of calcium carbonate in water. Geochimica et Cosmochimica Acta. 51: 2757-2767.;;Raz, S. et al. 2002. Stable Amorphous Calcium Carbonate is the Main Component of the Calcium Storage Structures of the Crustacean Orchestia cavimana. Biol. Bull. 203: 269-274.;;Shen, Q. et al. 2006. Properties of Amorphous Calcium Carbonate and the Template Action of Vaterite Spheres. J. Phys. Chem. B. 110: 2994-3000.;;Spanos, N. et al. 1998. The transformation of vaterite to calcite: effect of the conditions of the solutions in contact with the mineral phase. Journal of Crystal Growth. 191: 783-790.;;Tang, H. et al. 2008. Creation of calcite hollow microspheres with attached bundles of aragonite needles. Cryst. Res. Technol. 43(5): 473-478.;;Turnbull, A.G. 1973. A thermochemical study of vaterite. Geochimica et Cosmochimica Acta. 37: 1593-1601.;;""U.S. Energy Information Administration, Emissions of Greenhouse Gases in the United States 2008, Report #: DOE/EIA-0573(2008), Release on Dec. 3, 2009. http://www.eia.doe.gov/oiaf/1605/ggrpt/carbon.html . Accessed on Feb. 27, 2010."";;Voglis, N. et al. 2005. Portland-limestone cements. Their properties and hydration compared to those of other composite cements. Cement & Concrete Composites. 27: 191-196.;;Weiner, S. et al. 2003. Biologically Formed Amorphous Calcium Carbonate. Connective Tissue Research. 44(Suppl. 1): 214-218.;;Winn, R.T. 2003. Stable Isotope Geochemistry of Aeolian Sediment at Owens Lake, California. A thesis in Geoscience. Submitted to the Graduate Faculty of Texas Tech University.;;Wolf, G. et al. 2000. Thermodynamic Aspects of the Vaterite-Calcite Phase Transition. Journal of Thermal Analysis and Calorimetry. 60: 463-472.;;Wolf et. al. 2001. Thermophysical Investigations of the Polymorphous Phases of Calcium Carbonate. Journal of Thermal Analysis and Calorimetry, 65: 687-698.;;""Metz, B. et al. Intergovernmental Panel on Climate Change, 2005-Carbon Dioxide Capture and Storage, IPCC Special Report. Bert Metz, Ogunlade Davidson, Heleen de Coninck, Manuela Loos and Leo Meyer (Eds.) Cambridge University Press, UK. pp. 431. http://www.ipcc.ch/publications-and-data/publications-and-data-reports.htm. Accessed on Mar. 2, 2010."";;International Search Report dated Oct. 1, 2010 of PCT/US2010/45620.;;Constantz, B. 2009. The Risk of Implementing New Regulations on Game-Changing Technology: Sequestering CO2 in the Built Environment. AGU, 90(22), Jt. Assem, Suppl., Abstract.",ACTIVE
401,WO,A1,WO 2019/132781 A1,028-200-270-122-992,2019-07-04,2019,SG 2018050637 W,2018-12-28,SG 10201710888P A,2017-12-28,MOTION COMPENSATION PLATFORM FOR IMAGE GUIDED PERCUTANEOUS ACCESS TO BODILY ORGANS AND STRUCTURES,"A method and a system for registering real-time intra-operative image data of a body to a model of the body, the method comprising, segmenting a plurality of image data of the body obtained using a pre-operative imaging device; constructing the model of the body from the segmented plurality of image data; identifying one or more landmark features on the model of the body; acquiring the real-time intra-operative image data of the body using an intra-operative imaging device; and registering the real-time intra-operative image data of the body to the model of the body by matching one or more landmark features labelled on the real-time intra-operative image data to one or more corresponding landmark features on the model of the body, wherein the one or more landmark features comprises a superior and an inferior pole of the body.",CHANGI GENERAL HOSPITAL PTE LTD;;UNIV SINGAPORE TECHNOLOGY & DESIGN,NG FOO CHEONG;;LIM SEY KIAT TERENCE;;KARUPPPASAMY SUBBURAJ;;TAN U-XUAN;;CHEN LUJIE;;FOONG SHAOHUI;;YANG LIANGJING;;LI HSIEH-YU;;PARANAWITHANA ISHARA CHAMINDA KARIYAWASAM;;CHAU ZHONG HOO;;MOOKIAH MUTHU RAMA KRISHNAN,,https://lens.org/028-200-270-122-992,Patent Application,yes,2,9,5,5,0,A61B5/0037;;G06T7/55;;G06T7/344;;G06T7/38;;A61B2576/00;;A61B6/5247;;A61B8/5261;;A61B34/70;;A61B34/76;;A61B2034/2065;;G06T15/08;;G06T2207/30004;;G06V20/20;;A61B5/05;;A61B34/20;;G06T17/00;;A61B90/37;;A61B2090/378;;A61B34/10;;A61B2034/105;;A61B2034/107;;A61B34/75;;A61B34/25;;A61B2034/2059;;A61B2090/3784;;A61B2034/2063;;G06T2210/41;;A61B2017/00699;;A61B2090/364;;A61B17/3403;;A61B90/11;;A61B2017/3409;;A61B34/30;;G06T7/33;;G06T2207/30084;;G06T2207/10132;;G06T2207/10072;;A61B2017/3413;;A61B34/10;;A61B2034/105;;A61B2034/107;;A61B34/20;;A61B34/25;;A61B34/30;;A61B34/70;;A61B34/76;;A61B90/37;;A61B2090/378;;G06T7/11;;G06T7/344;;A61B5/0037;;A61B5/055;;A61B5/7425;;A61B6/032;;A61B8/52;;A61B17/3403;;A61B2503/40;;G06T3/40;;G06T17/20;;G06T2207/10081;;G06T2207/10088;;G06T2207/10132;;G06T2207/20156;;G06T2207/30084;;G06T2210/41,A61B34/20;;G06T3/00;;G06T7/10;;G06T11/00;;G06T15/00;;G06T17/00,,3,3,018-508-933-820-280;;086-874-805-002-140;;075-995-348-019-01X,10.1109/tmech.2010.2078827;;10.1109/jbhi.2013.2287202;;pmc4113118;;24235279;;10.1109/iros.2016.7759099,"YANG, L. ET AL.: ""A Robotic System for Overlapping Radiofrequency Ablation in Large Tumor Treatment"", IEEE /ASME TRANSACTIONS ON MECHATRONICS, vol. 15, no. 6, 2010, pages 887 - 897, XP011339832, doi:10.1109/TMECH.2010.2078827;;REN, H. ET AL.: ""Treatment Planning and Image Guidance for Radiofrequency Ablations of Large Tumors"", IEEE JOURNAL OF BIOMEDICAL HEALTH INFORMATICS, vol. 18, no. 3, 2014, pages 920 - 928, XP011547025, doi:10.1109/JBHI.2013.2287202;;HAOUCHINE, N. ET AL.: ""Using contours as Boundary Conditions for Elastic Registration during Minimally Invasive Hepatic Surgery"", INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND SYSTEMS (IROS, 2016, pages 495 - 500, XP033011449, doi:10.1109/IROS.2016.7759099",PENDING
402,US,A1,US 2021/0059762 A1,009-084-364-924-086,2021-03-04,2021,US 201816958587 A,2018-12-28,SG 10201710888P A;;SG 2018050637 W,2017-12-28,MOTION COMPENSATION PLATFORM FOR IMAGE GUIDED PERCUTANEOUS ACCESS TO BODILY ORGANS AND STRUCTURES,"A method and a system for registering real-time intra-operative image data of a body to a model of the body, the method comprising, segmenting a plurality of image data of the body obtained using a pre-operative imaging device; constructing the model of the body from the segmented plurality of image data; identifying one or more landmark features on the model of the body; acquiring the real-time intra-operative image data of the body using an intra-operative imaging device; and registering the real-time intra-operative image data of the body to the model of the body by matching one or more landmark features labelled on the real-time intra-operative image data to one or more corresponding landmark features on the model of the body, wherein the one or more landmark features comprises a superior and an inferior pole of the body.",CHANGI GENERAL HOSPITAL PTE LTD;;UNIV SINGAPORE TECHNOLOGY & DESIGN,NG FOO CHEONG;;LIM SEY KIAT TERENCE;;KARUPPPASAMY SUBBURAJ;;TAN U-XUAN;;CHEN LUJIE;;FOONG SHAOHUI;;YANG LIANGJING;;LI HSIEH-YU;;PARANAWITHANA ISHARA CHAMINDA KARIYAWASAM;;CHAU ZHONG HOO;;MOOKIAH MUTHU RAMA KRISHNAN,SINGAPORE UNIVERSITY OF TECHNOLOGY AND DESIGN (2020-10-13);;CHANGI GENERAL HOSPITAL PTE LTD (2020-10-13),https://lens.org/009-084-364-924-086,Patent Application,yes,4,17,5,5,0,A61B5/0037;;G06T7/55;;G06T7/344;;G06T7/38;;A61B2576/00;;A61B6/5247;;A61B8/5261;;A61B34/70;;A61B34/76;;A61B2034/2065;;G06T15/08;;G06T2207/30004;;G06V20/20;;A61B5/05;;A61B34/20;;G06T17/00;;A61B90/37;;A61B2090/378;;A61B34/10;;A61B2034/105;;A61B2034/107;;A61B34/75;;A61B34/25;;A61B2034/2059;;A61B2090/3784;;A61B2034/2063;;G06T2210/41;;A61B2017/00699;;A61B2090/364;;A61B17/3403;;A61B90/11;;A61B2017/3409;;A61B34/30;;G06T7/33;;G06T2207/30084;;G06T2207/10132;;G06T2207/10072;;A61B2017/3413;;A61B34/10;;A61B2034/105;;A61B2034/107;;A61B34/20;;A61B34/25;;A61B34/30;;A61B34/70;;A61B34/76;;A61B90/37;;A61B2090/378;;G06T7/11;;G06T7/344;;A61B5/0037;;A61B5/055;;A61B5/7425;;A61B6/032;;A61B8/52;;A61B17/3403;;A61B2503/40;;G06T3/40;;G06T17/20;;G06T2207/10081;;G06T2207/10088;;G06T2207/10132;;G06T2207/20156;;G06T2207/30084;;G06T2210/41,A61B34/20;;A61B5/00;;A61B5/055;;A61B6/03;;A61B8/08;;A61B17/34;;A61B34/00;;A61B34/10;;A61B90/00;;G06T3/40;;G06T7/11;;G06T7/33;;G06T17/20,,0,0,,,,DISCONTINUED
403,SG,A,SG 11202005483X A,007-706-149-647-195,2020-07-29,2020,SG 11202005483X A,2018-12-28,SG 10201710888P A;;SG 2018050637 W,2017-12-28,MOTION COMPENSATION PLATFORM FOR IMAGE GUIDED PERCUTANEOUS ACCESS TO BODILY ORGANS AND STRUCTURES,,CHANGI GENERAL HOSPITAL PTE LTD;;UNIV SINGAPORE TECHNOLOGY & DESIGN,NG FOO CHEONG;;LIM SEY KIAT TERENCE;;KARUPPPASAMY SUBBURAJ;;TAN U-XUAN;;CHEN LUJIE;;FOONG SHAOHUI;;YANG LIANGJING;;LI HSIEH-YU;;PARANAWITHANA ISHARA CHAMINDA KARIYAWASAM;;CHAU ZHONG HOO;;MOOKIAH MUTHU RAMA KRISHNAN,,https://lens.org/007-706-149-647-195,Unknown,no,0,0,5,5,0,A61B5/0037;;G06T7/55;;G06T7/344;;G06T7/38;;A61B2576/00;;A61B6/5247;;A61B8/5261;;A61B34/70;;A61B34/76;;A61B2034/2065;;G06T15/08;;G06T2207/30004;;G06V20/20;;A61B5/05;;A61B34/20;;G06T17/00;;A61B90/37;;A61B2090/378;;A61B34/10;;A61B2034/105;;A61B2034/107;;A61B34/75;;A61B34/25;;A61B2034/2059;;A61B2090/3784;;A61B2034/2063;;G06T2210/41;;A61B2017/00699;;A61B2090/364;;A61B17/3403;;A61B90/11;;A61B2017/3409;;A61B34/30;;G06T7/33;;G06T2207/30084;;G06T2207/10132;;G06T2207/10072;;A61B2017/3413;;A61B34/10;;A61B2034/105;;A61B2034/107;;A61B34/20;;A61B34/25;;A61B34/30;;A61B34/70;;A61B34/76;;A61B90/37;;A61B2090/378;;G06T7/11;;G06T7/344;;A61B5/0037;;A61B5/055;;A61B5/7425;;A61B6/032;;A61B8/52;;A61B17/3403;;A61B2503/40;;G06T3/40;;G06T17/20;;G06T2207/10081;;G06T2207/10088;;G06T2207/10132;;G06T2207/20156;;G06T2207/30084;;G06T2210/41,A61B34/20;;G06T3/00;;G06T7/10;;G06T11/00;;G06T15/00;;G06T17/00,,0,0,,,,PENDING
404,EP,A4,EP 3716879 A4,018-442-611-612-121,2022-01-26,2022,EP 18897064 A,2018-12-28,SG 10201710888P A;;SG 2018050637 W,2017-12-28,MOTION COMPENSATION PLATFORM FOR IMAGE GUIDED PERCUTANEOUS ACCESS TO BODILY ORGANS AND STRUCTURES,,CHANGI GENERAL HOSPITAL PTE LTD;;UNIV SINGAPORE TECHNOLOGY & DESIGN,NG FOO CHEONG;;LIM SEY KIAT TERENCE;;KARUPPPASAMY SUBBURAJ;;TAN U-XUAN;;CHEN LUJIE;;FOONG SHAOHUI;;YANG LIANGJING;;LI HSIEH-YU;;PARANAWITHANA ISHARA CHAMINDA KARIYAWASAM;;CHAU ZHONG HOO;;MOOKIAH MUTHU RAMA KRISHNAN,,https://lens.org/018-442-611-612-121,Search Report,no,10,0,5,5,0,A61B5/0037;;G06T7/55;;G06T7/344;;G06T7/38;;A61B2576/00;;A61B6/5247;;A61B8/5261;;A61B34/70;;A61B34/76;;A61B2034/2065;;G06T15/08;;G06T2207/30004;;G06V20/20;;A61B5/05;;A61B34/20;;G06T17/00;;A61B90/37;;A61B2090/378;;A61B34/10;;A61B2034/105;;A61B2034/107;;A61B34/75;;A61B34/25;;A61B2034/2059;;A61B2090/3784;;A61B2034/2063;;G06T2210/41;;A61B2017/00699;;A61B2090/364;;A61B17/3403;;A61B90/11;;A61B2017/3409;;A61B34/30;;G06T7/33;;G06T2207/30084;;G06T2207/10132;;G06T2207/10072;;A61B2017/3413;;A61B34/10;;A61B2034/105;;A61B2034/107;;A61B34/20;;A61B34/25;;A61B34/30;;A61B34/70;;A61B34/76;;A61B90/37;;A61B2090/378;;G06T7/11;;G06T7/344;;A61B5/0037;;A61B5/055;;A61B5/7425;;A61B6/032;;A61B8/52;;A61B17/3403;;A61B2503/40;;G06T3/40;;G06T17/20;;G06T2207/10081;;G06T2207/10088;;G06T2207/10132;;G06T2207/20156;;G06T2207/30084;;G06T2210/41,A61B34/20;;A61B17/34;;A61B34/30;;G06T3/00;;G06T7/10;;G06T7/33;;G06T11/00;;G06T15/00;;G06T17/00,,2,1,002-571-218-578-422,22920687;;10.1186/1475-925x-11-60;;pmc3494559,"MAHDI MARSOUSI: ""Automated Kidney Segmentation in 3D Ultrasound Imagery, and its Application in Computer-Assisted Trauma Diagnosis"", 1 January 2016 (2016-01-01), Ann Arbor, pages 1 - 164, XP055718058, ISBN: 978-1-369-67345-6, Retrieved from the Internet <URL:https://tspace.library.utoronto.ca/bitstream/1807/76563/1/Marsousi_Mahdi_201611_PhD_thesis.pdf> [retrieved on 20200727];;ZHI-CHENG LI ET AL: ""Augmenting intraoperative ultrasound with preoperative magnetic resonance planning models for percutaneous renal access"", BIOMEDICAL ENGINEERING ONLINE, BIOMED CENTRAL LTD, LONDON, GB, vol. 11, no. 1, 24 August 2012 (2012-08-24), pages 60, XP021121486, ISSN: 1475-925X, DOI: 10.1186/1475-925X-11-60",DISCONTINUED
405,EP,A1,EP 3716879 A1,196-794-185-351-478,2020-10-07,2020,EP 18897064 A,2018-12-28,SG 10201710888P A;;SG 2018050637 W,2017-12-28,MOTION COMPENSATION PLATFORM FOR IMAGE GUIDED PERCUTANEOUS ACCESS TO BODILY ORGANS AND STRUCTURES,,CHANGI GENERAL HOSPITAL PTE LTD;;UNIV SINGAPORE TECHNOLOGY & DESIGN,NG FOO CHEONG;;LIM SEY KIAT TERENCE;;KARUPPPASAMY SUBBURAJ;;TAN U-XUAN;;CHEN LUJIE;;FOONG SHAOHUI;;YANG LIANGJING;;LI HSIEH-YU;;PARANAWITHANA ISHARA CHAMINDA KARIYAWASAM;;CHAU ZHONG HOO;;MOOKIAH MUTHU RAMA KRISHNAN,,https://lens.org/196-794-185-351-478,Patent Application,yes,0,0,5,5,0,A61B5/0037;;G06T7/55;;G06T7/344;;G06T7/38;;A61B2576/00;;A61B6/5247;;A61B8/5261;;A61B34/70;;A61B34/76;;A61B2034/2065;;G06T15/08;;G06T2207/30004;;G06V20/20;;A61B5/05;;A61B34/20;;G06T17/00;;A61B90/37;;A61B2090/378;;A61B34/10;;A61B2034/105;;A61B2034/107;;A61B34/75;;A61B34/25;;A61B2034/2059;;A61B2090/3784;;A61B2034/2063;;G06T2210/41;;A61B2017/00699;;A61B2090/364;;A61B17/3403;;A61B90/11;;A61B2017/3409;;A61B34/30;;G06T7/33;;G06T2207/30084;;G06T2207/10132;;G06T2207/10072;;A61B2017/3413;;A61B34/10;;A61B2034/105;;A61B2034/107;;A61B34/20;;A61B34/25;;A61B34/30;;A61B34/70;;A61B34/76;;A61B90/37;;A61B2090/378;;G06T7/11;;G06T7/344;;A61B5/0037;;A61B5/055;;A61B5/7425;;A61B6/032;;A61B8/52;;A61B17/3403;;A61B2503/40;;G06T3/40;;G06T17/20;;G06T2207/10081;;G06T2207/10088;;G06T2207/10132;;G06T2207/20156;;G06T2207/30084;;G06T2210/41,G06T3/00;;A61B34/20;;G06T7/10;;G06T11/00;;G06T15/00;;G06T17/00,,0,0,,,,DISCONTINUED
406,EP,A1,EP 1470580 A1,170-695-475-130-799,2004-10-27,2004,EP 02784578 A,2002-11-22,US 0237758 W;;US 4796402 A,2002-01-15,Method for bilayer HDP CVD / PE CVD cap in advanced BEOL interconnect structures,"An advanced back-end-of-line (BEOL) metallization structure is disclosed. The structure includes a bilayer diffusion barrier or cap, where the first cap layer is formed of a dielectric material preferably deposited by a high density plasma chemical vapor deposition (HDP CVD) process, and the second cap layer is formed of a dielectric material preferably deposited by a plasma-enhanced chemical vapor deposition (PE CVD) process. A method for forming the BEOL metallization structure is also disclosed. The invention is particularly useful in interconnect structure comprising low-k dielectric material for the inter-layer dielectric (ILD) and copper for the conductors.",INFINEON TECHNOLOGIES AG;;INFINEON TECHNOLOGIES CORP,CHEN TZE-CHIANG;;ENGEL BRETT H;;FITZSIMMONS JOHN A;;KANE TERENCE;;LUSTIG NAFTALI E;;MCDONALD ANN C O IBM UNITED KI;;MCGAHAY VINCENT;;SEO SOON-CHEON;;STAMPER ANTHONY K;;WANG YUN YU;;KALTALIOGLU ERDEM,INFINEON TECHNOLOGIES AG (2010-06-02);;INTERNATIONAL BUSINESS MACHINES CORPORATION (2010-06-02),https://lens.org/170-695-475-130-799,Patent Application,yes,0,0,22,22,0,H01L21/76807;;H01L21/76832;;H01L21/76834;;H01L23/5226;;H01L23/53228;;H01L23/53295;;H01L2924/0002;;H01L21/768;;H01L21/76834;;H01L23/53295;;H01L21/76832;;H01L23/53228;;H01L23/5226;;H01L21/76807;;H01L21/76801;;H01L2924/0002,H01L21/768;;H01L23/522;;H01L23/532,,0,0,,,,EXPIRED
407,AU,B2,AU 2010/337357 B2,192-120-146-953-816,2013-11-28,2013,AU 2010/337357 A,2010-08-16,US 29181109 P;;US 37160610 P;;US 36082910 P;;US 2010/0045620 W,2009-12-31,Methods and compositions using calcium carbonate,"Provided herein are compositions and methods including hydraulic cement, supplementary cementitious material, and/or self-cementing material. Methods for making the compositions and using the compositions are provided.",ARELAC INC,CONSTANTZ BRENT R;;FARSAD KASRA;;CAMIRE CHRIS;;PATTERSON JOSHUA;;FERNANDEZ MIGUEL;;GINDER-VOGEL MATTHEW;;YACCATO KARIN;;THATCHER RYAN;;STAGNARO JOHN;;CHEN IRVIN;;OMELON SIDNEY;;HODSON KEITH;;CLODIC LAURENCE;;DEVENNEY MARTIN;;GERAMITA KATHARINE;;HOLLAND TERENCE C,"ARELAC, INC. (2019-10-03)",https://lens.org/192-120-146-953-816,Granted Patent,no,4,0,26,33,0,C04B28/02;;Y10S264/43;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y02C20/40;;Y02P40/10;;C04B28/02;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y10S264/43;;Y02C20/40;;C04B14/28;;C04B28/04,C04B40/00,,0,0,,,,ACTIVE
408,CA,A1,CA 2785143 A1,039-055-663-793-130,2011-07-07,2011,CA 2785143 A,2010-08-16,US 29181109 P;;US 36082910 P;;US 37160610 P;;US 2010/0045620 W,2009-12-31,METHODS AND COMPOSITIONS USING CALCIUM CARBONATE,"Provided herein are compositions and methods including hydraulic cement, supplementary cementitious material, and/or self-cementing material. Methods for making the compositions and using the compositions are provided.",CALERA CORP,CONSTANTZ BRENT R;;FARSAD KASRA;;CAMIRE CHRIS;;PATTERSON JOSHUA;;FERNANDEZ MIGUEL;;GINDER-VOGEL MATTHEW;;YACCATO KARIN;;THATCHER RYAN;;STAGNARO JOHN;;CHEN IRVIN;;OMELON SIDNEY;;HODSON KEITH;;CLODIC LAURENCE;;DEVENNEY MARTIN;;GERAMITA KATHARINE;;HOLLAND TERENCE C,,https://lens.org/039-055-663-793-130,Patent Application,no,0,13,26,33,0,C04B28/02;;Y10S264/43;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y02C20/40;;Y02P40/10;;C04B28/02;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y10S264/43;;Y02C20/40;;C04B14/28;;C04B28/04,C04B40/00,,0,0,,,,ACTIVE
409,EP,A4,EP 2519483 A4,163-678-511-613-651,2014-03-12,2014,EP 10841411 A,2010-08-16,US 37160610 P;;US 36082910 P;;US 29181109 P;;US 2010/0045620 W,2009-12-31,METHODS AND COMPOSITIONS USING CALCIUM CARBONATE,,CALERA CORP,CONSTANTZ BRENT R;;FARSAD KASRA;;CAMIRE CHRIS;;PATTERSON JOSHUA;;FERNANDEZ MIGUEL;;GINDER-VOGEL MATTHEW;;YACCATO KARIN;;THATCHER RYAN;;STAGNARO JOHN;;CHEN IRVIN;;OMELON SIDNEY;;HODSON KEITH;;CLODIC LAURENCE;;DEVENNEY MARTIN;;GERAMITA KATHARINE;;HOLLAND TERENCE C,CALERA CORPORATION (2014-11-19),https://lens.org/163-678-511-613-651,Search Report,no,5,0,26,33,0,C04B28/02;;Y10S264/43;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y02C20/40;;Y02P40/10;;C04B28/02;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y10S264/43;;Y02C20/40;;C04B14/28;;C04B28/04,C04B40/00;;B01D53/62;;C04B28/02,,3,2,004-303-333-784-960;;033-485-869-185-570,10.1021/es802910z;;19368202;;16941549;;10.1002/rcm.2688,"HUNTZINGER D N ET AL: ""Carbon Dioxide Sequestration in Cement Kiln Dust Through Mineral Carbonation"", ENVIRONMENTAL SCIENCE & TECHNOLOGY, AMERICAN CHEMICAL SOCIETY, vol. 43, no. 6, 9 January 2009 (2009-01-09), pages 1986 - 1992, XP008134503, ISSN: 0013-936X, [retrieved on 20090205], DOI: 10.1021/ES802910Z;;BIELLO D: ""Cement from CO2: a concrete cure for global warming"", INTERNET CITATION, 7 August 2008 (2008-08-07), pages 1 - 2, XP002614229, Retrieved from the Internet <URL:http://www.scientificamerican.com/article.cfm?id=cement-from-carbon-dioxide> [retrieved on 20101214];;SKRZYPEK G ET AL: ""d13C analyses of calcium carbonate: comparison between the GasBench and elemental analyzer techniques"", RAPID COMMUNICATIONS IN MASS SPECTROMETRY, JOHN WILEY & SONS, GB, vol. 20, 15 October 2006 (2006-10-15), pages 2915 - 2920, XP002614230, ISSN: 0951-4198, [retrieved on 20060829], DOI: 10.1002/RCM.2688",DISCONTINUED
410,CN,A,CN 104003669 A,042-956-280-116-34X,2014-08-27,2014,CN 201410049870 A,2010-08-16,US 29181109 P;;US 36082910 P;;US 37160610 P,2009-12-31,Methods and compositions using calcium carbonate,"Provided herein are compositions and methods including hydraulic cement, supplementary cementitious material, and/or self-cementing material. Methods for making the compositions and using the compositions are provided.",CALERA CORP,CONSTANTZ BRENT R;;FARSAD KASRA;;CAMIRE CHRIS;;PATTERSON JOSHUA;;FERNANDEZ MIGUEL;;GINDER-VOGEL MATTHEW;;YACCATO KARIN;;THATCHER RYAN;;STAGNARO JOHN;;CHEN IRVIN;;OMELON SIDNEY;;HODSON KEITH;;CLODIC LAURENCE;;DEVENNEY MARTIN;;GERAMITA KATHARINE;;HOLLAND TERENCE C,,https://lens.org/042-956-280-116-34X,Patent Application,no,5,2,26,33,0,C04B28/02;;Y10S264/43;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y02C20/40;;Y02P40/10;;C04B28/02;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y10S264/43;;Y02C20/40;;C04B14/28;;C04B28/04,C04B28/02,,0,0,,,,DISCONTINUED
411,AU,A1,AU 2010/337357 A1,038-102-913-052-62X,2012-07-05,2012,AU 2010/337357 A,2010-08-16,US 29181109 P;;US 37160610 P;;US 36082910 P;;US 2010/0045620 W,2009-12-31,Methods and compositions using calcium carbonate,"Provided herein are compositions and methods including hydraulic cement, supplementary cementitious material, and/or self-cementing material. Methods for making the compositions and using the compositions are provided.",CALERA CORP,CONSTANTZ BRENT R;;FARSAD KASRA;;CAMIRE CHRIS;;PATTERSON JOSHUA;;FERNANDEZ MIGUEL;;GINDER-VOGEL MATTHEW;;YACCATO KARIN;;THATCHER RYAN;;STAGNARO JOHN;;CHEN IRVIN;;OMELON SIDNEY;;HODSON KEITH;;CLODIC LAURENCE;;DEVENNEY MARTIN;;GERAMITA KATHARINE;;HOLLAND TERENCE C,"ARELAC, INC. (2019-10-03)",https://lens.org/038-102-913-052-62X,Patent Application,no,0,0,26,33,0,C04B28/02;;Y10S264/43;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y02C20/40;;Y02P40/10;;C04B28/02;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y10S264/43;;Y02C20/40;;C04B14/28;;C04B28/04,C04B40/00,,0,0,,,,ACTIVE
412,CN,B,CN 102712548 B,076-661-847-387-18X,2014-03-26,2014,CN 201080059980 A,2010-08-16,US 2010/0045620 W;;US 29181109 P;;US 36082910 P;;US 37160610 P,2009-12-31,Methods and compositions using calcium carbonate,,CALERA CORP,CONSTANTZ BRENT R;;FARSAD KASRA;;CAMIRE CHRIS;;PATTERSON JOSHUA;;FERNANDEZ MIGUEL;;GINDER-VOGEL MATTHEW;;YACCATO KARIN;;THATCHER RYAN;;STAGNARO JOHN;;CHEN IRVIN;;OMELON SIDNEY;;HODSON KEITH;;CLODIC LAURENCE;;DEVENNEY MARTIN;;GERAMITA KATHARINE;;HOLLAND TERENCE C,,https://lens.org/076-661-847-387-18X,Granted Patent,no,0,0,26,33,0,C04B28/02;;Y10S264/43;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y02C20/40;;Y02P40/10;;C04B28/02;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y10S264/43;;Y02C20/40;;C04B14/28;;C04B28/04,C04B40/00,,0,0,,,,ACTIVE
413,CN,A,CN 102712548 A,147-470-746-980-138,2012-10-03,2012,CN 201080059980 A,2010-08-16,US 2010/0045620 W;;US 29181109 P;;US 36082910 P;;US 37160610 P,2009-12-31,Methods and compositions using calcium carbonate,"Provided herein are compositions and methods including hydraulic cement, supplementary cementitious material, and/or self-cementing material. Methods for making the compositions and using the compositions are provided.",CALERA CORP,CONSTANTZ BRENT R;;KASRA FARSAD;;CHRIS CAMIRE;;JOSHUA PATTERSON;;MIGUEL FERNANDEZ;;MATTHEW GINDER-VOGEL;;KARIN YACCATO;;RYAN THATCHER;;JOHN STAGNARO;;IRVIN CHEN;;SIDNEY OMELON;;KEITH HODSON;;LAURENCE CLODIC;;MARTIN DEVENNEY;;KATHARINE GERAMITA;;HOLLAND TERENCE C,,https://lens.org/147-470-746-980-138,Patent Application,no,2,10,26,33,0,C04B28/02;;Y10S264/43;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y02C20/40;;Y02P40/10;;C04B28/02;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y10S264/43;;Y02C20/40;;C04B14/28;;C04B28/04,C04B40/00,,0,0,,,,ACTIVE
414,WO,A1,WO 2011/081681 A1,183-843-580-346-421,2011-07-07,2011,US 2010/0045620 W,2010-08-16,US 37160610 P;;US 36082910 P;;US 29181109 P,2009-12-31,METHODS AND COMPOSITIONS USING CALCIUM CARBONATE,"Provided herein are compositions and methods including hydraulic cement, supplementary cementitious material, and/or self-cementing material. Methods for making the compositions and using the compositions are provided.",CALERA CORP;;CONSTANTZ BRENT R;;FARSAD KASRA;;CAMIRE CHRIS;;PATTERSON JOSHUA;;FERNANDEZ MIGUEL;;GINDER-VOGEL MATTHEW;;YACCATO KARIN;;THATCHER RYAN;;STAGNARO JOHN;;CHEN IRVIN;;OMELON SIDNEY;;HODSON KEITH;;CLODIC LAURENCE;;DEVENNEY MARTIN;;GERAMITA KATHARINE;;HOLLAND TERENCE C,CONSTANTZ BRENT R;;FARSAD KASRA;;CAMIRE CHRIS;;PATTERSON JOSHUA;;FERNANDEZ MIGUEL;;GINDER-VOGEL MATTHEW;;YACCATO KARIN;;THATCHER RYAN;;STAGNARO JOHN;;CHEN IRVIN;;OMELON SIDNEY;;HODSON KEITH;;CLODIC LAURENCE;;DEVENNEY MARTIN;;GERAMITA KATHARINE;;HOLLAND TERENCE C,,https://lens.org/183-843-580-346-421,Patent Application,yes,2,36,26,33,0,C04B28/02;;Y10S264/43;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y02C20/40;;Y02P40/10;;C04B28/02;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y10S264/43;;Y02C20/40;;C04B14/28;;C04B28/04,C04B40/00,,0,0,,,,PENDING
415,EP,A1,EP 2519483 A1,078-358-088-846-824,2012-11-07,2012,EP 10841411 A,2010-08-16,US 37160610 P;;US 36082910 P;;US 29181109 P;;US 2010/0045620 W,2009-12-31,METHODS AND COMPOSITIONS USING CALCIUM CARBONATE,,CALERA CORP,CONSTANTZ BRENT R;;FARSAD KASRA;;CAMIRE CHRIS;;PATTERSON JOSHUA;;FERNANDEZ MIGUEL;;GINDER-VOGEL MATTHEW;;YACCATO KARIN;;THATCHER RYAN;;STAGNARO JOHN;;CHEN IRVIN;;OMELON SIDNEY;;HODSON KEITH;;CLODIC LAURENCE;;DEVENNEY MARTIN;;GERAMITA KATHARINE;;HOLLAND TERENCE C;;RIES JUSTIN,CALERA CORPORATION (2014-11-19),https://lens.org/078-358-088-846-824,Patent Application,yes,0,2,26,33,0,C04B28/02;;Y10S264/43;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y02C20/40;;Y02P40/10;;C04B28/02;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y10S264/43;;Y02C20/40;;C04B14/28;;C04B28/04,C04B40/00;;B01D53/62;;C04B28/02,,0,0,,,,DISCONTINUED
416,CA,C,CA 2785143 C,181-521-404-618-622,2014-10-14,2014,CA 2785143 A,2010-08-16,US 29181109 P;;US 36082910 P;;US 37160610 P;;US 2010/0045620 W,2009-12-31,METHODS AND COMPOSITIONS USING CALCIUM CARBONATE,"Provided herein are compositions and methods including hydraulic cement, supplementary cementitious material, and/or self-cementing material. Methods for making the compositions and using the compositions are provided.",CALERA CORP,CONSTANTZ BRENT R;;FARSAD KASRA;;CAMIRE CHRIS;;PATTERSON JOSHUA;;FERNANDEZ MIGUEL;;GINDER-VOGEL MATTHEW;;YACCATO KARIN;;THATCHER RYAN;;STAGNARO JOHN;;CHEN IRVIN;;OMELON SIDNEY;;HODSON KEITH;;CLODIC LAURENCE;;DEVENNEY MARTIN;;GERAMITA KATHARINE;;HOLLAND TERENCE C;;RIES JUSTIN,,https://lens.org/181-521-404-618-622,Granted Patent,no,0,0,26,33,0,C04B28/02;;Y10S264/43;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y02C20/40;;Y02P40/10;;C04B28/02;;B01D53/62;;B01D2251/404;;B01D2257/504;;B01D2258/0233;;Y10S264/43;;Y02C20/40;;C04B14/28;;C04B28/04,C04B7/345;;C04B28/02,,0,0,,,,ACTIVE
417,US,A,US 6055268 A,053-022-168-512-473,2000-04-25,2000,US 66726796 A,1996-06-20,US 66726796 A;;CA 2217073 A;;US 64502096 A,1996-05-09,Multimode digital modem,"A modem communication system with receiving and transmission paths includes a direct equalizer system having an adaptive filter (1532) in the transmission path to compensate for frequency distortion of the communication channel. The transmitter filter coefficients are adapted by a filter coefficient calculator (1528), under control of a data detector (1526) which detects incoming data in the receiving path. A switch (1534) is controlled by status of a transmit output data buffer to multiplex either the training sequence or output data into the transmission path. When the buffer is idle, the training sequence generator (1540) is linked to a digital-to-analog (D/A) converter (1536) and line driver (1538). The receiving path includes an isolation switch (1520), a receiver amplifier (1522) and a slicer (1524). The receiver correlates the received training sequence with a known training sequence and updates the equalizer filter coefficients using an adaptation algorithm, such as a least mean squared algorithm. A first embodiment utilizes a high speed digital programmable filter (1532). Another embodiment utilizes a data buffer (1533) which is periodically filled with data filtered by a digital signal processor (DSP).",TEXAS INSTRUMENTS INC,TIMM WILLIAM C;;CHEN WALTER Y;;FRANTZ GENE A;;GARCIA DOMINGO G;;LU XIAOLIN;;MANNERING DENNIS G;;POLLEY MICHAEL O;;RILEY TERENCE J;;SHAVER DONALD P;;WU SONG S;;GATHERER ALAN;;SCHURR PAUL E;;WEINER DOUGLAS B,TEXAS INSTRUMENTS INCORPORATED (1996-07-17),https://lens.org/053-022-168-512-473,Granted Patent,yes,22,282,6,24,0,H04L1/0003;;H04L1/0009;;H04L1/0016;;H04L1/0023;;H04L1/0059;;H04L1/16;;H04L5/1438;;H04L25/03;;H04L25/03343;;H04L25/4921;;H04L27/2647;;H04L2025/03414;;H04L2025/03611;;H04M11/06;;H04M11/062;;H04L27/2675;;Y02D30/50;;H04L1/0023;;H04L25/03343;;H04L2025/03414;;H04L27/2647;;H04L2025/03611;;H04L1/0059;;H04L1/0009;;H04L1/0003;;H04M11/062;;H04L1/0016;;H04L5/1438;;H04L25/03;;H04L25/4921;;H04L1/16;;H04M11/06;;H04L27/2675;;Y02D30/50,H04L29/10;;H04J11/00;;H04L1/00;;H04L1/16;;H04L5/14;;H04L25/03;;H04L25/49;;H04L27/26;;H04M11/00;;H04M11/06,375/229;;375/231,27,4,116-493-584-883-366;;041-825-444-145-926;;077-689-611-505-590;;027-651-150-403-788,10.1109/glocom.1990.116683;;10.1109/glocom.1990.116684;;10.1109/49.127783;;10.1109/glocom.1990.116682,"Crespo, P., et al., Pole Zero Decision Feedback Equalization for the Digital Subscriber Loop Globecom 90, IEEE Global Telecomm. Conf. & Exhibit, San Diego, CA, Dec. 2 5, 1990, Communications: Connecting the Future ; CH2827 4/90/0000 11666, 1990 IEEE, pp. 1166 1171.;;Sistanizadeh, K., Analysis and Performance Evaluation Studies of High Bit Rate Digital Subscriber Lines ( HDSL ) Using QAM and PAM Schemes With Ideal Decision Feedback Equalization ( DFE ) Within a Carrier Serving Area ( CSA ), Globecom 90, IEEE Global Telecomm. Conf. & Exhibit, San Diego, CA, Dec. 2 5, 1990, Communications: Connecting the Future ; CH2827 4/90/0000 1172, 1990 IEEE.;;Veeneman, D., et al., ADSL for Video and Data Service , ICC 95 Seattle, WA, Communications Gateway to Globalization, 1995 IEEE Int l Conf. on Comm., Jun. 18 22, 1995; 0 7803 2486 2/95, 1995 IEEE.;;Cook, John, Splitter for VDSL , T1E1.4 Contribution, American Nat l Standards Institute Telecommunications Committee (ANSI/T1), Jan. 22 25, 1996, Irvine, CA Meeting, 10 pages.;;Honig, M.L., et al., Suppression of Near and Far End Crosstalk by Linear Pre and Post Filtering , IEEE Journal on Selection Areas in Comm., vol. 10, No. 3, Apr. 1992, pp. 614 629.;;Cioffi, J.M., et al., Detailed DMT Transmitter Description for ADSL , ANSI T1E1.4 Committee Contribution No. 93 084, Chicago, Apr. 1993, pgs.;;Cioffi, J.M., et al., DMT Specification Overview for ADSL , ANSI T1E1.4 Committee Contribution No. 93 083, Chicago, Apr. 1993, pgs.;;Chow, J.S., Finite Length Equalization for Multi Carrier Transmission Systems , Ph.D. Dissertation, Stanford University, California, Jun. 1992.;;Chow, J.S., et al., Equalizer Training Algorithms for Multicarrier Modulation Systems , 1993 Int l Conf. on Communications, Geneva, May 1993, pp. 761 765.;;Chow, J.S., et al., Recommended Training Sequence for Time domain Equalizers ( TQE ) With DMT , ANSI T1E1.4 Committee Contribution No. 93 968, pgs.;;The Applied Technologies Group, AT&T Paradyne, ADSL, SDSL, HDSL, Copper Phone Line Technologies for Multimedia , Pocket Guide, One Apple Hill, 316, Natick, MA 01760 pp. 1 41.;;AT&T Paradyne, News Release, Bell Atlantic Supports AT & T Paradyne s GlobeSpan Technology , Largo, Florida, Nov. 1, 1995, 34 pages.;;Maxwell, Kim, Study Project: ADSL Issue II Variable Rate ADSL , Independent Editions, Apr. 22, 1996, 1057 University Ave., Palo Alto, CA 94301, T1E1.4/95 129, 2 pages.;;Starr, Tom, Project: ADSL Rate Adaptive DSL , Apr. 22, 1996, Colorado Springs, Ameritech, 2000 W. Ameritech Drive, Rm. 3C52, Hoffman Estates, IL 60196, pp. 1 5.;;Keyes, Philip J., ADSL Standard Project Proposal for Annex to ADSL Standard , Apr. 22, 1996, Col. Springs, CO, Bell South Telcomm., 3535 Colonnade Pkwy, Rm W1D1, Birmingham, AL 35243, 3 pgs.;;Cook, John, Telephony Transmission and Splitters, Passive and Active , T1E1.4 Contribution, American Nat l Standards Institute Telecomm. Comm. (ANSI/T1), Feb. 14 18, 1994 San Francisco Mtg, 14 pages.;;Cioffi, J.M., et al., Project: T1E1.4: ADSL Rate Adaptation and the ANSI T1.413 DMT ADSL Data Rate Throttle , Amati Comm. Corp., 1975 Mountain View, CA 94040, pp. 1 10.;;Scholtz, W.H., et al., Study Project: HDSL Study Project Variable Bit Rate ADSL Using Carrierless AM/PM ( CAP ), Lucent Technologies, 101 Crawfords Corner Rd., Rm. 4L 322, Holmdel, NJ 07733 3030, pp. 1 4.;;Lechleider, J.W., The Capacity of Next Impaired Subscriber Loops , Bellcore, Globecom 90, IEEE Global Telecomm. Conf. & Exhibit, San Diego, CA, Dec. 2 5, 1990, Communications: Connecting the Future ; CH2827 4/90/0000,1990 IEEE.;;ADSL Forum WWW Site, Dec., 1995: About the ADSL Forum , 8 pages.;;ADSL Forum WWW Site, Dec., 1995: ADSL Twisted Pair Access to the Information Highway , 4 pages.;;ADSL Forum WWW Site, Dec., 1995: VDSL Fiber Copper Access to the Information Highway , 7 pages.;;ADSL Forum WWW Site, Dec., 1995: A Tutorial Glossary of Copper Access Transmission Terminology , 10 pages.;;ADSL Forum WWW Site, Dec., 1995: The World is Already Wired for Multimedia Communications , 2 pages.;;ADSL Forum WWW Site, Dec., 1995: Working Text: Interfaces and System Configurations for ADSL: Bit Synchronous Mode , 15 pages.;;ADSL Forum WWW Site, Dec., 1995: Daly, Tom (editor), Study Project: Packet Mode Technical Group Working Text , 12 pages.;;Integrated Circuit Engineering Corporation, A Study of the MPU, MCU & DSP Markets, Digital Signal Processors , Microprocessor 1996, Editor: Bill McClean, Author: Jack Quinn, Scottsdale, AZ, pp. 12 19 to 12 33.",EXPIRED
418,TW,A,TW 202315618 A,047-800-127-980-351,2023-04-16,2023,TW 111121145 A,2022-06-08,US 202163209555 P;;US 202263319826 P,2021-06-11,O-linked thiadiazolyl compounds as DNA Polymerase Theta inhibitors,"Disclosed herein are certain thiadiazolyl derivatives Formula (I): that inhibit DNA Polymerase Theta (Pol[theta]) activity, in particular inhibit Pol[theta] activity by inhibiting ATP dependent helicase domain activity of Pol[theta]. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating and/or preventing diseases treatable by inhibition of Pol[theta] such as cancer, including homologous recombination (HR) deficient cancers.",IDEAYA BIOSCIENCES INC;;GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 4 LTD,BARSANTI PAUL A;;JAIPURI FIROZ ALI;;LEE SEVERANCE DANIEL;;WANG CHEN-BO;;DUFFY KEVIN J;;LAWHORN BRIAN G;;ADAMS NICHOLAS DAVID;;BOTYANSZKI JANOS;;DARCY MICHAEL G;;KIESOW TERENCE J;;MCATEE JOHN J;;MARTYR CUTHBERT;;BUITRAGO SANTANILLA ALEXANDER;;TIAN XINRONG,,https://lens.org/047-800-127-980-351,Patent of Addition,no,0,1,5,6,0,C07D417/12;;C07D417/14;;A61P35/00;;C07D417/12;;C07D417/14;;A61P35/00,A61K31/41;;A61K31/4439;;A61K31/444;;A61P35/00;;C07D417/12;;C07D417/14,,0,0,,,,PENDING
419,CN,A,CN 104114282 A,032-486-120-473-288,2014-10-22,2014,CN 201280058549 A,2012-09-28,US 2012/0058096 W;;US 201161541371 P;;US 201161564027 P,2011-09-30,SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,"A biological analysis system is provided. The system comprises an interchangeable assembly configured to accommodate any one of a plurality of sample holders, each respective sample holder configured to receive a plurality of samples. The system also includes a control system configured to cycle the plurality of samples through a series of temperatures. The system further includes an optical system configured to detect fluorescent signals emitted from the plurality of samples. The optical system, in particular, can comprise a single field lens, an excitation source, an optical sensor, and a plurality of filter components. The excitation source can be one or more light emitting diodes. The field lens can be a bi-convex lens.",LIFE TECHNOLOGIES CORP,FREUDENTHAL JACOB K;;DAHLHOFF GEOFFREY;;MAHER KEVIN;;CHEN MINGSONG;;LIM GARY;;DANEHY RONALD;;FORTESCUE DAVID;;SHEN MING;;SOH WOON LIANG TERENCE;;CHENG FRANCIS;;WU RUOYUN;;LEE THIAM CHYE;;CHAPPELL GARY;;LIM CHEE KIONG;;DERE JEFF;;STRAUB TED;;FONSECA JORGE;;BOO KUAN MOON;;LAU SOO YONG,,https://lens.org/032-486-120-473-288,Patent Application,no,5,5,20,20,0,B01L3/50855;;B01L3/50857;;B01L7/52;;C12Q1/686;;G01N21/01;;B01L2300/046;;B01L2300/021;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L2300/0654;;B01L2200/023;;B01L2200/028;;B01L2200/025;;B01L2200/143;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;C12Q1/686,B01L7/00;;B01L3/00;;C12Q1/68,,0,0,,,,ACTIVE
420,WO,A2,WO 2013/049702 A2,130-339-944-371-789,2013-04-04,2013,US 2012/0058096 W,2012-09-28,US 201161541371 P;;US 201161564027 P,2011-09-30,SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,"A biological analysis system is provided. The system comprises an interchangeable assembly configured to accommodate any one of a plurality of sample holders, each respective sample holder configured to receive a plurality of samples. The system also includes a control system configured to cycle the plurality of samples through a series of temperatures. The system further includes an optical system configured to detect fluorescent signals emitted from the plurality of samples. The optical system, in particular, can comprise a single field lens, an excitation source, an optical sensor, and a plurality of filter components. The excitation source can be one or more light emitting diodes. The field lens can be a bi-convex lens.",LIFE TECHNOLOGIES CORP,FREUDENTHAL JACOB K;;DAHLHOFF GEOFFREY;;MAHER KEVIN;;CHEN MINGSONG;;LIM GARY;;DANEHY RONALD;;FORTESCUE DAVID;;SHEN MING;;SOH WOON LIANG TERENCE;;CHENG FRANCIS;;WU RUOYUN;;LEE THIAM CHYE;;CHAPPELL GARY;;LIM CHEE KIONG;;DERE JEFF;;STRAUB TED;;FONSECA JORGE;;BOO KUAN MOON;;LAU SOO YONG,,https://lens.org/130-339-944-371-789,Patent Application,yes,1,10,20,20,0,B01L3/50855;;B01L3/50857;;B01L7/52;;C12Q1/686;;G01N21/01;;B01L2300/046;;B01L2300/021;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L2300/0654;;B01L2200/023;;B01L2200/028;;B01L2200/025;;B01L2200/143;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;C12Q1/686,B01L3/00;;B01L7/00;;C12Q1/68,,0,0,,,,PENDING
421,WO,A3,WO 2013/049702 A3,158-643-306-482-831,2013-10-10,2013,US 2012/0058096 W,2012-09-28,US 201161541371 P;;US 201161564027 P,2011-09-30,SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,"A biological analysis system is provided. The system comprises an interchangeable assembly configured to accommodate any one of a plurality of sample holders, each respective sample holder configured to receive a plurality of samples. The system also includes a control system configured to cycle the plurality of samples through a series of temperatures. The system further includes an optical system configured to detect fluorescent signals emitted from the plurality of samples. The optical system, in particular, can comprise a single field lens, an excitation source, an optical sensor, and a plurality of filter components. The excitation source can be one or more light emitting diodes. The field lens can be a bi-convex lens.",LIFE TECHNOLOGIES CORP,FREUDENTHAL JACOB K;;DAHLHOFF GEOFFREY;;MAHER KEVIN;;CHEN MINGSONG;;LIM GARY;;DANEHY RONALD;;FORTESCUE DAVID;;SHEN MING;;SOH WOON LIANG TERENCE;;CHENG FRANCIS;;WU RUOYUN;;LEE THIAM CHYE;;CHAPPELL GARY;;LIM CHEE KIONG;;DERE JEFF;;STRAUB TED;;FONSECA JORGE;;BOO KUAN MOON;;LAU SOO YONG,,https://lens.org/158-643-306-482-831,Search Report,yes,4,0,20,20,0,B01L3/50855;;B01L3/50857;;B01L7/52;;C12Q1/686;;G01N21/01;;B01L2300/046;;B01L2300/021;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L2300/0654;;B01L2200/023;;B01L2200/028;;B01L2200/025;;B01L2200/143;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;C12Q1/686,B01L7/00;;B01L3/00;;C12Q1/68,,0,0,,,,PENDING
422,SG,A,SG 11201401913Y A,191-566-353-367-780,2014-09-26,2014,SG 11201401913Y A,2012-09-28,US 201161541371 P;;US 201161564027 P;;US 2012/0058096 W,2011-09-30,SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,,LIFE TECHNOLOGIES CORP,FREUDENTHAL JACOB K;;DAHLHOFF GEOFFREY;;MAHER KEVIN;;CHEN MINGSONG;;LIM GARY;;DANEHY RONALD;;FORTESCUE DAVID;;SHEN MING;;SOH WOON LIANG TERENCE;;CHENG FRANCIS;;WU RUOYUN;;LEE THIAM CHYE;;CHAPPELL GARY;;LIM CHEE KIONG;;DERE JEFF;;STRAUB TED;;FONSECA JORGE;;BOO KUAN MOON;;LAU SOO YONG,,https://lens.org/191-566-353-367-780,Unknown,no,0,0,20,20,0,B01L3/50855;;B01L3/50857;;B01L7/52;;C12Q1/686;;G01N21/01;;B01L2300/046;;B01L2300/021;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L2300/0654;;B01L2200/023;;B01L2200/028;;B01L2200/025;;B01L2200/143;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;C12Q1/686,B01L7/00;;B01L3/00;;C12Q1/68,,0,0,,,,PENDING
423,EP,A2,EP 2760585 A2,106-611-036-648-674,2014-08-06,2014,EP 12784373 A,2012-09-28,US 201161541371 P;;US 201161564027 P;;US 2012/0058096 W,2011-09-30,SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,,LIFE TECHNOLOGIES CORP,FREUDENTHAL JACOB K;;DAHLHOFF GEOFFREY;;MAHER KEVIN;;CHEN MINGSONG;;LIM GARY;;DANEHY RONALD;;FORTESCUE DAVID;;SHEN MING;;SOH WOON LIANG TERENCE;;CHENG FRANCIS;;WU RUOYUN;;LEE THIAM CHYE;;CHAPPELL GARY;;LIM CHEE KIONG;;DERE JEFF;;STRAUB TED;;FONSECA JORGE;;BOO KUAN MOON;;LAU SOO YONG,LIFE TECHNOLOGIES CORPORATION (2016-11-23),https://lens.org/106-611-036-648-674,Patent Application,yes,0,0,20,20,0,B01L3/50855;;B01L3/50857;;B01L7/52;;C12Q1/686;;G01N21/01;;B01L2300/046;;B01L2300/021;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L2300/0654;;B01L2200/023;;B01L2200/028;;B01L2200/025;;B01L2200/143;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;C12Q1/686,B01L7/00;;B01L3/00;;C12Q1/68,,0,0,,,,PENDING
424,SG,A,SG 10201602113T A,131-430-381-142-985,2016-04-28,2016,SG 10201602113T A,2012-09-28,US 201161541371 P;;US 201161564027 P,2011-09-30,Systems And Methods For Biological Analysis,,LIFE TECHNOLOGIES CORP,FREUDENTHAL JACOB K;;DAHLHOFF GEOFFREY;;MAHER KEVIN;;CHEN MINGSONG;;LIM GARY;;DANEHY RONALD;;FORTESCUE DAVID;;SHEN MING;;SOH WOON LIANG TERENCE;;CHENG FRANCIS;;WU RUOYUN;;LEE THIAM CHYE;;CHAPPELL GARY;;LIM CHEE KIONG;;DERE JEFF;;STRAUB TED;;FONSECA JORGE;;BOO KUAN MOON;;LAU SOO YONG,,https://lens.org/131-430-381-142-985,Unknown,no,0,0,20,20,0,B01L3/50855;;B01L3/50857;;B01L7/52;;C12Q1/686;;G01N21/01;;B01L2300/046;;B01L2300/021;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L2300/0654;;B01L2200/023;;B01L2200/028;;B01L2200/025;;B01L2200/143;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;C12Q1/686,,,0,0,,,,PENDING
425,WO,A9,WO 2013/049702 A9,070-263-388-994-957,2014-05-01,2014,US 2012/0058096 W,2012-09-28,US 201161541371 P;;US 201161564027 P,2011-09-30,SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,"A biological analysis system is provided. The system comprises an interchangeable assembly configured to accommodate any one of a plurality of sample holders, each respective sample holder configured to receive a plurality of samples. The system also includes a control system configured to cycle the plurality of samples through a series of temperatures. The system further includes an optical system configured to detect fluorescent signals emitted from the plurality of samples. The optical system, in particular, can comprise a single field lens, an excitation source, an optical sensor, and a plurality of filter components. The excitation source can be one or more light emitting diodes. The field lens can be a bi-convex lens.",LIFE TECHNOLOGIES CORP,FREUDENTHAL JACOB K;;DAHLHOFF GEOFFREY;;MAHER KEVIN;;CHEN MINGSONG;;LIM GARY;;DANEHY RONALD;;FORTESCUE DAVID;;SHEN MING;;SOH WOON LIANG TERENCE;;CHENG FRANCIS;;WU RUOYUN;;LEE THIAM CHYE;;CHAPPELL GARY;;LIM CHEE KIONG;;DERE JEFF;;STRAUB TED;;FONSECA JORGE;;BOO KUAN MOON;;LAU SOO YONG,,https://lens.org/070-263-388-994-957,Search Report,yes,0,0,20,20,0,B01L3/50855;;B01L3/50857;;B01L7/52;;C12Q1/686;;G01N21/01;;B01L2300/046;;B01L2300/021;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L2300/0654;;B01L2200/023;;B01L2200/028;;B01L2200/025;;B01L2200/143;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;C12Q1/686,B01L7/00;;B01L3/00;;C12Q1/68,,0,0,,,,PENDING
426,JP,A,JP 2019164170 A,047-674-632-304-878,2019-09-26,2019,JP 2019124325 A,2019-07-03,US 201161541371 P;;US 201161564027 P,2011-09-30,SYSTEM AND METHOD FOR BIOLOGICAL ANALYSIS,"To provide a system and a method for biological analysis.SOLUTION: A biological analysis system comprises a replaceable assembly configured to store arbitrary one of a plurality of sample holders and each of the sample holders is configured to receive a plurality of samples. The system further comprises a control system configured to circulate the plurality of samples through a series of temperature. The system further comprises an optical system configured to detect fluorescence signals emitted from the plurality of samples. The optical system, specially a single field lens, an excitation source, an optical sensor and a plurality of filter construction elements can be provided. The excitation source can be one or more light emission diodes. The field lens can be a biconvex lens.SELECTED DRAWING: Figure 1",LIFE TECHNOLOGIES CORP,JACOB FREUDENTHAL;;GEOFFREY DAHLHOFF;;KEVIN MAHER;;CHEN MINGSONG;;GARY LIM;;RONALD DANEHY;;DAVID FORTESCUE;;SHEN MING;;WOON LIANG TERENCE SOH;;FRANCIS CHENG;;WU RUOYUN;;LEE THIAM CHYE;;GARY CHAPPELL;;LIM CHEE KIONG;;JEFF DERE;;TED STRAUD;;JORGE FONSECA;;BOO KUAN MOON;;LAU SO-YONG,,https://lens.org/047-674-632-304-878,Patent Application,no,13,1,20,20,0,B01L3/50855;;B01L3/50857;;B01L7/52;;C12Q1/686;;G01N21/01;;B01L2300/046;;B01L2300/021;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L2300/0654;;B01L2200/023;;B01L2200/028;;B01L2200/025;;B01L2200/143;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;C12Q1/686,G01N35/02;;C12M1/00;;G01N21/64;;G01N21/75;;G01N21/78,,0,0,,,,PENDING
427,KR,A,KR 20140070649 A,079-748-285-451-178,2014-06-10,2014,KR 20147011695 A,2012-09-28,US 201161541371 P;;US 201161564027 P;;US 2012/0058096 W,2011-09-30,SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,,LIFE TECHNOLOGIES CORP,FREUDENTHAL JACOB K;;DAHLHOFF GEOFFREY;;MAHER KEVIN;;CHEN MINGSONG;;LIM GARY;;DANEHY RONALD;;FORTESCUE DAVID;;SHEN MING;;SOH WOON LIANG TERENCE;;CHENG FRANCIS;;WU RUOYUN;;LEE THIAM CHYE;;CHAPPELL GARY;;LIM CHEE KIONG;;DERE JEFF;;STRAUB TED;;FONSECA JORGE;;BOO KUAN MOON;;LAU SOO YONG,,https://lens.org/079-748-285-451-178,Patent Application,no,0,0,20,20,0,B01L3/50855;;B01L3/50857;;B01L7/52;;C12Q1/686;;G01N21/01;;B01L2300/046;;B01L2300/021;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L2300/0654;;B01L2200/023;;B01L2200/028;;B01L2200/025;;B01L2200/143;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;C12Q1/686,G01N33/52;;C12M1/38;;G06F19/28,,0,0,,,,DISCONTINUED
428,JP,A,JP 2017102122 A,135-140-135-944-894,2017-06-08,2017,JP 2017000047 A,2017-01-04,US 201161541371 P;;US 201161564027 P,2011-09-30,SYSTEMS AND METHODS FOR BIOLOGICAL ANALYSIS,"PROBLEM TO BE SOLVED: To provide systems and methods for a biological analysis.SOLUTION: A biological analysis system comprises an interchangeable assembly configured to accommodate arbitrary one of a plurality of sample holders, in which each respective sample holder is configured to receive a plurality of samples. The system also includes a control system 120 configured to cycle the plurality of samples through a series of temperatures. The system further includes an optical system 124 configured to detect fluorescent signals emitted from the plurality of samples. The optical system, in particular, may comprise: a single field lens; an excitation source; an optical sensor, and a plurality of filter components. The excitation source may be one or more light emitting diodes. The field lens may be a bi-convex lens.SELECTED DRAWING: Figure 1",LIFE TECHNOLOGIES CORP,JACOB FREUDENTHAL;;GEOFFREY DAHLHOFF;;KEVIN MAHER;;CHEN MINGSONG;;GARY LIM;;RONALD DANEHY;;DAVID FORTESCUE;;SHEN MING;;WOON LIANG TERENCE SOH;;FRANCIS CHENG;;WU RUOYUN;;LEE THIAM CHYE;;GARY CHAPPELL;;LIM CHEE KIONG;;JEFF DERE;;TED STRAUD;;JORGE FONSECA;;BOO KUAN MOON;;LAU SO-YONG,,https://lens.org/135-140-135-944-894,Patent Application,no,7,0,20,20,0,B01L3/50855;;B01L3/50857;;B01L7/52;;C12Q1/686;;G01N21/01;;B01L2300/046;;B01L2300/021;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L2300/0654;;B01L2200/023;;B01L2200/028;;B01L2200/025;;B01L2200/143;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;C12Q1/686,G01N35/02;;C12M1/00;;C12M1/34;;G01N21/78,,0,0,,,,DISCONTINUED
429,BR,A2,BR 112014007789 A2,049-073-443-721-858,2017-04-11,2017,BR 112014007789 A,2012-09-28,US 2012/0058096 W;;US 201161541371 P;;US 201161564027 P,2011-09-30,sistemas e métodos para análise biológica,,LIFE TECHNOLOGIES CORP,CHEE KIONG LIM;;DAVID FORTESCUE;;FRANCIS CHENG;;GARY CHAPPELL;;GARY LIM;;GEOFFREY DAHLHOFF;;JACOB K FREUDENTHAL;;JEFF DERE;;JORGE FONSECA;;KEVIN MAHER;;KUAM MOON BOO;;MING SHEN;;MINGSONG CHEN;;RONALD DANEHY;;RUOYUM WU;;SOO YONG LAU;;TED STRAUD;;THIAM CHYE LEE;;WOON LIANG;;WOON LIANG TERENCE SOH,,https://lens.org/049-073-443-721-858,Patent Application,no,0,0,20,20,0,B01L3/50855;;B01L3/50857;;B01L7/52;;C12Q1/686;;G01N21/01;;B01L2300/046;;B01L2300/021;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L2300/0654;;B01L2200/023;;B01L2200/028;;B01L2200/025;;B01L2200/143;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;B01L3/50855;;B01L3/50857;;B01L2200/023;;B01L2200/025;;B01L2200/028;;B01L2200/143;;B01L2300/021;;B01L2300/046;;B01L2300/0654;;B01L2300/0829;;B01L2300/1827;;B01L2300/1844;;B01L7/52;;C12Q1/686,B01L3/00;;B01L7/00;;C12Q1/68,,0,0,,,,DISCONTINUED
430,WO,A2,WO 2022/261543 A2,062-871-866-941-438,2022-12-15,2022,US 2022/0033259 W,2022-06-13,US 202163209673 P,2021-06-11,"DRUG CARTRIDGE, DRUG DELIVERY DEVICE, AND METHODS FOR PREPARING THEREOF","In one aspect, a drug delivery device is provided herein including: a monolithic body having a plurality of fluid ducts and at least one outlet duct formed therein; a plurality of drug cartridges attached to the body, the drug cartridges each including a reservoir for accommodating at least one drug wherein, the plurality of fluid ducts is arranged to convey the drugs from the drug cartridges to the at least one outlet duct; and, a needle support spaced from the body, the needle support including a needle configured for insertion into a patient for drug delivery, the needle support including adhesive for releasable securement to a patient, wherein, the needle support is connected to the body by a flexible tether through which passes at least one fluid passageway formed to convey drug from the at least one outlet duct to the needle.",BRISTOL MYERS SQUIBB CO,MCLOUGHLIN MARTIN;;HOWANSKY MARK;;CURRIER GEORGE;;HEYMAN PETER;;WU YUHONG;;SAHIN ERINC;;KULKARNI SHREYA;;KULSHRESTHA ANKUR;;CHEN XIAODONG;;MORE HARESH;;PATEL KRISHNA;;KNUTSEN JOHN;;BRADFORD JAMES;;BRERETON SIMON;;BARROW-WILLIAMS TIMOTHY;;ROSIER CHRISTOPHER;;PHILIPPSON JEFFREY;;MCGINLEY RYAN;;SASIA FRANCESCO;;PALMER HOLLY;;CORREA TOMAS ALEXANDER;;LEE CARYS ELERI;;MERRITT PAUL ANTONY;;SEOW TERENCE ZHI,,https://lens.org/062-871-866-941-438,Patent Application,yes,0,0,4,4,0,A61M5/14248;;A61M39/22;;A61M2005/1586;;A61M5/1409;;A61M2005/14252;;A61M5/1408;;A61M5/16827;;A61M5/16831;;A61M2205/121;;A61M2205/128;;A61M2205/50;;A61M2205/82;;A61M2205/8206,A61M5/14;;A61M5/142;;A61M5/168,,0,0,,,,PENDING
431,WO,A3,WO 2022/261543 A3,033-113-236-836-444,2023-03-02,2023,US 2022/0033259 W,2022-06-13,US 202163209673 P,2021-06-11,"DRUG CARTRIDGE, DRUG DELIVERY DEVICE, AND METHODS FOR PREPARING THEREOF","In one aspect, a drug delivery device is provided herein including: a monolithic body having a plurality of fluid ducts and at least one outlet duct formed therein; a plurality of drug cartridges attached to the body, the drug cartridges each including a reservoir for accommodating at least one drug wherein, the plurality of fluid ducts is arranged to convey the drugs from the drug cartridges to the at least one outlet duct; and, a needle support spaced from the body, the needle support including a needle configured for insertion into a patient for drug delivery, the needle support including adhesive for releasable securement to a patient, wherein, the needle support is connected to the body by a flexible tether through which passes at least one fluid passageway formed to convey drug from the at least one outlet duct to the needle.",BRISTOL MYERS SQUIBB CO,MCLOUGHLIN MARTIN;;HOWANSKY MARK;;CURRIER GEORGE;;HEYMAN PETER;;WU YUHONG;;SAHIN ERINC;;KULKARNI SHREYA;;KULSHRESTHA ANKUR;;CHEN XIAODONG;;MORE HARESH;;PATEL KRISHNA;;KNUTSEN JOHN;;BRADFORD JAMES;;BRERETON SIMON;;BARROW-WILLIAMS TIMOTHY;;ROSIER CHRISTOPHER;;PHILIPPSON JEFFREY;;MCGINLEY RYAN;;SASIA FRANCESCO;;PALMER HOLLY;;CORREA TOMAS ALEXANDER;;LEE CARYS ELERI;;MERRITT PAUL ANTONY;;SEOW TERENCE ZHI,,https://lens.org/033-113-236-836-444,Search Report,yes,9,0,4,4,0,A61M5/14248;;A61M39/22;;A61M2005/1586;;A61M5/1409;;A61M2005/14252;;A61M5/1408;;A61M5/16827;;A61M5/16831;;A61M2205/121;;A61M2205/128;;A61M2205/50;;A61M2205/82;;A61M2205/8206,A61M5/14;;A61M5/142;;A61M5/158;;A61M5/168;;A61M39/22,,0,0,,,,PENDING
432,WO,A4,WO 2022/261543 A4,134-689-474-494-084,2023-05-11,2023,US 2022/0033259 W,2022-06-13,US 202163209673 P,2021-06-11,"DRUG CARTRIDGE, DRUG DELIVERY DEVICE, AND METHODS FOR PREPARING THEREOF","In one aspect, a drug delivery device is provided herein including: a monolithic body having a plurality of fluid ducts and at least one outlet duct formed therein; a plurality of drug cartridges attached to the body, the drug cartridges each including a reservoir for accommodating at least one drug wherein, the plurality of fluid ducts is arranged to convey the drugs from the drug cartridges to the at least one outlet duct; and, a needle support spaced from the body, the needle support including a needle configured for insertion into a patient for drug delivery, the needle support including adhesive for releasable securement to a patient, wherein, the needle support is connected to the body by a flexible tether through which passes at least one fluid passageway formed to convey drug from the at least one outlet duct to the needle.",BRISTOL MYERS SQUIBB CO,MCLOUGHLIN MARTIN;;HOWANSKY MARK;;CURRIER GEORGE;;HEYMAN PETER;;WU YUHONG;;SAHIN ERINC;;KULKARNI SHREYA;;KULSHRESTHA ANKUR;;CHEN XIAODONG;;MORE HARESH;;PATEL KRISHNA;;KNUTSEN JOHN;;BRADFORD JAMES;;BRERETON SIMON;;BARROW-WILLIAMS TIMOTHY;;ROSIER CHRISTOPHER;;PHILIPPSON JEFFREY;;MCGINLEY RYAN;;SASIA FRANCESCO;;PALMER HOLLY;;CORREA TOMAS ALEXANDER;;LEE CARYS ELERI;;MERRITT PAUL ANTONY;;SEOW TERENCE ZHI,,https://lens.org/134-689-474-494-084,Patent Application,yes,0,0,4,4,0,A61M5/14248;;A61M39/22;;A61M2005/1586;;A61M5/1409;;A61M2005/14252;;A61M5/1408;;A61M5/16827;;A61M5/16831;;A61M2205/121;;A61M2205/128;;A61M2205/50;;A61M2205/82;;A61M2205/8206,A61M5/14;;A61M5/142;;A61M5/158;;A61M5/168;;A61M39/22,,0,0,,,,PENDING
